id	sid	tid	token	lemma	pos
admet-7	1	1	doi	doi	NOUN
admet-7	1	2	:	:	PUNCT
admet-7	1	3	10.5599	10.5599	NUM
admet-7	1	4	/	/	SYM
admet-7	1	5	admet.1.3.7	admet.1.3.7	NOUN
admet-7	1	6	29	29	NUM
admet-7	1	7	admet	admet	X
admet-7	1	8	&	&	CCONJ
admet-7	1	9	dmpk	dmpk	PROPN
admet-7	1	10	1(3	1(3	NUM
admet-7	1	11	)	)	PUNCT
admet-7	1	12	(	(	PUNCT
admet-7	1	13	2013	2013	NUM
admet-7	1	14	)	)	PUNCT
admet-7	1	15	29	29	NUM
admet-7	1	16	-	-	SYM
admet-7	1	17	44	44	NUM
admet-7	1	18	;	;	PUNCT
admet-7	1	19	doi	doi	NOUN
admet-7	1	20	:	:	PUNCT
admet-7	1	21	10.5599	10.5599	NUM
admet-7	1	22	/	/	SYM
admet-7	1	23	admet.1.3.7	admet.1.3.7	NOUN
admet-7	1	24	open	open	ADJ
admet-7	1	25	access	access	NOUN
admet-7	1	26	:	:	PUNCT
admet-7	1	27	issn	issn	PROPN
admet-7	1	28	:	:	PUNCT
admet-7	1	29	1848	1848	NUM
admet-7	1	30	-	-	SYM
admet-7	1	31	7718	7718	NUM
admet-7	1	32	http://www.pub.iapchem.org/ojs/index.php/admet/index	http://www.pub.iapchem.org/ojs/index.php/admet/index	NOUN
admet-7	1	33	mini	mini	NOUN
admet-7	1	34	review	review	NOUN
admet-7	1	35	the	the	DET
admet-7	1	36	roles	role	NOUN
admet-7	1	37	of	of	ADP
admet-7	1	38	doxorubicin	doxorubicin	PROPN
admet-7	1	39	in	in	ADP
admet-7	1	40	hepatocellular	hepatocellular	ADJ
admet-7	1	41	carcinoma	carcinoma	NOUN
admet-7	1	42	kin	kin	X
admet-7	1	43	tam	tam	PROPN
admet-7	1	44	faculty	faculty	PROPN
admet-7	1	45	of	of	ADP
admet-7	1	46	health	health	NOUN
admet-7	1	47	science	science	NOUN
admet-7	1	48	,	,	PUNCT
admet-7	1	49	university	university	PROPN
admet-7	1	50	of	of	ADP
admet-7	1	51	macau	macau	PROPN
admet-7	1	52	,	,	PUNCT
admet-7	1	53	macau	macau	PROPN
admet-7	1	54	,	,	PUNCT
admet-7	1	55	china	china	PROPN
admet-7	1	56	e	e	PROPN
admet-7	1	57	-	-	NOUN
admet-7	1	58	mail	mail	NOUN
admet-7	1	59	:	:	PUNCT
admet-7	1	60	kintam@umac.mo	kintam@umac.mo	PROPN
admet-7	1	61	;	;	PUNCT
admet-7	1	62	tel	tel	PROPN
admet-7	1	63	.	.	PUNCT
admet-7	1	64	:	:	PUNCT
admet-7	2	1	+853	+853	NUM
admet-7	2	2	-	-	PUNCT
admet-7	2	3	8397	8397	NUM
admet-7	2	4	-	-	SYM
admet-7	2	5	8501	8501	NUM
admet-7	2	6	;	;	PUNCT
admet-7	2	7	fax	fax	NOUN
admet-7	2	8	:	:	PUNCT
admet-7	2	9	+853	+853	NOUN
admet-7	2	10	-	-	PUNCT
admet-7	2	11	8397	8397	NUM
admet-7	2	12	-	-	SYM
admet-7	2	13	8500	8500	NUM
admet-7	2	14	received	receive	VERB
admet-7	2	15	:	:	PUNCT
admet-7	2	16	june	june	PROPN
admet-7	2	17	01	01	NUM
admet-7	2	18	st	st	PROPN
admet-7	2	19	,	,	PUNCT
admet-7	2	20	2013	2013	NUM
admet-7	2	21	;	;	PUNCT
admet-7	2	22	revised	revise	VERB
admet-7	2	23	:	:	PUNCT
admet-7	2	24	july	july	PROPN
admet-7	2	25	03	03	NUM
admet-7	2	26	rd	rd	PROPN
admet-7	2	27	,	,	PUNCT
admet-7	2	28	2013	2013	NUM
admet-7	2	29	,	,	PUNCT
admet-7	2	30	published	publish	VERB
admet-7	2	31	:	:	PUNCT
admet-7	3	1	july	july	PROPN
admet-7	3	2	03	03	NUM
admet-7	3	3	rd	rd	PROPN
admet-7	3	4	,	,	PUNCT
admet-7	3	5	2013	2013	NUM
admet-7	3	6	abstract	abstract	ADJ
admet-7	3	7	liver	liver	NOUN
admet-7	3	8	cancer	cancer	NOUN
admet-7	3	9	is	be	AUX
admet-7	3	10	the	the	DET
admet-7	3	11	third	third	ADJ
admet-7	3	12	most	most	ADV
admet-7	3	13	common	common	ADJ
admet-7	3	14	cause	cause	NOUN
admet-7	3	15	of	of	ADP
admet-7	3	16	death	death	NOUN
admet-7	3	17	from	from	ADP
admet-7	3	18	cancer	cancer	NOUN
admet-7	3	19	worldwide	worldwide	ADV
admet-7	3	20	.	.	PUNCT
admet-7	4	1	hepatocellular	hepatocellular	ADJ
admet-7	4	2	carcinoma	carcinoma	NOUN
admet-7	4	3	(	(	PUNCT
admet-7	4	4	hcc	hcc	NOUN
admet-7	4	5	)	)	PUNCT
admet-7	4	6	accounts	account	NOUN
admet-7	4	7	for	for	ADP
admet-7	4	8	80	80	NUM
admet-7	4	9	–	–	SYM
admet-7	4	10	90	90	NUM
admet-7	4	11	%	%	NOUN
admet-7	4	12	of	of	ADP
admet-7	4	13	all	all	DET
admet-7	4	14	primary	primary	ADJ
admet-7	4	15	liver	liver	NOUN
admet-7	4	16	cancers	cancer	NOUN
admet-7	4	17	.	.	PUNCT
admet-7	5	1	the	the	DET
admet-7	5	2	mortality	mortality	NOUN
admet-7	5	3	of	of	ADP
admet-7	5	4	hcc	hcc	PROPN
admet-7	5	5	is	be	AUX
admet-7	5	6	high	high	ADJ
admet-7	5	7	,	,	PUNCT
admet-7	5	8	and	and	CCONJ
admet-7	5	9	the	the	DET
admet-7	5	10	treatment	treatment	NOUN
admet-7	5	11	options	option	NOUN
admet-7	5	12	are	be	AUX
admet-7	5	13	limited	limited	ADJ
admet-7	5	14	.	.	PUNCT
admet-7	6	1	doxorubicin	doxorubicin	PROPN
admet-7	6	2	exhibits	exhibit	VERB
admet-7	6	3	a	a	DET
admet-7	6	4	broad	broad	ADJ
admet-7	6	5	spectrum	spectrum	NOUN
admet-7	6	6	of	of	ADP
admet-7	6	7	anti	anti	ADJ
admet-7	6	8	-	-	ADJ
admet-7	6	9	tumour	tumour	ADJ
admet-7	6	10	activity	activity	NOUN
admet-7	6	11	.	.	PUNCT
admet-7	7	1	when	when	SCONJ
admet-7	7	2	administrated	administrate	VERB
admet-7	7	3	via	via	ADP
admet-7	7	4	the	the	DET
admet-7	7	5	hepatic	hepatic	ADJ
admet-7	7	6	artery	artery	NOUN
admet-7	7	7	,	,	PUNCT
admet-7	7	8	doxorubicin	doxorubicin	PROPN
admet-7	7	9	showed	show	VERB
admet-7	7	10	anti	anti	ADJ
admet-7	7	11	-	-	ADJ
admet-7	7	12	tumour	tumour	ADJ
admet-7	7	13	effects	effect	NOUN
admet-7	7	14	and	and	CCONJ
admet-7	7	15	partial	partial	ADJ
admet-7	7	16	response	response	NOUN
admet-7	7	17	in	in	ADP
admet-7	7	18	hcc	hcc	PROPN
admet-7	7	19	patients	patient	NOUN
admet-7	7	20	.	.	PUNCT
admet-7	8	1	in	in	ADP
admet-7	8	2	this	this	DET
admet-7	8	3	mini	mini	ADJ
admet-7	8	4	review	review	NOUN
admet-7	8	5	,	,	PUNCT
admet-7	8	6	we	we	PRON
admet-7	8	7	will	will	AUX
admet-7	8	8	first	first	ADV
admet-7	8	9	outline	outline	VERB
admet-7	8	10	the	the	DET
admet-7	8	11	treatment	treatment	NOUN
admet-7	8	12	options	option	NOUN
admet-7	8	13	for	for	ADP
admet-7	8	14	hcc	hcc	PROPN
admet-7	8	15	.	.	PUNCT
admet-7	9	1	then	then	ADV
admet-7	9	2	,	,	PUNCT
admet-7	9	3	we	we	PRON
admet-7	9	4	will	will	AUX
admet-7	9	5	briefly	briefly	ADV
admet-7	9	6	discuss	discuss	VERB
admet-7	9	7	the	the	DET
admet-7	9	8	pharmacological	pharmacological	NOUN
admet-7	9	9	,	,	PUNCT
admet-7	9	10	toxicological	toxicological	ADJ
admet-7	9	11	and	and	CCONJ
admet-7	9	12	pharmacokinetic	pharmacokinetic	ADJ
admet-7	9	13	aspects	aspect	NOUN
admet-7	9	14	of	of	ADP
admet-7	9	15	doxorubicin	doxorubicin	PROPN
admet-7	9	16	.	.	PUNCT
admet-7	10	1	finally	finally	ADV
admet-7	10	2	,	,	PUNCT
admet-7	10	3	we	we	PRON
admet-7	10	4	will	will	AUX
admet-7	10	5	review	review	VERB
admet-7	10	6	the	the	DET
admet-7	10	7	new	new	ADJ
admet-7	10	8	developments	development	NOUN
admet-7	10	9	and	and	CCONJ
admet-7	10	10	future	future	ADJ
admet-7	10	11	directions	direction	NOUN
admet-7	10	12	of	of	ADP
admet-7	10	13	using	use	VERB
admet-7	10	14	doxorubicin	doxorubicin	PROPN
admet-7	10	15	in	in	ADP
admet-7	10	16	the	the	DET
admet-7	10	17	therapy	therapy	NOUN
admet-7	10	18	of	of	ADP
admet-7	10	19	hcc	hcc	PROPN
admet-7	10	20	.	.	PUNCT
admet-7	11	1	keywords	keyword	VERB
admet-7	11	2	primary	primary	ADJ
admet-7	11	3	liver	liver	NOUN
admet-7	11	4	cancer	cancer	NOUN
admet-7	11	5	;	;	PUNCT
admet-7	11	6	anticancer	anticancer	NOUN
admet-7	11	7	;	;	PUNCT
admet-7	11	8	cytotoxic	cytotoxic	ADJ
admet-7	11	9	drug	drug	NOUN
admet-7	11	10	;	;	PUNCT
admet-7	11	11	transarterial	transarterial	ADJ
admet-7	11	12	chemoembolization	chemoembolization	NOUN
admet-7	11	13	;	;	PUNCT
admet-7	11	14	drug	drug	NOUN
admet-7	11	15	eluting	eluting	NOUN
admet-7	11	16	beads	bead	NOUN
admet-7	11	17	1	1	NUM
admet-7	11	18	.	.	PUNCT
admet-7	12	1	introduction	introduction	NOUN
admet-7	12	2	liver	liver	NOUN
admet-7	12	3	cancer	cancer	NOUN
admet-7	12	4	is	be	AUX
admet-7	12	5	the	the	DET
admet-7	12	6	third	third	ADJ
admet-7	12	7	most	most	ADV
admet-7	12	8	common	common	ADJ
admet-7	12	9	cause	cause	NOUN
admet-7	12	10	of	of	ADP
admet-7	12	11	death	death	NOUN
admet-7	12	12	from	from	ADP
admet-7	12	13	cancer	cancer	NOUN
admet-7	12	14	worldwide	worldwide	ADV
admet-7	12	15	.	.	PUNCT
admet-7	13	1	globally	globally	ADV
admet-7	13	2	,	,	PUNCT
admet-7	13	3	over	over	ADP
admet-7	13	4	600,000	600,000	NUM
admet-7	13	5	people	people	NOUN
admet-7	13	6	develop	develop	VERB
admet-7	13	7	liver	liver	NOUN
admet-7	13	8	cancer	cancer	NOUN
admet-7	13	9	and	and	CCONJ
admet-7	13	10	the	the	DET
admet-7	13	11	fatality	fatality	NOUN
admet-7	13	12	rate	rate	NOUN
admet-7	13	13	is	be	AUX
admet-7	13	14	high	high	ADJ
admet-7	13	15	[	[	X
admet-7	13	16	1	1	NUM
admet-7	13	17	]	]	PUNCT
admet-7	13	18	.	.	PUNCT
admet-7	14	1	the	the	DET
admet-7	14	2	highest	high	ADJ
admet-7	14	3	incidence	incidence	NOUN
admet-7	14	4	of	of	ADP
admet-7	14	5	liver	liver	NOUN
admet-7	14	6	cancer	cancer	NOUN
admet-7	14	7	occurs	occur	VERB
admet-7	14	8	mostly	mostly	ADV
admet-7	14	9	in	in	ADP
admet-7	14	10	developing	develop	VERB
admet-7	14	11	countries	country	NOUN
admet-7	14	12	,	,	PUNCT
admet-7	14	13	such	such	ADJ
admet-7	14	14	as	as	ADP
admet-7	14	15	in	in	ADP
admet-7	14	16	sub	sub	ADJ
admet-7	14	17	-	-	ADJ
admet-7	14	18	saharan	saharan	ADJ
admet-7	14	19	africa	africa	PROPN
admet-7	14	20	and	and	CCONJ
admet-7	14	21	eastern	eastern	PROPN
admet-7	14	22	asia	asia	PROPN
admet-7	14	23	,	,	PUNCT
admet-7	14	24	and	and	CCONJ
admet-7	14	25	especially	especially	ADV
admet-7	14	26	in	in	ADP
admet-7	14	27	men	man	NOUN
admet-7	14	28	:	:	PUNCT
admet-7	14	29	the	the	DET
admet-7	14	30	overall	overall	ADJ
admet-7	14	31	male	male	NOUN
admet-7	14	32	:	:	PUNCT
admet-7	14	33	female	female	ADJ
admet-7	14	34	sex	sex	NOUN
admet-7	14	35	ratio	ratio	NOUN
admet-7	14	36	is	be	AUX
admet-7	14	37	about	about	ADV
admet-7	14	38	2.4	2.4	NUM
admet-7	14	39	[	[	SYM
admet-7	14	40	1	1	NUM
admet-7	14	41	]	]	PUNCT
admet-7	14	42	.	.	PUNCT
admet-7	15	1	regions	region	NOUN
admet-7	15	2	with	with	ADP
admet-7	15	3	low	low	ADJ
admet-7	15	4	incidence	incidence	NOUN
admet-7	15	5	include	include	VERB
admet-7	15	6	north	north	ADJ
admet-7	15	7	and	and	CCONJ
admet-7	15	8	south	south	PROPN
admet-7	15	9	america	america	PROPN
admet-7	15	10	,	,	PUNCT
admet-7	15	11	australia	australia	PROPN
admet-7	15	12	,	,	PUNCT
admet-7	15	13	and	and	CCONJ
admet-7	15	14	northern	northern	PROPN
admet-7	15	15	europe	europe	PROPN
admet-7	15	16	.	.	PUNCT
admet-7	16	1	hepatocellular	hepatocellular	ADJ
admet-7	16	2	carcinoma	carcinoma	NOUN
admet-7	16	3	(	(	PUNCT
admet-7	16	4	hcc	hcc	NOUN
admet-7	16	5	)	)	PUNCT
admet-7	16	6	accounts	account	NOUN
admet-7	16	7	for	for	ADP
admet-7	16	8	80	80	NUM
admet-7	16	9	–	–	SYM
admet-7	16	10	90	90	NUM
admet-7	16	11	%	%	NOUN
admet-7	16	12	of	of	ADP
admet-7	16	13	all	all	DET
admet-7	16	14	primary	primary	ADJ
admet-7	16	15	liver	liver	NOUN
admet-7	16	16	cancers	cancer	NOUN
admet-7	16	17	[	[	X
admet-7	16	18	2	2	NUM
admet-7	16	19	]	]	PUNCT
admet-7	16	20	.	.	PUNCT
admet-7	17	1	patients	patient	NOUN
admet-7	17	2	with	with	ADP
admet-7	17	3	cirrhosis	cirrhosis	NOUN
admet-7	17	4	exhibit	exhibit	VERB
admet-7	17	5	a	a	DET
admet-7	17	6	high	high	ADJ
admet-7	17	7	probability	probability	NOUN
admet-7	17	8	of	of	ADP
admet-7	17	9	developing	develop	VERB
admet-7	17	10	hcc	hcc	PROPN
admet-7	18	1	[	[	X
admet-7	18	2	3	3	NUM
admet-7	18	3	]	]	PUNCT
admet-7	18	4	.	.	PUNCT
admet-7	19	1	many	many	ADJ
admet-7	19	2	factors	factor	NOUN
admet-7	19	3	can	can	AUX
admet-7	19	4	lead	lead	VERB
admet-7	19	5	to	to	ADP
admet-7	19	6	the	the	DET
admet-7	19	7	development	development	NOUN
admet-7	19	8	of	of	ADP
admet-7	19	9	cirrhosis	cirrhosis	NOUN
admet-7	19	10	.	.	PUNCT
admet-7	20	1	these	these	PRON
admet-7	20	2	include	include	VERB
admet-7	20	3	:	:	PUNCT
admet-7	20	4	infection	infection	NOUN
admet-7	20	5	with	with	ADP
admet-7	20	6	the	the	DET
admet-7	20	7	hepatitis	hepatitis	PROPN
admet-7	20	8	b	b	PROPN
admet-7	20	9	or	or	CCONJ
admet-7	20	10	hepatitis	hepatitis	NOUN
admet-7	20	11	c	c	NOUN
admet-7	20	12	viruses	virus	NOUN
admet-7	20	13	,	,	PUNCT
admet-7	20	14	alcoholism	alcoholism	NOUN
admet-7	20	15	,	,	PUNCT
admet-7	20	16	inherited	inherit	VERB
admet-7	20	17	metabolic	metabolic	NOUN
admet-7	20	18	diseases	disease	NOUN
admet-7	20	19	,	,	PUNCT
admet-7	20	20	diabetes	diabetes	NOUN
admet-7	20	21	and	and	CCONJ
admet-7	20	22	smoking	smoking	NOUN
admet-7	20	23	as	as	ADV
admet-7	20	24	well	well	ADV
admet-7	20	25	as	as	ADP
admet-7	20	26	exposure	exposure	NOUN
admet-7	20	27	to	to	ADP
admet-7	20	28	aflatoxins	aflatoxin	NOUN
admet-7	20	29	,	,	PUNCT
admet-7	20	30	which	which	PRON
admet-7	20	31	is	be	AUX
admet-7	20	32	a	a	DET
admet-7	20	33	group	group	NOUN
admet-7	20	34	of	of	ADP
admet-7	20	35	mycotoxins	mycotoxin	NOUN
admet-7	20	36	produced	produce	VERB
admet-7	20	37	by	by	ADP
admet-7	20	38	the	the	DET
admet-7	20	39	aspergillus	aspergillus	PROPN
admet-7	20	40	fungus	fungus	NOUN
admet-7	20	41	in	in	ADP
admet-7	20	42	foodstuffs	foodstuff	NOUN
admet-7	20	43	like	like	ADP
admet-7	20	44	corn	corn	NOUN
admet-7	20	45	and	and	CCONJ
admet-7	20	46	peanuts	peanut	NOUN
admet-7	20	47	during	during	ADP
admet-7	20	48	storage	storage	NOUN
admet-7	20	49	in	in	ADP
admet-7	20	50	warm	warm	ADJ
admet-7	20	51	,	,	PUNCT
admet-7	20	52	damp	damp	ADJ
admet-7	20	53	conditions	condition	NOUN
admet-7	20	54	[	[	X
admet-7	20	55	4	4	NUM
admet-7	20	56	-	-	SYM
admet-7	20	57	7	7	NUM
admet-7	20	58	]	]	PUNCT
admet-7	20	59	.	.	PUNCT
admet-7	21	1	doxorubicin	doxorubicin	PROPN
admet-7	21	2	was	be	AUX
admet-7	21	3	one	one	NUM
admet-7	21	4	of	of	ADP
admet-7	21	5	the	the	DET
admet-7	21	6	early	early	ADJ
admet-7	21	7	anthracyclines	anthracycline	NOUN
admet-7	21	8	,	,	PUNCT
admet-7	21	9	isolated	isolate	VERB
admet-7	21	10	from	from	ADP
admet-7	21	11	streptomyces	streptomyce	NOUN
admet-7	21	12	peucetius	peucetius	NOUN
admet-7	21	13	almost	almost	ADV
admet-7	21	14	four	four	NUM
admet-7	21	15	decades	decade	NOUN
admet-7	21	16	ago	ago	ADV
admet-7	21	17	[	[	X
admet-7	21	18	8	8	NUM
admet-7	21	19	]	]	PUNCT
admet-7	21	20	.	.	PUNCT
admet-7	22	1	it	it	PRON
admet-7	22	2	has	have	AUX
admet-7	22	3	been	be	AUX
admet-7	22	4	regarded	regard	VERB
admet-7	22	5	as	as	ADP
admet-7	22	6	one	one	NUM
admet-7	22	7	of	of	ADP
admet-7	22	8	the	the	DET
admet-7	22	9	effective	effective	ADJ
admet-7	22	10	chemotherapy	chemotherapy	NOUN
admet-7	22	11	drugs	drug	NOUN
admet-7	22	12	for	for	ADP
admet-7	22	13	cancer	cancer	NOUN
admet-7	22	14	treatment	treatment	NOUN
admet-7	22	15	[	[	X
admet-7	22	16	9	9	NUM
admet-7	22	17	]	]	PUNCT
admet-7	22	18	.	.	PUNCT
admet-7	23	1	unfortunately	unfortunately	ADV
admet-7	23	2	,	,	PUNCT
admet-7	23	3	the	the	DET
admet-7	23	4	clinical	clinical	ADJ
admet-7	23	5	uses	use	NOUN
admet-7	23	6	of	of	ADP
admet-7	23	7	this	this	DET
admet-7	23	8	drug	drug	NOUN
admet-7	23	9	are	be	AUX
admet-7	23	10	hampered	hamper	VERB
admet-7	23	11	by	by	ADP
admet-7	23	12	cumulative	cumulative	ADJ
admet-7	23	13	cardiotoxicity	cardiotoxicity	NOUN
admet-7	23	14	,	,	PUNCT
admet-7	23	15	with	with	ADP
admet-7	23	16	the	the	DET
admet-7	23	17	risk	risk	NOUN
admet-7	23	18	becoming	become	VERB
admet-7	23	19	ever	ever	ADV
admet-7	23	20	greater	great	ADJ
admet-7	23	21	at	at	ADP
admet-7	23	22	cumulative	cumulative	ADJ
admet-7	23	23	doses	dose	NOUN
admet-7	23	24	≥	≥	NUM
admet-7	23	25	550	550	NUM
admet-7	23	26	mg	mg	NUM
admet-7	23	27	/	/	SYM
admet-7	23	28	m2	m2	PROPN
admet-7	24	1	[	[	X
admet-7	24	2	10	10	NUM
admet-7	24	3	]	]	PUNCT
admet-7	24	4	.	.	PUNCT
admet-7	25	1	in	in	ADP
admet-7	25	2	hcc	hcc	PROPN
admet-7	25	3	chemotherapy	chemotherapy	PROPN
admet-7	25	4	,	,	PUNCT
admet-7	25	5	clinical	clinical	ADJ
admet-7	25	6	studies	study	NOUN
admet-7	25	7	showed	show	VERB
admet-7	25	8	that	that	SCONJ
admet-7	25	9	systemic	systemic	ADJ
admet-7	25	10	administration	administration	NOUN
admet-7	25	11	of	of	ADP
admet-7	25	12	doxorubicin	doxorubicin	PROPN
admet-7	25	13	showed	show	VERB
admet-7	25	14	limited	limited	ADJ
admet-7	25	15	clinical	clinical	ADJ
admet-7	25	16	benefits	benefit	NOUN
admet-7	25	17	.	.	PUNCT
admet-7	26	1	however	however	ADV
admet-7	26	2	,	,	PUNCT
admet-7	26	3	when	when	SCONJ
admet-7	26	4	the	the	DET
admet-7	26	5	drug	drug	NOUN
admet-7	26	6	was	be	AUX
admet-7	26	7	given	give	VERB
admet-7	26	8	by	by	ADP
admet-7	26	9	the	the	DET
admet-7	26	10	hepatic	hepatic	ADJ
admet-7	26	11	artery	artery	NOUN
admet-7	26	12	route	route	NOUN
admet-7	26	13	,	,	PUNCT
admet-7	26	14	tumour	tumour	NOUN
admet-7	26	15	shrinkage	shrinkage	NOUN
admet-7	26	16	and	and	CCONJ
admet-7	26	17	partial	partial	ADJ
admet-7	26	18	responses	response	NOUN
admet-7	26	19	were	be	AUX
admet-7	26	20	seen	see	VERB
admet-7	26	21	in	in	ADP
admet-7	26	22	30	30	NUM
admet-7	26	23	–	–	SYM
admet-7	26	24	70	70	NUM
admet-7	26	25	%	%	NOUN
admet-7	26	26	of	of	ADP
admet-7	26	27	patients	patient	NOUN
admet-7	26	28	,	,	PUNCT
admet-7	26	29	usually	usually	ADV
admet-7	26	30	associated	associate	VERB
admet-7	26	31	with	with	ADP
admet-7	26	32	some	some	DET
admet-7	26	33	form	form	NOUN
admet-7	26	34	of	of	ADP
admet-7	26	35	hepatic	hepatic	ADJ
admet-7	26	36	artery	artery	NOUN
admet-7	26	37	occluding	occlude	VERB
admet-7	26	38	agent	agent	NOUN
admet-7	26	39	[	[	X
admet-7	26	40	11	11	NUM
admet-7	26	41	]	]	PUNCT
admet-7	26	42	.	.	PUNCT
admet-7	27	1	http://www.pub.iapchem.org/ojs/index.php/admet/index	http://www.pub.iapchem.org/ojs/index.php/admet/index	PROPN
admet-7	27	2	mailto:kintam@umac.mo	mailto:kintam@umac.mo	VERB
admet-7	27	3	tam	tam	PROPN
admet-7	27	4	admet	admet	PROPN
admet-7	27	5	&	&	CCONJ
admet-7	27	6	dmpk	dmpk	PROPN
admet-7	27	7	1(3	1(3	NUM
admet-7	27	8	)	)	PUNCT
admet-7	27	9	(	(	PUNCT
admet-7	27	10	2013	2013	NUM
admet-7	27	11	)	)	PUNCT
admet-7	27	12	29	29	NUM
admet-7	27	13	-	-	SYM
admet-7	27	14	44	44	NUM
admet-7	27	15	30	30	NUM
admet-7	27	16	there	there	PRON
admet-7	27	17	are	be	VERB
admet-7	27	18	ongoing	ongoing	ADJ
admet-7	27	19	intensive	intensive	ADJ
admet-7	27	20	preclinical	preclinical	ADJ
admet-7	27	21	and	and	CCONJ
admet-7	27	22	clinical	clinical	ADJ
admet-7	27	23	efforts	effort	NOUN
admet-7	27	24	to	to	PART
admet-7	27	25	search	search	VERB
admet-7	27	26	for	for	ADP
admet-7	27	27	better	well	ADJ
admet-7	27	28	drugs	drug	NOUN
admet-7	27	29	and	and	CCONJ
admet-7	27	30	treatment	treatment	NOUN
admet-7	27	31	regimens	regimen	NOUN
admet-7	27	32	for	for	ADP
admet-7	27	33	hcc	hcc	PROPN
admet-7	27	34	.	.	PUNCT
admet-7	28	1	while	while	SCONJ
admet-7	28	2	the	the	DET
admet-7	28	3	research	research	NOUN
admet-7	28	4	continues	continue	VERB
admet-7	28	5	,	,	PUNCT
admet-7	28	6	it	it	PRON
admet-7	28	7	is	be	AUX
admet-7	28	8	valuable	valuable	ADJ
admet-7	28	9	to	to	PART
admet-7	28	10	pursue	pursue	VERB
admet-7	28	11	a	a	DET
admet-7	28	12	deeper	deep	ADJ
admet-7	28	13	understanding	understanding	NOUN
admet-7	28	14	of	of	ADP
admet-7	28	15	old	old	ADJ
admet-7	28	16	drugs	drug	NOUN
admet-7	28	17	like	like	ADP
admet-7	28	18	doxorubicin	doxorubicin	PROPN
admet-7	28	19	,	,	PUNCT
admet-7	28	20	with	with	ADP
admet-7	28	21	the	the	DET
admet-7	28	22	broad	broad	ADJ
admet-7	28	23	aims	aim	NOUN
admet-7	28	24	of	of	ADP
admet-7	28	25	identifying	identify	VERB
admet-7	28	26	and/or	and/or	CCONJ
admet-7	28	27	devising	devise	VERB
admet-7	28	28	new	new	ADJ
admet-7	28	29	strategies	strategy	NOUN
admet-7	28	30	for	for	ADP
admet-7	28	31	its	its	PRON
admet-7	28	32	better	well	ADJ
admet-7	28	33	use	use	NOUN
admet-7	28	34	in	in	ADP
admet-7	28	35	patients	patient	NOUN
admet-7	28	36	.	.	PUNCT
admet-7	29	1	in	in	ADP
admet-7	29	2	this	this	DET
admet-7	29	3	mini	mini	ADJ
admet-7	29	4	review	review	NOUN
admet-7	29	5	,	,	PUNCT
admet-7	29	6	we	we	PRON
admet-7	29	7	will	will	AUX
admet-7	29	8	first	first	ADV
admet-7	29	9	outline	outline	VERB
admet-7	29	10	the	the	DET
admet-7	29	11	treatment	treatment	NOUN
admet-7	29	12	options	option	NOUN
admet-7	29	13	for	for	ADP
admet-7	29	14	hcc	hcc	PROPN
admet-7	29	15	.	.	PUNCT
admet-7	30	1	then	then	ADV
admet-7	30	2	,	,	PUNCT
admet-7	30	3	we	we	PRON
admet-7	30	4	will	will	AUX
admet-7	30	5	briefly	briefly	ADV
admet-7	30	6	discuss	discuss	VERB
admet-7	30	7	the	the	DET
admet-7	30	8	pharmacological	pharmacological	NOUN
admet-7	30	9	,	,	PUNCT
admet-7	30	10	toxicological	toxicological	ADJ
admet-7	30	11	and	and	CCONJ
admet-7	30	12	pharmacokinetic	pharmacokinetic	ADJ
admet-7	30	13	aspects	aspect	NOUN
admet-7	30	14	of	of	ADP
admet-7	30	15	doxorubicin	doxorubicin	PROPN
admet-7	30	16	.	.	PUNCT
admet-7	31	1	finally	finally	ADV
admet-7	31	2	,	,	PUNCT
admet-7	31	3	we	we	PRON
admet-7	31	4	will	will	AUX
admet-7	31	5	review	review	VERB
admet-7	31	6	the	the	DET
admet-7	31	7	development	development	NOUN
admet-7	31	8	and	and	CCONJ
admet-7	31	9	future	future	ADJ
admet-7	31	10	directions	direction	NOUN
admet-7	31	11	of	of	ADP
admet-7	31	12	using	use	VERB
admet-7	31	13	doxorubicin	doxorubicin	PROPN
admet-7	31	14	in	in	ADP
admet-7	31	15	therapy	therapy	NOUN
admet-7	31	16	for	for	ADP
admet-7	31	17	hcc	hcc	PROPN
admet-7	31	18	.	.	PROPN
admet-7	32	1	2	2	NUM
admet-7	32	2	.	.	X
admet-7	32	3	treatment	treatment	NOUN
admet-7	32	4	options	option	NOUN
admet-7	32	5	for	for	ADP
admet-7	32	6	hepatocellular	hepatocellular	ADJ
admet-7	32	7	carcinoma	carcinoma	NOUN
admet-7	32	8	hcc	hcc	PROPN
admet-7	32	9	is	be	AUX
admet-7	32	10	often	often	ADV
admet-7	32	11	diagnosed	diagnose	VERB
admet-7	32	12	late	late	ADV
admet-7	32	13	in	in	ADP
admet-7	32	14	its	its	PRON
admet-7	32	15	course	course	NOUN
admet-7	32	16	,	,	PUNCT
admet-7	32	17	partly	partly	ADV
admet-7	32	18	because	because	SCONJ
admet-7	32	19	of	of	ADP
admet-7	32	20	the	the	DET
admet-7	32	21	lack	lack	NOUN
admet-7	32	22	of	of	ADP
admet-7	32	23	distinctive	distinctive	ADJ
admet-7	32	24	pathological	pathological	ADJ
admet-7	32	25	symptoms	symptom	NOUN
admet-7	32	26	[	[	X
admet-7	32	27	12	12	NUM
admet-7	32	28	]	]	PUNCT
admet-7	32	29	.	.	PUNCT
admet-7	33	1	as	as	ADP
admet-7	33	2	a	a	DET
admet-7	33	3	result	result	NOUN
admet-7	33	4	,	,	PUNCT
admet-7	33	5	the	the	DET
admet-7	33	6	prognosis	prognosis	NOUN
admet-7	33	7	is	be	AUX
admet-7	33	8	poor	poor	ADJ
admet-7	33	9	,	,	PUNCT
admet-7	33	10	with	with	ADP
admet-7	33	11	a	a	DET
admet-7	33	12	median	median	ADJ
admet-7	33	13	survival	survival	NOUN
admet-7	33	14	of	of	ADP
admet-7	33	15	1	1	NUM
admet-7	33	16	–	–	SYM
admet-7	33	17	8	8	NUM
admet-7	33	18	months	month	NOUN
admet-7	33	19	and	and	CCONJ
admet-7	33	20	a	a	DET
admet-7	33	21	5	5	NUM
admet-7	33	22	-	-	PUNCT
admet-7	33	23	year	year	NOUN
admet-7	33	24	survival	survival	NOUN
admet-7	33	25	rate	rate	NOUN
admet-7	33	26	of	of	ADP
admet-7	33	27	only	only	ADV
admet-7	33	28	3	3	NUM
admet-7	33	29	%	%	NOUN
admet-7	33	30	[	[	X
admet-7	33	31	13	13	NUM
admet-7	33	32	]	]	PUNCT
admet-7	33	33	.	.	PUNCT
admet-7	34	1	despite	despite	SCONJ
admet-7	34	2	the	the	DET
admet-7	34	3	progress	progress	NOUN
admet-7	34	4	in	in	ADP
admet-7	34	5	early	early	ADJ
admet-7	34	6	diagnosis	diagnosis	NOUN
admet-7	34	7	[	[	X
admet-7	34	8	14	14	NUM
admet-7	34	9	]	]	PUNCT
admet-7	34	10	,	,	PUNCT
admet-7	34	11	the	the	DET
admet-7	34	12	treatment	treatment	NOUN
admet-7	34	13	options	option	NOUN
admet-7	34	14	are	be	AUX
admet-7	34	15	limited	limited	ADJ
admet-7	34	16	.	.	PUNCT
admet-7	35	1	hepatic	hepatic	ADJ
admet-7	35	2	resection	resection	NOUN
admet-7	35	3	and	and	CCONJ
admet-7	35	4	liver	liver	NOUN
admet-7	35	5	transplantation	transplantation	NOUN
admet-7	35	6	represent	represent	VERB
admet-7	35	7	the	the	DET
admet-7	35	8	curative	curative	ADJ
admet-7	35	9	treatment	treatment	NOUN
admet-7	35	10	options	option	NOUN
admet-7	35	11	,	,	PUNCT
admet-7	35	12	offering	offer	VERB
admet-7	35	13	the	the	DET
admet-7	35	14	prospect	prospect	NOUN
admet-7	35	15	of	of	ADP
admet-7	35	16	cure	cure	NOUN
admet-7	35	17	with	with	ADP
admet-7	35	18	5	5	NUM
admet-7	35	19	-	-	PUNCT
admet-7	35	20	year	year	NOUN
admet-7	35	21	survival	survival	NOUN
admet-7	35	22	rates	rate	NOUN
admet-7	35	23	of	of	ADP
admet-7	35	24	up	up	ADP
admet-7	35	25	to	to	PART
admet-7	35	26	50	50	NUM
admet-7	36	1	[	[	X
admet-7	36	2	15,16	15,16	NUM
admet-7	36	3	]	]	PUNCT
admet-7	36	4	and	and	CCONJ
admet-7	36	5	70	70	NUM
admet-7	36	6	%	%	NOUN
admet-7	37	1	[	[	X
admet-7	37	2	17,18	17,18	X
admet-7	37	3	]	]	X
admet-7	37	4	,	,	PUNCT
admet-7	37	5	respectively	respectively	ADV
admet-7	37	6	.	.	PUNCT
admet-7	38	1	however	however	ADV
admet-7	38	2	,	,	PUNCT
admet-7	38	3	only	only	ADV
admet-7	38	4	10	10	NUM
admet-7	38	5	–	–	SYM
admet-7	38	6	20	20	NUM
admet-7	38	7	%	%	NOUN
admet-7	38	8	of	of	ADP
admet-7	38	9	patients	patient	NOUN
admet-7	38	10	are	be	AUX
admet-7	38	11	suitable	suitable	ADJ
admet-7	38	12	for	for	ADP
admet-7	38	13	surgical	surgical	ADJ
admet-7	38	14	resection	resection	NOUN
admet-7	38	15	due	due	ADP
admet-7	38	16	to	to	ADP
admet-7	38	17	the	the	DET
admet-7	38	18	burden	burden	NOUN
admet-7	38	19	of	of	ADP
admet-7	38	20	hepatic	hepatic	ADJ
admet-7	38	21	tumour	tumour	NOUN
admet-7	38	22	,	,	PUNCT
admet-7	38	23	the	the	DET
admet-7	38	24	presence	presence	NOUN
admet-7	38	25	of	of	ADP
admet-7	38	26	extrahepatic	extrahepatic	ADJ
admet-7	38	27	spread	spread	NOUN
admet-7	38	28	,	,	PUNCT
admet-7	38	29	or	or	CCONJ
admet-7	38	30	the	the	DET
admet-7	38	31	extent	extent	NOUN
admet-7	38	32	of	of	ADP
admet-7	38	33	underlying	underlie	VERB
admet-7	38	34	liver	liver	NOUN
admet-7	38	35	disease	disease	NOUN
admet-7	38	36	.	.	PUNCT
admet-7	39	1	liver	liver	NOUN
admet-7	39	2	transplantation	transplantation	NOUN
admet-7	39	3	is	be	AUX
admet-7	39	4	the	the	DET
admet-7	39	5	only	only	ADJ
admet-7	39	6	surgical	surgical	ADJ
admet-7	39	7	option	option	NOUN
admet-7	39	8	for	for	ADP
admet-7	39	9	hcc	hcc	PROPN
admet-7	39	10	patients	patient	NOUN
admet-7	39	11	with	with	ADP
admet-7	39	12	impaired	impaired	ADJ
admet-7	39	13	liver	liver	NOUN
admet-7	39	14	function	function	NOUN
admet-7	39	15	.	.	PUNCT
admet-7	40	1	in	in	ADP
admet-7	40	2	view	view	NOUN
admet-7	40	3	of	of	ADP
admet-7	40	4	the	the	DET
admet-7	40	5	severe	severe	ADJ
admet-7	40	6	shortage	shortage	NOUN
admet-7	40	7	of	of	ADP
admet-7	40	8	liver	liver	NOUN
admet-7	40	9	donors	donor	NOUN
admet-7	40	10	,	,	PUNCT
admet-7	40	11	hepatic	hepatic	ADJ
admet-7	40	12	resection	resection	NOUN
admet-7	40	13	is	be	AUX
admet-7	40	14	still	still	ADV
admet-7	40	15	regarded	regard	VERB
admet-7	40	16	as	as	ADP
admet-7	40	17	the	the	DET
admet-7	40	18	mainstay	mainstay	NOUN
admet-7	40	19	of	of	ADP
admet-7	40	20	therapy	therapy	NOUN
admet-7	40	21	in	in	ADP
admet-7	40	22	patients	patient	NOUN
admet-7	40	23	with	with	ADP
admet-7	40	24	preserved	preserve	VERB
admet-7	40	25	hepatic	hepatic	ADJ
admet-7	40	26	function	function	NOUN
admet-7	40	27	.	.	PUNCT
admet-7	41	1	for	for	ADP
admet-7	41	2	non	non	ADJ
admet-7	41	3	-	-	ADJ
admet-7	41	4	surgical	surgical	ADJ
admet-7	41	5	patients	patient	NOUN
admet-7	41	6	with	with	ADP
admet-7	41	7	early	early	ADJ
admet-7	41	8	stage	stage	NOUN
admet-7	41	9	hcc	hcc	PROPN
admet-7	41	10	,	,	PUNCT
admet-7	41	11	ablative	ablative	ADJ
admet-7	41	12	techniques	technique	NOUN
admet-7	41	13	could	could	AUX
admet-7	41	14	be	be	AUX
admet-7	41	15	beneficial	beneficial	ADJ
admet-7	41	16	.	.	PUNCT
admet-7	42	1	commonly	commonly	ADV
admet-7	42	2	used	use	VERB
admet-7	42	3	liver	liver	NOUN
admet-7	42	4	-	-	PUNCT
admet-7	42	5	directed	direct	VERB
admet-7	42	6	therapies	therapy	NOUN
admet-7	42	7	include	include	VERB
admet-7	42	8	percutaneous	percutaneous	ADJ
admet-7	42	9	ethanol	ethanol	NOUN
admet-7	42	10	injection	injection	NOUN
admet-7	42	11	and	and	CCONJ
admet-7	42	12	radiofrequency	radiofrequency	NOUN
admet-7	42	13	ablation	ablation	NOUN
admet-7	42	14	(	(	PUNCT
admet-7	42	15	see	see	VERB
admet-7	42	16	also	also	ADV
admet-7	42	17	section	section	VERB
admet-7	42	18	5.3	5.3	NUM
admet-7	42	19	)	)	PUNCT
admet-7	42	20	.	.	PUNCT
admet-7	43	1	other	other	ADJ
admet-7	43	2	investigative	investigative	ADJ
admet-7	43	3	techniques	technique	NOUN
admet-7	43	4	include	include	VERB
admet-7	43	5	percutaneous	percutaneous	ADJ
admet-7	43	6	acetic	acetic	ADJ
admet-7	43	7	acid	acid	NOUN
admet-7	43	8	injection	injection	NOUN
admet-7	43	9	[	[	X
admet-7	43	10	19	19	NUM
admet-7	43	11	]	]	PUNCT
admet-7	43	12	,	,	PUNCT
admet-7	43	13	microwave	microwave	NOUN
admet-7	43	14	coagulation	coagulation	NOUN
admet-7	43	15	[	[	X
admet-7	43	16	20	20	NUM
admet-7	43	17	]	]	PUNCT
admet-7	43	18	,	,	PUNCT
admet-7	43	19	cryoablation	cryoablation	NOUN
admet-7	44	1	[	[	X
admet-7	44	2	21	21	NUM
admet-7	44	3	]	]	PUNCT
admet-7	44	4	,	,	PUNCT
admet-7	44	5	and	and	CCONJ
admet-7	44	6	laser	laser	NOUN
admet-7	44	7	thermotherapy	thermotherapy	NOUN
admet-7	45	1	[	[	X
admet-7	45	2	22	22	NUM
admet-7	45	3	]	]	PUNCT
admet-7	45	4	.	.	PUNCT
admet-7	46	1	chemotherapy	chemotherapy	NOUN
admet-7	46	2	is	be	AUX
admet-7	46	3	often	often	ADV
admet-7	46	4	used	use	VERB
admet-7	46	5	to	to	PART
admet-7	46	6	slow	slow	VERB
admet-7	46	7	the	the	DET
admet-7	46	8	progress	progress	NOUN
admet-7	46	9	of	of	ADP
admet-7	46	10	advanced	advanced	ADJ
admet-7	46	11	liver	liver	NOUN
admet-7	46	12	cancer	cancer	NOUN
admet-7	46	13	[	[	X
admet-7	46	14	23	23	NUM
admet-7	46	15	]	]	PUNCT
admet-7	46	16	.	.	PUNCT
admet-7	47	1	typically	typically	ADV
admet-7	47	2	,	,	PUNCT
admet-7	47	3	this	this	PRON
admet-7	47	4	involves	involve	VERB
admet-7	47	5	systemic	systemic	ADJ
admet-7	47	6	administration	administration	NOUN
admet-7	47	7	(	(	PUNCT
admet-7	47	8	either	either	CCONJ
admet-7	47	9	intravenous	intravenous	ADJ
admet-7	47	10	or	or	CCONJ
admet-7	47	11	oral	oral	ADJ
admet-7	47	12	)	)	PUNCT
admet-7	47	13	of	of	ADP
admet-7	47	14	anti	anti	ADJ
admet-7	47	15	-	-	ADJ
admet-7	47	16	cancer	cancer	ADJ
admet-7	47	17	drugs	drug	NOUN
admet-7	47	18	such	such	ADJ
admet-7	47	19	as	as	ADP
admet-7	47	20	doxorubicin	doxorubicin	PROPN
admet-7	47	21	,	,	PUNCT
admet-7	47	22	5	5	NUM
admet-7	47	23	-	-	PUNCT
admet-7	47	24	fluorouracil	fluorouracil	NOUN
admet-7	47	25	,	,	PUNCT
admet-7	47	26	or	or	CCONJ
admet-7	47	27	cisplatin	cisplatin	NOUN
admet-7	47	28	.	.	PUNCT
admet-7	48	1	even	even	ADV
admet-7	48	2	these	these	DET
admet-7	48	3	drugs	drug	NOUN
admet-7	48	4	shrink	shrink	VERB
admet-7	48	5	only	only	ADV
admet-7	48	6	a	a	DET
admet-7	48	7	small	small	ADJ
admet-7	48	8	portion	portion	NOUN
admet-7	48	9	of	of	ADP
admet-7	48	10	tumours	tumour	NOUN
admet-7	48	11	and	and	CCONJ
admet-7	48	12	the	the	DET
admet-7	48	13	responses	response	NOUN
admet-7	48	14	often	often	ADV
admet-7	48	15	do	do	AUX
admet-7	48	16	not	not	PART
admet-7	48	17	last	last	VERB
admet-7	48	18	long	long	ADV
admet-7	48	19	.	.	PUNCT
admet-7	49	1	in	in	ADP
admet-7	49	2	particular	particular	ADJ
admet-7	49	3	,	,	PUNCT
admet-7	49	4	the	the	DET
admet-7	49	5	side	side	NOUN
admet-7	49	6	effects	effect	NOUN
admet-7	49	7	and	and	CCONJ
admet-7	49	8	cardiotoxicity	cardiotoxicity	NOUN
admet-7	49	9	of	of	ADP
admet-7	49	10	doxorubicin	doxorubicin	PROPN
admet-7	49	11	can	can	AUX
admet-7	49	12	limit	limit	VERB
admet-7	49	13	its	its	PRON
admet-7	49	14	routine	routine	ADJ
admet-7	49	15	use	use	NOUN
admet-7	49	16	at	at	ADP
admet-7	49	17	an	an	DET
admet-7	49	18	efficacious	efficacious	ADJ
admet-7	49	19	dose	dose	NOUN
admet-7	49	20	.	.	PUNCT
admet-7	50	1	targeted	target	VERB
admet-7	50	2	chemotherapy	chemotherapy	NOUN
admet-7	50	3	,	,	PUNCT
admet-7	50	4	represented	represent	VERB
admet-7	50	5	by	by	ADP
admet-7	50	6	newer	new	ADJ
admet-7	50	7	drugs	drug	NOUN
admet-7	50	8	such	such	ADJ
admet-7	50	9	as	as	ADP
admet-7	50	10	sorafenib	sorafenib	NOUN
admet-7	50	11	,	,	PUNCT
admet-7	50	12	has	have	AUX
admet-7	50	13	been	be	AUX
admet-7	50	14	shown	show	VERB
admet-7	50	15	to	to	PART
admet-7	50	16	slow	slow	VERB
admet-7	50	17	the	the	DET
admet-7	50	18	growth	growth	NOUN
admet-7	50	19	of	of	ADP
admet-7	50	20	advanced	advanced	ADJ
admet-7	50	21	liver	liver	NOUN
admet-7	50	22	cancer	cancer	NOUN
admet-7	50	23	and	and	CCONJ
admet-7	50	24	exhibit	exhibit	VERB
admet-7	50	25	less	less	ADV
admet-7	50	26	severe	severe	ADJ
admet-7	50	27	side	side	NOUN
admet-7	50	28	effects	effect	NOUN
admet-7	50	29	[	[	X
admet-7	50	30	24	24	NUM
admet-7	50	31	]	]	PUNCT
admet-7	50	32	.	.	PUNCT
admet-7	51	1	sorafenib	sorafenib	PROPN
admet-7	51	2	is	be	AUX
admet-7	51	3	a	a	DET
admet-7	51	4	potent	potent	ADJ
admet-7	51	5	multikinase	multikinase	NOUN
admet-7	51	6	inhibitor	inhibitor	NOUN
admet-7	51	7	with	with	ADP
admet-7	51	8	antiangiogenic	antiangiogenic	ADJ
admet-7	51	9	and	and	CCONJ
admet-7	51	10	antiproliferative	antiproliferative	NOUN
admet-7	51	11	properties	property	NOUN
admet-7	51	12	.	.	PUNCT
admet-7	52	1	it	it	PRON
admet-7	52	2	targets	target	VERB
admet-7	52	3	the	the	DET
admet-7	52	4	serine	serine	NOUN
admet-7	52	5	-	-	PUNCT
admet-7	52	6	threonine	threonine	ADJ
admet-7	52	7	kinases	kinase	NOUN
admet-7	52	8	raf-1	raf-1	ADP
admet-7	52	9	and	and	CCONJ
admet-7	52	10	b	b	X
admet-7	52	11	-	-	PUNCT
admet-7	52	12	raf	raf	PROPN
admet-7	52	13	,	,	PUNCT
admet-7	52	14	the	the	DET
admet-7	52	15	tyrosine	tyrosine	NOUN
admet-7	52	16	kinases	kinase	NOUN
admet-7	52	17	of	of	ADP
admet-7	52	18	vascular	vascular	ADJ
admet-7	52	19	endothelial	endothelial	ADJ
admet-7	52	20	growth	growth	NOUN
admet-7	52	21	factor	factor	NOUN
admet-7	52	22	receptors	receptor	NOUN
admet-7	52	23	(	(	PUNCT
admet-7	52	24	vegfr-1/2/3	vegfr-1/2/3	PROPN
admet-7	52	25	)	)	PUNCT
admet-7	52	26	as	as	ADV
admet-7	52	27	well	well	ADV
admet-7	52	28	as	as	ADP
admet-7	52	29	the	the	DET
admet-7	52	30	platelet	platelet	NOUN
admet-7	52	31	-	-	PUNCT
admet-7	52	32	derived	derive	VERB
admet-7	52	33	growth	growth	NOUN
admet-7	52	34	factor	factor	NOUN
admet-7	52	35	receptor	receptor	NOUN
admet-7	52	36	β	β	X
admet-7	52	37	(	(	PUNCT
admet-7	52	38	pdgfr	pdgfr	PROPN
admet-7	52	39	-	-	PUNCT
admet-7	52	40	β	β	NOUN
admet-7	52	41	)	)	PUNCT
admet-7	52	42	.	.	PUNCT
admet-7	53	1	cellular	cellular	ADJ
admet-7	53	2	signalling	signal	VERB
admet-7	53	3	in	in	ADP
admet-7	53	4	connection	connection	NOUN
admet-7	53	5	with	with	ADP
admet-7	53	6	raf-1	raf-1	NUM
admet-7	53	7	and	and	CCONJ
admet-7	53	8	vegf	vegf	PROPN
admet-7	53	9	plays	play	VERB
admet-7	53	10	an	an	DET
admet-7	53	11	important	important	ADJ
admet-7	53	12	role	role	NOUN
admet-7	53	13	in	in	ADP
admet-7	53	14	the	the	DET
admet-7	53	15	development	development	NOUN
admet-7	53	16	of	of	ADP
admet-7	53	17	hcc	hcc	PROPN
admet-7	54	1	[	[	X
admet-7	54	2	25	25	NUM
admet-7	54	3	]	]	PUNCT
admet-7	54	4	.	.	PUNCT
admet-7	55	1	with	with	ADP
admet-7	55	2	this	this	DET
admet-7	55	3	new	new	ADJ
admet-7	55	4	treatment	treatment	NOUN
admet-7	55	5	,	,	PUNCT
admet-7	55	6	median	median	ADJ
admet-7	55	7	survival	survival	NOUN
admet-7	55	8	and	and	CCONJ
admet-7	55	9	time	time	NOUN
admet-7	55	10	to	to	ADP
admet-7	55	11	radiologic	radiologic	ADJ
admet-7	55	12	progression	progression	NOUN
admet-7	55	13	were	be	AUX
admet-7	55	14	extended	extend	VERB
admet-7	55	15	by	by	ADP
admet-7	55	16	about	about	ADV
admet-7	55	17	3	3	NUM
admet-7	55	18	months	month	NOUN
admet-7	55	19	for	for	ADP
admet-7	55	20	patients	patient	NOUN
admet-7	55	21	with	with	ADP
admet-7	55	22	advanced	advanced	ADJ
admet-7	55	23	hcc	hcc	PROPN
admet-7	56	1	[	[	X
admet-7	56	2	25	25	NUM
admet-7	56	3	]	]	PUNCT
admet-7	56	4	.	.	PUNCT
admet-7	57	1	over	over	ADP
admet-7	57	2	the	the	DET
admet-7	57	3	years	year	NOUN
admet-7	57	4	,	,	PUNCT
admet-7	57	5	clinical	clinical	ADJ
admet-7	57	6	studies	study	NOUN
admet-7	57	7	have	have	AUX
admet-7	57	8	been	be	AUX
admet-7	57	9	carried	carry	VERB
admet-7	57	10	out	out	ADP
admet-7	57	11	to	to	PART
admet-7	57	12	broaden	broaden	VERB
admet-7	57	13	the	the	DET
admet-7	57	14	treatment	treatment	NOUN
admet-7	57	15	options	option	NOUN
admet-7	57	16	.	.	PUNCT
admet-7	58	1	these	these	PRON
admet-7	58	2	include	include	VERB
admet-7	58	3	radioembolotherapy	radioembolotherapy	PROPN
admet-7	58	4	,	,	PUNCT
admet-7	58	5	adjuvant	adjuvant	ADJ
admet-7	58	6	therapy	therapy	NOUN
admet-7	58	7	,	,	PUNCT
admet-7	58	8	and	and	CCONJ
admet-7	58	9	intra	intra	ADJ
admet-7	58	10	-	-	ADJ
admet-7	58	11	arterial	arterial	ADJ
admet-7	58	12	approaches	approach	NOUN
admet-7	58	13	[	[	X
admet-7	58	14	26,27	26,27	NUM
admet-7	58	15	]	]	PUNCT
admet-7	58	16	.	.	PUNCT
admet-7	59	1	palliative	palliative	ADJ
admet-7	59	2	therapies	therapy	NOUN
admet-7	59	3	via	via	ADP
admet-7	59	4	transarterial	transarterial	ADJ
admet-7	59	5	chemoembolization	chemoembolization	NOUN
admet-7	59	6	(	(	PUNCT
admet-7	59	7	tace	tace	NOUN
admet-7	59	8	)	)	PUNCT
admet-7	59	9	are	be	AUX
admet-7	59	10	used	use	VERB
admet-7	59	11	for	for	ADP
admet-7	59	12	liver	liver	NOUN
admet-7	59	13	cancer	cancer	NOUN
admet-7	59	14	not	not	PART
admet-7	59	15	amenable	amenable	ADJ
admet-7	59	16	to	to	ADP
admet-7	59	17	surgical	surgical	ADJ
admet-7	59	18	procedures	procedure	NOUN
admet-7	59	19	[	[	X
admet-7	59	20	28,29	28,29	NUM
admet-7	59	21	]	]	X
admet-7	59	22	.	.	PUNCT
admet-7	60	1	in	in	ADP
admet-7	60	2	the	the	DET
admet-7	60	3	next	next	ADJ
admet-7	60	4	section	section	NOUN
admet-7	60	5	(	(	PUNCT
admet-7	60	6	2.1	2.1	NUM
admet-7	60	7	)	)	PUNCT
admet-7	60	8	,	,	PUNCT
admet-7	60	9	we	we	PRON
admet-7	60	10	will	will	AUX
admet-7	60	11	briefly	briefly	ADV
admet-7	60	12	discuss	discuss	VERB
admet-7	60	13	the	the	DET
admet-7	60	14	tace	tace	NOUN
admet-7	60	15	procedure	procedure	NOUN
admet-7	60	16	.	.	PUNCT
admet-7	61	1	2.1	2.1	NUM
admet-7	61	2	.	.	PUNCT
admet-7	61	3	transarterial	transarterial	ADJ
admet-7	61	4	chemoembolization	chemoembolization	NOUN
admet-7	61	5	(	(	PUNCT
admet-7	61	6	tace	tace	NOUN
admet-7	61	7	)	)	PUNCT
admet-7	61	8	figure	figure	NOUN
admet-7	61	9	1	1	NUM
admet-7	61	10	shows	show	VERB
admet-7	61	11	a	a	DET
admet-7	61	12	schematic	schematic	ADJ
admet-7	61	13	diagram	diagram	NOUN
admet-7	61	14	of	of	ADP
admet-7	61	15	a	a	DET
admet-7	61	16	tace	tace	NOUN
admet-7	61	17	procedure	procedure	NOUN
admet-7	61	18	,	,	PUNCT
admet-7	61	19	which	which	PRON
admet-7	61	20	involves	involve	VERB
admet-7	61	21	combined	combined	ADJ
admet-7	61	22	intra	intra	ADJ
admet-7	61	23	-	-	ADJ
admet-7	61	24	arterial	arterial	ADJ
admet-7	61	25	administration	administration	NOUN
admet-7	61	26	of	of	ADP
admet-7	61	27	cytotoxic	cytotoxic	ADJ
admet-7	61	28	anticancer	anticancer	NOUN
admet-7	61	29	drug(s	drug(s	NOUN
admet-7	61	30	)	)	PUNCT
admet-7	61	31	and	and	CCONJ
admet-7	61	32	embolization	embolization	NOUN
admet-7	61	33	agent(s	agent(s	PROPN
admet-7	61	34	)	)	PUNCT
admet-7	61	35	into	into	ADP
admet-7	61	36	a	a	DET
admet-7	61	37	liver	liver	NOUN
admet-7	61	38	tumour	tumour	NOUN
admet-7	61	39	.	.	PUNCT
admet-7	62	1	admet	admet	PROPN
admet-7	62	2	&	&	CCONJ
admet-7	62	3	dmpk	dmpk	PROPN
admet-7	62	4	1(3	1(3	NUM
admet-7	62	5	)	)	PUNCT
admet-7	62	6	(	(	PUNCT
admet-7	62	7	2013	2013	NUM
admet-7	62	8	)	)	PUNCT
admet-7	62	9	29	29	NUM
admet-7	62	10	-	-	SYM
admet-7	62	11	44	44	NUM
admet-7	62	12	doxorubicin	doxorubicin	NOUN
admet-7	62	13	and	and	CCONJ
admet-7	62	14	hcc	hcc	PROPN
admet-7	62	15	doi	doi	PROPN
admet-7	62	16	:	:	PUNCT
admet-7	62	17	10.5599	10.5599	NUM
admet-7	62	18	/	/	SYM
admet-7	62	19	admet.1.3.7	admet.1.3.7	NOUN
admet-7	62	20	31	31	NUM
admet-7	62	21	figure	figure	NOUN
admet-7	62	22	1	1	NUM
admet-7	62	23	.	.	PUNCT
admet-7	63	1	schematic	schematic	ADJ
admet-7	63	2	diagrams	diagram	NOUN
admet-7	63	3	show	show	VERB
admet-7	63	4	:	:	PUNCT
admet-7	63	5	(	(	PUNCT
admet-7	63	6	a	a	X
admet-7	63	7	)	)	PUNCT
admet-7	63	8	targeted	target	VERB
admet-7	63	9	intra	intra	ADJ
admet-7	63	10	-	-	ADJ
admet-7	63	11	arterial	arterial	ADJ
admet-7	63	12	infusion	infusion	NOUN
admet-7	63	13	of	of	ADP
admet-7	63	14	anti	anti	ADJ
admet-7	63	15	-	-	ADJ
admet-7	63	16	cancer	cancer	ADJ
admet-7	63	17	drugs	drug	NOUN
admet-7	63	18	leading	lead	VERB
admet-7	63	19	to	to	ADP
admet-7	63	20	high	high	ADJ
admet-7	63	21	local	local	ADJ
admet-7	63	22	concentration	concentration	NOUN
admet-7	63	23	at	at	ADP
admet-7	63	24	the	the	DET
admet-7	63	25	cancerous	cancerous	ADJ
admet-7	63	26	mass	mass	NOUN
admet-7	63	27	,	,	PUNCT
admet-7	63	28	(	(	PUNCT
admet-7	63	29	b	b	X
admet-7	63	30	)	)	PUNCT
admet-7	63	31	the	the	DET
admet-7	63	32	infusion	infusion	NOUN
admet-7	63	33	of	of	ADP
admet-7	63	34	embolization	embolization	NOUN
admet-7	63	35	particles	particle	NOUN
admet-7	63	36	leading	lead	VERB
admet-7	63	37	to	to	ADP
admet-7	63	38	ischemia	ischemia	NOUN
admet-7	63	39	of	of	ADP
admet-7	63	40	the	the	DET
admet-7	63	41	cancerous	cancerous	ADJ
admet-7	63	42	mass	mass	NOUN
admet-7	63	43	,	,	PUNCT
admet-7	63	44	and	and	CCONJ
admet-7	63	45	(	(	PUNCT
admet-7	63	46	c	c	X
admet-7	63	47	)	)	PUNCT
admet-7	63	48	the	the	DET
admet-7	63	49	intra	intra	ADJ
admet-7	63	50	-	-	ADJ
admet-7	63	51	arterial	arterial	ADJ
admet-7	63	52	infusion	infusion	NOUN
admet-7	63	53	procedure	procedure	NOUN
admet-7	63	54	which	which	PRON
admet-7	63	55	involves	involve	VERB
admet-7	63	56	placement	placement	NOUN
admet-7	63	57	of	of	ADP
admet-7	63	58	a	a	DET
admet-7	63	59	catheter	catheter	NOUN
admet-7	63	60	through	through	ADP
admet-7	63	61	the	the	DET
admet-7	63	62	femoral	femoral	ADJ
admet-7	63	63	artery	artery	NOUN
admet-7	63	64	into	into	ADP
admet-7	63	65	a	a	DET
admet-7	63	66	branch	branch	NOUN
admet-7	63	67	of	of	ADP
admet-7	63	68	the	the	DET
admet-7	63	69	hepatic	hepatic	ADJ
admet-7	63	70	artery	artery	NOUN
admet-7	63	71	(	(	PUNCT
admet-7	63	72	anti	anti	ADJ
admet-7	63	73	-	-	ADJ
admet-7	63	74	cancer	cancer	ADJ
admet-7	63	75	drugs	drug	NOUN
admet-7	63	76	,	,	PUNCT
admet-7	63	77	embolization	embolization	NOUN
admet-7	63	78	particles	particle	NOUN
admet-7	63	79	,	,	PUNCT
admet-7	63	80	or	or	CCONJ
admet-7	63	81	drug	drug	NOUN
admet-7	63	82	eluting	eluting	NOUN
admet-7	63	83	beads	bead	NOUN
admet-7	63	84	can	can	AUX
admet-7	63	85	be	be	AUX
admet-7	63	86	delivered	deliver	VERB
admet-7	63	87	to	to	ADP
admet-7	63	88	the	the	DET
admet-7	63	89	cancerous	cancerous	ADJ
admet-7	63	90	mass	mass	NOUN
admet-7	63	91	)	)	PUNCT
admet-7	63	92	.	.	PUNCT
admet-7	64	1	a	a	DET
admet-7	64	2	multidisciplinary	multidisciplinary	ADJ
admet-7	64	3	team	team	NOUN
admet-7	64	4	consisting	consist	VERB
admet-7	64	5	of	of	ADP
admet-7	64	6	a	a	DET
admet-7	64	7	surgeon	surgeon	NOUN
admet-7	64	8	,	,	PUNCT
admet-7	64	9	clinical	clinical	ADJ
admet-7	64	10	oncologist	oncologist	NOUN
admet-7	64	11	and	and	CCONJ
admet-7	64	12	radiologist	radiologist	NOUN
admet-7	64	13	in	in	ADP
admet-7	64	14	a	a	DET
admet-7	64	15	hospital	hospital	NOUN
admet-7	64	16	usually	usually	ADV
admet-7	64	17	conduct	conduct	VERB
admet-7	64	18	the	the	DET
admet-7	64	19	procedure	procedure	NOUN
admet-7	64	20	.	.	PUNCT
admet-7	65	1	there	there	PRON
admet-7	65	2	are	be	VERB
admet-7	65	3	variants	variant	NOUN
admet-7	65	4	on	on	ADP
admet-7	65	5	these	these	DET
admet-7	65	6	transarterial	transarterial	ADJ
admet-7	65	7	techniques	technique	NOUN
admet-7	65	8	,	,	PUNCT
admet-7	65	9	which	which	PRON
admet-7	65	10	are	be	AUX
admet-7	65	11	dependent	dependent	ADJ
admet-7	65	12	on	on	ADP
admet-7	65	13	the	the	DET
admet-7	65	14	experience	experience	NOUN
admet-7	65	15	of	of	ADP
admet-7	65	16	the	the	DET
admet-7	65	17	clinical	clinical	ADJ
admet-7	65	18	specialists	specialist	NOUN
admet-7	65	19	and	and	CCONJ
admet-7	65	20	the	the	DET
admet-7	65	21	particular	particular	ADJ
admet-7	65	22	treatment	treatment	NOUN
admet-7	65	23	protocols	protocol	NOUN
admet-7	65	24	of	of	ADP
admet-7	65	25	the	the	DET
admet-7	65	26	hospital	hospital	NOUN
admet-7	65	27	.	.	PUNCT
admet-7	66	1	the	the	DET
admet-7	66	2	simplest	simple	ADJ
admet-7	66	3	form	form	NOUN
admet-7	66	4	of	of	ADP
admet-7	66	5	transarterial	transarterial	ADJ
admet-7	66	6	chemoembolization	chemoembolization	NOUN
admet-7	66	7	(	(	PUNCT
admet-7	66	8	tace	tace	NOUN
admet-7	66	9	)	)	PUNCT
admet-7	66	10	involves	involve	VERB
admet-7	66	11	a	a	DET
admet-7	66	12	2	2	NUM
admet-7	66	13	-	-	PUNCT
admet-7	66	14	step	step	NOUN
admet-7	66	15	process	process	NOUN
admet-7	66	16	,	,	PUNCT
admet-7	66	17	namely	namely	ADV
admet-7	66	18	,	,	PUNCT
admet-7	66	19	(	(	PUNCT
admet-7	66	20	1	1	X
admet-7	66	21	)	)	PUNCT
admet-7	66	22	intra	intra	ADJ
admet-7	66	23	-	-	ADJ
admet-7	66	24	arterial	arterial	ADJ
admet-7	66	25	administration	administration	NOUN
admet-7	66	26	of	of	ADP
admet-7	66	27	chemotherapeutic	chemotherapeutic	ADJ
admet-7	66	28	agents	agent	NOUN
admet-7	66	29	into	into	ADP
admet-7	66	30	the	the	DET
admet-7	66	31	tumour	tumour	NOUN
admet-7	66	32	-	-	PUNCT
admet-7	66	33	feeding	feed	VERB
admet-7	66	34	artery	artery	NOUN
admet-7	66	35	via	via	ADP
admet-7	66	36	an	an	DET
admet-7	66	37	intra	intra	ADJ
admet-7	66	38	-	-	ADJ
admet-7	66	39	arterially	arterially	ADV
admet-7	66	40	inserted	insert	VERB
admet-7	66	41	catheter	catheter	NOUN
admet-7	66	42	,	,	PUNCT
admet-7	66	43	and	and	CCONJ
admet-7	66	44	(	(	PUNCT
admet-7	66	45	2	2	X
admet-7	66	46	)	)	PUNCT
admet-7	66	47	selective	selective	ADJ
admet-7	66	48	embolization	embolization	NOUN
admet-7	66	49	of	of	ADP
admet-7	66	50	the	the	DET
admet-7	66	51	tumour	tumour	NOUN
admet-7	66	52	-	-	PUNCT
admet-7	66	53	feeding	feed	VERB
admet-7	66	54	artery	artery	NOUN
admet-7	66	55	.	.	PUNCT
admet-7	67	1	some	some	DET
admet-7	67	2	investigators	investigator	NOUN
admet-7	67	3	refer	refer	VERB
admet-7	67	4	to	to	ADP
admet-7	67	5	this	this	DET
admet-7	67	6	approach	approach	NOUN
admet-7	67	7	as	as	ADP
admet-7	67	8	conventional	conventional	ADJ
admet-7	67	9	tace	tace	NOUN
admet-7	67	10	.	.	PUNCT
admet-7	68	1	the	the	DET
admet-7	68	2	liver	liver	NOUN
admet-7	68	3	has	have	VERB
admet-7	68	4	a	a	DET
admet-7	68	5	unique	unique	ADJ
admet-7	68	6	dual	dual	ADJ
admet-7	68	7	blood	blood	NOUN
admet-7	68	8	supply	supply	NOUN
admet-7	68	9	from	from	ADP
admet-7	68	10	both	both	CCONJ
admet-7	68	11	the	the	DET
admet-7	68	12	portal	portal	ADJ
admet-7	68	13	vein	vein	VERB
admet-7	68	14	and	and	CCONJ
admet-7	68	15	the	the	DET
admet-7	68	16	hepatic	hepatic	ADJ
admet-7	68	17	artery	artery	NOUN
admet-7	68	18	.	.	PUNCT
admet-7	69	1	the	the	DET
admet-7	69	2	normal	normal	ADJ
admet-7	69	3	parenchyma	parenchyma	NOUN
admet-7	69	4	of	of	ADP
admet-7	69	5	the	the	DET
admet-7	69	6	liver	liver	NOUN
admet-7	69	7	receives	receive	VERB
admet-7	69	8	two	two	NUM
admet-7	69	9	-	-	PUNCT
admet-7	69	10	thirds	third	NOUN
admet-7	69	11	of	of	ADP
admet-7	69	12	its	its	PRON
admet-7	69	13	necessary	necessary	ADJ
admet-7	69	14	blood	blood	NOUN
admet-7	69	15	supply	supply	NOUN
admet-7	69	16	from	from	ADP
admet-7	69	17	the	the	DET
admet-7	69	18	portal	portal	ADJ
admet-7	69	19	vein	vein	VERB
admet-7	69	20	and	and	CCONJ
admet-7	69	21	receives	receive	VERB
admet-7	69	22	the	the	DET
admet-7	69	23	remaining	remain	VERB
admet-7	69	24	one	one	NUM
admet-7	69	25	-	-	PUNCT
admet-7	69	26	third	third	NOUN
admet-7	69	27	from	from	ADP
admet-7	69	28	the	the	DET
admet-7	69	29	hepatic	hepatic	ADJ
admet-7	69	30	artery	artery	NOUN
admet-7	69	31	.	.	PUNCT
admet-7	70	1	hypervascular	hypervascular	ADJ
admet-7	70	2	tumours	tumour	NOUN
admet-7	70	3	such	such	ADJ
admet-7	70	4	as	as	ADP
admet-7	70	5	hepatocellular	hepatocellular	ADJ
admet-7	70	6	carcinomas	carcinoma	NOUN
admet-7	70	7	(	(	PUNCT
admet-7	70	8	hccs	hccs	NOUN
admet-7	70	9	)	)	PUNCT
admet-7	70	10	receive	receive	VERB
admet-7	70	11	their	their	PRON
admet-7	70	12	blood	blood	NOUN
admet-7	70	13	supply	supply	NOUN
admet-7	70	14	mainly	mainly	ADV
admet-7	70	15	from	from	ADP
admet-7	70	16	the	the	DET
admet-7	70	17	hepatic	hepatic	ADJ
admet-7	70	18	artery	artery	NOUN
admet-7	71	1	[	[	X
admet-7	71	2	30,31	30,31	NOUN
admet-7	71	3	]	]	PUNCT
admet-7	71	4	.	.	PUNCT
admet-7	72	1	thus	thus	ADV
admet-7	72	2	,	,	PUNCT
admet-7	72	3	intra	intra	ADJ
admet-7	72	4	-	-	ADJ
admet-7	72	5	arterial	arterial	ADJ
admet-7	72	6	infusion	infusion	NOUN
admet-7	72	7	of	of	ADP
admet-7	72	8	a	a	DET
admet-7	72	9	cytotoxic	cytotoxic	ADJ
admet-7	72	10	anticancer	anticancer	NOUN
admet-7	72	11	drug	drug	NOUN
admet-7	72	12	(	(	PUNCT
admet-7	72	13	see	see	VERB
admet-7	72	14	section	section	NOUN
admet-7	72	15	2.2	2.2	NUM
admet-7	72	16	)	)	PUNCT
admet-7	72	17	with	with	ADP
admet-7	72	18	a	a	DET
admet-7	72	19	viscous	viscous	ADJ
admet-7	72	20	oily	oily	ADJ
admet-7	72	21	material	material	NOUN
admet-7	72	22	,	,	PUNCT
admet-7	72	23	lipiodol	lipiodol	NOUN
admet-7	72	24	,	,	PUNCT
admet-7	72	25	followed	follow	VERB
admet-7	72	26	by	by	ADP
admet-7	72	27	embolization	embolization	NOUN
admet-7	72	28	of	of	ADP
admet-7	72	29	the	the	DET
admet-7	72	30	artery	artery	NOUN
admet-7	72	31	with	with	ADP
admet-7	72	32	embolic	embolic	PROPN
admet-7	72	33	agent(s	agent(s	PROPN
admet-7	72	34	)	)	PUNCT
admet-7	72	35	which	which	PRON
admet-7	72	36	themselves	themselves	PRON
admet-7	72	37	will	will	AUX
admet-7	72	38	occlude	occlude	VERB
admet-7	72	39	the	the	DET
admet-7	72	40	arterial	arterial	ADJ
admet-7	72	41	blood	blood	NOUN
admet-7	72	42	supply	supply	NOUN
admet-7	72	43	to	to	ADP
admet-7	72	44	the	the	DET
admet-7	72	45	tumour	tumour	NOUN
admet-7	72	46	,	,	PUNCT
admet-7	72	47	cause	cause	VERB
admet-7	72	48	an	an	DET
admet-7	72	49	infarct	infarct	NOUN
admet-7	72	50	and	and	CCONJ
admet-7	72	51	subsequent	subsequent	ADJ
admet-7	72	52	necrosis	necrosis	NOUN
admet-7	72	53	of	of	ADP
admet-7	72	54	the	the	DET
admet-7	72	55	tumour	tumour	NOUN
admet-7	72	56	.	.	PUNCT
admet-7	73	1	embolic	embolic	PROPN
admet-7	73	2	agents	agent	NOUN
admet-7	73	3	commonly	commonly	ADV
admet-7	73	4	used	use	VERB
admet-7	73	5	in	in	ADP
admet-7	73	6	tace	tace	NOUN
admet-7	73	7	procedure	procedure	NOUN
admet-7	73	8	include	include	VERB
admet-7	73	9	gelatin	gelatin	NOUN
admet-7	73	10	sponge	sponge	NOUN
admet-7	73	11	,	,	PUNCT
admet-7	73	12	polyvinyl	polyvinyl	NOUN
admet-7	73	13	alcohol	alcohol	NOUN
admet-7	73	14	(	(	PUNCT
admet-7	73	15	pva	pva	NOUN
admet-7	73	16	)	)	PUNCT
admet-7	73	17	particles	particle	NOUN
admet-7	73	18	,	,	PUNCT
admet-7	73	19	and	and	CCONJ
admet-7	73	20	degradable	degradable	ADJ
admet-7	73	21	starch	starch	NOUN
admet-7	73	22	microspheres	microsphere	NOUN
admet-7	73	23	.	.	PUNCT
admet-7	74	1	tace	tace	NOUN
admet-7	74	2	treatment	treatment	NOUN
admet-7	74	3	for	for	ADP
admet-7	74	4	liver	liver	NOUN
admet-7	74	5	malignance	malignance	NOUN
admet-7	74	6	can	can	AUX
admet-7	74	7	induce	induce	VERB
admet-7	74	8	extensive	extensive	ADJ
admet-7	74	9	tumour	tumour	NOUN
admet-7	74	10	necrosis	necrosis	NOUN
admet-7	74	11	in	in	ADP
admet-7	74	12	most	most	ADJ
admet-7	74	13	patients	patient	NOUN
admet-7	74	14	.	.	PUNCT
admet-7	75	1	however	however	ADV
admet-7	75	2	,	,	PUNCT
admet-7	75	3	the	the	DET
admet-7	75	4	ability	ability	NOUN
admet-7	75	5	of	of	ADP
admet-7	75	6	tace	tace	NOUN
admet-7	75	7	to	to	PART
admet-7	75	8	induce	induce	VERB
admet-7	75	9	tumour	tumour	NOUN
admet-7	75	10	necrosis	necrosis	NOUN
admet-7	75	11	does	do	AUX
admet-7	75	12	not	not	PART
admet-7	75	13	necessarily	necessarily	ADV
admet-7	75	14	mean	mean	VERB
admet-7	75	15	longer	long	ADJ
admet-7	75	16	survival	survival	NOUN
admet-7	75	17	rates	rate	NOUN
admet-7	75	18	for	for	ADP
admet-7	75	19	hcc	hcc	PROPN
admet-7	75	20	patients	patient	NOUN
admet-7	75	21	.	.	PUNCT
admet-7	76	1	almost	almost	ADV
admet-7	76	2	70	70	NUM
admet-7	76	3	–	–	SYM
admet-7	76	4	80	80	NUM
admet-7	76	5	%	%	NOUN
admet-7	76	6	of	of	ADP
admet-7	76	7	patients	patient	NOUN
admet-7	76	8	treated	treat	VERB
admet-7	76	9	with	with	ADP
admet-7	76	10	tace	tace	NOUN
admet-7	76	11	die	die	NOUN
admet-7	76	12	due	due	ADP
admet-7	76	13	to	to	ADP
admet-7	76	14	tumour	tumour	NOUN
admet-7	76	15	progression	progression	NOUN
admet-7	76	16	during	during	ADP
admet-7	76	17	follow	follow	NOUN
admet-7	76	18	-	-	PUNCT
admet-7	76	19	up	up	NOUN
admet-7	76	20	because	because	SCONJ
admet-7	76	21	of	of	ADP
admet-7	76	22	the	the	DET
admet-7	76	23	eventual	eventual	ADJ
admet-7	76	24	re	re	NOUN
admet-7	76	25	-	-	NOUN
admet-7	76	26	growth	growth	NOUN
admet-7	76	27	of	of	ADP
admet-7	76	28	residual	residual	ADJ
admet-7	76	29	tumour	tumour	NOUN
admet-7	76	30	cells	cell	NOUN
admet-7	76	31	after	after	ADP
admet-7	76	32	regaining	regain	VERB
admet-7	76	33	a	a	DET
admet-7	76	34	vascular	vascular	ADJ
admet-7	76	35	supply	supply	NOUN
admet-7	76	36	or	or	CCONJ
admet-7	76	37	remote	remote	ADJ
admet-7	76	38	recurrence	recurrence	NOUN
admet-7	76	39	of	of	ADP
admet-7	76	40	tumours	tumour	NOUN
admet-7	76	41	in	in	ADP
admet-7	76	42	other	other	ADJ
admet-7	76	43	areas	area	NOUN
admet-7	76	44	of	of	ADP
admet-7	76	45	the	the	DET
admet-7	76	46	liver	liver	NOUN
admet-7	76	47	[	[	X
admet-7	76	48	32	32	NUM
admet-7	76	49	]	]	PUNCT
admet-7	76	50	.	.	PUNCT
admet-7	77	1	tace	tace	NOUN
admet-7	77	2	is	be	AUX
admet-7	77	3	not	not	PART
admet-7	77	4	indicated	indicate	VERB
admet-7	77	5	for	for	ADP
admet-7	77	6	curative	curative	ADJ
admet-7	77	7	therapies	therapy	NOUN
admet-7	77	8	.	.	PUNCT
admet-7	78	1	in	in	ADP
admet-7	78	2	2002	2002	NUM
admet-7	78	3	,	,	PUNCT
admet-7	78	4	two	two	NUM
admet-7	78	5	randomized	randomize	VERB
admet-7	78	6	controlled	control	VERB
admet-7	78	7	trials	trial	NOUN
admet-7	78	8	(	(	PUNCT
admet-7	78	9	rcts	rct	NOUN
admet-7	78	10	)	)	PUNCT
admet-7	78	11	from	from	ADP
admet-7	78	12	hong	hong	PROPN
admet-7	78	13	kong	kong	PROPN
admet-7	79	1	[	[	X
admet-7	79	2	33	33	NUM
admet-7	79	3	]	]	PUNCT
admet-7	79	4	and	and	CCONJ
admet-7	79	5	spain	spain	PROPN
admet-7	80	1	[	[	X
admet-7	80	2	34	34	NUM
admet-7	80	3	]	]	PUNCT
admet-7	80	4	showed	show	VERB
admet-7	80	5	the	the	DET
admet-7	80	6	survival	survival	NOUN
admet-7	80	7	benefits	benefit	NOUN
admet-7	80	8	of	of	ADP
admet-7	80	9	tace	tace	NOUN
admet-7	80	10	compared	compare	VERB
admet-7	80	11	to	to	ADP
admet-7	80	12	the	the	DET
admet-7	80	13	best	good	ADJ
admet-7	80	14	conservative	conservative	ADJ
admet-7	80	15	treatment	treatment	NOUN
admet-7	80	16	.	.	PUNCT
admet-7	81	1	these	these	DET
admet-7	81	2	rcts	rct	NOUN
admet-7	81	3	were	be	AUX
admet-7	81	4	followed	follow	VERB
admet-7	81	5	by	by	ADP
admet-7	81	6	cumulative	cumulative	ADJ
admet-7	81	7	metatam	metatam	NOUN
admet-7	81	8	admet	admet	PROPN
admet-7	81	9	&	&	CCONJ
admet-7	81	10	dmpk	dmpk	PROPN
admet-7	81	11	1(3	1(3	NUM
admet-7	81	12	)	)	PUNCT
admet-7	81	13	(	(	PUNCT
admet-7	81	14	2013	2013	NUM
admet-7	81	15	)	)	PUNCT
admet-7	81	16	29	29	NUM
admet-7	81	17	-	-	SYM
admet-7	81	18	44	44	NUM
admet-7	81	19	32	32	NUM
admet-7	81	20	analyses	analysis	NOUN
admet-7	81	21	that	that	PRON
admet-7	81	22	included	include	VERB
admet-7	81	23	all	all	DET
admet-7	81	24	published	publish	VERB
admet-7	81	25	rcts	rct	NOUN
admet-7	81	26	[	[	X
admet-7	81	27	35,36	35,36	NUM
admet-7	81	28	]	]	PUNCT
admet-7	81	29	,	,	PUNCT
admet-7	81	30	showing	show	VERB
admet-7	81	31	that	that	SCONJ
admet-7	81	32	tace	tace	NOUN
admet-7	81	33	significantly	significantly	ADV
admet-7	81	34	reduced	reduce	VERB
admet-7	81	35	the	the	DET
admet-7	81	36	overall	overall	ADJ
admet-7	81	37	2	2	NUM
admet-7	81	38	-	-	PUNCT
admet-7	81	39	year	year	NOUN
admet-7	81	40	mortality	mortality	NOUN
admet-7	81	41	rate	rate	NOUN
admet-7	81	42	compared	compare	VERB
admet-7	81	43	to	to	AUX
admet-7	81	44	control	control	VERB
admet-7	81	45	patients	patient	NOUN
admet-7	81	46	who	who	PRON
admet-7	81	47	received	receive	VERB
admet-7	81	48	conservative	conservative	ADJ
admet-7	81	49	or	or	CCONJ
admet-7	81	50	inactive	inactive	ADJ
admet-7	81	51	treatments	treatment	NOUN
admet-7	81	52	.	.	PUNCT
admet-7	82	1	2.2	2.2	NUM
admet-7	82	2	.	.	PUNCT
admet-7	83	1	cytotoxic	cytotoxic	ADJ
admet-7	83	2	anticancer	anticancer	NOUN
admet-7	83	3	drugs	drug	NOUN
admet-7	83	4	in	in	ADP
admet-7	83	5	tace	tace	NOUN
admet-7	83	6	,	,	PUNCT
admet-7	83	7	the	the	DET
admet-7	83	8	most	most	ADV
admet-7	83	9	common	common	ADJ
admet-7	83	10	cytotoxic	cytotoxic	ADJ
admet-7	83	11	drugs	drug	NOUN
admet-7	83	12	are	be	AUX
admet-7	83	13	doxorubicin	doxorubicin	PROPN
admet-7	83	14	,	,	PUNCT
admet-7	83	15	followed	follow	VERB
admet-7	83	16	by	by	ADP
admet-7	83	17	cisplatin	cisplatin	NOUN
admet-7	83	18	,	,	PUNCT
admet-7	83	19	epi	epi	X
admet-7	83	20	/	/	SYM
admet-7	83	21	doxorubicin	doxorubicin	PROPN
admet-7	83	22	,	,	PUNCT
admet-7	83	23	mitoxantrone	mitoxantrone	NOUN
admet-7	83	24	and	and	CCONJ
admet-7	83	25	mitomycin	mitomycin	PROPN
admet-7	83	26	c.	c.	PROPN
admet-7	83	27	the	the	DET
admet-7	83	28	dose	dose	NOUN
admet-7	83	29	of	of	ADP
admet-7	83	30	the	the	DET
admet-7	83	31	cytotoxic	cytotoxic	ADJ
admet-7	83	32	drug	drug	NOUN
admet-7	83	33	given	give	VERB
admet-7	83	34	depends	depend	VERB
admet-7	83	35	on	on	ADP
admet-7	83	36	the	the	DET
admet-7	83	37	size	size	NOUN
admet-7	83	38	of	of	ADP
admet-7	83	39	the	the	DET
admet-7	83	40	tumour	tumour	NOUN
admet-7	83	41	,	,	PUNCT
admet-7	83	42	the	the	DET
admet-7	83	43	position	position	NOUN
admet-7	83	44	of	of	ADP
admet-7	83	45	the	the	DET
admet-7	83	46	catheter	catheter	NOUN
admet-7	83	47	,	,	PUNCT
admet-7	83	48	the	the	DET
admet-7	83	49	patient	patient	NOUN
admet-7	83	50	’s	’s	PART
admet-7	83	51	liver	liver	NOUN
admet-7	83	52	function	function	NOUN
admet-7	83	53	,	,	PUNCT
admet-7	83	54	and	and	CCONJ
admet-7	83	55	the	the	DET
admet-7	83	56	response	response	NOUN
admet-7	83	57	to	to	ADP
admet-7	83	58	previous	previous	ADJ
admet-7	83	59	courses	course	NOUN
admet-7	83	60	of	of	ADP
admet-7	83	61	tace	tace	NOUN
admet-7	83	62	,	,	PUNCT
admet-7	83	63	if	if	SCONJ
admet-7	83	64	any	any	PRON
admet-7	83	65	.	.	PUNCT
admet-7	84	1	however	however	ADV
admet-7	84	2	,	,	PUNCT
admet-7	84	3	the	the	DET
admet-7	84	4	criteria	criterion	NOUN
admet-7	84	5	for	for	ADP
admet-7	84	6	determining	determine	VERB
admet-7	84	7	the	the	DET
admet-7	84	8	dosages	dosage	NOUN
admet-7	84	9	of	of	ADP
admet-7	84	10	chemotherapeutic	chemotherapeutic	ADJ
admet-7	84	11	agents	agent	NOUN
admet-7	84	12	are	be	AUX
admet-7	84	13	variable	variable	ADJ
admet-7	84	14	and	and	CCONJ
admet-7	84	15	not	not	PART
admet-7	84	16	standardized	standardize	VERB
admet-7	84	17	:	:	PUNCT
admet-7	84	18	some	some	DET
admet-7	84	19	clinicians	clinician	NOUN
admet-7	84	20	prefer	prefer	VERB
admet-7	84	21	to	to	PART
admet-7	84	22	factor	factor	VERB
admet-7	84	23	in	in	ADP
admet-7	84	24	the	the	DET
admet-7	84	25	patient	patient	NOUN
admet-7	84	26	's	's	PART
admet-7	84	27	body	body	NOUN
admet-7	84	28	surface	surface	NOUN
admet-7	84	29	area	area	NOUN
admet-7	84	30	,	,	PUNCT
admet-7	84	31	weight	weight	NOUN
admet-7	84	32	,	,	PUNCT
admet-7	84	33	tumour	tumour	NOUN
admet-7	84	34	burden	burden	NOUN
admet-7	84	35	or	or	CCONJ
admet-7	84	36	bilirubin	bilirubin	NOUN
admet-7	84	37	level	level	NOUN
admet-7	84	38	,	,	PUNCT
admet-7	84	39	while	while	SCONJ
admet-7	84	40	others	other	NOUN
admet-7	84	41	use	use	VERB
admet-7	84	42	a	a	DET
admet-7	84	43	fixed	fix	VERB
admet-7	84	44	dose	dose	NOUN
admet-7	84	45	.	.	PUNCT
admet-7	85	1	in	in	ADP
admet-7	85	2	some	some	DET
admet-7	85	3	early	early	ADJ
admet-7	85	4	studies	study	NOUN
admet-7	85	5	,	,	PUNCT
admet-7	85	6	40	40	NUM
admet-7	85	7	–	–	SYM
admet-7	85	8	100	100	NUM
admet-7	85	9	mg	mg	ADP
admet-7	85	10	of	of	ADP
admet-7	85	11	doxorubicin	doxorubicin	PROPN
admet-7	86	1	[	[	X
admet-7	86	2	37	37	NUM
admet-7	86	3	]	]	PUNCT
admet-7	86	4	or	or	CCONJ
admet-7	86	5	10	10	NUM
admet-7	86	6	–	–	SYM
admet-7	86	7	70	70	NUM
admet-7	86	8	mg	mg	ADP
admet-7	86	9	of	of	ADP
admet-7	86	10	cisplatin	cisplatin	NOUN
admet-7	86	11	[	[	X
admet-7	86	12	38	38	NUM
admet-7	86	13	]	]	PUNCT
admet-7	86	14	per	per	ADP
admet-7	86	15	session	session	NOUN
admet-7	86	16	was	be	AUX
admet-7	86	17	used	use	VERB
admet-7	86	18	.	.	PUNCT
admet-7	87	1	a	a	DET
admet-7	87	2	few	few	ADJ
admet-7	87	3	randomized	randomized	ADJ
admet-7	87	4	controlled	control	VERB
admet-7	87	5	trials	trial	NOUN
admet-7	87	6	(	(	PUNCT
admet-7	87	7	rcts	rct	NOUN
admet-7	87	8	)	)	PUNCT
admet-7	87	9	failed	fail	VERB
admet-7	87	10	to	to	PART
admet-7	87	11	show	show	VERB
admet-7	87	12	significant	significant	ADJ
admet-7	87	13	differences	difference	NOUN
admet-7	87	14	in	in	ADP
admet-7	87	15	survival	survival	NOUN
admet-7	87	16	between	between	ADP
admet-7	87	17	the	the	DET
admet-7	87	18	use	use	NOUN
admet-7	87	19	of	of	ADP
admet-7	87	20	doxorubicin	doxorubicin	PROPN
admet-7	87	21	and	and	CCONJ
admet-7	87	22	other	other	ADJ
admet-7	87	23	drugs	drug	NOUN
admet-7	87	24	such	such	ADJ
admet-7	87	25	as	as	ADP
admet-7	87	26	cisplatin	cisplatin	NOUN
admet-7	87	27	or	or	CCONJ
admet-7	87	28	epirubicin	epirubicin	VERB
admet-7	87	29	and	and	CCONJ
admet-7	87	30	,	,	PUNCT
admet-7	87	31	to	to	ADP
admet-7	87	32	date	date	NOUN
admet-7	87	33	,	,	PUNCT
admet-7	87	34	there	there	PRON
admet-7	87	35	is	be	VERB
admet-7	87	36	no	no	DET
admet-7	87	37	evidence	evidence	NOUN
admet-7	87	38	of	of	ADP
admet-7	87	39	the	the	DET
admet-7	87	40	superiority	superiority	NOUN
admet-7	87	41	of	of	ADP
admet-7	87	42	any	any	DET
admet-7	87	43	single	single	ADJ
admet-7	87	44	chemotherapeutic	chemotherapeutic	ADJ
admet-7	87	45	agent	agent	NOUN
admet-7	87	46	over	over	ADP
admet-7	87	47	other	other	ADJ
admet-7	87	48	drugs	drug	NOUN
admet-7	87	49	or	or	CCONJ
admet-7	87	50	for	for	ADP
admet-7	87	51	mono	mono	NOUN
admet-7	87	52	-	-	PUNCT
admet-7	87	53	drug	drug	NOUN
admet-7	87	54	chemotherapy	chemotherapy	NOUN
admet-7	87	55	versus	versus	ADP
admet-7	87	56	combination	combination	NOUN
admet-7	87	57	chemotherapy	chemotherapy	NOUN
admet-7	87	58	.	.	PUNCT
admet-7	88	1	in	in	ADP
admet-7	88	2	the	the	DET
admet-7	88	3	united	united	PROPN
admet-7	88	4	states	states	PROPN
admet-7	88	5	,	,	PUNCT
admet-7	88	6	the	the	DET
admet-7	88	7	most	most	ADV
admet-7	88	8	common	common	ADJ
admet-7	88	9	combination	combination	NOUN
admet-7	88	10	of	of	ADP
admet-7	88	11	chemotherapeutic	chemotherapeutic	ADJ
admet-7	88	12	agents	agent	NOUN
admet-7	88	13	includes	include	VERB
admet-7	88	14	a	a	DET
admet-7	88	15	mixture	mixture	NOUN
admet-7	88	16	of	of	ADP
admet-7	88	17	100	100	NUM
admet-7	88	18	mg	mg	PROPN
admet-7	88	19	cisplatin	cisplatin	NOUN
admet-7	88	20	,	,	PUNCT
admet-7	88	21	50	50	NUM
admet-7	88	22	mg	mg	NOUN
admet-7	88	23	doxorubicin	doxorubicin	PROPN
admet-7	88	24	and	and	CCONJ
admet-7	88	25	10	10	NUM
admet-7	88	26	mg	mg	PROPN
admet-7	88	27	mitomycin	mitomycin	PROPN
admet-7	88	28	c.	c.	PROPN
admet-7	89	1	it	it	PRON
admet-7	89	2	should	should	AUX
admet-7	89	3	be	be	AUX
admet-7	89	4	noted	note	VERB
admet-7	89	5	that	that	SCONJ
admet-7	89	6	some	some	PRON
admet-7	89	7	of	of	ADP
admet-7	89	8	the	the	DET
admet-7	89	9	commonly	commonly	ADV
admet-7	89	10	used	use	VERB
admet-7	89	11	cytotoxic	cytotoxic	ADJ
admet-7	89	12	drugs	drug	NOUN
admet-7	89	13	in	in	ADP
admet-7	89	14	tace	tace	NOUN
admet-7	89	15	,	,	PUNCT
admet-7	89	16	such	such	ADJ
admet-7	89	17	as	as	ADP
admet-7	89	18	doxorubicin	doxorubicin	PROPN
admet-7	89	19	,	,	PUNCT
admet-7	89	20	could	could	AUX
admet-7	89	21	be	be	AUX
admet-7	89	22	infused	infuse	VERB
admet-7	89	23	directly	directly	ADV
admet-7	89	24	into	into	ADP
admet-7	89	25	the	the	DET
admet-7	89	26	systemic	systemic	ADJ
admet-7	89	27	circulation	circulation	NOUN
admet-7	89	28	for	for	ADP
admet-7	89	29	cancer	cancer	NOUN
admet-7	89	30	chemotherapy	chemotherapy	NOUN
admet-7	89	31	but	but	CCONJ
admet-7	89	32	patients	patient	NOUN
admet-7	89	33	who	who	PRON
admet-7	89	34	receive	receive	VERB
admet-7	89	35	this	this	DET
admet-7	89	36	treatment	treatment	NOUN
admet-7	89	37	may	may	AUX
admet-7	89	38	suffer	suffer	VERB
admet-7	89	39	from	from	ADP
admet-7	89	40	serious	serious	ADJ
admet-7	89	41	side	side	NOUN
admet-7	89	42	effects	effect	NOUN
admet-7	89	43	(	(	PUNCT
admet-7	89	44	e.g.	e.g.	ADV
admet-7	89	45	cardiac	cardiac	ADJ
admet-7	89	46	toxicity	toxicity	NOUN
admet-7	89	47	)	)	PUNCT
admet-7	90	1	[	[	X
admet-7	90	2	10	10	NUM
admet-7	90	3	]	]	PUNCT
admet-7	90	4	.	.	PUNCT
admet-7	91	1	moreover	moreover	ADV
admet-7	91	2	,	,	PUNCT
admet-7	91	3	efficacy	efficacy	NOUN
admet-7	91	4	could	could	AUX
admet-7	91	5	be	be	AUX
admet-7	91	6	compromised	compromise	VERB
admet-7	91	7	by	by	ADP
admet-7	91	8	suboptimal	suboptimal	ADJ
admet-7	91	9	drug	drug	NOUN
admet-7	91	10	concentration	concentration	NOUN
admet-7	91	11	at	at	ADP
admet-7	91	12	the	the	DET
admet-7	91	13	liver	liver	NOUN
admet-7	91	14	,	,	PUNCT
admet-7	91	15	since	since	SCONJ
admet-7	91	16	the	the	DET
admet-7	91	17	dose	dose	NOUN
admet-7	91	18	distribution	distribution	NOUN
admet-7	91	19	is	be	AUX
admet-7	91	20	mainly	mainly	ADV
admet-7	91	21	achieved	achieve	VERB
admet-7	91	22	via	via	ADP
admet-7	91	23	the	the	DET
admet-7	91	24	systemic	systemic	ADJ
admet-7	91	25	circulation	circulation	NOUN
admet-7	91	26	.	.	PUNCT
admet-7	92	1	indeed	indeed	ADV
admet-7	92	2	,	,	PUNCT
admet-7	92	3	the	the	DET
admet-7	92	4	local	local	ADJ
admet-7	92	5	drug	drug	NOUN
admet-7	92	6	concentration	concentration	NOUN
admet-7	92	7	could	could	AUX
admet-7	92	8	be	be	AUX
admet-7	92	9	further	far	ADV
admet-7	92	10	limited	limit	VERB
admet-7	92	11	by	by	ADP
admet-7	92	12	the	the	DET
admet-7	92	13	fact	fact	NOUN
admet-7	92	14	that	that	SCONJ
admet-7	92	15	doxorubicin	doxorubicin	PROPN
admet-7	92	16	can	can	AUX
admet-7	92	17	not	not	PART
admet-7	92	18	diffuse	diffuse	VERB
admet-7	92	19	very	very	ADV
admet-7	92	20	far	far	ADV
admet-7	92	21	through	through	ADP
admet-7	92	22	tissue	tissue	NOUN
admet-7	92	23	that	that	PRON
admet-7	92	24	is	be	AUX
admet-7	92	25	necrotic	necrotic	ADJ
admet-7	92	26	,	,	PUNCT
admet-7	92	27	and	and	CCONJ
admet-7	92	28	the	the	DET
admet-7	92	29	drug	drug	NOUN
admet-7	92	30	is	be	AUX
admet-7	92	31	not	not	PART
admet-7	92	32	carried	carry	VERB
admet-7	92	33	to	to	ADP
admet-7	92	34	the	the	DET
admet-7	92	35	site	site	NOUN
admet-7	92	36	when	when	SCONJ
admet-7	92	37	the	the	DET
admet-7	92	38	neighbouring	neighbouring	NOUN
admet-7	92	39	microvasculature	microvasculature	NOUN
admet-7	92	40	is	be	AUX
admet-7	92	41	destroyed	destroy	VERB
admet-7	92	42	[	[	PUNCT
admet-7	92	43	39	39	NUM
admet-7	92	44	]	]	PUNCT
admet-7	92	45	.	.	PUNCT
admet-7	93	1	2.3	2.3	NUM
admet-7	93	2	.	.	PUNCT
admet-7	93	3	drug	drug	NOUN
admet-7	93	4	eluting	eluting	NOUN
admet-7	93	5	beads	bead	NOUN
admet-7	93	6	more	more	ADV
admet-7	93	7	recently	recently	ADV
admet-7	93	8	,	,	PUNCT
admet-7	93	9	advances	advance	NOUN
admet-7	93	10	have	have	AUX
admet-7	93	11	been	be	AUX
admet-7	93	12	made	make	VERB
admet-7	93	13	in	in	ADP
admet-7	93	14	materials	material	NOUN
admet-7	93	15	design	design	NOUN
admet-7	93	16	,	,	PUNCT
admet-7	93	17	such	such	ADJ
admet-7	93	18	that	that	SCONJ
admet-7	93	19	the	the	DET
admet-7	93	20	embolic	embolic	ADJ
admet-7	93	21	agent	agent	NOUN
admet-7	93	22	itself	itself	PRON
admet-7	93	23	can	can	AUX
admet-7	93	24	also	also	ADV
admet-7	93	25	be	be	AUX
admet-7	93	26	a	a	DET
admet-7	93	27	drug	drug	NOUN
admet-7	93	28	carrier	carrier	NOUN
admet-7	93	29	,	,	PUNCT
admet-7	93	30	which	which	PRON
admet-7	93	31	appears	appear	VERB
admet-7	93	32	to	to	PART
admet-7	93	33	be	be	AUX
admet-7	93	34	a	a	DET
admet-7	93	35	more	more	ADV
admet-7	93	36	convenient	convenient	ADJ
admet-7	93	37	and	and	CCONJ
admet-7	93	38	efficient	efficient	ADJ
admet-7	93	39	procedure	procedure	NOUN
admet-7	93	40	.	.	PUNCT
admet-7	94	1	specifically	specifically	ADV
admet-7	94	2	,	,	PUNCT
admet-7	94	3	these	these	DET
admet-7	94	4	drugloaded	drugloade	VERB
admet-7	94	5	carriers	carrier	NOUN
admet-7	94	6	are	be	AUX
admet-7	94	7	directly	directly	ADV
admet-7	94	8	injected	inject	VERB
admet-7	94	9	intra	intra	ADJ
admet-7	94	10	-	-	ADJ
admet-7	94	11	arterially	arterially	ADV
admet-7	94	12	for	for	ADP
admet-7	94	13	the	the	DET
admet-7	94	14	treatment	treatment	NOUN
admet-7	94	15	of	of	ADP
admet-7	94	16	liver	liver	NOUN
admet-7	94	17	cancer	cancer	NOUN
admet-7	94	18	in	in	ADP
admet-7	94	19	a	a	DET
admet-7	94	20	single	single	ADJ
admet-7	94	21	operation	operation	NOUN
admet-7	94	22	.	.	PUNCT
admet-7	95	1	this	this	DET
admet-7	95	2	kind	kind	NOUN
admet-7	95	3	of	of	ADP
admet-7	95	4	drug	drug	NOUN
admet-7	95	5	carrier	carrier	NOUN
admet-7	95	6	is	be	AUX
admet-7	95	7	referred	refer	VERB
admet-7	95	8	to	to	ADP
admet-7	95	9	as	as	ADP
admet-7	95	10	a	a	DET
admet-7	95	11	drug	drug	NOUN
admet-7	95	12	-	-	PUNCT
admet-7	95	13	eluting	elute	VERB
admet-7	95	14	bead	bead	NOUN
admet-7	95	15	(	(	PUNCT
admet-7	95	16	deb	deb	PROPN
admet-7	95	17	)	)	PUNCT
admet-7	95	18	in	in	ADP
admet-7	95	19	the	the	DET
admet-7	95	20	literature	literature	NOUN
admet-7	95	21	.	.	PUNCT
admet-7	96	1	a	a	DET
admet-7	96	2	typical	typical	ADJ
admet-7	96	3	example	example	NOUN
admet-7	96	4	includes	include	VERB
admet-7	96	5	the	the	DET
admet-7	96	6	dc	dc	PROPN
admet-7	96	7	bead	bead	NOUN
admet-7	96	8	(	(	PUNCT
admet-7	96	9	biocompatibles	biocompatible	NOUN
admet-7	96	10	,	,	PUNCT
admet-7	96	11	surrey	surrey	NOUN
admet-7	96	12	,	,	PUNCT
admet-7	96	13	uk	uk	PROPN
admet-7	96	14	)	)	PUNCT
admet-7	96	15	,	,	PUNCT
admet-7	96	16	which	which	PRON
admet-7	96	17	has	have	AUX
admet-7	96	18	undergone	undergo	VERB
admet-7	96	19	clinical	clinical	ADJ
admet-7	96	20	investigations	investigation	NOUN
admet-7	97	1	[	[	X
admet-7	97	2	40,41	40,41	NOUN
admet-7	97	3	]	]	X
admet-7	97	4	.	.	PUNCT
admet-7	98	1	dc	dc	PROPN
admet-7	98	2	beads	bead	NOUN
admet-7	98	3	are	be	AUX
admet-7	98	4	indicated	indicate	VERB
admet-7	98	5	for	for	ADP
admet-7	98	6	the	the	DET
admet-7	98	7	treatment	treatment	NOUN
admet-7	98	8	of	of	ADP
admet-7	98	9	a	a	DET
admet-7	98	10	variety	variety	NOUN
admet-7	98	11	of	of	ADP
admet-7	98	12	malignant	malignant	ADJ
admet-7	98	13	hypervascularised	hypervascularise	VERB
admet-7	98	14	tumours	tumour	NOUN
admet-7	98	15	,	,	PUNCT
admet-7	98	16	including	include	VERB
admet-7	98	17	hcc	hcc	PROPN
admet-7	98	18	.	.	PUNCT
admet-7	99	1	it	it	PRON
admet-7	99	2	is	be	AUX
admet-7	99	3	a	a	DET
admet-7	99	4	pva	pva	NOUN
admet-7	99	5	based	base	VERB
admet-7	99	6	microspherical	microspherical	ADJ
admet-7	99	7	embolization	embolization	NOUN
admet-7	99	8	agent	agent	NOUN
admet-7	99	9	,	,	PUNCT
admet-7	99	10	prepared	prepare	VERB
admet-7	99	11	from	from	ADP
admet-7	99	12	n	n	CCONJ
admet-7	99	13	-	-	PUNCT
admet-7	99	14	acrylamidoacetaldehyde	acrylamidoacetaldehyde	NOUN
admet-7	99	15	derivatized	derivatize	VERB
admet-7	99	16	polyvinyl	polyvinyl	NOUN
admet-7	99	17	alcohol	alcohol	NOUN
admet-7	99	18	copolymerized	copolymerize	VERB
admet-7	99	19	with	with	ADP
admet-7	99	20	2	2	NUM
admet-7	99	21	-	-	PUNCT
admet-7	99	22	acrylamido-2	acrylamido-2	NUM
admet-7	99	23	-	-	PUNCT
admet-7	99	24	methylpropane	methylpropane	NOUN
admet-7	99	25	sulfonate	sulfonate	NOUN
admet-7	99	26	.	.	PUNCT
admet-7	100	1	the	the	DET
admet-7	100	2	presence	presence	NOUN
admet-7	100	3	of	of	ADP
admet-7	100	4	the	the	DET
admet-7	100	5	anionic	anionic	PROPN
admet-7	100	6	sulphonate	sulphonate	PROPN
admet-7	100	7	group	group	PROPN
admet-7	100	8	enables	enable	VERB
admet-7	100	9	the	the	DET
admet-7	100	10	sequestering	sequestering	NOUN
admet-7	100	11	of	of	ADP
admet-7	100	12	positively	positively	ADV
admet-7	100	13	charged	charge	VERB
admet-7	100	14	drugs	drug	NOUN
admet-7	100	15	,	,	PUNCT
admet-7	100	16	such	such	ADJ
admet-7	100	17	as	as	ADP
admet-7	100	18	doxorubicin	doxorubicin	PROPN
admet-7	100	19	,	,	PUNCT
admet-7	100	20	epirubicin	epirubicin	VERB
admet-7	100	21	or	or	CCONJ
admet-7	100	22	irinotecan	irinotecan	NOUN
admet-7	100	23	,	,	PUNCT
admet-7	100	24	by	by	ADP
admet-7	100	25	coulomb	coulomb	NOUN
admet-7	100	26	charge	charge	NOUN
admet-7	100	27	interactions	interaction	NOUN
admet-7	100	28	.	.	PUNCT
admet-7	101	1	the	the	DET
admet-7	101	2	drug	drug	NOUN
admet-7	101	3	is	be	AUX
admet-7	101	4	slowly	slowly	ADV
admet-7	101	5	released	release	VERB
admet-7	101	6	from	from	ADP
admet-7	101	7	the	the	DET
admet-7	101	8	beads	bead	NOUN
admet-7	101	9	at	at	ADP
admet-7	101	10	the	the	DET
admet-7	101	11	site	site	NOUN
admet-7	101	12	of	of	ADP
admet-7	101	13	administration	administration	NOUN
admet-7	101	14	.	.	PUNCT
admet-7	102	1	in	in	ADP
admet-7	102	2	particular	particular	ADJ
admet-7	102	3	,	,	PUNCT
admet-7	102	4	the	the	DET
admet-7	102	5	interventional	interventional	ADJ
admet-7	102	6	procedure	procedure	NOUN
admet-7	102	7	is	be	AUX
admet-7	102	8	greatly	greatly	ADV
admet-7	102	9	simplified	simplify	VERB
admet-7	102	10	as	as	SCONJ
admet-7	102	11	the	the	DET
admet-7	102	12	drug	drug	NOUN
admet-7	102	13	(	(	PUNCT
admet-7	102	14	e.g.	e.g.	ADV
admet-7	102	15	doxorubicin	doxorubicin	PROPN
admet-7	102	16	)	)	PUNCT
admet-7	102	17	and	and	CCONJ
admet-7	102	18	the	the	DET
admet-7	102	19	embolizing	embolize	VERB
admet-7	102	20	device	device	NOUN
admet-7	102	21	(	(	PUNCT
admet-7	102	22	the	the	DET
admet-7	102	23	sulfonate	sulfonate	NOUN
admet-7	102	24	-	-	PUNCT
admet-7	102	25	modified	modify	VERB
admet-7	102	26	pva	pva	NOUN
admet-7	102	27	bead	bead	NOUN
admet-7	102	28	)	)	PUNCT
admet-7	102	29	are	be	AUX
admet-7	102	30	delivered	deliver	VERB
admet-7	102	31	at	at	ADP
admet-7	102	32	the	the	DET
admet-7	102	33	same	same	ADJ
admet-7	102	34	time	time	NOUN
admet-7	102	35	,	,	PUNCT
admet-7	102	36	which	which	PRON
admet-7	102	37	greatly	greatly	ADV
admet-7	102	38	facilitates	facilitate	VERB
admet-7	102	39	the	the	DET
admet-7	102	40	local	local	ADJ
admet-7	102	41	and	and	CCONJ
admet-7	102	42	sustained	sustained	ADJ
admet-7	102	43	delivery	delivery	NOUN
admet-7	102	44	of	of	ADP
admet-7	102	45	the	the	DET
admet-7	102	46	drug	drug	NOUN
admet-7	102	47	.	.	PUNCT
admet-7	103	1	dc	dc	PROPN
admet-7	103	2	beads	bead	NOUN
admet-7	103	3	are	be	AUX
admet-7	103	4	generally	generally	ADV
admet-7	103	5	supplied	supply	VERB
admet-7	103	6	in	in	ADP
admet-7	103	7	a	a	DET
admet-7	103	8	hydrated	hydrated	ADJ
admet-7	103	9	form	form	NOUN
admet-7	103	10	in	in	ADP
admet-7	103	11	a	a	DET
admet-7	103	12	saline	saline	ADJ
admet-7	103	13	solution	solution	NOUN
admet-7	103	14	of	of	ADP
admet-7	103	15	suitable	suitable	ADJ
admet-7	103	16	ionic	ionic	ADJ
admet-7	103	17	strength	strength	NOUN
admet-7	103	18	in	in	ADP
admet-7	103	19	a	a	DET
admet-7	103	20	vial	vial	NOUN
admet-7	103	21	.	.	PUNCT
admet-7	104	1	before	before	ADP
admet-7	104	2	performing	perform	VERB
admet-7	104	3	embolization	embolization	NOUN
admet-7	104	4	,	,	PUNCT
admet-7	104	5	the	the	DET
admet-7	104	6	saline	saline	ADJ
admet-7	104	7	solution	solution	NOUN
admet-7	104	8	is	be	AUX
admet-7	104	9	removed	remove	VERB
admet-7	104	10	and	and	CCONJ
admet-7	104	11	the	the	DET
admet-7	104	12	drug	drug	NOUN
admet-7	104	13	solution	solution	NOUN
admet-7	104	14	at	at	ADP
admet-7	104	15	the	the	DET
admet-7	104	16	suggested	suggest	VERB
admet-7	104	17	concentration	concentration	NOUN
admet-7	104	18	is	be	AUX
admet-7	104	19	mixed	mix	VERB
admet-7	104	20	with	with	ADP
admet-7	104	21	the	the	DET
admet-7	104	22	beads	bead	NOUN
admet-7	104	23	and	and	CCONJ
admet-7	104	24	left	leave	VERB
admet-7	104	25	for	for	ADP
admet-7	104	26	an	an	DET
admet-7	104	27	appropriate	appropriate	ADJ
admet-7	104	28	time	time	NOUN
admet-7	104	29	,	,	PUNCT
admet-7	104	30	depending	depend	VERB
admet-7	104	31	on	on	ADP
admet-7	104	32	the	the	DET
admet-7	104	33	drug	drug	NOUN
admet-7	104	34	,	,	PUNCT
admet-7	104	35	the	the	DET
admet-7	104	36	loading	loading	NOUN
admet-7	104	37	solution	solution	NOUN
admet-7	104	38	concentration	concentration	NOUN
admet-7	104	39	and	and	CCONJ
admet-7	104	40	the	the	DET
admet-7	104	41	bead	bead	NOUN
admet-7	104	42	size	size	NOUN
admet-7	104	43	.	.	PUNCT
admet-7	105	1	typically	typically	ADV
admet-7	105	2	,	,	PUNCT
admet-7	105	3	loading	loading	NOUN
admet-7	105	4	will	will	AUX
admet-7	105	5	require	require	VERB
admet-7	105	6	a	a	DET
admet-7	105	7	minimum	minimum	NOUN
admet-7	105	8	of	of	ADP
admet-7	105	9	20	20	NUM
admet-7	105	10	minutes	minute	NOUN
admet-7	105	11	for	for	ADP
admet-7	105	12	the	the	DET
admet-7	105	13	smallest	small	ADJ
admet-7	105	14	bead	bead	NOUN
admet-7	105	15	size	size	NOUN
admet-7	105	16	and	and	CCONJ
admet-7	105	17	up	up	ADP
admet-7	105	18	to	to	PART
admet-7	105	19	120	120	NUM
admet-7	105	20	minutes	minute	NOUN
admet-7	105	21	for	for	ADP
admet-7	105	22	the	the	DET
admet-7	105	23	largest	large	ADJ
admet-7	105	24	.	.	PUNCT
admet-7	106	1	the	the	DET
admet-7	106	2	beads	bead	NOUN
admet-7	106	3	are	be	AUX
admet-7	106	4	available	available	ADJ
admet-7	106	5	in	in	ADP
admet-7	106	6	different	different	ADJ
admet-7	106	7	size	size	NOUN
admet-7	106	8	ranges	range	VERB
admet-7	106	9	:	:	PUNCT
admet-7	106	10	100	100	NUM
admet-7	106	11	–	–	SYM
admet-7	106	12	300	300	NUM
admet-7	106	13	μm	μm	NOUN
admet-7	106	14	,	,	PUNCT
admet-7	106	15	300	300	NUM
admet-7	106	16	–	–	SYM
admet-7	106	17	500	500	NUM
admet-7	106	18	μm	μm	NOUN
admet-7	106	19	,	,	PUNCT
admet-7	106	20	500	500	NUM
admet-7	106	21	–	–	SYM
admet-7	106	22	700	700	NUM
admet-7	106	23	μm	μm	NOUN
admet-7	106	24	,	,	PUNCT
admet-7	106	25	and	and	CCONJ
admet-7	106	26	700	700	NUM
admet-7	106	27	–	–	SYM
admet-7	106	28	900	900	NUM
admet-7	106	29	μm	μm	NOUN
admet-7	106	30	.	.	PUNCT
admet-7	107	1	different	different	ADJ
admet-7	107	2	drug	drug	NOUN
admet-7	107	3	loadings	loading	NOUN
admet-7	107	4	,	,	PUNCT
admet-7	107	5	varying	vary	VERB
admet-7	107	6	from	from	ADP
admet-7	107	7	5	5	NUM
admet-7	107	8	mg	mg	NOUN
admet-7	107	9	/	/	SYM
admet-7	107	10	ml	ml	NOUN
admet-7	107	11	to	to	ADP
admet-7	107	12	45	45	NUM
admet-7	107	13	mg	mg	NUM
admet-7	107	14	/	/	SYM
admet-7	107	15	ml	ml	PROPN
admet-7	107	16	of	of	ADP
admet-7	107	17	hydrated	hydrated	ADJ
admet-7	107	18	beads	bead	NOUN
admet-7	107	19	,	,	PUNCT
admet-7	107	20	have	have	AUX
admet-7	107	21	been	be	AUX
admet-7	107	22	reported	report	VERB
admet-7	107	23	[	[	X
admet-7	107	24	42	42	NUM
admet-7	107	25	]	]	PUNCT
admet-7	107	26	.	.	PUNCT
admet-7	108	1	the	the	DET
admet-7	108	2	recommended	recommend	VERB
admet-7	108	3	maximum	maximum	ADJ
admet-7	108	4	dose	dose	NOUN
admet-7	108	5	of	of	ADP
admet-7	108	6	doxorubicin	doxorubicin	PROPN
admet-7	108	7	administered	administer	VERB
admet-7	108	8	per	per	ADP
admet-7	108	9	treatment	treatment	NOUN
admet-7	108	10	is	be	AUX
admet-7	108	11	150	150	NUM
admet-7	108	12	mg	mg	NOUN
admet-7	108	13	(	(	PUNCT
admet-7	108	14	75	75	NUM
admet-7	108	15	mg	mg	PROPN
admet-7	108	16	/	/	SYM
admet-7	108	17	m2	m2	PROPN
admet-7	108	18	)	)	PUNCT
admet-7	108	19	,	,	PUNCT
admet-7	108	20	with	with	ADP
admet-7	108	21	a	a	DET
admet-7	108	22	maximum	maximum	ADJ
admet-7	108	23	recommended	recommend	VERB
admet-7	108	24	lifetime	lifetime	NOUN
admet-7	108	25	admet	admet	PROPN
admet-7	108	26	&	&	CCONJ
admet-7	108	27	dmpk	dmpk	PROPN
admet-7	108	28	1(3	1(3	NUM
admet-7	108	29	)	)	PUNCT
admet-7	108	30	(	(	PUNCT
admet-7	108	31	2013	2013	NUM
admet-7	108	32	)	)	PUNCT
admet-7	108	33	29	29	NUM
admet-7	108	34	-	-	SYM
admet-7	108	35	44	44	NUM
admet-7	108	36	doxorubicin	doxorubicin	NOUN
admet-7	108	37	and	and	CCONJ
admet-7	108	38	hcc	hcc	PROPN
admet-7	108	39	doi	doi	PROPN
admet-7	108	40	:	:	PUNCT
admet-7	108	41	10.5599	10.5599	NUM
admet-7	108	42	/	/	SYM
admet-7	108	43	admet.1.3.7	admet.1.3.7	NOUN
admet-7	108	44	33	33	NUM
admet-7	108	45	dose	dose	NOUN
admet-7	108	46	of	of	ADP
admet-7	108	47	450	450	NUM
admet-7	108	48	mg	mg	NOUN
admet-7	108	49	/	/	SYM
admet-7	108	50	m2	m2	PROPN
admet-7	108	51	in	in	ADP
admet-7	108	52	light	light	NOUN
admet-7	108	53	of	of	ADP
admet-7	108	54	cardiac	cardiac	ADJ
admet-7	108	55	toxicity	toxicity	NOUN
admet-7	108	56	induced	induce	VERB
admet-7	108	57	by	by	ADP
admet-7	108	58	the	the	DET
admet-7	108	59	drug	drug	NOUN
admet-7	108	60	when	when	SCONJ
admet-7	108	61	it	it	PRON
admet-7	108	62	is	be	AUX
admet-7	108	63	introduced	introduce	VERB
admet-7	108	64	systemically	systemically	ADV
admet-7	108	65	[	[	X
admet-7	108	66	43	43	NUM
admet-7	108	67	]	]	PUNCT
admet-7	108	68	.	.	PUNCT
admet-7	109	1	drug	drug	NOUN
admet-7	109	2	-	-	PUNCT
admet-7	109	3	loaded	load	VERB
admet-7	109	4	beads	bead	NOUN
admet-7	109	5	can	can	AUX
admet-7	109	6	be	be	AUX
admet-7	109	7	aspirated	aspirate	VERB
admet-7	109	8	directly	directly	ADV
admet-7	109	9	for	for	ADP
admet-7	109	10	the	the	DET
admet-7	109	11	catheter	catheter	NOUN
admet-7	109	12	delivery	delivery	NOUN
admet-7	109	13	procedure	procedure	NOUN
admet-7	109	14	.	.	PUNCT
admet-7	110	1	patients	patient	NOUN
admet-7	110	2	may	may	AUX
admet-7	110	3	receive	receive	VERB
admet-7	110	4	three	three	NUM
admet-7	110	5	or	or	CCONJ
admet-7	110	6	four	four	NUM
admet-7	110	7	chemoembolization	chemoembolization	NOUN
admet-7	110	8	treatments	treatment	NOUN
admet-7	110	9	within	within	ADP
admet-7	110	10	6	6	NUM
admet-7	110	11	months	month	NOUN
admet-7	110	12	.	.	PUNCT
admet-7	111	1	it	it	PRON
admet-7	111	2	has	have	AUX
admet-7	111	3	been	be	AUX
admet-7	111	4	demonstrated	demonstrate	VERB
admet-7	111	5	that	that	SCONJ
admet-7	111	6	dc	dc	PROPN
admet-7	111	7	bead	bead	NOUN
admet-7	111	8	spheres	sphere	NOUN
admet-7	111	9	can	can	AUX
admet-7	111	10	easily	easily	ADV
admet-7	111	11	be	be	AUX
admet-7	111	12	loaded	load	VERB
admet-7	111	13	with	with	ADP
admet-7	111	14	doxorubicin	doxorubicin	PROPN
admet-7	111	15	to	to	ADP
admet-7	111	16	a	a	DET
admet-7	111	17	recommended	recommend	VERB
admet-7	111	18	level	level	NOUN
admet-7	111	19	of	of	ADP
admet-7	111	20	25	25	NUM
admet-7	111	21	mg	mg	NUM
admet-7	111	22	/	/	SYM
admet-7	111	23	ml	ml	NOUN
admet-7	111	24	hydrated	hydrated	ADJ
admet-7	111	25	beads	bead	NOUN
admet-7	112	1	[	[	X
admet-7	112	2	42	42	NUM
admet-7	112	3	]	]	PUNCT
admet-7	112	4	.	.	PUNCT
admet-7	113	1	lammer	lammer	PROPN
admet-7	113	2	et	et	PROPN
admet-7	113	3	al	al	PROPN
admet-7	113	4	.	.	PROPN
admet-7	113	5	reported	report	VERB
admet-7	113	6	a	a	DET
admet-7	113	7	clinical	clinical	ADJ
admet-7	113	8	study	study	NOUN
admet-7	113	9	comparing	compare	VERB
admet-7	113	10	deb	deb	PROPN
admet-7	113	11	-	-	PUNCT
admet-7	113	12	tace	tace	NOUN
admet-7	113	13	(	(	PUNCT
admet-7	113	14	intra	intra	ADJ
admet-7	113	15	-	-	ADJ
admet-7	113	16	arterial	arterial	ADJ
admet-7	113	17	injection	injection	NOUN
admet-7	113	18	of	of	ADP
admet-7	113	19	dc	dc	PROPN
admet-7	113	20	beads	bead	NOUN
admet-7	113	21	loaded	load	VERB
admet-7	113	22	with	with	ADP
admet-7	113	23	doxorubicin	doxorubicin	PROPN
admet-7	113	24	)	)	PUNCT
admet-7	113	25	with	with	ADP
admet-7	113	26	conventional	conventional	ADJ
admet-7	113	27	tace	tace	NOUN
admet-7	113	28	(	(	PUNCT
admet-7	113	29	intra	intra	ADJ
admet-7	113	30	-	-	ADJ
admet-7	113	31	arterial	arterial	ADJ
admet-7	113	32	injection	injection	NOUN
admet-7	113	33	of	of	ADP
admet-7	113	34	doxorubicin	doxorubicin	PROPN
admet-7	113	35	in	in	ADP
admet-7	113	36	lipiodol	lipiodol	NOUN
admet-7	113	37	followed	follow	VERB
admet-7	113	38	by	by	ADP
admet-7	113	39	particle	particle	NOUN
admet-7	113	40	embolization	embolization	NOUN
admet-7	113	41	with	with	ADP
admet-7	113	42	an	an	DET
admet-7	113	43	embolic	embolic	ADJ
admet-7	113	44	agent	agent	NOUN
admet-7	113	45	,	,	PUNCT
admet-7	113	46	such	such	ADJ
admet-7	113	47	as	as	ADP
admet-7	113	48	pva	pva	NOUN
admet-7	113	49	particles	particle	NOUN
admet-7	113	50	)	)	PUNCT
admet-7	113	51	for	for	ADP
admet-7	113	52	the	the	DET
admet-7	113	53	treatment	treatment	NOUN
admet-7	113	54	of	of	ADP
admet-7	113	55	cirrhotic	cirrhotic	ADJ
admet-7	113	56	patients	patient	NOUN
admet-7	113	57	with	with	ADP
admet-7	113	58	hcc	hcc	PROPN
admet-7	114	1	[	[	X
admet-7	114	2	44	44	NUM
admet-7	114	3	]	]	PUNCT
admet-7	114	4	.	.	PUNCT
admet-7	115	1	the	the	DET
admet-7	115	2	patient	patient	ADJ
admet-7	115	3	group	group	NOUN
admet-7	115	4	treated	treat	VERB
admet-7	115	5	with	with	ADP
admet-7	115	6	deb	deb	PROPN
admet-7	115	7	-	-	PUNCT
admet-7	115	8	tace	tace	NOUN
admet-7	115	9	showed	show	VERB
admet-7	115	10	higher	high	ADJ
admet-7	115	11	response	response	NOUN
admet-7	115	12	rates	rate	NOUN
admet-7	115	13	than	than	ADP
admet-7	115	14	the	the	DET
admet-7	115	15	group	group	NOUN
admet-7	115	16	treated	treat	VERB
admet-7	115	17	with	with	ADP
admet-7	115	18	conventional	conventional	ADJ
admet-7	115	19	tace	tace	NOUN
admet-7	115	20	.	.	PUNCT
admet-7	116	1	despite	despite	SCONJ
admet-7	116	2	the	the	DET
admet-7	116	3	hypothesis	hypothesis	NOUN
admet-7	116	4	of	of	ADP
admet-7	116	5	superiority	superiority	NOUN
admet-7	116	6	not	not	PART
admet-7	116	7	being	be	AUX
admet-7	116	8	met	meet	VERB
admet-7	116	9	,	,	PUNCT
admet-7	116	10	the	the	DET
admet-7	116	11	clinical	clinical	ADJ
admet-7	116	12	data	datum	NOUN
admet-7	116	13	suggested	suggest	VERB
admet-7	116	14	that	that	SCONJ
admet-7	116	15	the	the	DET
admet-7	116	16	drug	drug	NOUN
admet-7	116	17	eluting	eluting	NOUN
admet-7	116	18	bead	bead	NOUN
admet-7	116	19	treatment	treatment	NOUN
admet-7	116	20	offered	offer	VERB
admet-7	116	21	improved	improve	VERB
admet-7	116	22	tolerance	tolerance	NOUN
admet-7	116	23	,	,	PUNCT
admet-7	116	24	with	with	ADP
admet-7	116	25	a	a	DET
admet-7	116	26	significant	significant	ADJ
admet-7	116	27	reduction	reduction	NOUN
admet-7	116	28	in	in	ADP
admet-7	116	29	serious	serious	ADJ
admet-7	116	30	liver	liver	NOUN
admet-7	116	31	toxicity	toxicity	NOUN
admet-7	116	32	,	,	PUNCT
admet-7	116	33	and	and	CCONJ
admet-7	116	34	a	a	DET
admet-7	116	35	significantly	significantly	ADV
admet-7	116	36	lower	low	ADJ
admet-7	116	37	rate	rate	NOUN
admet-7	116	38	of	of	ADP
admet-7	116	39	doxorubicin	doxorubicin	PROPN
admet-7	116	40	-	-	PUNCT
admet-7	116	41	related	relate	VERB
admet-7	116	42	side	side	NOUN
admet-7	116	43	effects	effect	NOUN
admet-7	116	44	[	[	X
admet-7	116	45	44	44	NUM
admet-7	116	46	]	]	PUNCT
admet-7	116	47	.	.	PUNCT
admet-7	117	1	in	in	ADP
admet-7	117	2	a	a	DET
admet-7	117	3	more	more	ADV
admet-7	117	4	recent	recent	ADJ
admet-7	117	5	clinical	clinical	ADJ
admet-7	117	6	study	study	NOUN
admet-7	117	7	[	[	X
admet-7	117	8	45	45	NUM
admet-7	117	9	]	]	PUNCT
admet-7	117	10	,	,	PUNCT
admet-7	117	11	malagari	malagari	PROPN
admet-7	117	12	reported	report	VERB
admet-7	117	13	the	the	DET
admet-7	117	14	meta	meta	NOUN
admet-7	117	15	-	-	PUNCT
admet-7	117	16	analysis	analysis	NOUN
admet-7	117	17	on	on	ADP
admet-7	117	18	the	the	DET
admet-7	117	19	5	5	NUM
admet-7	117	20	-	-	PUNCT
admet-7	117	21	year	year	NOUN
admet-7	117	22	survival	survival	NOUN
admet-7	117	23	of	of	ADP
admet-7	117	24	hcc	hcc	PROPN
admet-7	117	25	patients	patient	NOUN
admet-7	117	26	treated	treat	VERB
admet-7	117	27	with	with	ADP
admet-7	117	28	deb	deb	NOUN
admet-7	117	29	-	-	PUNCT
admet-7	117	30	tace	tace	NOUN
admet-7	117	31	.	.	PUNCT
admet-7	118	1	it	it	PRON
admet-7	118	2	has	have	AUX
admet-7	118	3	demonstrated	demonstrate	VERB
admet-7	118	4	good	good	ADJ
admet-7	118	5	responses	response	NOUN
admet-7	118	6	,	,	PUNCT
admet-7	118	7	with	with	ADP
admet-7	118	8	overall	overall	ADJ
admet-7	118	9	survival	survival	NOUN
admet-7	118	10	rates	rate	NOUN
admet-7	118	11	of	of	ADP
admet-7	118	12	93.6	93.6	NUM
admet-7	118	13	,	,	PUNCT
admet-7	118	14	62	62	NUM
admet-7	118	15	,	,	PUNCT
admet-7	118	16	and	and	CCONJ
admet-7	118	17	22.5	22.5	NUM
admet-7	118	18	%	%	NOUN
admet-7	118	19	at	at	ADP
admet-7	118	20	1	1	NUM
admet-7	118	21	,	,	PUNCT
admet-7	118	22	3	3	NUM
admet-7	118	23	,	,	PUNCT
admet-7	118	24	and	and	CCONJ
admet-7	118	25	5	5	NUM
admet-7	118	26	years	year	NOUN
admet-7	118	27	after	after	SCONJ
admet-7	118	28	sequential	sequential	ADJ
admet-7	118	29	sessions	session	NOUN
admet-7	118	30	of	of	ADP
admet-7	118	31	deb	deb	PROPN
admet-7	118	32	-	-	PUNCT
admet-7	118	33	tace	tace	NOUN
admet-7	118	34	in	in	ADP
admet-7	118	35	hcc	hcc	PROPN
admet-7	118	36	patients	patient	NOUN
admet-7	118	37	not	not	PART
admet-7	118	38	amenable	amenable	ADJ
admet-7	118	39	to	to	ADP
admet-7	118	40	curative	curative	ADJ
admet-7	118	41	treatments	treatment	NOUN
admet-7	118	42	.	.	PUNCT
admet-7	119	1	thus	thus	ADV
admet-7	119	2	,	,	PUNCT
admet-7	119	3	deb	deb	PROPN
admet-7	119	4	-	-	PUNCT
admet-7	119	5	tace	tace	NOUN
admet-7	119	6	appears	appear	VERB
admet-7	119	7	to	to	PART
admet-7	119	8	be	be	AUX
admet-7	119	9	safe	safe	ADJ
admet-7	119	10	and	and	CCONJ
admet-7	119	11	effective	effective	ADJ
admet-7	119	12	in	in	ADP
admet-7	119	13	the	the	DET
admet-7	119	14	treatment	treatment	NOUN
admet-7	119	15	of	of	ADP
admet-7	119	16	hcc	hcc	PROPN
admet-7	119	17	and	and	CCONJ
admet-7	119	18	could	could	AUX
admet-7	119	19	offer	offer	VERB
admet-7	119	20	a	a	DET
admet-7	119	21	benefit	benefit	NOUN
admet-7	119	22	to	to	ADP
admet-7	119	23	patients	patient	NOUN
admet-7	119	24	.	.	PUNCT
admet-7	120	1	regardless	regardless	ADV
admet-7	120	2	of	of	ADP
admet-7	120	3	the	the	DET
admet-7	120	4	means	mean	NOUN
admet-7	120	5	of	of	ADP
admet-7	120	6	implementation	implementation	NOUN
admet-7	120	7	,	,	PUNCT
admet-7	120	8	tace	tace	NOUN
admet-7	120	9	is	be	AUX
admet-7	120	10	able	able	ADJ
admet-7	120	11	to	to	PART
admet-7	120	12	offer	offer	VERB
admet-7	120	13	highly	highly	ADV
admet-7	120	14	concentrated	concentrate	VERB
admet-7	120	15	doses	dose	NOUN
admet-7	120	16	of	of	ADP
admet-7	120	17	chemotherapy	chemotherapy	NOUN
admet-7	120	18	for	for	ADP
admet-7	120	19	effective	effective	ADJ
admet-7	120	20	delivery	delivery	NOUN
admet-7	120	21	to	to	ADP
admet-7	120	22	the	the	DET
admet-7	120	23	tumour	tumour	NOUN
admet-7	120	24	bed	bed	NOUN
admet-7	120	25	,	,	PUNCT
admet-7	120	26	while	while	SCONJ
admet-7	120	27	sparing	spare	VERB
admet-7	120	28	the	the	DET
admet-7	120	29	surrounding	surround	VERB
admet-7	120	30	hepatic	hepatic	ADJ
admet-7	120	31	parenchyma	parenchyma	NOUN
admet-7	120	32	[	[	X
admet-7	120	33	46	46	NUM
admet-7	120	34	]	]	PUNCT
admet-7	120	35	.	.	PUNCT
admet-7	121	1	moreover	moreover	ADV
admet-7	121	2	,	,	PUNCT
admet-7	121	3	particle	particle	NOUN
admet-7	121	4	embolization	embolization	NOUN
admet-7	121	5	of	of	ADP
admet-7	121	6	the	the	DET
admet-7	121	7	tumour	tumour	NOUN
admet-7	121	8	-	-	PUNCT
admet-7	121	9	feeding	feed	VERB
admet-7	121	10	arteries	artery	NOUN
admet-7	121	11	sustains	sustain	VERB
admet-7	121	12	the	the	DET
admet-7	121	13	effects	effect	NOUN
admet-7	121	14	of	of	ADP
admet-7	121	15	the	the	DET
admet-7	121	16	chemotherapy	chemotherapy	NOUN
admet-7	121	17	by	by	ADP
admet-7	121	18	reducing	reduce	VERB
admet-7	121	19	its	its	PRON
admet-7	121	20	washout	washout	NOUN
admet-7	121	21	,	,	PUNCT
admet-7	121	22	allowing	allow	VERB
admet-7	121	23	prolonged	prolonged	ADJ
admet-7	121	24	contact	contact	NOUN
admet-7	121	25	with	with	ADP
admet-7	121	26	the	the	DET
admet-7	121	27	tumour	tumour	NOUN
admet-7	121	28	.	.	PUNCT
admet-7	122	1	as	as	ADP
admet-7	122	2	a	a	DET
admet-7	122	3	result	result	NOUN
admet-7	122	4	,	,	PUNCT
admet-7	122	5	selective	selective	ADJ
admet-7	122	6	arterial	arterial	ADJ
admet-7	122	7	obstruction	obstruction	NOUN
admet-7	122	8	-	-	PUNCT
admet-7	122	9	induced	induce	VERB
admet-7	122	10	ischemic	ischemic	ADJ
admet-7	122	11	tumour	tumour	NOUN
admet-7	122	12	necrosis	necrosis	NOUN
admet-7	122	13	is	be	AUX
admet-7	122	14	achievable	achievable	ADJ
admet-7	122	15	while	while	SCONJ
admet-7	122	16	minimizing	minimize	VERB
admet-7	122	17	any	any	DET
admet-7	122	18	damage	damage	NOUN
admet-7	122	19	to	to	ADP
admet-7	122	20	normal	normal	ADJ
admet-7	122	21	liver	liver	NOUN
admet-7	122	22	tissue	tissue	NOUN
admet-7	122	23	,	,	PUNCT
admet-7	122	24	as	as	SCONJ
admet-7	122	25	the	the	DET
admet-7	122	26	blood	blood	NOUN
admet-7	122	27	supply	supply	NOUN
admet-7	122	28	to	to	ADP
admet-7	122	29	the	the	DET
admet-7	122	30	normal	normal	ADJ
admet-7	122	31	liver	liver	NOUN
admet-7	122	32	tissue	tissue	NOUN
admet-7	122	33	is	be	AUX
admet-7	122	34	still	still	ADV
admet-7	122	35	maintained	maintain	VERB
admet-7	122	36	by	by	ADP
admet-7	122	37	the	the	DET
admet-7	122	38	dominant	dominant	ADJ
admet-7	122	39	blood	blood	NOUN
admet-7	122	40	flow	flow	NOUN
admet-7	122	41	from	from	ADP
admet-7	122	42	the	the	DET
admet-7	122	43	portal	portal	ADJ
admet-7	122	44	vein	vein	NOUN
admet-7	122	45	.	.	PUNCT
admet-7	123	1	this	this	DET
admet-7	123	2	combination	combination	NOUN
admet-7	123	3	of	of	ADP
admet-7	123	4	embolotherapy	embolotherapy	NOUN
admet-7	123	5	and	and	CCONJ
admet-7	123	6	regional	regional	ADJ
admet-7	123	7	chemotherapy	chemotherapy	NOUN
admet-7	123	8	has	have	VERB
admet-7	123	9	synergistic	synergistic	ADJ
admet-7	123	10	,	,	PUNCT
admet-7	123	11	anti	anti	ADJ
admet-7	123	12	-	-	ADJ
admet-7	123	13	tumour	tumour	ADJ
admet-7	123	14	effects	effect	NOUN
admet-7	123	15	,	,	PUNCT
admet-7	123	16	resulting	result	VERB
admet-7	123	17	in	in	ADP
admet-7	123	18	a	a	DET
admet-7	123	19	high	high	ADJ
admet-7	123	20	objective	objective	ADJ
admet-7	123	21	response	response	NOUN
admet-7	123	22	rate	rate	NOUN
admet-7	123	23	.	.	PUNCT
admet-7	124	1	in	in	ADP
admet-7	124	2	next	next	ADJ
admet-7	124	3	two	two	NUM
admet-7	124	4	sections	section	NOUN
admet-7	124	5	,	,	PUNCT
admet-7	124	6	we	we	PRON
admet-7	124	7	will	will	AUX
admet-7	124	8	turn	turn	VERB
admet-7	124	9	our	our	PRON
admet-7	124	10	attention	attention	NOUN
admet-7	124	11	to	to	ADP
admet-7	124	12	the	the	DET
admet-7	124	13	pharmacology	pharmacology	NOUN
admet-7	124	14	,	,	PUNCT
admet-7	124	15	toxicity	toxicity	NOUN
admet-7	124	16	and	and	CCONJ
admet-7	124	17	pharmacokinetics	pharmacokinetic	NOUN
admet-7	124	18	of	of	ADP
admet-7	124	19	doxorubicin	doxorubicin	PROPN
admet-7	124	20	.	.	PUNCT
admet-7	125	1	3	3	X
admet-7	125	2	.	.	X
admet-7	125	3	pharmacology	pharmacology	NOUN
admet-7	125	4	and	and	CCONJ
admet-7	125	5	toxicity	toxicity	NOUN
admet-7	125	6	of	of	ADP
admet-7	125	7	doxorubicin	doxorubicin	PROPN
admet-7	125	8	doxorubicin	doxorubicin	PROPN
admet-7	125	9	is	be	AUX
admet-7	125	10	a	a	DET
admet-7	125	11	cytotoxic	cytotoxic	ADJ
admet-7	125	12	anthracycline	anthracycline	NOUN
admet-7	125	13	antibiotic	antibiotic	NOUN
admet-7	125	14	isolated	isolate	VERB
admet-7	125	15	from	from	ADP
admet-7	125	16	cultures	culture	NOUN
admet-7	125	17	of	of	ADP
admet-7	125	18	streptomyces	streptomyce	NOUN
admet-7	125	19	peucetius	peucetius	NOUN
admet-7	125	20	.	.	PUNCT
admet-7	126	1	it	it	PRON
admet-7	126	2	consists	consist	VERB
admet-7	126	3	of	of	ADP
admet-7	126	4	a	a	DET
admet-7	126	5	naphthacenequinone	naphthacenequinone	NOUN
admet-7	126	6	linked	link	VERB
admet-7	126	7	through	through	ADP
admet-7	126	8	a	a	DET
admet-7	126	9	glycosidic	glycosidic	ADJ
admet-7	126	10	bond	bond	NOUN
admet-7	126	11	at	at	ADP
admet-7	126	12	ring	ring	NOUN
admet-7	126	13	atom	atom	NOUN
admet-7	126	14	7	7	NUM
admet-7	126	15	to	to	ADP
admet-7	126	16	an	an	DET
admet-7	126	17	amino	amino	NOUN
admet-7	126	18	sugar	sugar	NOUN
admet-7	126	19	,	,	PUNCT
admet-7	126	20	daunosamine	daunosamine	NOUN
admet-7	126	21	,	,	PUNCT
admet-7	126	22	with	with	ADP
admet-7	126	23	the	the	DET
admet-7	126	24	structural	structural	ADJ
admet-7	126	25	formula	formula	NOUN
admet-7	126	26	shown	show	VERB
admet-7	126	27	in	in	ADP
admet-7	126	28	fig	fig	NOUN
admet-7	126	29	.	.	PUNCT
admet-7	127	1	2	2	NUM
admet-7	127	2	.	.	NUM
admet-7	128	1	o	o	NOUN
admet-7	129	1	o	o	X
admet-7	130	1	o	o	X
admet-7	131	1	o	o	X
admet-7	131	2	hooh	hooh	NOUN
admet-7	132	1	oh	oh	INTJ
admet-7	133	1	oh	oh	INTJ
admet-7	133	2	o	o	INTJ
admet-7	134	1	o	o	INTJ
admet-7	134	2	oh	oh	INTJ
admet-7	134	3	nh2	nh2	NOUN
admet-7	134	4	1	1	NUM
admet-7	134	5	2	2	NUM
admet-7	134	6	3	3	NUM
admet-7	134	7	4	4	NUM
admet-7	134	8	5	5	NUM
admet-7	134	9	6	6	NUM
admet-7	134	10	7	7	NUM
admet-7	134	11	8	8	NUM
admet-7	134	12	9	9	NUM
admet-7	134	13	101112	101112	NUM
admet-7	134	14	13	13	NUM
admet-7	134	15	14	14	NUM
admet-7	134	16	abcd	abcd	PROPN
admet-7	134	17	figure	figure	NOUN
admet-7	134	18	2	2	NUM
admet-7	134	19	.	.	PUNCT
admet-7	134	20	structure	structure	NOUN
admet-7	134	21	of	of	ADP
admet-7	134	22	doxorubicin	doxorubicin	PROPN
admet-7	134	23	.	.	PUNCT
admet-7	135	1	tam	tam	PROPN
admet-7	135	2	admet	admet	PROPN
admet-7	135	3	&	&	CCONJ
admet-7	135	4	dmpk	dmpk	PROPN
admet-7	135	5	1(3	1(3	NUM
admet-7	135	6	)	)	PUNCT
admet-7	135	7	(	(	PUNCT
admet-7	135	8	2013	2013	NUM
admet-7	135	9	)	)	PUNCT
admet-7	135	10	29	29	NUM
admet-7	135	11	-	-	SYM
admet-7	135	12	44	44	NUM
admet-7	135	13	34	34	NUM
admet-7	135	14	the	the	DET
admet-7	135	15	tetracyclic	tetracyclic	NOUN
admet-7	135	16	ring	ring	NOUN
admet-7	135	17	system	system	NOUN
admet-7	135	18	is	be	AUX
admet-7	135	19	lipophilic	lipophilic	ADJ
admet-7	135	20	,	,	PUNCT
admet-7	135	21	but	but	CCONJ
admet-7	135	22	the	the	DET
admet-7	135	23	saturated	saturate	VERB
admet-7	135	24	end	end	NOUN
admet-7	135	25	of	of	ADP
admet-7	135	26	the	the	DET
admet-7	135	27	ring	ring	NOUN
admet-7	135	28	system	system	NOUN
admet-7	135	29	contains	contain	VERB
admet-7	135	30	several	several	ADJ
admet-7	135	31	groups	group	NOUN
admet-7	135	32	and	and	CCONJ
admet-7	135	33	the	the	DET
admet-7	135	34	amino	amino	NOUN
admet-7	135	35	sugar	sugar	NOUN
admet-7	135	36	,	,	PUNCT
admet-7	135	37	which	which	PRON
admet-7	135	38	forms	form	VERB
admet-7	135	39	a	a	DET
admet-7	135	40	hydrophilic	hydrophilic	ADJ
admet-7	135	41	centre	centre	NOUN
admet-7	135	42	.	.	PUNCT
admet-7	136	1	the	the	DET
admet-7	136	2	molecule	molecule	NOUN
admet-7	136	3	itself	itself	PRON
admet-7	136	4	is	be	AUX
admet-7	136	5	amphoteric	amphoteric	ADJ
admet-7	136	6	,	,	PUNCT
admet-7	136	7	containing	contain	VERB
admet-7	136	8	acidic	acidic	ADJ
admet-7	136	9	functions	function	NOUN
admet-7	136	10	in	in	ADP
admet-7	136	11	the	the	DET
admet-7	136	12	phenolic	phenolic	ADJ
admet-7	136	13	groups	group	NOUN
admet-7	136	14	and	and	CCONJ
admet-7	136	15	a	a	DET
admet-7	136	16	basic	basic	ADJ
admet-7	136	17	function	function	NOUN
admet-7	136	18	in	in	ADP
admet-7	136	19	the	the	DET
admet-7	136	20	sugar	sugar	NOUN
admet-7	136	21	amino	amino	NOUN
admet-7	136	22	group	group	NOUN
admet-7	136	23	.	.	PUNCT
admet-7	137	1	doxorubicin	doxorubicin	PROPN
admet-7	137	2	is	be	AUX
admet-7	137	3	now	now	ADV
admet-7	137	4	widely	widely	ADV
admet-7	137	5	used	use	VERB
admet-7	137	6	in	in	ADP
admet-7	137	7	the	the	DET
admet-7	137	8	treatment	treatment	NOUN
admet-7	137	9	of	of	ADP
admet-7	137	10	several	several	ADJ
admet-7	137	11	of	of	ADP
admet-7	137	12	the	the	DET
admet-7	137	13	most	most	ADV
admet-7	137	14	commonly	commonly	ADV
admet-7	137	15	diagnosed	diagnose	VERB
admet-7	137	16	malignancies	malignancy	NOUN
admet-7	137	17	including	include	VERB
admet-7	137	18	leukaemia	leukaemia	NOUN
admet-7	137	19	,	,	PUNCT
admet-7	137	20	lymphoma	lymphoma	NOUN
admet-7	137	21	,	,	PUNCT
admet-7	137	22	bronchogenic	bronchogenic	ADJ
admet-7	137	23	,	,	PUNCT
admet-7	137	24	and	and	CCONJ
admet-7	137	25	traditional	traditional	ADJ
admet-7	137	26	cell	cell	NOUN
admet-7	137	27	bladder	bladder	NOUN
admet-7	137	28	carcinoma	carcinoma	NOUN
admet-7	137	29	,	,	PUNCT
admet-7	137	30	as	as	ADV
admet-7	137	31	well	well	ADV
admet-7	137	32	as	as	ADP
admet-7	137	33	in	in	ADP
admet-7	137	34	the	the	DET
admet-7	137	35	treatment	treatment	NOUN
admet-7	137	36	of	of	ADP
admet-7	137	37	wilms	wilm	NOUN
admet-7	137	38	’	'	PUNCT
admet-7	137	39	tumour	tumour	NOUN
admet-7	137	40	,	,	PUNCT
admet-7	137	41	neuroblastoma	neuroblastoma	ADJ
admet-7	137	42	,	,	PUNCT
admet-7	137	43	sarcoma	sarcoma	NOUN
admet-7	137	44	,	,	PUNCT
admet-7	137	45	and	and	CCONJ
admet-7	137	46	carcinoma	carcinoma	NOUN
admet-7	137	47	of	of	ADP
admet-7	137	48	the	the	DET
admet-7	137	49	breast	breast	NOUN
admet-7	137	50	,	,	PUNCT
admet-7	137	51	ovary	ovary	ADJ
admet-7	137	52	,	,	PUNCT
admet-7	137	53	and	and	CCONJ
admet-7	137	54	stomach	stomach	NOUN
admet-7	138	1	[	[	X
admet-7	138	2	47	47	NUM
admet-7	138	3	]	]	PUNCT
admet-7	138	4	.	.	PUNCT
admet-7	139	1	liposomal	liposomal	PROPN
admet-7	139	2	doxorubicin	doxorubicin	PROPN
admet-7	139	3	formulations	formulation	NOUN
admet-7	139	4	(	(	PUNCT
admet-7	139	5	doxil	doxil	NOUN
admet-7	139	6	®	®	NOUN
admet-7	139	7	or	or	CCONJ
admet-7	139	8	lipodox	lipodox	PROPN
admet-7	139	9	®	®	NOUN
admet-7	139	10	)	)	PUNCT
admet-7	139	11	have	have	AUX
admet-7	139	12	been	be	AUX
admet-7	139	13	developed	develop	VERB
admet-7	139	14	to	to	PART
admet-7	139	15	improve	improve	VERB
admet-7	139	16	the	the	DET
admet-7	139	17	therapeutic	therapeutic	ADJ
admet-7	139	18	index	index	NOUN
admet-7	139	19	of	of	ADP
admet-7	139	20	doxorubicin	doxorubicin	PROPN
admet-7	139	21	for	for	ADP
admet-7	139	22	use	use	NOUN
admet-7	139	23	in	in	ADP
admet-7	139	24	conventional	conventional	ADJ
admet-7	139	25	chemotherapy	chemotherapy	NOUN
admet-7	139	26	(	(	PUNCT
admet-7	139	27	systemic	systemic	ADJ
admet-7	139	28	administration	administration	NOUN
admet-7	139	29	)	)	PUNCT
admet-7	139	30	while	while	SCONJ
admet-7	139	31	maintaining	maintain	VERB
admet-7	139	32	its	its	PRON
admet-7	139	33	anti	anti	ADJ
admet-7	139	34	-	-	ADJ
admet-7	139	35	tumour	tumour	ADJ
admet-7	139	36	activity	activity	NOUN
admet-7	139	37	.	.	PUNCT
admet-7	140	1	these	these	DET
admet-7	140	2	liposomal	liposomal	PROPN
admet-7	140	3	formulations	formulation	NOUN
admet-7	140	4	have	have	AUX
admet-7	140	5	been	be	AUX
admet-7	140	6	used	use	VERB
admet-7	140	7	for	for	ADP
admet-7	140	8	the	the	DET
admet-7	140	9	treatment	treatment	NOUN
admet-7	140	10	of	of	ADP
admet-7	140	11	metastatic	metastatic	ADJ
admet-7	140	12	breast	breast	NOUN
admet-7	140	13	/	/	SYM
admet-7	140	14	ovary	ovary	ADJ
admet-7	140	15	cancers	cancer	NOUN
admet-7	140	16	and	and	CCONJ
admet-7	140	17	of	of	ADP
admet-7	140	18	aids	aids	PROPN
admet-7	140	19	related	relate	VERB
admet-7	140	20	kaposi	kaposi	PROPN
admet-7	140	21	’s	’s	PART
admet-7	140	22	sarcoma	sarcoma	NOUN
admet-7	141	1	[	[	X
admet-7	141	2	48	48	NUM
admet-7	141	3	]	]	PUNCT
admet-7	141	4	.	.	PUNCT
admet-7	142	1	doxorubicin	doxorubicin	PROPN
admet-7	142	2	in	in	ADP
admet-7	142	3	a	a	DET
admet-7	142	4	heat	heat	NOUN
admet-7	142	5	sensitive	sensitive	ADJ
admet-7	142	6	liposome	liposome	NOUN
admet-7	142	7	formulation	formulation	NOUN
admet-7	142	8	has	have	AUX
admet-7	142	9	been	be	AUX
admet-7	142	10	given	give	VERB
admet-7	142	11	an	an	DET
admet-7	142	12	orphan	orphan	NOUN
admet-7	142	13	designation	designation	NOUN
admet-7	142	14	(	(	PUNCT
admet-7	142	15	eu/3/10/833	eu/3/10/833	PROPN
admet-7	142	16	)	)	PUNCT
admet-7	142	17	in	in	ADP
admet-7	142	18	europe	europe	PROPN
admet-7	142	19	for	for	ADP
admet-7	142	20	the	the	DET
admet-7	142	21	treatment	treatment	NOUN
admet-7	142	22	of	of	ADP
admet-7	142	23	hepatocellular	hepatocellular	ADJ
admet-7	142	24	carcinoma	carcinoma	NOUN
admet-7	142	25	[	[	X
admet-7	142	26	49	49	NUM
admet-7	142	27	]	]	PUNCT
admet-7	142	28	.	.	PUNCT
admet-7	143	1	despite	despite	SCONJ
admet-7	143	2	extensive	extensive	ADJ
admet-7	143	3	clinical	clinical	ADJ
admet-7	143	4	utilization	utilization	NOUN
admet-7	143	5	,	,	PUNCT
admet-7	143	6	the	the	DET
admet-7	143	7	exact	exact	ADJ
admet-7	143	8	mechanisms	mechanism	NOUN
admet-7	143	9	of	of	ADP
admet-7	143	10	action	action	NOUN
admet-7	143	11	of	of	ADP
admet-7	143	12	doxorubicin	doxorubicin	PROPN
admet-7	143	13	in	in	ADP
admet-7	143	14	cancer	cancer	NOUN
admet-7	143	15	cells	cell	NOUN
admet-7	143	16	remain	remain	VERB
admet-7	143	17	a	a	DET
admet-7	143	18	matter	matter	NOUN
admet-7	143	19	of	of	ADP
admet-7	143	20	controversy	controversy	NOUN
admet-7	143	21	.	.	PUNCT
admet-7	144	1	for	for	ADP
admet-7	144	2	instance	instance	NOUN
admet-7	144	3	,	,	PUNCT
admet-7	144	4	doxorubicin	doxorubicin	PROPN
admet-7	144	5	has	have	AUX
admet-7	144	6	been	be	AUX
admet-7	144	7	reported	report	VERB
admet-7	144	8	to	to	PART
admet-7	144	9	have	have	VERB
admet-7	144	10	at	at	ADV
admet-7	144	11	least	least	ADV
admet-7	144	12	seven	seven	NUM
admet-7	144	13	different	different	ADJ
admet-7	144	14	means	mean	NOUN
admet-7	144	15	of	of	ADP
admet-7	144	16	producing	produce	VERB
admet-7	144	17	cellular	cellular	ADJ
admet-7	144	18	dysfunction	dysfunction	NOUN
admet-7	144	19	or	or	CCONJ
admet-7	144	20	death	death	NOUN
admet-7	145	1	[	[	X
admet-7	145	2	50	50	NUM
admet-7	145	3	]	]	PUNCT
admet-7	145	4	.	.	PUNCT
admet-7	146	1	it	it	PRON
admet-7	146	2	is	be	AUX
admet-7	146	3	generally	generally	ADV
admet-7	146	4	believed	believe	VERB
admet-7	146	5	that	that	SCONJ
admet-7	146	6	the	the	DET
admet-7	146	7	cytotoxic	cytotoxic	ADJ
admet-7	146	8	effects	effect	NOUN
admet-7	146	9	of	of	ADP
admet-7	146	10	doxorubicin	doxorubicin	PROPN
admet-7	146	11	on	on	ADP
admet-7	146	12	cancer	cancer	NOUN
admet-7	146	13	cells	cell	NOUN
admet-7	146	14	are	be	AUX
admet-7	146	15	related	relate	VERB
admet-7	146	16	to	to	PART
admet-7	146	17	nucleotide	nucleotide	ADJ
admet-7	146	18	base	base	NOUN
admet-7	146	19	intercalation	intercalation	NOUN
admet-7	146	20	.	.	PUNCT
admet-7	147	1	in	in	ADP
admet-7	147	2	particular	particular	ADJ
admet-7	147	3	,	,	PUNCT
admet-7	147	4	the	the	DET
admet-7	147	5	drug	drug	NOUN
admet-7	147	6	molecule	molecule	NOUN
admet-7	147	7	stabilizes	stabilize	VERB
admet-7	147	8	the	the	DET
admet-7	147	9	topoisomerase	topoisomerase	ADJ
admet-7	147	10	ii	ii	NOUN
admet-7	147	11	complex	complex	NOUN
admet-7	147	12	after	after	SCONJ
admet-7	147	13	it	it	PRON
admet-7	147	14	has	have	AUX
admet-7	147	15	broken	break	VERB
admet-7	147	16	the	the	DET
admet-7	147	17	dna	dna	PROPN
admet-7	147	18	chain	chain	NOUN
admet-7	147	19	for	for	ADP
admet-7	147	20	replication	replication	NOUN
admet-7	147	21	,	,	PUNCT
admet-7	147	22	preventing	prevent	VERB
admet-7	147	23	the	the	DET
admet-7	147	24	dna	dna	PROPN
admet-7	147	25	double	double	ADJ
admet-7	147	26	helix	helix	NOUN
admet-7	147	27	from	from	ADP
admet-7	147	28	being	be	AUX
admet-7	147	29	resealed	reseal	VERB
admet-7	147	30	and	and	CCONJ
admet-7	147	31	thereby	thereby	ADV
admet-7	147	32	stopping	stop	VERB
admet-7	147	33	the	the	DET
admet-7	147	34	process	process	NOUN
admet-7	147	35	of	of	ADP
admet-7	147	36	replication	replication	NOUN
admet-7	147	37	.	.	PUNCT
admet-7	148	1	crystallographic	crystallographic	ADJ
admet-7	148	2	data	datum	NOUN
admet-7	148	3	[	[	X
admet-7	148	4	51	51	NUM
admet-7	148	5	]	]	PUNCT
admet-7	148	6	suggest	suggest	VERB
admet-7	148	7	that	that	SCONJ
admet-7	148	8	the	the	DET
admet-7	148	9	planar	planar	ADJ
admet-7	148	10	tetracyclic	tetracyclic	NOUN
admet-7	148	11	portion	portion	NOUN
admet-7	148	12	of	of	ADP
admet-7	148	13	the	the	DET
admet-7	148	14	molecule	molecule	NOUN
admet-7	148	15	intercalates	intercalate	NOUN
admet-7	148	16	between	between	ADP
admet-7	148	17	two	two	NUM
admet-7	148	18	base	base	NOUN
admet-7	148	19	pairs	pair	NOUN
admet-7	148	20	of	of	ADP
admet-7	148	21	the	the	DET
admet-7	148	22	dna	dna	NOUN
admet-7	148	23	,	,	PUNCT
admet-7	148	24	while	while	SCONJ
admet-7	148	25	the	the	DET
admet-7	148	26	sugar	sugar	NOUN
admet-7	148	27	amino	amino	PROPN
admet-7	148	28	group	group	NOUN
admet-7	148	29	sits	sit	VERB
admet-7	148	30	in	in	ADP
admet-7	148	31	the	the	DET
admet-7	148	32	minor	minor	ADJ
admet-7	148	33	groove	groove	NOUN
admet-7	148	34	and	and	CCONJ
admet-7	148	35	interacts	interact	VERB
admet-7	148	36	with	with	ADP
admet-7	148	37	flanking	flank	VERB
admet-7	148	38	base	base	NOUN
admet-7	148	39	pairs	pair	NOUN
admet-7	148	40	immediately	immediately	ADV
admet-7	148	41	adjacent	adjacent	ADJ
admet-7	148	42	to	to	ADP
admet-7	148	43	the	the	DET
admet-7	148	44	intercalation	intercalation	NOUN
admet-7	148	45	site	site	NOUN
admet-7	148	46	.	.	PUNCT
admet-7	149	1	moreover	moreover	ADV
admet-7	149	2	,	,	PUNCT
admet-7	149	3	it	it	PRON
admet-7	149	4	has	have	AUX
admet-7	149	5	been	be	AUX
admet-7	149	6	suggested	suggest	VERB
admet-7	149	7	that	that	SCONJ
admet-7	149	8	doxorubicin	doxorubicin	PROPN
admet-7	149	9	activates	activate	VERB
admet-7	149	10	p53	p53	NOUN
admet-7	149	11	-	-	PUNCT
admet-7	149	12	dna	dna	NOUN
admet-7	149	13	binding	bind	VERB
admet-7	149	14	,	,	PUNCT
admet-7	149	15	leading	lead	VERB
admet-7	149	16	to	to	ADP
admet-7	149	17	induced	induced	ADJ
admet-7	149	18	apoptosis	apoptosis	NOUN
admet-7	150	1	[	[	X
admet-7	150	2	52,53	52,53	NOUN
admet-7	150	3	]	]	PUNCT
admet-7	150	4	.	.	PUNCT
admet-7	151	1	doxorubicin	doxorubicin	PROPN
admet-7	151	2	-	-	PUNCT
admet-7	151	3	induced	induce	VERB
admet-7	151	4	apoptosis	apoptosis	NOUN
admet-7	151	5	may	may	AUX
admet-7	151	6	result	result	VERB
admet-7	151	7	in	in	ADP
admet-7	151	8	therapeutic	therapeutic	ADJ
admet-7	151	9	effects	effect	NOUN
admet-7	151	10	and/or	and/or	CCONJ
admet-7	151	11	toxicities	toxicity	NOUN
admet-7	151	12	.	.	PUNCT
admet-7	152	1	doxorubicin	doxorubicin	PROPN
admet-7	152	2	may	may	AUX
admet-7	152	3	undergo	undergo	VERB
admet-7	152	4	a	a	DET
admet-7	152	5	cascade	cascade	NOUN
admet-7	152	6	of	of	ADP
admet-7	152	7	free	free	ADJ
admet-7	152	8	radical	radical	ADJ
admet-7	152	9	processes	process	NOUN
admet-7	152	10	in	in	ADP
admet-7	152	11	normal	normal	ADJ
admet-7	152	12	and	and	CCONJ
admet-7	152	13	cancer	cancer	NOUN
admet-7	152	14	cells	cell	NOUN
admet-7	152	15	.	.	PUNCT
admet-7	153	1	typically	typically	ADV
admet-7	153	2	this	this	PRON
admet-7	153	3	involves	involve	VERB
admet-7	153	4	interactions	interaction	NOUN
admet-7	153	5	of	of	ADP
admet-7	153	6	the	the	DET
admet-7	153	7	molecule	molecule	NOUN
admet-7	153	8	with	with	ADP
admet-7	153	9	the	the	DET
admet-7	153	10	cell	cell	NOUN
admet-7	153	11	's	's	PART
admet-7	153	12	electron	electron	NOUN
admet-7	153	13	transport	transport	NOUN
admet-7	153	14	chain	chain	NOUN
admet-7	153	15	,	,	PUNCT
admet-7	153	16	specifically	specifically	ADV
admet-7	153	17	the	the	DET
admet-7	153	18	cytochrome	cytochrome	ADJ
admet-7	153	19	p450	p450	ADJ
admet-7	153	20	reductase	reductase	NOUN
admet-7	153	21	(	(	PUNCT
admet-7	153	22	p450r	p450r	PROPN
admet-7	153	23	)	)	PUNCT
admet-7	154	1	[	[	X
admet-7	154	2	54,55	54,55	X
admet-7	154	3	]	]	PUNCT
admet-7	154	4	.	.	PUNCT
admet-7	155	1	as	as	SCONJ
admet-7	155	2	shown	show	VERB
admet-7	155	3	in	in	ADP
admet-7	155	4	fig	fig	NOUN
admet-7	155	5	.	.	PUNCT
admet-7	156	1	3	3	NUM
admet-7	156	2	,	,	PUNCT
admet-7	156	3	the	the	DET
admet-7	156	4	quinone	quinone	NOUN
admet-7	156	5	moiety	moiety	NOUN
admet-7	156	6	readily	readily	ADV
admet-7	156	7	accepts	accept	VERB
admet-7	156	8	the	the	DET
admet-7	156	9	transfer	transfer	NOUN
admet-7	156	10	of	of	ADP
admet-7	156	11	a	a	DET
admet-7	156	12	single	single	ADJ
admet-7	156	13	electron	electron	NOUN
admet-7	156	14	to	to	PART
admet-7	156	15	form	form	VERB
admet-7	156	16	the	the	DET
admet-7	156	17	semiquinone	semiquinone	NOUN
admet-7	156	18	free	free	ADJ
admet-7	156	19	radical	radical	NOUN
admet-7	156	20	,	,	PUNCT
admet-7	156	21	which	which	PRON
admet-7	156	22	could	could	AUX
admet-7	156	23	be	be	AUX
admet-7	156	24	directly	directly	ADV
admet-7	156	25	cytotoxic	cytotoxic	ADJ
admet-7	156	26	in	in	ADP
admet-7	156	27	hypoxic	hypoxic	ADJ
admet-7	156	28	environments	environment	NOUN
admet-7	156	29	via	via	ADP
admet-7	156	30	covalent	covalent	ADJ
admet-7	156	31	modification	modification	NOUN
admet-7	156	32	of	of	ADP
admet-7	156	33	cellular	cellular	ADJ
admet-7	156	34	macromolecules	macromolecule	NOUN
admet-7	156	35	.	.	PUNCT
admet-7	157	1	under	under	ADP
admet-7	157	2	aerobic	aerobic	ADJ
admet-7	157	3	conditions	condition	NOUN
admet-7	157	4	,	,	PUNCT
admet-7	157	5	the	the	DET
admet-7	157	6	semiquinone	semiquinone	NOUN
admet-7	157	7	radicals	radical	NOUN
admet-7	157	8	can	can	AUX
admet-7	157	9	shuttle	shuttle	VERB
admet-7	157	10	electrons	electron	NOUN
admet-7	157	11	to	to	ADP
admet-7	157	12	molecular	molecular	ADJ
admet-7	157	13	oxygen	oxygen	NOUN
admet-7	157	14	,	,	PUNCT
admet-7	157	15	giving	give	VERB
admet-7	157	16	rise	rise	NOUN
admet-7	157	17	to	to	ADP
admet-7	157	18	superoxide	superoxide	NOUN
admet-7	157	19	anion	anion	NOUN
admet-7	157	20	radicals	radical	NOUN
admet-7	157	21	[	[	X
admet-7	157	22	56	56	NUM
admet-7	157	23	-	-	SYM
admet-7	157	24	59	59	NUM
admet-7	157	25	]	]	PUNCT
admet-7	157	26	.	.	PUNCT
admet-7	158	1	these	these	DET
admet-7	158	2	toxic	toxic	ADJ
admet-7	158	3	intracellular	intracellular	ADJ
admet-7	158	4	radicals	radical	NOUN
admet-7	158	5	can	can	AUX
admet-7	158	6	be	be	AUX
admet-7	158	7	further	far	ADV
admet-7	158	8	converted	convert	VERB
admet-7	158	9	to	to	ADP
admet-7	158	10	hydrogen	hydrogen	NOUN
admet-7	158	11	peroxide	peroxide	NOUN
admet-7	158	12	and	and	CCONJ
admet-7	158	13	hydroxyl	hydroxyl	NOUN
admet-7	158	14	radicals	radical	NOUN
admet-7	158	15	,	,	PUNCT
admet-7	158	16	which	which	PRON
admet-7	158	17	can	can	AUX
admet-7	158	18	directly	directly	ADV
admet-7	158	19	damage	damage	VERB
admet-7	158	20	dna	dna	PROPN
admet-7	158	21	,	,	PUNCT
admet-7	158	22	rna	rna	NOUN
admet-7	158	23	,	,	PUNCT
admet-7	158	24	lipids	lipid	NOUN
admet-7	158	25	,	,	PUNCT
admet-7	158	26	and	and	CCONJ
admet-7	158	27	proteins	protein	NOUN
admet-7	158	28	[	[	X
admet-7	158	29	60,61	60,61	NOUN
admet-7	158	30	]	]	PUNCT
admet-7	158	31	.	.	PUNCT
admet-7	159	1	this	this	DET
admet-7	159	2	oxidative	oxidative	ADJ
admet-7	159	3	stress	stress	NOUN
admet-7	159	4	mechanism	mechanism	NOUN
admet-7	159	5	appears	appear	VERB
admet-7	159	6	to	to	PART
admet-7	159	7	be	be	AUX
admet-7	159	8	a	a	DET
admet-7	159	9	contributor	contributor	NOUN
admet-7	159	10	to	to	ADP
admet-7	159	11	doxorubicin	doxorubicin	PROPN
admet-7	159	12	’s	’s	PART
admet-7	159	13	ability	ability	NOUN
admet-7	159	14	to	to	PART
admet-7	159	15	cause	cause	VERB
admet-7	159	16	cell	cell	NOUN
admet-7	159	17	death	death	NOUN
admet-7	159	18	,	,	PUNCT
admet-7	159	19	as	as	ADV
admet-7	159	20	well	well	ADV
admet-7	159	21	as	as	ADP
admet-7	159	22	its	its	PRON
admet-7	159	23	dose	dose	NOUN
admet-7	159	24	-	-	PUNCT
admet-7	159	25	limiting	limit	VERB
admet-7	159	26	cardiotoxicity	cardiotoxicity	NOUN
admet-7	159	27	.	.	PUNCT
admet-7	160	1	in	in	ADP
admet-7	160	2	the	the	DET
admet-7	160	3	process	process	NOUN
admet-7	160	4	of	of	ADP
admet-7	160	5	electron	electron	NOUN
admet-7	160	6	shuttling	shuttling	NOUN
admet-7	160	7	,	,	PUNCT
admet-7	160	8	the	the	DET
admet-7	160	9	doxorubicin	doxorubicin	PROPN
admet-7	160	10	ring	ring	NOUN
admet-7	160	11	system	system	NOUN
admet-7	160	12	is	be	AUX
admet-7	160	13	restored	restore	VERB
admet-7	160	14	to	to	ADP
admet-7	160	15	its	its	PRON
admet-7	160	16	original	original	ADJ
admet-7	160	17	state	state	NOUN
admet-7	160	18	and	and	CCONJ
admet-7	160	19	can	can	AUX
admet-7	160	20	be	be	AUX
admet-7	160	21	available	available	ADJ
admet-7	160	22	for	for	ADP
admet-7	160	23	additional	additional	ADJ
admet-7	160	24	redox	redox	ADJ
admet-7	160	25	cycling	cycling	NOUN
admet-7	160	26	reactions	reaction	NOUN
admet-7	160	27	.	.	PUNCT
admet-7	161	1	admet	admet	PROPN
admet-7	161	2	&	&	CCONJ
admet-7	161	3	dmpk	dmpk	PROPN
admet-7	161	4	1(3	1(3	NUM
admet-7	161	5	)	)	PUNCT
admet-7	161	6	(	(	PUNCT
admet-7	161	7	2013	2013	NUM
admet-7	161	8	)	)	PUNCT
admet-7	161	9	29	29	NUM
admet-7	161	10	-	-	SYM
admet-7	161	11	44	44	NUM
admet-7	161	12	doxorubicin	doxorubicin	NOUN
admet-7	161	13	and	and	CCONJ
admet-7	161	14	hcc	hcc	PROPN
admet-7	161	15	doi	doi	PROPN
admet-7	161	16	:	:	PUNCT
admet-7	161	17	10.5599	10.5599	NUM
admet-7	161	18	/	/	SYM
admet-7	161	19	admet.1.3.7	admet.1.3.7	NOUN
admet-7	161	20	35	35	NUM
admet-7	161	21	o	o	NOUN
admet-7	161	22	o	o	NOUN
admet-7	161	23	5	5	NUM
admet-7	161	24	12	12	NUM
admet-7	162	1	c	c	NOUN
admet-7	162	2	o	o	NOUN
admet-7	162	3	o	o	NOUN
admet-7	162	4	5	5	NUM
admet-7	162	5	12	12	NUM
admet-7	162	6	c	c	PROPN
admet-7	162	7	nadph	nadph	PROPN
admet-7	162	8	nadp+	nadp+	PROPN
admet-7	163	1	p450r	p450r	PROPN
admet-7	163	2	o2	o2	PROPN
admet-7	163	3	o2	o2	PROPN
admet-7	163	4	h2o2	h2o2	PROPN
admet-7	163	5	oh	oh	PROPN
admet-7	163	6	dna	dna	PROPN
admet-7	163	7	&	&	CCONJ
admet-7	163	8	protein	protein	NOUN
admet-7	163	9	damage	damage	NOUN
admet-7	163	10	.	.	PUNCT
admet-7	163	11	.	.	PUNCT
admet-7	164	1	.	.	PUNCT
admet-7	165	1	1e1/2	1e1/2	NUM
admet-7	165	2	1/2	1/2	NUM
admet-7	165	3	1e	1e	NOUN
admet-7	165	4	figure	figure	NOUN
admet-7	165	5	3	3	NUM
admet-7	165	6	.	.	PUNCT
admet-7	165	7	simplified	simplify	VERB
admet-7	165	8	schematic	schematic	ADJ
admet-7	165	9	of	of	ADP
admet-7	165	10	the	the	DET
admet-7	165	11	redox	redox	ADJ
admet-7	165	12	cycling	cycling	NOUN
admet-7	165	13	of	of	ADP
admet-7	165	14	doxorubicin	doxorubicin	PROPN
admet-7	165	15	.	.	PUNCT
admet-7	166	1	the	the	DET
admet-7	166	2	major	major	ADJ
admet-7	166	3	doxorubicin	doxorubicin	PROPN
admet-7	166	4	metabolite	metabolite	NOUN
admet-7	166	5	in	in	ADP
admet-7	166	6	humans	human	NOUN
admet-7	166	7	is	be	AUX
admet-7	166	8	doxorubicinol	doxorubicinol	ADJ
admet-7	166	9	,	,	PUNCT
admet-7	166	10	which	which	PRON
admet-7	166	11	is	be	AUX
admet-7	166	12	produced	produce	VERB
admet-7	166	13	via	via	ADP
admet-7	166	14	the	the	DET
admet-7	166	15	cytosolic	cytosolic	ADJ
admet-7	166	16	carbonyl	carbonyl	NOUN
admet-7	166	17	reductase	reductase	NOUN
admet-7	166	18	-	-	PUNCT
admet-7	166	19	catalyzed	catalyze	VERB
admet-7	166	20	reduction	reduction	NOUN
admet-7	166	21	of	of	ADP
admet-7	166	22	the	the	DET
admet-7	166	23	ketone	ketone	NOUN
admet-7	166	24	at	at	ADP
admet-7	166	25	c-13	c-13	PROPN
admet-7	166	26	on	on	ADP
admet-7	166	27	the	the	DET
admet-7	166	28	parent	parent	NOUN
admet-7	166	29	drug	drug	NOUN
admet-7	166	30	(	(	PUNCT
admet-7	166	31	fig	fig	NOUN
admet-7	166	32	.	.	PUNCT
admet-7	167	1	2	2	NUM
admet-7	167	2	)	)	PUNCT
admet-7	168	1	[	[	X
admet-7	168	2	62,63	62,63	NOUN
admet-7	168	3	]	]	PUNCT
admet-7	168	4	.	.	PUNCT
admet-7	169	1	reductive	reductive	ADJ
admet-7	169	2	deglycosylation	deglycosylation	NOUN
admet-7	169	3	at	at	ADP
admet-7	169	4	c-7	c-7	NOUN
admet-7	169	5	by	by	ADP
admet-7	169	6	p450r	p450r	PROPN
admet-7	169	7	leads	lead	VERB
admet-7	169	8	to	to	ADP
admet-7	169	9	formation	formation	NOUN
admet-7	169	10	of	of	ADP
admet-7	169	11	the	the	DET
admet-7	169	12	7	7	NUM
admet-7	169	13	-	-	PUNCT
admet-7	169	14	deoxy	deoxy	ADJ
admet-7	169	15	-	-	ADJ
admet-7	169	16	doxorubicinol	doxorubicinol	ADJ
admet-7	169	17	metabolite	metabolite	NOUN
admet-7	169	18	.	.	PUNCT
admet-7	170	1	pharmacokinetic	pharmacokinetic	ADJ
admet-7	170	2	studies	study	NOUN
admet-7	170	3	in	in	ADP
admet-7	170	4	humans	human	NOUN
admet-7	170	5	revealed	reveal	VERB
admet-7	170	6	that	that	SCONJ
admet-7	170	7	doxorubicinol	doxorubicinol	ADJ
admet-7	170	8	and	and	CCONJ
admet-7	170	9	7	7	NUM
admet-7	170	10	-	-	PUNCT
admet-7	170	11	deoxy	deoxy	NOUN
admet-7	170	12	-	-	ADJ
admet-7	170	13	doxorubicinol	doxorubicinol	ADJ
admet-7	170	14	were	be	AUX
admet-7	170	15	the	the	DET
admet-7	170	16	metabolites	metabolite	NOUN
admet-7	170	17	detected	detect	VERB
admet-7	170	18	in	in	ADP
admet-7	170	19	vivo	vivo	NOUN
admet-7	170	20	[	[	X
admet-7	170	21	64	64	NUM
admet-7	170	22	]	]	PUNCT
admet-7	170	23	.	.	PUNCT
admet-7	171	1	doxorubicinol	doxorubicinol	PROPN
admet-7	171	2	also	also	ADV
admet-7	171	3	exhibits	exhibit	VERB
admet-7	171	4	antiproliferative	antiproliferative	NOUN
admet-7	171	5	and	and	CCONJ
admet-7	171	6	antineoplastic	antineoplastic	ADJ
admet-7	171	7	properties	property	NOUN
admet-7	171	8	.	.	PUNCT
admet-7	172	1	because	because	SCONJ
admet-7	172	2	doxorubicinol	doxorubicinol	ADJ
admet-7	172	3	is	be	AUX
admet-7	172	4	more	more	ADV
admet-7	172	5	polar	polar	ADJ
admet-7	172	6	than	than	ADP
admet-7	172	7	the	the	DET
admet-7	172	8	parent	parent	NOUN
admet-7	172	9	drug	drug	NOUN
admet-7	172	10	molecule	molecule	NOUN
admet-7	172	11	,	,	PUNCT
admet-7	172	12	it	it	PRON
admet-7	172	13	is	be	AUX
admet-7	172	14	less	less	ADV
admet-7	172	15	likely	likely	ADJ
admet-7	172	16	to	to	PART
admet-7	172	17	traverse	traverse	VERB
admet-7	172	18	through	through	ADP
admet-7	172	19	the	the	DET
admet-7	172	20	cell	cell	NOUN
admet-7	172	21	membrane	membrane	NOUN
admet-7	172	22	back	back	ADV
admet-7	172	23	to	to	ADP
admet-7	172	24	the	the	DET
admet-7	172	25	extracellular	extracellular	ADJ
admet-7	172	26	space	space	NOUN
admet-7	172	27	.	.	PUNCT
admet-7	173	1	hence	hence	ADV
admet-7	173	2	,	,	PUNCT
admet-7	173	3	it	it	PRON
admet-7	173	4	is	be	AUX
admet-7	173	5	more	more	ADV
admet-7	173	6	likely	likely	ADJ
admet-7	173	7	to	to	PART
admet-7	173	8	stay	stay	VERB
admet-7	173	9	inside	inside	ADP
admet-7	173	10	cells	cell	NOUN
admet-7	173	11	,	,	PUNCT
admet-7	173	12	increasing	increase	VERB
admet-7	173	13	its	its	PRON
admet-7	173	14	cytotoxic	cytotoxic	ADJ
admet-7	173	15	effects	effect	NOUN
admet-7	173	16	[	[	X
admet-7	173	17	65,66	65,66	NOUN
admet-7	173	18	]	]	X
admet-7	173	19	.	.	PUNCT
admet-7	174	1	7	7	NUM
admet-7	174	2	-	-	PUNCT
admet-7	174	3	deoxy	deoxy	NOUN
admet-7	174	4	-	-	ADJ
admet-7	174	5	doxorubicinol	doxorubicinol	NOUN
admet-7	174	6	is	be	AUX
admet-7	174	7	considerably	considerably	ADV
admet-7	174	8	less	less	ADV
admet-7	174	9	potent	potent	ADJ
admet-7	174	10	in	in	ADP
admet-7	174	11	inhibiting	inhibit	VERB
admet-7	174	12	tumour	tumour	NOUN
admet-7	174	13	growth	growth	NOUN
admet-7	174	14	in	in	ADP
admet-7	174	15	a	a	DET
admet-7	174	16	mouse	mouse	NOUN
admet-7	174	17	lymphocytic	lymphocytic	ADJ
admet-7	174	18	leukaemia	leukaemia	NOUN
admet-7	174	19	cell	cell	NOUN
admet-7	174	20	line	line	NOUN
admet-7	174	21	[	[	X
admet-7	174	22	67	67	NUM
admet-7	174	23	]	]	PUNCT
admet-7	174	24	.	.	PUNCT
admet-7	175	1	it	it	PRON
admet-7	175	2	has	have	AUX
admet-7	175	3	been	be	AUX
admet-7	175	4	suggested	suggest	VERB
admet-7	175	5	that	that	SCONJ
admet-7	175	6	doxorubicinol	doxorubicinol	NOUN
admet-7	175	7	could	could	AUX
admet-7	175	8	accumulate	accumulate	VERB
admet-7	175	9	in	in	ADP
admet-7	175	10	the	the	DET
admet-7	175	11	heart	heart	NOUN
admet-7	175	12	and	and	CCONJ
admet-7	175	13	contribute	contribute	VERB
admet-7	175	14	significantly	significantly	ADV
admet-7	175	15	to	to	ADP
admet-7	175	16	the	the	DET
admet-7	175	17	chronic	chronic	ADJ
admet-7	175	18	cumulative	cumulative	ADJ
admet-7	175	19	cardiotoxicity	cardiotoxicity	NOUN
admet-7	175	20	of	of	ADP
admet-7	175	21	doxorubicin	doxorubicin	PROPN
admet-7	175	22	therapy	therapy	NOUN
admet-7	176	1	[	[	X
admet-7	176	2	68	68	NUM
admet-7	176	3	]	]	PUNCT
admet-7	176	4	.	.	PUNCT
admet-7	177	1	three	three	NUM
admet-7	177	2	types	type	NOUN
admet-7	177	3	of	of	ADP
admet-7	177	4	toxicities	toxicity	NOUN
admet-7	177	5	are	be	AUX
admet-7	177	6	recognized	recognize	VERB
admet-7	177	7	for	for	ADP
admet-7	177	8	doxorubicin	doxorubicin	PROPN
admet-7	177	9	,	,	PUNCT
admet-7	177	10	namely	namely	ADV
admet-7	177	11	acute	acute	ADJ
admet-7	177	12	,	,	PUNCT
admet-7	177	13	chronic	chronic	NOUN
admet-7	177	14	,	,	PUNCT
admet-7	177	15	and	and	CCONJ
admet-7	177	16	local	local	ADJ
admet-7	177	17	.	.	PUNCT
admet-7	178	1	the	the	DET
admet-7	178	2	acute	acute	ADJ
admet-7	178	3	toxicities	toxicity	NOUN
admet-7	178	4	including	include	VERB
admet-7	178	5	nausea	nausea	NOUN
admet-7	178	6	,	,	PUNCT
admet-7	178	7	vomiting	vomiting	NOUN
admet-7	178	8	,	,	PUNCT
admet-7	178	9	blood	blood	NOUN
admet-7	178	10	count	count	NOUN
admet-7	178	11	suppression	suppression	NOUN
admet-7	178	12	,	,	PUNCT
admet-7	178	13	and	and	CCONJ
admet-7	178	14	stomatitis	stomatitis	NOUN
admet-7	178	15	are	be	AUX
admet-7	178	16	usually	usually	ADV
admet-7	178	17	dose	dose	VERB
admet-7	178	18	limiting	limit	VERB
admet-7	178	19	.	.	PUNCT
admet-7	179	1	also	also	ADV
admet-7	179	2	,	,	PUNCT
admet-7	179	3	alopecia	alopecia	NOUN
admet-7	179	4	occurs	occur	VERB
admet-7	179	5	in	in	ADP
admet-7	179	6	more	more	ADJ
admet-7	179	7	than	than	ADP
admet-7	179	8	half	half	NOUN
admet-7	179	9	of	of	ADP
admet-7	179	10	patients	patient	NOUN
admet-7	179	11	receiving	receive	VERB
admet-7	179	12	standard	standard	ADJ
admet-7	179	13	intermittent	intermittent	ADJ
admet-7	179	14	doses	dose	NOUN
admet-7	179	15	[	[	X
admet-7	179	16	9	9	NUM
admet-7	179	17	]	]	PUNCT
admet-7	179	18	.	.	PUNCT
admet-7	180	1	congestive	congestive	ADJ
admet-7	180	2	heart	heart	NOUN
admet-7	180	3	failure	failure	NOUN
admet-7	180	4	and	and	CCONJ
admet-7	180	5	dilated	dilate	VERB
admet-7	180	6	cardiomyopathy	cardiomyopathy	ADJ
admet-7	180	7	are	be	AUX
admet-7	180	8	chronic	chronic	ADJ
admet-7	180	9	toxicities	toxicity	NOUN
admet-7	180	10	of	of	ADP
admet-7	180	11	doxorubicin	doxorubicin	PROPN
admet-7	180	12	that	that	PRON
admet-7	180	13	have	have	AUX
admet-7	180	14	received	receive	VERB
admet-7	180	15	considerable	considerable	ADJ
admet-7	180	16	attention	attention	NOUN
admet-7	180	17	[	[	X
admet-7	180	18	10	10	NUM
admet-7	180	19	]	]	PUNCT
admet-7	180	20	and	and	CCONJ
admet-7	180	21	generated	generate	VERB
admet-7	180	22	much	much	ADJ
admet-7	180	23	worry	worry	NOUN
admet-7	180	24	,	,	PUNCT
admet-7	180	25	especially	especially	ADV
admet-7	180	26	when	when	SCONJ
admet-7	180	27	patients	patient	NOUN
admet-7	180	28	have	have	AUX
admet-7	180	29	received	receive	VERB
admet-7	180	30	large	large	ADJ
admet-7	180	31	cumulative	cumulative	ADJ
admet-7	180	32	dosages	dosage	NOUN
admet-7	180	33	.	.	PUNCT
admet-7	181	1	pathologic	pathologic	ADJ
admet-7	181	2	findings	finding	NOUN
admet-7	181	3	from	from	ADP
admet-7	181	4	patients	patient	NOUN
admet-7	181	5	’	'	PUNCT
admet-7	181	6	endomyocardial	endomyocardial	ADJ
admet-7	181	7	biopsies	biopsy	NOUN
admet-7	181	8	revealed	reveal	VERB
admet-7	181	9	loss	loss	NOUN
admet-7	181	10	of	of	ADP
admet-7	181	11	myofibrils	myofibril	NOUN
admet-7	181	12	,	,	PUNCT
admet-7	181	13	dilation	dilation	NOUN
admet-7	181	14	of	of	ADP
admet-7	181	15	the	the	DET
admet-7	181	16	sarcoplasmic	sarcoplasmic	ADJ
admet-7	181	17	reticulum	reticulum	NOUN
admet-7	181	18	,	,	PUNCT
admet-7	181	19	vascular	vascular	ADJ
admet-7	181	20	degeneration	degeneration	NOUN
admet-7	181	21	,	,	PUNCT
admet-7	181	22	swelling	swell	VERB
admet-7	181	23	of	of	ADP
admet-7	181	24	mitochondria	mitochondria	NOUN
admet-7	181	25	,	,	PUNCT
admet-7	181	26	and	and	CCONJ
admet-7	181	27	increased	increase	VERB
admet-7	181	28	numbers	number	NOUN
admet-7	181	29	of	of	ADP
admet-7	181	30	lysosomes	lysosome	NOUN
admet-7	181	31	.	.	PUNCT
admet-7	182	1	this	this	DET
admet-7	182	2	morphologic	morphologic	ADJ
admet-7	182	3	pattern	pattern	NOUN
admet-7	182	4	has	have	AUX
admet-7	182	5	also	also	ADV
admet-7	182	6	been	be	AUX
admet-7	182	7	seen	see	VERB
admet-7	182	8	in	in	ADP
admet-7	182	9	rodents	rodent	NOUN
admet-7	182	10	(	(	PUNCT
admet-7	182	11	e.g.	e.g.	ADV
admet-7	182	12	mice	mouse	NOUN
admet-7	182	13	and	and	CCONJ
admet-7	182	14	rats	rat	NOUN
admet-7	182	15	)	)	PUNCT
admet-7	182	16	dosed	dose	VERB
admet-7	182	17	with	with	ADP
admet-7	182	18	doxorubicin	doxorubicin	PROPN
admet-7	182	19	,	,	PUNCT
admet-7	182	20	suggesting	suggest	VERB
admet-7	182	21	the	the	DET
admet-7	182	22	existence	existence	NOUN
admet-7	182	23	of	of	ADP
admet-7	182	24	a	a	DET
admet-7	182	25	species	species	NOUN
admet-7	182	26	-	-	PUNCT
admet-7	182	27	independent	independent	ADJ
admet-7	182	28	pathway	pathway	NOUN
admet-7	182	29	leading	lead	VERB
admet-7	182	30	to	to	ADP
admet-7	182	31	these	these	DET
admet-7	182	32	morphologic	morphologic	ADJ
admet-7	182	33	changes	change	NOUN
admet-7	182	34	[	[	X
admet-7	182	35	69	69	NUM
admet-7	182	36	]	]	PUNCT
admet-7	182	37	.	.	PUNCT
admet-7	183	1	an	an	DET
admet-7	183	2	early	early	ADJ
admet-7	183	3	clinical	clinical	ADJ
admet-7	183	4	study	study	NOUN
admet-7	183	5	demonstrated	demonstrate	VERB
admet-7	183	6	a	a	DET
admet-7	183	7	10	10	NUM
admet-7	183	8	%	%	NOUN
admet-7	183	9	incidence	incidence	NOUN
admet-7	183	10	of	of	ADP
admet-7	183	11	clinical	clinical	ADJ
admet-7	183	12	cardiomyopathy	cardiomyopathy	ADJ
admet-7	183	13	at	at	ADP
admet-7	183	14	a	a	DET
admet-7	183	15	cumulative	cumulative	ADJ
admet-7	183	16	doxorubicin	doxorubicin	ADJ
admet-7	183	17	dosage	dosage	NOUN
admet-7	183	18	of	of	ADP
admet-7	183	19	550	550	NUM
admet-7	183	20	mg	mg	NUM
admet-7	183	21	/	/	SYM
admet-7	183	22	m2	m2	PROPN
admet-7	183	23	,	,	PUNCT
admet-7	183	24	with	with	ADP
admet-7	183	25	a	a	DET
admet-7	183	26	sharp	sharp	ADJ
admet-7	183	27	increase	increase	NOUN
admet-7	183	28	in	in	ADP
admet-7	183	29	the	the	DET
admet-7	183	30	incidence	incidence	NOUN
admet-7	183	31	curve	curve	NOUN
admet-7	183	32	at	at	ADP
admet-7	183	33	progressively	progressively	ADV
admet-7	183	34	higher	high	ADJ
admet-7	183	35	dosages	dosage	NOUN
admet-7	183	36	[	[	X
admet-7	183	37	10	10	NUM
admet-7	183	38	]	]	PUNCT
admet-7	183	39	.	.	PUNCT
admet-7	184	1	however	however	ADV
admet-7	184	2	,	,	PUNCT
admet-7	184	3	it	it	PRON
admet-7	184	4	has	have	AUX
admet-7	184	5	been	be	AUX
admet-7	184	6	reported	report	VERB
admet-7	184	7	that	that	SCONJ
admet-7	184	8	the	the	DET
admet-7	184	9	probability	probability	NOUN
admet-7	184	10	of	of	ADP
admet-7	184	11	clinical	clinical	ADJ
admet-7	184	12	congestive	congestive	ADJ
admet-7	184	13	heart	heart	NOUN
admet-7	184	14	failure	failure	NOUN
admet-7	184	15	is	be	AUX
admet-7	184	16	never	never	ADV
admet-7	184	17	zero	zero	NUM
admet-7	184	18	with	with	ADP
admet-7	184	19	any	any	DET
admet-7	184	20	dose	dose	NOUN
admet-7	184	21	of	of	ADP
admet-7	184	22	doxorubicin	doxorubicin	PROPN
admet-7	184	23	,	,	PUNCT
admet-7	184	24	with	with	ADP
admet-7	184	25	some	some	DET
admet-7	184	26	patients	patient	NOUN
admet-7	184	27	developing	develop	VERB
admet-7	184	28	this	this	DET
admet-7	184	29	complication	complication	NOUN
admet-7	184	30	even	even	ADV
admet-7	184	31	after	after	ADP
admet-7	184	32	a	a	DET
admet-7	184	33	single	single	ADJ
admet-7	184	34	dose	dose	NOUN
admet-7	184	35	[	[	X
admet-7	184	36	70	70	NUM
admet-7	184	37	]	]	PUNCT
admet-7	184	38	.	.	PUNCT
admet-7	185	1	long	long	ADJ
admet-7	185	2	-	-	PUNCT
admet-7	185	3	term	term	NOUN
admet-7	185	4	follow	follow	NOUN
admet-7	185	5	-	-	PUNCT
admet-7	185	6	up	up	NOUN
admet-7	185	7	is	be	AUX
admet-7	185	8	usually	usually	ADV
admet-7	185	9	necessary	necessary	ADJ
admet-7	185	10	because	because	SCONJ
admet-7	185	11	congestive	congestive	ADJ
admet-7	185	12	heart	heart	NOUN
admet-7	185	13	failure	failure	NOUN
admet-7	185	14	may	may	AUX
admet-7	185	15	develop	develop	VERB
admet-7	185	16	several	several	ADJ
admet-7	185	17	years	year	NOUN
admet-7	185	18	after	after	SCONJ
admet-7	185	19	therapy	therapy	NOUN
admet-7	185	20	is	be	AUX
admet-7	185	21	completed	complete	VERB
admet-7	185	22	.	.	PUNCT
admet-7	186	1	although	although	SCONJ
admet-7	186	2	the	the	DET
admet-7	186	3	mechanisms	mechanism	NOUN
admet-7	186	4	leading	lead	VERB
admet-7	186	5	to	to	ADP
admet-7	186	6	the	the	DET
admet-7	186	7	cardiotoxicity	cardiotoxicity	NOUN
admet-7	186	8	are	be	AUX
admet-7	186	9	not	not	PART
admet-7	186	10	tam	tam	X
admet-7	186	11	admet	admet	PROPN
admet-7	186	12	&	&	CCONJ
admet-7	186	13	dmpk	dmpk	PROPN
admet-7	186	14	1(3	1(3	NUM
admet-7	186	15	)	)	PUNCT
admet-7	186	16	(	(	PUNCT
admet-7	186	17	2013	2013	NUM
admet-7	186	18	)	)	PUNCT
admet-7	186	19	29	29	NUM
admet-7	186	20	-	-	SYM
admet-7	186	21	44	44	NUM
admet-7	186	22	36	36	NUM
admet-7	186	23	fully	fully	ADV
admet-7	186	24	understood	understand	VERB
admet-7	186	25	,	,	PUNCT
admet-7	186	26	these	these	PRON
admet-7	186	27	are	be	AUX
admet-7	186	28	thought	think	VERB
admet-7	186	29	to	to	PART
admet-7	186	30	related	related	VERB
admet-7	186	31	to	to	ADP
admet-7	186	32	the	the	DET
admet-7	186	33	activities	activity	NOUN
admet-7	186	34	of	of	ADP
admet-7	186	35	toxic	toxic	ADJ
admet-7	186	36	metabolites	metabolite	NOUN
admet-7	186	37	,	,	PUNCT
admet-7	186	38	particularly	particularly	ADV
admet-7	186	39	doxorubicinol	doxorubicinol	ADJ
admet-7	186	40	,	,	PUNCT
admet-7	186	41	and	and	CCONJ
admet-7	186	42	to	to	ADP
admet-7	186	43	the	the	DET
admet-7	186	44	generation	generation	NOUN
admet-7	186	45	of	of	ADP
admet-7	186	46	reactive	reactive	ADJ
admet-7	186	47	oxygen	oxygen	NOUN
admet-7	186	48	species	specie	NOUN
admet-7	186	49	within	within	ADP
admet-7	186	50	the	the	DET
admet-7	186	51	cardiomyocytes	cardiomyocyte	NOUN
admet-7	186	52	(	(	PUNCT
admet-7	186	53	see	see	VERB
admet-7	186	54	fig	fig	NOUN
admet-7	186	55	.	.	PUNCT
admet-7	187	1	3	3	NUM
admet-7	187	2	)	)	PUNCT
admet-7	187	3	.	.	PUNCT
admet-7	188	1	the	the	DET
admet-7	188	2	most	most	ADV
admet-7	188	3	common	common	ADJ
admet-7	188	4	hypothesis	hypothesis	NOUN
admet-7	188	5	of	of	ADP
admet-7	188	6	doxorubicin	doxorubicin	PROPN
admet-7	188	7	-	-	PUNCT
admet-7	188	8	induced	induce	VERB
admet-7	188	9	cardiotoxicity	cardiotoxicity	NOUN
admet-7	188	10	is	be	AUX
admet-7	188	11	the	the	DET
admet-7	188	12	oxidative	oxidative	ADJ
admet-7	188	13	stress	stress	NOUN
admet-7	188	14	theory	theory	NOUN
admet-7	188	15	,	,	PUNCT
admet-7	188	16	where	where	SCONJ
admet-7	188	17	the	the	DET
admet-7	188	18	principal	principal	ADJ
admet-7	188	19	toxic	toxic	ADJ
admet-7	188	20	mechanisms	mechanism	NOUN
admet-7	188	21	involve	involve	VERB
admet-7	188	22	iron	iron	NOUN
admet-7	188	23	and	and	CCONJ
admet-7	188	24	redox	redox	ADJ
admet-7	188	25	reactions	reaction	NOUN
admet-7	188	26	[	[	X
admet-7	188	27	71	71	NUM
admet-7	188	28	]	]	PUNCT
admet-7	188	29	.	.	PUNCT
admet-7	189	1	it	it	PRON
admet-7	189	2	has	have	AUX
admet-7	189	3	been	be	AUX
admet-7	189	4	reported	report	VERB
admet-7	189	5	that	that	SCONJ
admet-7	189	6	when	when	SCONJ
admet-7	189	7	cardiomyocytes	cardiomyocyte	NOUN
admet-7	189	8	are	be	AUX
admet-7	189	9	exposed	expose	VERB
admet-7	189	10	to	to	ADP
admet-7	189	11	doxorubicin	doxorubicin	PROPN
admet-7	189	12	,	,	PUNCT
admet-7	189	13	activation	activation	NOUN
admet-7	189	14	of	of	ADP
admet-7	189	15	the	the	DET
admet-7	189	16	nuclear	nuclear	ADJ
admet-7	189	17	transcription	transcription	NOUN
admet-7	189	18	factor	factor	NOUN
admet-7	189	19	nfkb	nfkb	PROPN
admet-7	189	20	and	and	CCONJ
admet-7	189	21	apoptosis	apoptosis	NOUN
admet-7	189	22	occurred	occur	VERB
admet-7	189	23	after	after	ADP
admet-7	189	24	redox	redox	NOUN
admet-7	189	25	cycling	cycling	NOUN
admet-7	189	26	and	and	CCONJ
admet-7	189	27	formation	formation	NOUN
admet-7	189	28	of	of	ADP
admet-7	189	29	superoxide	superoxide	NOUN
admet-7	189	30	anion	anion	NOUN
admet-7	189	31	radicals	radical	NOUN
admet-7	189	32	and	and	CCONJ
admet-7	189	33	hydrogen	hydrogen	NOUN
admet-7	189	34	peroxides	peroxide	NOUN
admet-7	189	35	[	[	X
admet-7	189	36	72	72	NUM
admet-7	189	37	]	]	PUNCT
admet-7	189	38	.	.	PUNCT
admet-7	190	1	moreover	moreover	ADV
admet-7	190	2	,	,	PUNCT
admet-7	190	3	it	it	PRON
admet-7	190	4	has	have	AUX
admet-7	190	5	been	be	AUX
admet-7	190	6	shown	show	VERB
admet-7	190	7	that	that	SCONJ
admet-7	190	8	iron	iron	NOUN
admet-7	190	9	(	(	PUNCT
admet-7	190	10	fe(ii	fe(ii	PROPN
admet-7	190	11	)	)	PUNCT
admet-7	190	12	)	)	PUNCT
admet-7	190	13	plays	play	VERB
admet-7	190	14	a	a	DET
admet-7	190	15	key	key	ADJ
admet-7	190	16	role	role	NOUN
admet-7	190	17	in	in	ADP
admet-7	190	18	lipid	lipid	NOUN
admet-7	190	19	peroxidation	peroxidation	NOUN
admet-7	191	1	[	[	X
admet-7	191	2	73	73	NUM
admet-7	191	3	]	]	PUNCT
admet-7	191	4	.	.	PUNCT
admet-7	192	1	because	because	SCONJ
admet-7	192	2	cells	cell	NOUN
admet-7	192	3	have	have	VERB
admet-7	192	4	very	very	ADV
admet-7	192	5	little	little	ADJ
admet-7	192	6	or	or	CCONJ
admet-7	192	7	no	no	DET
admet-7	192	8	free	free	ADJ
admet-7	192	9	iron	iron	NOUN
admet-7	192	10	available	available	ADJ
admet-7	192	11	to	to	PART
admet-7	192	12	catalyse	catalyse	VERB
admet-7	192	13	free	free	ADJ
admet-7	192	14	radical	radical	ADJ
admet-7	192	15	reactions	reaction	NOUN
admet-7	192	16	[	[	X
admet-7	192	17	74	74	NUM
admet-7	192	18	]	]	PUNCT
admet-7	192	19	,	,	PUNCT
admet-7	192	20	it	it	PRON
admet-7	192	21	is	be	AUX
admet-7	192	22	conceivable	conceivable	ADJ
admet-7	192	23	that	that	SCONJ
admet-7	192	24	doxorubicin	doxorubicin	PROPN
admet-7	192	25	and	and	CCONJ
admet-7	192	26	doxorubicinol	doxorubicinol	PROPN
admet-7	192	27	mediate	mediate	VERB
admet-7	192	28	iron	iron	NOUN
admet-7	192	29	release	release	NOUN
admet-7	192	30	from	from	ADP
admet-7	192	31	ferritin	ferritin	ADJ
admet-7	192	32	and	and	CCONJ
admet-7	192	33	other	other	ADJ
admet-7	192	34	cellular	cellular	ADJ
admet-7	192	35	stores	store	NOUN
admet-7	193	1	[	[	X
admet-7	193	2	73,75	73,75	NOUN
admet-7	193	3	]	]	PUNCT
admet-7	193	4	.	.	PUNCT
admet-7	194	1	toxic	toxic	ADJ
admet-7	194	2	effects	effect	NOUN
admet-7	194	3	on	on	ADP
admet-7	194	4	a	a	DET
admet-7	194	5	number	number	NOUN
admet-7	194	6	of	of	ADP
admet-7	194	7	mitochondrial	mitochondrial	ADJ
admet-7	194	8	functions	function	NOUN
admet-7	194	9	have	have	AUX
admet-7	194	10	been	be	AUX
admet-7	194	11	reported	report	VERB
admet-7	194	12	for	for	ADP
admet-7	194	13	metabolites	metabolite	NOUN
admet-7	194	14	of	of	ADP
admet-7	194	15	doxorubicin	doxorubicin	PROPN
admet-7	194	16	[	[	X
admet-7	194	17	76,77	76,77	NOUN
admet-7	194	18	]	]	X
admet-7	194	19	.	.	PUNCT
admet-7	195	1	two	two	NUM
admet-7	195	2	local	local	ADJ
admet-7	195	3	toxicities	toxicity	NOUN
admet-7	195	4	of	of	ADP
admet-7	195	5	doxorubicin	doxorubicin	PROPN
admet-7	195	6	with	with	ADP
admet-7	195	7	potentially	potentially	ADV
admet-7	195	8	devastating	devastating	ADJ
admet-7	195	9	consequences	consequence	NOUN
admet-7	195	10	are	be	AUX
admet-7	195	11	extravasation	extravasation	NOUN
admet-7	195	12	skin	skin	NOUN
admet-7	195	13	injury	injury	NOUN
admet-7	195	14	(	(	PUNCT
admet-7	195	15	necrosis	necrosis	NOUN
admet-7	195	16	)	)	PUNCT
admet-7	196	1	[	[	X
admet-7	196	2	78	78	NUM
admet-7	196	3	]	]	PUNCT
admet-7	196	4	and	and	CCONJ
admet-7	196	5	the	the	DET
admet-7	196	6	radiation	radiation	NOUN
admet-7	196	7	recall	recall	NOUN
admet-7	196	8	reaction	reaction	NOUN
admet-7	196	9	[	[	X
admet-7	196	10	79	79	NUM
admet-7	196	11	]	]	PUNCT
admet-7	196	12	.	.	PUNCT
admet-7	197	1	the	the	DET
admet-7	197	2	development	development	NOUN
admet-7	197	3	of	of	ADP
admet-7	197	4	extravasation	extravasation	NOUN
admet-7	197	5	skin	skin	NOUN
admet-7	197	6	injury	injury	NOUN
admet-7	197	7	in	in	ADP
admet-7	197	8	connection	connection	NOUN
admet-7	197	9	with	with	ADP
admet-7	197	10	doxorubicin	doxorubicin	PROPN
admet-7	197	11	is	be	AUX
admet-7	197	12	largely	largely	ADV
admet-7	197	13	related	relate	VERB
admet-7	197	14	to	to	ADP
admet-7	197	15	the	the	DET
admet-7	197	16	therapy	therapy	NOUN
admet-7	197	17	being	be	AUX
admet-7	197	18	given	give	VERB
admet-7	197	19	by	by	ADP
admet-7	197	20	intravenous	intravenous	ADJ
admet-7	197	21	infusion	infusion	NOUN
admet-7	197	22	.	.	PUNCT
admet-7	198	1	with	with	ADP
admet-7	198	2	this	this	DET
admet-7	198	3	route	route	NOUN
admet-7	198	4	of	of	ADP
admet-7	198	5	administration	administration	NOUN
admet-7	198	6	,	,	PUNCT
admet-7	198	7	tissue	tissue	NOUN
admet-7	198	8	damage	damage	NOUN
admet-7	198	9	can	can	AUX
admet-7	198	10	occur	occur	VERB
admet-7	198	11	in	in	ADP
admet-7	198	12	close	close	ADJ
admet-7	198	13	proximity	proximity	NOUN
admet-7	198	14	to	to	ADP
admet-7	198	15	the	the	DET
admet-7	198	16	infusion	infusion	NOUN
admet-7	198	17	site	site	NOUN
admet-7	198	18	,	,	PUNCT
admet-7	198	19	probably	probably	ADV
admet-7	198	20	due	due	ADP
admet-7	198	21	to	to	ADP
admet-7	198	22	the	the	DET
admet-7	198	23	drug	drug	NOUN
admet-7	198	24	is	be	AUX
admet-7	198	25	being	be	AUX
admet-7	198	26	absorbed	absorb	VERB
admet-7	198	27	by	by	ADP
admet-7	198	28	local	local	ADJ
admet-7	198	29	cells	cell	NOUN
admet-7	198	30	in	in	ADP
admet-7	198	31	the	the	DET
admet-7	198	32	tissue	tissue	NOUN
admet-7	198	33	leading	lead	VERB
admet-7	198	34	to	to	ADP
admet-7	198	35	cell	cell	NOUN
admet-7	198	36	death	death	NOUN
admet-7	198	37	.	.	PUNCT
admet-7	199	1	the	the	DET
admet-7	199	2	radiation	radiation	NOUN
admet-7	199	3	recall	recall	NOUN
admet-7	199	4	reaction	reaction	NOUN
admet-7	199	5	,	,	PUNCT
admet-7	199	6	which	which	PRON
admet-7	199	7	remains	remain	VERB
admet-7	199	8	a	a	DET
admet-7	199	9	poorly	poorly	ADV
admet-7	199	10	understood	understand	VERB
admet-7	199	11	phenomenon	phenomenon	NOUN
admet-7	199	12	,	,	PUNCT
admet-7	199	13	occurred	occur	VERB
admet-7	199	14	in	in	ADP
admet-7	199	15	patients	patient	NOUN
admet-7	199	16	who	who	PRON
admet-7	199	17	had	have	AUX
admet-7	199	18	had	have	VERB
admet-7	199	19	prior	prior	ADJ
admet-7	199	20	irradiation	irradiation	NOUN
admet-7	199	21	for	for	ADP
admet-7	199	22	neoplastic	neoplastic	ADJ
admet-7	199	23	disease	disease	NOUN
admet-7	199	24	.	.	PUNCT
admet-7	200	1	the	the	DET
admet-7	200	2	observed	observed	ADJ
admet-7	200	3	reactions	reaction	NOUN
admet-7	200	4	were	be	AUX
admet-7	200	5	painful	painful	ADJ
admet-7	200	6	,	,	PUNCT
admet-7	200	7	erythematous	erythematous	ADJ
admet-7	200	8	,	,	PUNCT
admet-7	200	9	and	and	CCONJ
admet-7	200	10	warm	warm	ADJ
admet-7	200	11	dermatitides	dermatitide	NOUN
admet-7	200	12	located	locate	VERB
admet-7	200	13	precisely	precisely	ADV
admet-7	200	14	in	in	ADP
admet-7	200	15	the	the	DET
admet-7	200	16	previous	previous	ADJ
admet-7	200	17	field	field	NOUN
admet-7	200	18	of	of	ADP
admet-7	200	19	irradiation	irradiation	NOUN
admet-7	200	20	.	.	PUNCT
admet-7	201	1	4	4	X
admet-7	201	2	.	.	X
admet-7	201	3	pharmacokinetics	pharmacokinetic	NOUN
admet-7	201	4	of	of	ADP
admet-7	201	5	doxorubicin	doxorubicin	PROPN
admet-7	201	6	4.1	4.1	NUM
admet-7	201	7	.	.	PUNCT
admet-7	202	1	systemic	systemic	ADJ
admet-7	202	2	administration	administration	NOUN
admet-7	202	3	doxorubicin	doxorubicin	PROPN
admet-7	202	4	exhibits	exhibit	VERB
admet-7	202	5	linear	linear	ADJ
admet-7	202	6	pharmacokinetics	pharmacokinetic	NOUN
admet-7	202	7	after	after	ADP
admet-7	202	8	intravenous	intravenous	ADJ
admet-7	202	9	administration	administration	NOUN
admet-7	202	10	.	.	PUNCT
admet-7	203	1	it	it	PRON
admet-7	203	2	is	be	AUX
admet-7	203	3	widely	widely	ADV
admet-7	203	4	distributed	distribute	VERB
admet-7	203	5	in	in	ADP
admet-7	203	6	the	the	DET
admet-7	203	7	plasma	plasma	NOUN
admet-7	203	8	and	and	CCONJ
admet-7	203	9	tissues	tissue	NOUN
admet-7	203	10	,	,	PUNCT
admet-7	203	11	with	with	ADP
admet-7	203	12	a	a	DET
admet-7	203	13	volume	volume	NOUN
admet-7	203	14	of	of	ADP
admet-7	203	15	distribution	distribution	NOUN
admet-7	203	16	exceeding	exceed	VERB
admet-7	203	17	500	500	NUM
admet-7	203	18	l	l	NOUN
admet-7	203	19	/	/	SYM
admet-7	203	20	m2	m2	PROPN
admet-7	203	21	.	.	PUNCT
admet-7	204	1	it	it	PRON
admet-7	204	2	undergoes	undergo	VERB
admet-7	204	3	triphasic	triphasic	ADJ
admet-7	204	4	plasma	plasma	NOUN
admet-7	204	5	decay	decay	NOUN
admet-7	204	6	,	,	PUNCT
admet-7	204	7	with	with	ADP
admet-7	204	8	an	an	DET
admet-7	204	9	initial	initial	ADJ
admet-7	204	10	half	half	ADJ
admet-7	204	11	-	-	PUNCT
admet-7	204	12	life	life	NOUN
admet-7	204	13	(	(	PUNCT
admet-7	204	14	t1⁄2α	t1⁄2α	NUM
admet-7	204	15	)	)	PUNCT
admet-7	204	16	of	of	ADP
admet-7	204	17	4.8	4.8	NUM
admet-7	204	18	min	min	NOUN
admet-7	204	19	,	,	PUNCT
admet-7	204	20	a	a	DET
admet-7	204	21	t1⁄2β	t1⁄2β	NOUN
admet-7	204	22	of	of	ADP
admet-7	204	23	2.6	2.6	NUM
admet-7	204	24	hours	hour	NOUN
admet-7	204	25	and	and	CCONJ
admet-7	204	26	a	a	DET
admet-7	204	27	terminal	terminal	NOUN
admet-7	204	28	t1⁄2γ	t1⁄2γ	PUNCT
admet-7	204	29	of	of	ADP
admet-7	204	30	about	about	ADV
admet-7	204	31	48	48	NUM
admet-7	204	32	hours	hour	NOUN
admet-7	204	33	[	[	X
admet-7	204	34	80	80	NUM
admet-7	204	35	]	]	PUNCT
admet-7	204	36	.	.	PUNCT
admet-7	205	1	in	in	ADP
admet-7	205	2	patients	patient	NOUN
admet-7	205	3	with	with	ADP
admet-7	205	4	normal	normal	ADJ
admet-7	205	5	liver	liver	NOUN
admet-7	205	6	function	function	NOUN
admet-7	205	7	,	,	PUNCT
admet-7	205	8	hepatic	hepatic	ADJ
admet-7	205	9	clearance	clearance	NOUN
admet-7	205	10	is	be	AUX
admet-7	205	11	high	high	ADJ
admet-7	205	12	and	and	CCONJ
admet-7	205	13	more	more	ADJ
admet-7	205	14	than	than	ADP
admet-7	205	15	50	50	NUM
admet-7	205	16	%	%	NOUN
admet-7	205	17	of	of	ADP
admet-7	205	18	the	the	DET
admet-7	205	19	drug	drug	NOUN
admet-7	205	20	is	be	AUX
admet-7	205	21	excreted	excrete	VERB
admet-7	205	22	in	in	ADP
admet-7	205	23	the	the	DET
admet-7	205	24	bile	bile	NOUN
admet-7	205	25	within	within	ADP
admet-7	205	26	7	7	NUM
admet-7	205	27	days	day	NOUN
admet-7	205	28	after	after	ADP
admet-7	205	29	treatment	treatment	NOUN
admet-7	205	30	.	.	PUNCT
admet-7	206	1	due	due	ADP
admet-7	206	2	to	to	ADP
admet-7	206	3	the	the	DET
admet-7	206	4	important	important	ADJ
admet-7	206	5	role	role	NOUN
admet-7	206	6	of	of	ADP
admet-7	206	7	hepatic	hepatic	ADJ
admet-7	206	8	metabolism	metabolism	NOUN
admet-7	206	9	and	and	CCONJ
admet-7	206	10	biliary	biliary	NOUN
admet-7	206	11	excretion	excretion	NOUN
admet-7	206	12	,	,	PUNCT
admet-7	206	13	patients	patient	NOUN
admet-7	206	14	with	with	ADP
admet-7	206	15	liver	liver	NOUN
admet-7	206	16	dysfunction	dysfunction	NOUN
admet-7	206	17	show	show	VERB
admet-7	206	18	a	a	DET
admet-7	206	19	rather	rather	ADV
admet-7	206	20	different	different	ADJ
admet-7	206	21	pattern	pattern	NOUN
admet-7	206	22	in	in	ADP
admet-7	206	23	drug	drug	NOUN
admet-7	206	24	distribution	distribution	NOUN
admet-7	206	25	.	.	PUNCT
admet-7	207	1	in	in	ADP
admet-7	207	2	particular	particular	ADJ
admet-7	207	3	,	,	PUNCT
admet-7	207	4	the	the	DET
admet-7	207	5	half	half	ADJ
admet-7	207	6	-	-	PUNCT
admet-7	207	7	life	life	NOUN
admet-7	207	8	and	and	CCONJ
admet-7	207	9	auc	auc	NOUN
admet-7	207	10	were	be	AUX
admet-7	207	11	found	find	VERB
admet-7	207	12	to	to	PART
admet-7	207	13	be	be	AUX
admet-7	207	14	increased	increase	VERB
admet-7	207	15	almost	almost	ADV
admet-7	207	16	by	by	ADP
admet-7	207	17	3	3	NUM
admet-7	207	18	-	-	ADJ
admet-7	207	19	fold	fold	ADJ
admet-7	207	20	(	(	PUNCT
admet-7	207	21	and	and	CCONJ
admet-7	207	22	clearance	clearance	NOUN
admet-7	207	23	decreased	decrease	VERB
admet-7	207	24	by	by	ADP
admet-7	207	25	almost	almost	ADV
admet-7	207	26	3fold	3fold	NUM
admet-7	207	27	)	)	PUNCT
admet-7	207	28	compared	compare	VERB
admet-7	207	29	with	with	ADP
admet-7	207	30	patients	patient	NOUN
admet-7	207	31	with	with	ADP
admet-7	207	32	normal	normal	ADJ
admet-7	207	33	hepatic	hepatic	ADJ
admet-7	207	34	function	function	NOUN
admet-7	207	35	[	[	X
admet-7	207	36	81	81	NUM
admet-7	207	37	]	]	PUNCT
admet-7	207	38	.	.	PUNCT
admet-7	208	1	on	on	ADP
admet-7	208	2	the	the	DET
admet-7	208	3	other	other	ADJ
admet-7	208	4	hand	hand	NOUN
admet-7	208	5	,	,	PUNCT
admet-7	208	6	the	the	DET
admet-7	208	7	pegylated	pegylated	ADJ
admet-7	208	8	liposomal	liposomal	ADJ
admet-7	208	9	formulations	formulation	NOUN
admet-7	208	10	of	of	ADP
admet-7	208	11	doxorubicin	doxorubicin	PROPN
admet-7	208	12	showed	show	VERB
admet-7	208	13	somewhat	somewhat	ADV
admet-7	208	14	different	different	ADJ
admet-7	208	15	pharmacokinetic	pharmacokinetic	ADJ
admet-7	208	16	performance	performance	NOUN
admet-7	208	17	.	.	PUNCT
admet-7	209	1	the	the	DET
admet-7	209	2	presence	presence	NOUN
admet-7	209	3	of	of	ADP
admet-7	209	4	the	the	DET
admet-7	209	5	outer	outer	ADJ
admet-7	209	6	polyethylene	polyethylene	NOUN
admet-7	209	7	glycol	glycol	NOUN
admet-7	209	8	polymer	polymer	NOUN
admet-7	209	9	layer	layer	NOUN
admet-7	209	10	greatly	greatly	ADV
admet-7	209	11	reduces	reduce	VERB
admet-7	209	12	uptake	uptake	NOUN
admet-7	209	13	of	of	ADP
admet-7	209	14	the	the	DET
admet-7	209	15	drug	drug	NOUN
admet-7	209	16	by	by	ADP
admet-7	209	17	the	the	DET
admet-7	209	18	reticulo	reticulo	NOUN
admet-7	209	19	-	-	PUNCT
admet-7	209	20	endothelial	endothelial	NOUN
admet-7	209	21	system	system	NOUN
admet-7	209	22	,	,	PUNCT
admet-7	209	23	resulting	result	VERB
admet-7	209	24	in	in	ADP
admet-7	209	25	prolonged	prolonged	ADJ
admet-7	209	26	circulation	circulation	NOUN
admet-7	209	27	in	in	ADP
admet-7	209	28	the	the	DET
admet-7	209	29	plasma	plasma	NOUN
admet-7	209	30	,	,	PUNCT
admet-7	209	31	relatively	relatively	ADV
admet-7	209	32	little	little	ADJ
admet-7	209	33	tissue	tissue	NOUN
admet-7	209	34	distribution	distribution	NOUN
admet-7	209	35	and	and	CCONJ
admet-7	209	36	reduced	reduce	VERB
admet-7	209	37	volume	volume	NOUN
admet-7	209	38	of	of	ADP
admet-7	209	39	distribution	distribution	NOUN
admet-7	209	40	.	.	PUNCT
admet-7	210	1	the	the	DET
admet-7	210	2	pharmacokinetics	pharmacokinetic	NOUN
admet-7	210	3	are	be	AUX
admet-7	210	4	reported	report	VERB
admet-7	210	5	to	to	PART
admet-7	210	6	be	be	AUX
admet-7	210	7	biphasic	biphasic	ADJ
admet-7	210	8	,	,	PUNCT
admet-7	210	9	with	with	ADP
admet-7	210	10	half	half	ADJ
admet-7	210	11	-	-	PUNCT
admet-7	210	12	lives	life	NOUN
admet-7	210	13	of	of	ADP
admet-7	210	14	1	1	NUM
admet-7	210	15	–	–	SYM
admet-7	210	16	3	3	NUM
admet-7	210	17	hours	hour	NOUN
admet-7	210	18	and	and	CCONJ
admet-7	210	19	30	30	NUM
admet-7	210	20	–	–	SYM
admet-7	210	21	90	90	NUM
admet-7	210	22	hours	hour	NOUN
admet-7	210	23	,	,	PUNCT
admet-7	210	24	respectively	respectively	ADV
admet-7	210	25	.	.	PUNCT
admet-7	211	1	the	the	DET
admet-7	211	2	auc	auc	NOUN
admet-7	211	3	after	after	ADP
admet-7	211	4	a	a	DET
admet-7	211	5	dose	dose	NOUN
admet-7	211	6	of	of	ADP
admet-7	211	7	50	50	NUM
admet-7	211	8	mg	mg	NOUN
admet-7	211	9	/	/	SYM
admet-7	211	10	m2	m2	PROPN
admet-7	211	11	is	be	AUX
admet-7	211	12	approximately	approximately	ADV
admet-7	211	13	300	300	NUM
admet-7	211	14	-	-	NUM
admet-7	211	15	fold	fold	VERB
admet-7	211	16	greater	great	ADJ
admet-7	211	17	than	than	ADP
admet-7	211	18	that	that	PRON
admet-7	211	19	with	with	ADP
admet-7	211	20	free	free	ADJ
admet-7	211	21	drug	drug	NOUN
admet-7	211	22	[	[	X
admet-7	211	23	82	82	NUM
admet-7	211	24	]	]	PUNCT
admet-7	211	25	.	.	PUNCT
admet-7	212	1	clearance	clearance	NOUN
admet-7	212	2	is	be	AUX
admet-7	212	3	drastically	drastically	ADV
admet-7	212	4	reduced	reduce	VERB
admet-7	212	5	(	(	PUNCT
admet-7	212	6	250	250	NUM
admet-7	212	7	-	-	NUM
admet-7	212	8	fold	fold	ADJ
admet-7	212	9	)	)	PUNCT
admet-7	212	10	.	.	PUNCT
admet-7	213	1	tumour	tumour	PRON
admet-7	213	2	neovasculature	neovasculature	NOUN
admet-7	213	3	has	have	AUX
admet-7	213	4	been	be	AUX
admet-7	213	5	reported	report	VERB
admet-7	213	6	to	to	PART
admet-7	213	7	permit	permit	VERB
admet-7	213	8	penetration	penetration	NOUN
admet-7	213	9	of	of	ADP
admet-7	213	10	liposomal	liposomal	PROPN
admet-7	213	11	doxorubicin	doxorubicin	PROPN
admet-7	213	12	into	into	ADP
admet-7	213	13	tumour	tumour	ADJ
admet-7	213	14	tissue	tissue	NOUN
admet-7	214	1	[	[	X
admet-7	214	2	82	82	NUM
admet-7	214	3	]	]	PUNCT
admet-7	214	4	.	.	PUNCT
admet-7	215	1	it	it	PRON
admet-7	215	2	has	have	AUX
admet-7	215	3	been	be	AUX
admet-7	215	4	shown	show	VERB
admet-7	215	5	that	that	SCONJ
admet-7	215	6	in	in	ADP
admet-7	215	7	a	a	DET
admet-7	215	8	preclinical	preclinical	ADJ
admet-7	215	9	model	model	NOUN
admet-7	215	10	,	,	PUNCT
admet-7	215	11	the	the	DET
admet-7	215	12	hepatic	hepatic	ADJ
admet-7	215	13	distribution	distribution	NOUN
admet-7	215	14	of	of	ADP
admet-7	215	15	liposomal	liposomal	ADJ
admet-7	215	16	doxorubicin	doxorubicin	PROPN
admet-7	215	17	was	be	AUX
admet-7	215	18	restricted	restrict	VERB
admet-7	215	19	to	to	ADP
admet-7	215	20	the	the	DET
admet-7	215	21	vascular	vascular	ADJ
admet-7	215	22	space	space	NOUN
admet-7	215	23	and	and	CCONJ
admet-7	215	24	the	the	DET
admet-7	215	25	liposomes	liposome	NOUN
admet-7	215	26	were	be	AUX
admet-7	215	27	unable	unable	ADJ
admet-7	215	28	to	to	PART
admet-7	215	29	pass	pass	VERB
admet-7	215	30	through	through	ADP
admet-7	215	31	the	the	DET
admet-7	215	32	fenestrations	fenestration	NOUN
admet-7	215	33	in	in	ADP
admet-7	215	34	the	the	DET
admet-7	215	35	sinusoidal	sinusoidal	ADJ
admet-7	215	36	endothelium	endothelium	NOUN
admet-7	215	37	of	of	ADP
admet-7	215	38	the	the	DET
admet-7	215	39	liver	liver	NOUN
admet-7	215	40	[	[	X
admet-7	215	41	83	83	NUM
admet-7	215	42	]	]	PUNCT
admet-7	215	43	.	.	PUNCT
admet-7	216	1	this	this	DET
admet-7	216	2	observation	observation	NOUN
admet-7	216	3	may	may	AUX
admet-7	216	4	offer	offer	VERB
admet-7	216	5	insight	insight	NOUN
admet-7	216	6	into	into	ADP
admet-7	216	7	the	the	DET
admet-7	216	8	reduced	reduce	VERB
admet-7	216	9	hepatic	hepatic	ADJ
admet-7	216	10	metabolism	metabolism	NOUN
admet-7	216	11	of	of	ADP
admet-7	216	12	liposomal	liposomal	ADJ
admet-7	216	13	doxorubicin	doxorubicin	PROPN
admet-7	216	14	,	,	PUNCT
admet-7	216	15	since	since	SCONJ
admet-7	216	16	the	the	DET
admet-7	216	17	drug	drug	NOUN
admet-7	216	18	is	be	AUX
admet-7	216	19	unable	unable	ADJ
admet-7	216	20	to	to	PART
admet-7	216	21	gain	gain	VERB
admet-7	216	22	access	access	NOUN
admet-7	216	23	to	to	ADP
admet-7	216	24	the	the	DET
admet-7	216	25	hepatocytes	hepatocyte	NOUN
admet-7	216	26	.	.	PUNCT
admet-7	217	1	in	in	ADP
admet-7	217	2	hcc	hcc	PROPN
admet-7	217	3	patients	patient	NOUN
admet-7	217	4	,	,	PUNCT
admet-7	217	5	it	it	PRON
admet-7	217	6	has	have	AUX
admet-7	217	7	been	be	AUX
admet-7	217	8	shown	show	VERB
admet-7	217	9	that	that	SCONJ
admet-7	217	10	when	when	SCONJ
admet-7	217	11	doxorubicin	doxorubicin	PROPN
admet-7	217	12	is	be	AUX
admet-7	217	13	dosed	dose	VERB
admet-7	217	14	intra	intra	ADJ
admet-7	217	15	-	-	ADJ
admet-7	217	16	arterially	arterially	ADV
admet-7	217	17	(	(	PUNCT
admet-7	217	18	without	without	ADP
admet-7	217	19	any	any	DET
admet-7	217	20	subsequent	subsequent	ADJ
admet-7	217	21	embolization	embolization	NOUN
admet-7	217	22	procedure	procedure	NOUN
admet-7	217	23	)	)	PUNCT
admet-7	217	24	,	,	PUNCT
admet-7	217	25	the	the	DET
admet-7	217	26	pharmacokinetics	pharmacokinetic	NOUN
admet-7	217	27	is	be	AUX
admet-7	217	28	very	very	ADV
admet-7	217	29	similar	similar	ADJ
admet-7	217	30	to	to	ADP
admet-7	217	31	that	that	PRON
admet-7	217	32	of	of	ADP
admet-7	217	33	the	the	DET
admet-7	217	34	intravenously	intravenously	ADV
admet-7	217	35	admet	admet	PROPN
admet-7	217	36	&	&	CCONJ
admet-7	217	37	dmpk	dmpk	PROPN
admet-7	217	38	1(3	1(3	NUM
admet-7	217	39	)	)	PUNCT
admet-7	217	40	(	(	PUNCT
admet-7	217	41	2013	2013	NUM
admet-7	217	42	)	)	PUNCT
admet-7	217	43	29	29	NUM
admet-7	217	44	-	-	SYM
admet-7	217	45	44	44	NUM
admet-7	217	46	doxorubicin	doxorubicin	NOUN
admet-7	217	47	and	and	CCONJ
admet-7	217	48	hcc	hcc	PROPN
admet-7	217	49	doi	doi	PROPN
admet-7	217	50	:	:	PUNCT
admet-7	217	51	10.5599	10.5599	NUM
admet-7	217	52	/	/	SYM
admet-7	217	53	admet.1.3.7	admet.1.3.7	NOUN
admet-7	217	54	37	37	NUM
admet-7	217	55	dosed	dose	VERB
admet-7	217	56	drug	drug	NOUN
admet-7	217	57	[	[	X
admet-7	217	58	84	84	NUM
admet-7	217	59	]	]	PUNCT
admet-7	217	60	.	.	PUNCT
admet-7	218	1	in	in	ADP
admet-7	218	2	other	other	ADJ
admet-7	218	3	words	word	NOUN
admet-7	218	4	,	,	PUNCT
admet-7	218	5	the	the	DET
admet-7	218	6	drug	drug	NOUN
admet-7	218	7	disappearance	disappearance	NOUN
admet-7	218	8	profiles	profile	NOUN
admet-7	218	9	obtained	obtain	VERB
admet-7	218	10	from	from	ADP
admet-7	218	11	intra	intra	ADJ
admet-7	218	12	-	-	ADJ
admet-7	218	13	arterial	arterial	ADJ
admet-7	218	14	and	and	CCONJ
admet-7	218	15	intravenous	intravenous	ADJ
admet-7	218	16	administrations	administration	NOUN
admet-7	218	17	were	be	AUX
admet-7	218	18	similar	similar	ADJ
admet-7	218	19	.	.	PUNCT
admet-7	219	1	clearly	clearly	ADV
admet-7	219	2	,	,	PUNCT
admet-7	219	3	intravenous	intravenous	ADJ
admet-7	219	4	or	or	CCONJ
admet-7	219	5	intra	intra	ADJ
admet-7	219	6	-	-	ADJ
admet-7	219	7	arterial	arterial	ADJ
admet-7	219	8	administration	administration	NOUN
admet-7	219	9	of	of	ADP
admet-7	219	10	doxorubicin	doxorubicin	PROPN
admet-7	219	11	alone	alone	ADV
admet-7	219	12	may	may	AUX
admet-7	219	13	not	not	PART
admet-7	219	14	necessarily	necessarily	ADV
admet-7	219	15	be	be	AUX
admet-7	219	16	able	able	ADJ
admet-7	219	17	to	to	PART
admet-7	219	18	deliver	deliver	VERB
admet-7	219	19	a	a	DET
admet-7	219	20	sufficient	sufficient	ADJ
admet-7	219	21	drug	drug	NOUN
admet-7	219	22	concentration	concentration	NOUN
admet-7	219	23	to	to	ADP
admet-7	219	24	a	a	DET
admet-7	219	25	hepatic	hepatic	ADJ
admet-7	219	26	tumour	tumour	NOUN
admet-7	219	27	.	.	PUNCT
admet-7	220	1	4.2	4.2	NUM
admet-7	220	2	.	.	PUNCT
admet-7	221	1	deb	deb	PROPN
admet-7	221	2	and	and	CCONJ
admet-7	221	3	locoregional	locoregional	PROPN
admet-7	221	4	administration	administration	NOUN
admet-7	221	5	next	next	ADV
admet-7	221	6	,	,	PUNCT
admet-7	221	7	we	we	PRON
admet-7	221	8	turn	turn	VERB
admet-7	221	9	our	our	PRON
admet-7	221	10	attention	attention	NOUN
admet-7	221	11	to	to	ADP
admet-7	221	12	deb	deb	PROPN
admet-7	221	13	,	,	PUNCT
admet-7	221	14	namely	namely	ADV
admet-7	221	15	the	the	DET
admet-7	221	16	dc	dc	PROPN
admet-7	221	17	beads	bead	NOUN
admet-7	221	18	loaded	load	VERB
admet-7	221	19	with	with	ADP
admet-7	221	20	doxorubicin	doxorubicin	PROPN
admet-7	221	21	.	.	PUNCT
admet-7	222	1	the	the	DET
admet-7	222	2	in	in	ADV
admet-7	222	3	vitro	vitro	X
admet-7	222	4	elution	elution	NOUN
admet-7	222	5	kinetics	kinetic	NOUN
admet-7	222	6	of	of	ADP
admet-7	222	7	doxorubicin	doxorubicin	PROPN
admet-7	222	8	from	from	ADP
admet-7	222	9	dc	dc	PROPN
admet-7	222	10	beads	bead	NOUN
admet-7	222	11	has	have	AUX
admet-7	222	12	been	be	AUX
admet-7	222	13	assessed	assess	VERB
admet-7	222	14	using	use	VERB
admet-7	222	15	a	a	DET
admet-7	222	16	t	t	NOUN
admet-7	222	17	-	-	PUNCT
admet-7	222	18	cell	cell	NOUN
admet-7	222	19	apparatus	apparatus	NOUN
admet-7	222	20	,	,	PUNCT
admet-7	222	21	with	with	ADP
admet-7	222	22	a	a	DET
admet-7	222	23	schematic	schematic	ADJ
admet-7	222	24	depicted	depict	VERB
admet-7	222	25	in	in	ADP
admet-7	222	26	fig	fig	NOUN
admet-7	222	27	.	.	PUNCT
admet-7	223	1	4	4	NUM
admet-7	224	1	[	[	SYM
admet-7	224	2	42	42	NUM
admet-7	224	3	]	]	PUNCT
admet-7	224	4	.	.	PUNCT
admet-7	225	1	figure	figure	NOUN
admet-7	225	2	4	4	NUM
admet-7	225	3	.	.	PUNCT
admet-7	225	4	schematic	schematic	ADJ
admet-7	225	5	diagram	diagram	NOUN
admet-7	225	6	of	of	ADP
admet-7	225	7	the	the	DET
admet-7	225	8	t	t	PROPN
admet-7	225	9	-	-	PUNCT
admet-7	225	10	cell	cell	NOUN
admet-7	225	11	apparatus	apparatus	NOUN
admet-7	225	12	(	(	PUNCT
admet-7	225	13	citation	citation	NOUN
admet-7	225	14	see	see	VERB
admet-7	225	15	text	text	NOUN
admet-7	225	16	)	)	PUNCT
admet-7	225	17	.	.	PUNCT
admet-7	226	1	it	it	PRON
admet-7	226	2	has	have	AUX
admet-7	226	3	been	be	AUX
admet-7	226	4	shown	show	VERB
admet-7	226	5	that	that	SCONJ
admet-7	226	6	the	the	DET
admet-7	226	7	doxorubicin	doxorubicin	PROPN
admet-7	226	8	did	do	AUX
admet-7	226	9	not	not	PART
admet-7	226	10	release	release	VERB
admet-7	226	11	from	from	ADP
admet-7	226	12	the	the	DET
admet-7	226	13	beads	bead	NOUN
admet-7	226	14	when	when	SCONJ
admet-7	226	15	the	the	DET
admet-7	226	16	elution	elution	NOUN
admet-7	226	17	medium	medium	NOUN
admet-7	226	18	was	be	AUX
admet-7	226	19	pure	pure	ADJ
admet-7	226	20	water	water	NOUN
admet-7	226	21	.	.	PUNCT
admet-7	227	1	when	when	SCONJ
admet-7	227	2	the	the	DET
admet-7	227	3	elution	elution	NOUN
admet-7	227	4	medium	medium	NOUN
admet-7	227	5	contained	contain	VERB
admet-7	227	6	ions	ion	NOUN
admet-7	227	7	and	and	CCONJ
admet-7	227	8	phosphate	phosphate	ADJ
admet-7	227	9	-	-	PUNCT
admet-7	227	10	buffered	buffer	VERB
admet-7	227	11	saline	saline	NOUN
admet-7	227	12	solution	solution	NOUN
admet-7	227	13	,	,	PUNCT
admet-7	227	14	reproducible	reproducible	ADJ
admet-7	227	15	and	and	CCONJ
admet-7	227	16	sustained	sustained	ADJ
admet-7	227	17	release	release	NOUN
admet-7	227	18	profiles	profile	NOUN
admet-7	227	19	were	be	AUX
admet-7	227	20	achievable	achievable	ADJ
admet-7	227	21	.	.	PUNCT
admet-7	228	1	with	with	ADP
admet-7	228	2	a	a	DET
admet-7	228	3	drug	drug	NOUN
admet-7	228	4	load	load	NOUN
admet-7	228	5	of	of	ADP
admet-7	228	6	25	25	NUM
admet-7	228	7	mg	mg	NUM
admet-7	228	8	/	/	SYM
admet-7	228	9	ml	ml	NOUN
admet-7	228	10	bead	bead	NOUN
admet-7	228	11	,	,	PUNCT
admet-7	228	12	it	it	PRON
admet-7	228	13	has	have	AUX
admet-7	228	14	been	be	AUX
admet-7	228	15	shown	show	VERB
admet-7	228	16	that	that	SCONJ
admet-7	228	17	the	the	DET
admet-7	228	18	rate	rate	NOUN
admet-7	228	19	of	of	ADP
admet-7	228	20	drug	drug	NOUN
admet-7	228	21	release	release	NOUN
admet-7	228	22	from	from	ADP
admet-7	228	23	700	700	NUM
admet-7	228	24	–	–	PUNCT
admet-7	228	25	900	900	NUM
admet-7	228	26	μm	μm	NOUN
admet-7	228	27	beads	bead	NOUN
admet-7	228	28	was	be	AUX
admet-7	228	29	slower	slow	ADJ
admet-7	228	30	than	than	ADP
admet-7	228	31	that	that	PRON
admet-7	228	32	from	from	ADP
admet-7	228	33	100	100	NUM
admet-7	228	34	–	–	PUNCT
admet-7	229	1	300	300	NUM
admet-7	229	2	μm	μm	NUM
admet-7	229	3	beads	bead	NOUN
admet-7	229	4	,	,	PUNCT
admet-7	229	5	with	with	ADP
admet-7	229	6	half	half	ADJ
admet-7	229	7	-	-	PUNCT
admet-7	229	8	lives	life	NOUN
admet-7	229	9	of	of	ADP
admet-7	229	10	1,730	1,730	NUM
admet-7	229	11	and	and	CCONJ
admet-7	229	12	150	150	NUM
admet-7	229	13	hours	hour	NOUN
admet-7	229	14	,	,	PUNCT
admet-7	229	15	respectively	respectively	ADV
admet-7	229	16	[	[	X
admet-7	229	17	42	42	NUM
admet-7	229	18	]	]	PUNCT
admet-7	229	19	.	.	PUNCT
admet-7	230	1	these	these	DET
admet-7	230	2	half	half	ADJ
admet-7	230	3	-	-	PUNCT
admet-7	230	4	life	life	NOUN
admet-7	230	5	data	datum	NOUN
admet-7	230	6	translate	translate	VERB
admet-7	230	7	to	to	ADP
admet-7	230	8	less	less	ADJ
admet-7	230	9	than	than	ADP
admet-7	230	10	1	1	NUM
admet-7	230	11	%	%	NOUN
admet-7	230	12	and	and	CCONJ
admet-7	230	13	20	20	NUM
admet-7	230	14	%	%	NOUN
admet-7	230	15	of	of	ADP
admet-7	230	16	drug	drug	NOUN
admet-7	230	17	being	be	AUX
admet-7	230	18	released	release	VERB
admet-7	230	19	over	over	ADP
admet-7	230	20	24	24	NUM
admet-7	230	21	hours	hour	NOUN
admet-7	230	22	from	from	ADP
admet-7	230	23	the	the	DET
admet-7	230	24	total	total	ADJ
admet-7	230	25	available	available	ADJ
admet-7	230	26	drug	drug	NOUN
admet-7	230	27	loaded	load	VERB
admet-7	230	28	on	on	ADP
admet-7	230	29	the	the	DET
admet-7	230	30	700	700	NUM
admet-7	230	31	–	–	SYM
admet-7	230	32	900	900	NUM
admet-7	230	33	μm	μm	NOUN
admet-7	230	34	beads	bead	NOUN
admet-7	230	35	and	and	CCONJ
admet-7	230	36	100	100	NUM
admet-7	230	37	–	–	SYM
admet-7	230	38	300	300	NUM
admet-7	230	39	μm	μm	NUM
admet-7	230	40	beads	bead	NOUN
admet-7	230	41	,	,	PUNCT
admet-7	230	42	respectively	respectively	ADV
admet-7	230	43	.	.	PUNCT
admet-7	231	1	these	these	DET
admet-7	231	2	in	in	ADP
admet-7	231	3	vitro	vitro	X
admet-7	231	4	data	datum	NOUN
admet-7	231	5	nicely	nicely	ADV
admet-7	231	6	demonstrated	demonstrate	VERB
admet-7	231	7	a	a	DET
admet-7	231	8	sustained	sustain	VERB
admet-7	231	9	and	and	CCONJ
admet-7	231	10	controlled	control	VERB
admet-7	231	11	delivery	delivery	NOUN
admet-7	231	12	of	of	ADP
admet-7	231	13	the	the	DET
admet-7	231	14	doxorubicin	doxorubicin	NOUN
admet-7	231	15	without	without	ADP
admet-7	231	16	any	any	DET
admet-7	231	17	burst	burst	ADJ
admet-7	231	18	effect	effect	NOUN
admet-7	231	19	,	,	PUNCT
admet-7	231	20	which	which	PRON
admet-7	231	21	may	may	AUX
admet-7	231	22	otherwise	otherwise	ADV
admet-7	231	23	lead	lead	VERB
admet-7	231	24	to	to	ADP
admet-7	231	25	acute	acute	ADJ
admet-7	231	26	toxicity	toxicity	NOUN
admet-7	231	27	in	in	ADP
admet-7	231	28	vivo	vivo	NOUN
admet-7	231	29	.	.	PUNCT
admet-7	232	1	in	in	ADP
admet-7	232	2	a	a	DET
admet-7	232	3	subsequent	subsequent	ADJ
admet-7	232	4	study	study	NOUN
admet-7	232	5	[	[	X
admet-7	232	6	85	85	NUM
admet-7	232	7	]	]	PUNCT
admet-7	232	8	,	,	PUNCT
admet-7	232	9	it	it	PRON
admet-7	232	10	was	be	AUX
admet-7	232	11	shown	show	VERB
admet-7	232	12	that	that	SCONJ
admet-7	232	13	the	the	DET
admet-7	232	14	loading	loading	NOUN
admet-7	232	15	and	and	CCONJ
admet-7	232	16	release	release	NOUN
admet-7	232	17	of	of	ADP
admet-7	232	18	doxorubicin	doxorubicin	PROPN
admet-7	232	19	followed	follow	VERB
admet-7	232	20	a	a	DET
admet-7	232	21	dose	dose	NOUN
admet-7	232	22	-	-	PUNCT
admet-7	232	23	response	response	NOUN
admet-7	232	24	curve	curve	NOUN
admet-7	232	25	.	.	PUNCT
admet-7	233	1	using	use	VERB
admet-7	233	2	500	500	NUM
admet-7	233	3	–	–	SYM
admet-7	233	4	700	700	NUM
admet-7	233	5	μm	μm	NUM
admet-7	233	6	beads	bead	NOUN
admet-7	233	7	,	,	PUNCT
admet-7	233	8	it	it	PRON
admet-7	233	9	was	be	AUX
admet-7	233	10	found	find	VERB
admet-7	233	11	that	that	SCONJ
admet-7	233	12	the	the	DET
admet-7	233	13	half	half	ADV
admet-7	233	14	-	-	PUNCT
admet-7	233	15	live	live	NOUN
admet-7	233	16	increased	increase	VERB
admet-7	233	17	from	from	ADP
admet-7	233	18	381	381	NUM
admet-7	233	19	hours	hour	NOUN
admet-7	233	20	to	to	ADP
admet-7	233	21	3658	3658	NUM
admet-7	233	22	hours	hour	NOUN
admet-7	233	23	as	as	SCONJ
admet-7	233	24	the	the	DET
admet-7	233	25	concentration	concentration	NOUN
admet-7	233	26	of	of	ADP
admet-7	233	27	the	the	DET
admet-7	233	28	doxorubicin	doxorubicin	PROPN
admet-7	233	29	load	load	NOUN
admet-7	233	30	increased	increase	VERB
admet-7	233	31	from	from	ADP
admet-7	233	32	6.25	6.25	NUM
admet-7	233	33	mg	mg	NUM
admet-7	233	34	/	/	SYM
admet-7	233	35	ml	ml	NOUN
admet-7	233	36	to	to	ADP
admet-7	233	37	37.5	37.5	NUM
admet-7	233	38	mg	mg	NOUN
admet-7	233	39	/	/	SYM
admet-7	233	40	ml	ml	NOUN
admet-7	233	41	.	.	PUNCT
admet-7	234	1	for	for	ADP
admet-7	234	2	a	a	DET
admet-7	234	3	fixed	fix	VERB
admet-7	234	4	drug	drug	NOUN
admet-7	234	5	load	load	NOUN
admet-7	234	6	of	of	ADP
admet-7	234	7	37.5	37.5	NUM
admet-7	234	8	mg	mg	NOUN
admet-7	234	9	/	/	SYM
admet-7	234	10	ml	ml	PROPN
admet-7	234	11	,	,	PUNCT
admet-7	234	12	the	the	DET
admet-7	234	13	half	half	ADJ
admet-7	234	14	-	-	PUNCT
admet-7	234	15	life	life	NOUN
admet-7	234	16	was	be	AUX
admet-7	234	17	only	only	ADV
admet-7	234	18	weakly	weakly	ADV
admet-7	234	19	dependent	dependent	ADJ
admet-7	234	20	on	on	ADP
admet-7	234	21	bead	bead	NOUN
admet-7	234	22	size	size	NOUN
admet-7	234	23	,	,	PUNCT
admet-7	234	24	with	with	ADP
admet-7	234	25	a	a	DET
admet-7	234	26	minimum	minimum	NOUN
admet-7	234	27	of	of	ADP
admet-7	234	28	1505	1505	NUM
admet-7	234	29	hours	hour	NOUN
admet-7	234	30	for	for	ADP
admet-7	234	31	the	the	DET
admet-7	234	32	100	100	NUM
admet-7	234	33	–	–	PUNCT
admet-7	234	34	300	300	NUM
admet-7	234	35	μm	μm	NUM
admet-7	234	36	beads	bead	NOUN
admet-7	234	37	.	.	PUNCT
admet-7	235	1	interestingly	interestingly	ADV
admet-7	235	2	,	,	PUNCT
admet-7	235	3	the	the	DET
admet-7	235	4	in	in	ADV
admet-7	235	5	vitro	vitro	X
admet-7	235	6	elution	elution	NOUN
admet-7	235	7	data	datum	NOUN
admet-7	235	8	of	of	ADP
admet-7	235	9	doxorubicin	doxorubicin	PROPN
admet-7	235	10	has	have	AUX
admet-7	235	11	been	be	AUX
admet-7	235	12	shown	show	VERB
admet-7	235	13	to	to	PART
admet-7	235	14	correlate	correlate	VERB
admet-7	235	15	well	well	ADV
admet-7	235	16	with	with	ADP
admet-7	235	17	the	the	DET
admet-7	235	18	areas	area	NOUN
admet-7	235	19	under	under	ADP
admet-7	235	20	the	the	DET
admet-7	235	21	curve	curve	NOUN
admet-7	235	22	(	(	PUNCT
admet-7	235	23	i.e.	i.e.	X
admet-7	235	24	the	the	DET
admet-7	235	25	doxorubicin	doxorubicin	PROPN
admet-7	235	26	concentration	concentration	NOUN
admet-7	235	27	in	in	ADP
admet-7	235	28	human	human	ADJ
admet-7	235	29	plasma	plasma	NOUN
admet-7	235	30	measured	measure	VERB
admet-7	235	31	as	as	ADP
admet-7	235	32	a	a	DET
admet-7	235	33	function	function	NOUN
admet-7	235	34	of	of	ADP
admet-7	235	35	time	time	NOUN
admet-7	235	36	)	)	PUNCT
admet-7	235	37	of	of	ADP
admet-7	235	38	15	15	NUM
admet-7	235	39	patients	patient	NOUN
admet-7	235	40	treated	treat	VERB
admet-7	235	41	with	with	ADP
admet-7	235	42	dc	dc	PROPN
admet-7	235	43	beads	bead	NOUN
admet-7	235	44	loaded	load	VERB
admet-7	235	45	with	with	ADP
admet-7	235	46	doxorubicin	doxorubicin	PROPN
admet-7	235	47	in	in	ADP
admet-7	235	48	the	the	DET
admet-7	235	49	precision	precision	NOUN
admet-7	235	50	clinical	clinical	ADJ
admet-7	235	51	study	study	NOUN
admet-7	235	52	[	[	X
admet-7	235	53	85	85	NUM
admet-7	235	54	]	]	PUNCT
admet-7	235	55	.	.	PUNCT
admet-7	236	1	this	this	PRON
admet-7	236	2	covered	cover	VERB
admet-7	236	3	all	all	DET
admet-7	236	4	doses	dose	NOUN
admet-7	236	5	used	use	VERB
admet-7	236	6	in	in	ADP
admet-7	236	7	the	the	DET
admet-7	236	8	study	study	NOUN
admet-7	236	9	:	:	PUNCT
admet-7	236	10	6.25	6.25	NUM
admet-7	236	11	mg	mg	NUM
admet-7	236	12	/	/	SYM
admet-7	236	13	ml	ml	NOUN
admet-7	236	14	,	,	PUNCT
admet-7	236	15	12.5	12.5	NUM
admet-7	236	16	mg	mg	NOUN
admet-7	236	17	/	/	SYM
admet-7	236	18	ml	ml	NOUN
admet-7	236	19	,	,	PUNCT
admet-7	236	20	18.75	18.75	NUM
admet-7	236	21	mg	mg	NUM
admet-7	236	22	/	/	SYM
admet-7	236	23	ml	ml	NOUN
admet-7	236	24	,	,	PUNCT
admet-7	236	25	25	25	NUM
admet-7	236	26	mg	mg	NUM
admet-7	236	27	/	/	SYM
admet-7	236	28	ml	ml	NOUN
admet-7	236	29	,	,	PUNCT
admet-7	236	30	and	and	CCONJ
admet-7	236	31	37.5	37.5	NUM
admet-7	236	32	mg	mg	NOUN
admet-7	236	33	/	/	SYM
admet-7	236	34	ml	ml	NOUN
admet-7	236	35	in	in	ADP
admet-7	236	36	24	24	NUM
admet-7	236	37	hours	hour	NOUN
admet-7	236	38	.	.	PUNCT
admet-7	237	1	as	as	ADV
admet-7	237	2	far	far	ADV
admet-7	237	3	as	as	SCONJ
admet-7	237	4	we	we	PRON
admet-7	237	5	are	be	AUX
admet-7	237	6	aware	aware	ADJ
admet-7	237	7	,	,	PUNCT
admet-7	237	8	this	this	PRON
admet-7	237	9	is	be	AUX
admet-7	237	10	the	the	DET
admet-7	237	11	first	first	ADJ
admet-7	237	12	report	report	NOUN
admet-7	237	13	available	available	ADJ
admet-7	237	14	in	in	ADP
admet-7	237	15	open	open	ADJ
admet-7	237	16	literature	literature	NOUN
admet-7	237	17	to	to	ADP
admet-7	237	18	tam	tam	PROPN
admet-7	237	19	admet	admet	PROPN
admet-7	237	20	&	&	CCONJ
admet-7	237	21	dmpk	dmpk	PROPN
admet-7	237	22	1(3	1(3	NUM
admet-7	237	23	)	)	PUNCT
admet-7	237	24	(	(	PUNCT
admet-7	237	25	2013	2013	NUM
admet-7	237	26	)	)	PUNCT
admet-7	237	27	29	29	NUM
admet-7	237	28	-	-	SYM
admet-7	237	29	44	44	NUM
admet-7	237	30	38	38	NUM
admet-7	237	31	demonstrate	demonstrate	VERB
admet-7	237	32	a	a	DET
admet-7	237	33	good	good	ADJ
admet-7	237	34	in	in	ADP
admet-7	237	35	-	-	PUNCT
admet-7	237	36	vivo	vivo	NOUN
admet-7	237	37	in	in	ADP
admet-7	237	38	-	-	PUNCT
admet-7	237	39	vitro	vitro	X
admet-7	237	40	correlation	correlation	NOUN
admet-7	237	41	(	(	PUNCT
admet-7	237	42	ivivc	ivivc	PROPN
admet-7	237	43	)	)	PUNCT
admet-7	237	44	for	for	ADP
admet-7	237	45	dc	dc	PROPN
admet-7	237	46	beads	bead	NOUN
admet-7	237	47	.	.	PUNCT
admet-7	238	1	undoubtedly	undoubtedly	ADV
admet-7	238	2	,	,	PUNCT
admet-7	238	3	this	this	DET
admet-7	238	4	kind	kind	NOUN
admet-7	238	5	of	of	ADP
admet-7	238	6	good	good	ADJ
admet-7	238	7	ivivc	ivivc	NOUN
admet-7	238	8	should	should	AUX
admet-7	238	9	help	help	VERB
admet-7	238	10	predict	predict	VERB
admet-7	238	11	the	the	DET
admet-7	238	12	local	local	ADJ
admet-7	238	13	dose	dose	NOUN
admet-7	238	14	that	that	PRON
admet-7	238	15	should	should	AUX
admet-7	238	16	be	be	AUX
admet-7	238	17	administered	administer	VERB
admet-7	238	18	before	before	SCONJ
admet-7	238	19	systemic	systemic	ADJ
admet-7	238	20	effects	effect	NOUN
admet-7	238	21	(	(	PUNCT
admet-7	238	22	e.g.	e.g.	ADV
admet-7	238	23	acute	acute	ADJ
admet-7	238	24	toxicity	toxicity	NOUN
admet-7	238	25	)	)	PUNCT
admet-7	238	26	occur	occur	VERB
admet-7	238	27	.	.	PUNCT
admet-7	239	1	however	however	ADV
admet-7	239	2	,	,	PUNCT
admet-7	239	3	the	the	DET
admet-7	239	4	amount	amount	NOUN
admet-7	239	5	of	of	ADP
admet-7	239	6	drug	drug	NOUN
admet-7	239	7	released	release	VERB
admet-7	239	8	in	in	ADP
admet-7	239	9	situ	situ	NOUN
admet-7	239	10	into	into	ADP
admet-7	239	11	tumour	tumour	ADJ
admet-7	239	12	tissue	tissue	NOUN
admet-7	239	13	in	in	ADP
admet-7	239	14	humans	human	NOUN
admet-7	239	15	is	be	AUX
admet-7	239	16	difficult	difficult	ADJ
admet-7	239	17	to	to	PART
admet-7	239	18	determine	determine	VERB
admet-7	239	19	and	and	CCONJ
admet-7	239	20	model	model	NOUN
admet-7	239	21	by	by	ADP
admet-7	239	22	this	this	DET
admet-7	239	23	kind	kind	NOUN
admet-7	239	24	of	of	ADV
admet-7	239	25	in	in	ADP
admet-7	239	26	vitro	vitro	X
admet-7	239	27	measure	measure	NOUN
admet-7	239	28	,	,	PUNCT
admet-7	239	29	because	because	SCONJ
admet-7	239	30	of	of	ADP
admet-7	239	31	practical	practical	ADJ
admet-7	239	32	and	and	CCONJ
admet-7	239	33	ethical	ethical	ADJ
admet-7	239	34	issues	issue	NOUN
admet-7	239	35	.	.	PUNCT
admet-7	240	1	studies	study	NOUN
admet-7	240	2	on	on	ADP
admet-7	240	3	pre	pre	ADJ
admet-7	240	4	-	-	ADJ
admet-7	240	5	clinical	clinical	ADJ
admet-7	240	6	species	specie	NOUN
admet-7	240	7	using	use	VERB
admet-7	240	8	a	a	DET
admet-7	240	9	vx-2	vx-2	NUM
admet-7	240	10	tumour	tumour	NOUN
admet-7	240	11	rabbit	rabbit	NOUN
admet-7	240	12	model	model	NOUN
admet-7	240	13	have	have	AUX
admet-7	240	14	been	be	AUX
admet-7	240	15	performed	perform	VERB
admet-7	240	16	,	,	PUNCT
admet-7	240	17	and	and	CCONJ
admet-7	240	18	confirmed	confirm	VERB
admet-7	240	19	a	a	DET
admet-7	240	20	high	high	ADJ
admet-7	240	21	level	level	NOUN
admet-7	240	22	of	of	ADP
admet-7	240	23	doxorubicin	doxorubicin	PROPN
admet-7	240	24	in	in	ADP
admet-7	240	25	the	the	DET
admet-7	240	26	tumour	tumour	NOUN
admet-7	240	27	over	over	ADP
admet-7	240	28	the	the	DET
admet-7	240	29	entire	entire	ADJ
admet-7	240	30	period	period	NOUN
admet-7	240	31	of	of	ADP
admet-7	240	32	study	study	NOUN
admet-7	240	33	(	(	PUNCT
admet-7	240	34	14	14	NUM
admet-7	240	35	days	day	NOUN
admet-7	240	36	)	)	PUNCT
admet-7	240	37	associated	associate	VERB
admet-7	240	38	with	with	ADP
admet-7	240	39	widespread	widespread	ADJ
admet-7	240	40	necrosis	necrosis	NOUN
admet-7	240	41	of	of	ADP
admet-7	240	42	the	the	DET
admet-7	240	43	tumour	tumour	ADJ
admet-7	240	44	tissue	tissue	NOUN
admet-7	241	1	[	[	X
admet-7	241	2	86	86	NUM
admet-7	241	3	]	]	PUNCT
admet-7	241	4	.	.	PUNCT
admet-7	242	1	the	the	DET
admet-7	242	2	pharmacokinetics	pharmacokinetic	NOUN
admet-7	242	3	of	of	ADP
admet-7	242	4	doxorubicin	doxorubicin	PROPN
admet-7	242	5	in	in	ADP
admet-7	242	6	hcc	hcc	PROPN
admet-7	242	7	patients	patient	NOUN
admet-7	242	8	have	have	AUX
admet-7	242	9	been	be	AUX
admet-7	242	10	determined	determine	VERB
admet-7	242	11	as	as	ADP
admet-7	242	12	part	part	NOUN
admet-7	242	13	of	of	ADP
admet-7	242	14	two	two	NUM
admet-7	242	15	phase	phase	NOUN
admet-7	242	16	i	i	PROPN
admet-7	242	17	/	/	SYM
admet-7	242	18	ii	ii	PROPN
admet-7	242	19	studies	study	NOUN
admet-7	242	20	to	to	PART
admet-7	242	21	evaluate	evaluate	VERB
admet-7	242	22	the	the	DET
admet-7	242	23	use	use	NOUN
admet-7	242	24	of	of	ADP
admet-7	242	25	dc	dc	PROPN
admet-7	242	26	beads	bead	NOUN
admet-7	242	27	in	in	ADP
admet-7	242	28	the	the	DET
admet-7	242	29	deb	deb	PROPN
admet-7	242	30	-	-	PUNCT
admet-7	242	31	tace	tace	NOUN
admet-7	242	32	procedure	procedure	NOUN
admet-7	242	33	.	.	PUNCT
admet-7	243	1	one	one	NUM
admet-7	243	2	of	of	ADP
admet-7	243	3	the	the	DET
admet-7	243	4	studies	study	NOUN
admet-7	243	5	compared	compare	VERB
admet-7	243	6	the	the	DET
admet-7	243	7	pharmacokinetic	pharmacokinetic	ADJ
admet-7	243	8	profiles	profile	NOUN
admet-7	243	9	of	of	ADP
admet-7	243	10	doxorubicin	doxorubicin	PROPN
admet-7	243	11	after	after	ADP
admet-7	243	12	injection	injection	NOUN
admet-7	243	13	of	of	ADP
admet-7	243	14	dc	dc	PROPN
admet-7	243	15	beads	bead	NOUN
admet-7	243	16	against	against	ADP
admet-7	243	17	those	those	PRON
admet-7	243	18	seen	see	VERB
admet-7	243	19	after	after	ADP
admet-7	243	20	intra	intra	ADJ
admet-7	243	21	-	-	ADJ
admet-7	243	22	arterial	arterial	ADJ
admet-7	243	23	injection	injection	NOUN
admet-7	243	24	[	[	X
admet-7	243	25	87	87	NUM
admet-7	243	26	]	]	PUNCT
admet-7	243	27	.	.	PUNCT
admet-7	244	1	the	the	DET
admet-7	244	2	average	average	ADJ
admet-7	244	3	auc	auc	NOUN
admet-7	244	4	after	after	SCONJ
admet-7	244	5	dc	dc	PROPN
admet-7	244	6	bead	bead	PROPN
admet-7	244	7	injection	injection	NOUN
admet-7	244	8	was	be	AUX
admet-7	244	9	found	find	VERB
admet-7	244	10	to	to	PART
admet-7	244	11	be	be	AUX
admet-7	244	12	about	about	ADV
admet-7	244	13	100	100	NUM
admet-7	244	14	-	-	NUM
admet-7	244	15	fold	fold	VERB
admet-7	244	16	lower	low	ADJ
admet-7	244	17	than	than	ADP
admet-7	244	18	intraarterial	intraarterial	ADJ
admet-7	244	19	injection	injection	NOUN
admet-7	244	20	,	,	PUNCT
admet-7	244	21	despite	despite	SCONJ
admet-7	244	22	a	a	DET
admet-7	244	23	higher	high	ADJ
admet-7	244	24	drug	drug	NOUN
admet-7	244	25	load	load	NOUN
admet-7	244	26	being	be	AUX
admet-7	244	27	used	use	VERB
admet-7	244	28	in	in	ADP
admet-7	244	29	the	the	DET
admet-7	244	30	dc	dc	PROPN
admet-7	244	31	beads	bead	NOUN
admet-7	244	32	.	.	PUNCT
admet-7	245	1	the	the	DET
admet-7	245	2	other	other	ADJ
admet-7	245	3	study	study	NOUN
admet-7	245	4	compared	compare	VERB
admet-7	245	5	the	the	DET
admet-7	245	6	pharmacokinetic	pharmacokinetic	ADJ
admet-7	245	7	profile	profile	NOUN
admet-7	245	8	of	of	ADP
admet-7	245	9	deb	deb	PROPN
admet-7	245	10	-	-	PUNCT
admet-7	245	11	tace	tace	NOUN
admet-7	245	12	against	against	ADP
admet-7	245	13	conventional	conventional	ADJ
admet-7	245	14	tace	tace	NOUN
admet-7	245	15	[	[	X
admet-7	245	16	88	88	NUM
admet-7	245	17	]	]	PUNCT
admet-7	245	18	.	.	PUNCT
admet-7	246	1	the	the	DET
admet-7	246	2	peak	peak	NOUN
admet-7	246	3	drug	drug	NOUN
admet-7	246	4	concentration	concentration	NOUN
admet-7	246	5	(	(	PUNCT
admet-7	246	6	cmax	cmax	NOUN
admet-7	246	7	)	)	PUNCT
admet-7	246	8	was	be	AUX
admet-7	246	9	reached	reach	VERB
admet-7	246	10	within	within	ADP
admet-7	246	11	5	5	NUM
admet-7	246	12	min	min	NOUN
admet-7	246	13	after	after	ADP
admet-7	246	14	injection	injection	NOUN
admet-7	246	15	,	,	PUNCT
admet-7	246	16	but	but	CCONJ
admet-7	246	17	it	it	PRON
admet-7	246	18	was	be	AUX
admet-7	246	19	about	about	ADV
admet-7	246	20	10	10	NUM
admet-7	246	21	-	-	ADJ
admet-7	246	22	fold	fold	VERB
admet-7	246	23	higher	higher	ADV
admet-7	246	24	in	in	ADP
admet-7	246	25	conventional	conventional	ADJ
admet-7	246	26	tace	tace	NOUN
admet-7	246	27	patients	patient	NOUN
admet-7	246	28	.	.	PUNCT
admet-7	247	1	the	the	DET
admet-7	247	2	auc	auc	NOUN
admet-7	247	3	was	be	AUX
admet-7	247	4	also	also	ADV
admet-7	247	5	about	about	ADV
admet-7	247	6	3	3	ADJ
admet-7	247	7	-	-	ADJ
admet-7	247	8	fold	fold	VERB
admet-7	247	9	higher	higher	ADV
admet-7	247	10	in	in	ADP
admet-7	247	11	the	the	DET
admet-7	247	12	conventional	conventional	ADJ
admet-7	247	13	tace	tace	NOUN
admet-7	247	14	patients	patient	NOUN
admet-7	247	15	.	.	PUNCT
admet-7	248	1	it	it	PRON
admet-7	248	2	is	be	AUX
admet-7	248	3	evident	evident	ADJ
admet-7	248	4	that	that	SCONJ
admet-7	248	5	deb	deb	PROPN
admet-7	248	6	-	-	PUNCT
admet-7	248	7	tace	tace	NOUN
admet-7	248	8	is	be	AUX
admet-7	248	9	effective	effective	ADJ
admet-7	248	10	in	in	ADP
admet-7	248	11	limiting	limit	VERB
admet-7	248	12	the	the	DET
admet-7	248	13	systemic	systemic	ADJ
admet-7	248	14	exposure	exposure	NOUN
admet-7	248	15	to	to	ADP
admet-7	248	16	doxorubicin	doxorubicin	PROPN
admet-7	248	17	,	,	PUNCT
admet-7	248	18	resulting	result	VERB
admet-7	248	19	in	in	ADP
admet-7	248	20	reduced	reduced	ADJ
admet-7	248	21	systemic	systemic	ADJ
admet-7	248	22	toxicity	toxicity	NOUN
admet-7	248	23	.	.	PUNCT
admet-7	249	1	the	the	DET
admet-7	249	2	hepatic	hepatic	ADJ
admet-7	249	3	distribution	distribution	NOUN
admet-7	249	4	of	of	ADP
admet-7	249	5	doxorubicin	doxorubicin	PROPN
admet-7	249	6	in	in	ADP
admet-7	249	7	hcc	hcc	PROPN
admet-7	249	8	patients	patient	NOUN
admet-7	249	9	has	have	AUX
admet-7	249	10	recently	recently	ADV
admet-7	249	11	been	be	AUX
admet-7	249	12	reported	report	VERB
admet-7	249	13	[	[	X
admet-7	249	14	89	89	NUM
admet-7	249	15	]	]	PUNCT
admet-7	249	16	.	.	PUNCT
admet-7	250	1	in	in	ADP
admet-7	250	2	this	this	DET
admet-7	250	3	reported	report	VERB
admet-7	250	4	study	study	NOUN
admet-7	250	5	,	,	PUNCT
admet-7	250	6	6	6	NUM
admet-7	250	7	hcc	hcc	PROPN
admet-7	250	8	patients	patient	NOUN
admet-7	250	9	were	be	AUX
admet-7	250	10	given	give	VERB
admet-7	250	11	the	the	DET
admet-7	250	12	same	same	ADJ
admet-7	250	13	deb	deb	PROPN
admet-7	250	14	-	-	PUNCT
admet-7	250	15	tace	tace	NOUN
admet-7	250	16	procedure	procedure	NOUN
admet-7	250	17	followed	follow	VERB
admet-7	250	18	by	by	ADP
admet-7	250	19	liver	liver	NOUN
admet-7	250	20	transplantation	transplantation	NOUN
admet-7	250	21	after	after	ADP
admet-7	250	22	embolization	embolization	NOUN
admet-7	250	23	from	from	ADP
admet-7	250	24	8	8	NUM
admet-7	250	25	hours	hour	NOUN
admet-7	250	26	to	to	ADP
admet-7	250	27	36	36	NUM
admet-7	250	28	days	day	NOUN
admet-7	250	29	.	.	PUNCT
admet-7	251	1	from	from	ADP
admet-7	251	2	liver	liver	NOUN
admet-7	251	3	explant	explant	NOUN
admet-7	251	4	samples	sample	NOUN
admet-7	251	5	,	,	PUNCT
admet-7	251	6	it	it	PRON
admet-7	251	7	was	be	AUX
admet-7	251	8	determined	determine	VERB
admet-7	251	9	that	that	SCONJ
admet-7	251	10	the	the	DET
admet-7	251	11	mean	mean	ADJ
admet-7	251	12	doxorubicin	doxorubicin	PROPN
admet-7	251	13	concentration	concentration	NOUN
admet-7	251	14	surrounding	surround	VERB
admet-7	251	15	the	the	DET
admet-7	251	16	debs	debs	NOUN
admet-7	251	17	peaked	peak	VERB
admet-7	251	18	at	at	ADP
admet-7	251	19	5	5	NUM
admet-7	251	20	μm	μm	NOUN
admet-7	251	21	at	at	ADP
admet-7	251	22	8	8	NUM
admet-7	251	23	hours	hour	NOUN
admet-7	251	24	,	,	PUNCT
admet-7	251	25	and	and	CCONJ
admet-7	251	26	then	then	ADV
admet-7	251	27	diminished	diminish	VERB
admet-7	251	28	to	to	ADP
admet-7	251	29	2.10	2.10	NUM
admet-7	251	30	μm	μm	NOUN
admet-7	251	31	at	at	ADP
admet-7	251	32	2	2	NUM
admet-7	251	33	weeks	week	NOUN
admet-7	251	34	,	,	PUNCT
admet-7	251	35	and	and	CCONJ
admet-7	251	36	0.65	0.65	NUM
admet-7	251	37	μm	μm	NOUN
admet-7	251	38	at	at	ADP
admet-7	251	39	32	32	NUM
admet-7	251	40	–	–	SYM
admet-7	251	41	36	36	NUM
admet-7	251	42	days	day	NOUN
admet-7	251	43	.	.	PUNCT
admet-7	252	1	most	most	ADJ
admet-7	252	2	of	of	ADP
admet-7	252	3	the	the	DET
admet-7	252	4	dc	dc	PROPN
admet-7	252	5	beads	bead	NOUN
admet-7	252	6	(	(	PUNCT
admet-7	252	7	100	100	NUM
admet-7	252	8	–	–	SYM
admet-7	252	9	300	300	NUM
admet-7	252	10	μm	μm	NUM
admet-7	252	11	)	)	PUNCT
admet-7	252	12	were	be	AUX
admet-7	252	13	confined	confine	VERB
admet-7	252	14	within	within	ADP
admet-7	252	15	10	10	NUM
admet-7	252	16	mm	mm	NOUN
admet-7	252	17	of	of	ADP
admet-7	252	18	the	the	DET
admet-7	252	19	tumour	tumour	NOUN
admet-7	252	20	boundary	boundary	NOUN
admet-7	252	21	.	.	PUNCT
admet-7	253	1	necrosis	necrosis	NOUN
admet-7	253	2	of	of	ADP
admet-7	253	3	tissues	tissue	NOUN
admet-7	253	4	surrounding	surround	VERB
admet-7	253	5	debs	debs	NOUN
admet-7	253	6	has	have	AUX
admet-7	253	7	been	be	AUX
admet-7	253	8	observed	observe	VERB
admet-7	253	9	in	in	ADP
admet-7	253	10	9	9	NUM
admet-7	253	11	–	–	SYM
admet-7	253	12	36	36	NUM
admet-7	253	13	day	day	NOUN
admet-7	253	14	liver	liver	NOUN
admet-7	253	15	explants	explant	NOUN
admet-7	253	16	,	,	PUNCT
admet-7	253	17	suggesting	suggest	VERB
admet-7	253	18	deb	deb	PROPN
admet-7	253	19	may	may	AUX
admet-7	253	20	lead	lead	VERB
admet-7	253	21	to	to	ADP
admet-7	253	22	antiproliferative	antiproliferative	NOUN
admet-7	253	23	and	and	CCONJ
admet-7	253	24	cytotoxic	cytotoxic	ADJ
admet-7	253	25	effects	effect	NOUN
admet-7	253	26	on	on	ADP
admet-7	253	27	the	the	DET
admet-7	253	28	tumour	tumour	NOUN
admet-7	253	29	cells	cell	NOUN
admet-7	253	30	surrounding	surround	VERB
admet-7	253	31	the	the	DET
admet-7	253	32	beads	bead	NOUN
admet-7	253	33	.	.	PUNCT
admet-7	254	1	5	5	X
admet-7	254	2	.	.	X
admet-7	254	3	the	the	DET
admet-7	254	4	new	new	ADJ
admet-7	254	5	developments	development	NOUN
admet-7	254	6	and	and	CCONJ
admet-7	254	7	future	future	ADJ
admet-7	254	8	directions	direction	NOUN
admet-7	254	9	hcc	hcc	PROPN
admet-7	254	10	mortality	mortality	NOUN
admet-7	254	11	is	be	AUX
admet-7	254	12	generally	generally	ADV
admet-7	254	13	high	high	ADJ
admet-7	254	14	and	and	CCONJ
admet-7	254	15	the	the	DET
admet-7	254	16	available	available	ADJ
admet-7	254	17	treatment	treatment	NOUN
admet-7	254	18	options	option	NOUN
admet-7	254	19	are	be	AUX
admet-7	254	20	limited	limited	ADJ
admet-7	254	21	.	.	PUNCT
admet-7	255	1	chemotherapy	chemotherapy	NOUN
admet-7	255	2	using	use	VERB
admet-7	255	3	anti	anti	ADJ
admet-7	255	4	-	-	ADJ
admet-7	255	5	tumour	tumour	ADJ
admet-7	255	6	cytotoxic	cytotoxic	ADJ
admet-7	255	7	agents	agent	NOUN
admet-7	255	8	,	,	PUNCT
admet-7	255	9	such	such	ADJ
admet-7	255	10	as	as	ADP
admet-7	255	11	doxorubicin	doxorubicin	PROPN
admet-7	255	12	,	,	PUNCT
admet-7	255	13	appears	appear	VERB
admet-7	255	14	to	to	PART
admet-7	255	15	be	be	AUX
admet-7	255	16	one	one	NUM
admet-7	255	17	of	of	ADP
admet-7	255	18	the	the	DET
admet-7	255	19	non	non	ADJ
admet-7	255	20	-	-	ADJ
admet-7	255	21	curative	curative	ADJ
admet-7	255	22	therapeutic	therapeutic	ADJ
admet-7	255	23	approaches	approach	NOUN
admet-7	255	24	to	to	PART
admet-7	255	25	help	help	VERB
admet-7	255	26	hcc	hcc	PROPN
admet-7	255	27	patients	patient	NOUN
admet-7	255	28	.	.	PUNCT
admet-7	256	1	systemic	systemic	ADJ
admet-7	256	2	chemotherapies	chemotherapy	NOUN
admet-7	256	3	have	have	AUX
admet-7	256	4	been	be	AUX
admet-7	256	5	evaluated	evaluate	VERB
admet-7	256	6	for	for	ADP
admet-7	256	7	many	many	ADJ
admet-7	256	8	years	year	NOUN
admet-7	257	1	[	[	X
admet-7	257	2	11	11	NUM
admet-7	257	3	]	]	PUNCT
admet-7	257	4	.	.	PUNCT
admet-7	258	1	the	the	DET
admet-7	258	2	response	response	NOUN
admet-7	258	3	rate	rate	NOUN
admet-7	258	4	is	be	AUX
admet-7	258	5	poor	poor	ADJ
admet-7	258	6	(	(	PUNCT
admet-7	258	7	below	below	ADP
admet-7	258	8	30	30	NUM
admet-7	258	9	%	%	NOUN
admet-7	258	10	)	)	PUNCT
admet-7	258	11	and	and	CCONJ
admet-7	258	12	the	the	DET
admet-7	258	13	survival	survival	NOUN
admet-7	258	14	advantage	advantage	NOUN
admet-7	258	15	is	be	AUX
admet-7	258	16	minimal	minimal	ADJ
admet-7	258	17	.	.	PUNCT
admet-7	259	1	the	the	DET
admet-7	259	2	uses	use	NOUN
admet-7	259	3	of	of	ADP
admet-7	259	4	adjuvant	adjuvant	NOUN
admet-7	259	5	or	or	CCONJ
admet-7	259	6	neoadjuvant	neoadjuvant	ADJ
admet-7	259	7	systemic	systemic	ADJ
admet-7	259	8	chemotherapy	chemotherapy	NOUN
admet-7	259	9	for	for	ADP
admet-7	259	10	liver	liver	NOUN
admet-7	259	11	resection	resection	NOUN
admet-7	259	12	also	also	ADV
admet-7	259	13	failed	fail	VERB
admet-7	259	14	to	to	PART
admet-7	259	15	show	show	VERB
admet-7	259	16	clinical	clinical	ADJ
admet-7	259	17	benefits	benefit	NOUN
admet-7	259	18	[	[	X
admet-7	259	19	11	11	NUM
admet-7	259	20	]	]	PUNCT
admet-7	259	21	.	.	PUNCT
admet-7	260	1	on	on	ADP
admet-7	260	2	the	the	DET
admet-7	260	3	other	other	ADJ
admet-7	260	4	hand	hand	NOUN
admet-7	260	5	,	,	PUNCT
admet-7	260	6	locoregional	locoregional	PROPN
admet-7	260	7	administration	administration	NOUN
admet-7	260	8	of	of	ADP
admet-7	260	9	doxorubicin	doxorubicin	PROPN
admet-7	260	10	via	via	ADP
admet-7	260	11	deb	deb	PROPN
admet-7	260	12	-	-	PUNCT
admet-7	260	13	tace	tace	NOUN
admet-7	260	14	produced	produce	VERB
admet-7	260	15	relatively	relatively	ADV
admet-7	260	16	high	high	ADJ
admet-7	260	17	response	response	NOUN
admet-7	260	18	rates	rate	NOUN
admet-7	260	19	and	and	CCONJ
admet-7	260	20	survival	survival	NOUN
admet-7	260	21	advantage	advantage	NOUN
admet-7	261	1	[	[	X
admet-7	261	2	45	45	NUM
admet-7	261	3	]	]	PUNCT
admet-7	261	4	.	.	PUNCT
admet-7	262	1	it	it	PRON
admet-7	262	2	would	would	AUX
admet-7	262	3	be	be	AUX
admet-7	262	4	particularly	particularly	ADV
admet-7	262	5	valuable	valuable	ADJ
admet-7	262	6	to	to	PART
admet-7	262	7	explore	explore	VERB
admet-7	262	8	the	the	DET
admet-7	262	9	best	good	ADJ
admet-7	262	10	use	use	NOUN
admet-7	262	11	of	of	ADP
admet-7	262	12	this	this	DET
admet-7	262	13	approach	approach	NOUN
admet-7	262	14	in	in	ADP
admet-7	262	15	combination	combination	NOUN
admet-7	262	16	with	with	ADP
admet-7	262	17	other	other	ADJ
admet-7	262	18	treatment	treatment	NOUN
admet-7	262	19	options	option	NOUN
admet-7	262	20	in	in	ADP
admet-7	262	21	the	the	DET
admet-7	262	22	therapy	therapy	NOUN
admet-7	262	23	of	of	ADP
admet-7	262	24	hcc	hcc	PROPN
admet-7	262	25	.	.	PUNCT
admet-7	263	1	5.1	5.1	NUM
admet-7	263	2	.	.	PUNCT
admet-7	263	3	standardization	standardization	NOUN
admet-7	263	4	of	of	ADP
admet-7	263	5	tace	tace	NOUN
admet-7	263	6	procedure	procedure	NOUN
admet-7	263	7	one	one	NUM
admet-7	263	8	of	of	ADP
admet-7	263	9	the	the	DET
admet-7	263	10	current	current	ADJ
admet-7	263	11	issues	issue	NOUN
admet-7	263	12	with	with	ADP
admet-7	263	13	tace	tace	NOUN
admet-7	263	14	concerns	concern	NOUN
admet-7	263	15	the	the	DET
admet-7	263	16	technique	technique	NOUN
admet-7	263	17	of	of	ADP
admet-7	263	18	chemoembolization	chemoembolization	NOUN
admet-7	263	19	.	.	PUNCT
admet-7	264	1	despite	despite	SCONJ
admet-7	264	2	deb	deb	PROPN
admet-7	264	3	offering	offer	VERB
admet-7	264	4	some	some	DET
admet-7	264	5	advantage	advantage	NOUN
admet-7	264	6	,	,	PUNCT
admet-7	264	7	conventional	conventional	ADJ
admet-7	264	8	tace	tace	NOUN
admet-7	264	9	is	be	AUX
admet-7	264	10	still	still	ADV
admet-7	264	11	being	be	AUX
admet-7	264	12	used	use	VERB
admet-7	264	13	widely	widely	ADV
admet-7	264	14	.	.	PUNCT
admet-7	265	1	while	while	SCONJ
admet-7	265	2	recommendations	recommendation	NOUN
admet-7	265	3	have	have	AUX
admet-7	265	4	been	be	AUX
admet-7	265	5	published	publish	VERB
admet-7	265	6	by	by	ADP
admet-7	265	7	a	a	DET
admet-7	265	8	panel	panel	NOUN
admet-7	265	9	of	of	ADP
admet-7	265	10	experts	expert	NOUN
admet-7	265	11	on	on	ADP
admet-7	265	12	the	the	DET
admet-7	265	13	use	use	NOUN
admet-7	265	14	of	of	ADP
admet-7	265	15	deb	deb	NOUN
admet-7	265	16	-	-	PUNCT
admet-7	265	17	tace	tace	NOUN
admet-7	266	1	[	[	X
admet-7	266	2	90	90	NUM
admet-7	266	3	]	]	PUNCT
admet-7	266	4	,	,	PUNCT
admet-7	266	5	there	there	PRON
admet-7	266	6	is	be	VERB
admet-7	266	7	still	still	ADV
admet-7	266	8	no	no	DET
admet-7	266	9	consensus	consensus	NOUN
admet-7	266	10	on	on	ADP
admet-7	266	11	how	how	SCONJ
admet-7	266	12	to	to	PART
admet-7	266	13	perform	perform	VERB
admet-7	266	14	conventional	conventional	ADJ
admet-7	266	15	tace	tace	NOUN
admet-7	266	16	.	.	PUNCT
admet-7	267	1	for	for	ADP
admet-7	267	2	instance	instance	NOUN
admet-7	267	3	,	,	PUNCT
admet-7	267	4	there	there	PRON
admet-7	267	5	are	be	VERB
admet-7	267	6	variants	variant	NOUN
admet-7	267	7	on	on	ADP
admet-7	267	8	how	how	SCONJ
admet-7	267	9	the	the	DET
admet-7	267	10	anticancer	anticancer	NOUN
admet-7	267	11	drug	drug	NOUN
admet-7	267	12	is	be	AUX
admet-7	267	13	formulated	formulate	VERB
admet-7	267	14	in	in	ADP
admet-7	267	15	lipiodol	lipiodol	NOUN
admet-7	267	16	.	.	PUNCT
admet-7	268	1	there	there	PRON
admet-7	268	2	is	be	VERB
admet-7	268	3	also	also	ADV
admet-7	268	4	a	a	DET
admet-7	268	5	wide	wide	ADJ
admet-7	268	6	range	range	NOUN
admet-7	268	7	of	of	ADP
admet-7	268	8	choices	choice	NOUN
admet-7	268	9	for	for	ADP
admet-7	268	10	embolizing	embolize	VERB
admet-7	268	11	agents	agent	NOUN
admet-7	268	12	[	[	X
admet-7	268	13	91,92	91,92	NUM
admet-7	268	14	]	]	X
admet-7	268	15	.	.	PUNCT
admet-7	269	1	consequently	consequently	ADV
admet-7	269	2	,	,	PUNCT
admet-7	269	3	implementation	implementation	NOUN
admet-7	269	4	could	could	AUX
admet-7	269	5	vary	vary	VERB
admet-7	269	6	depending	depend	VERB
admet-7	269	7	on	on	ADP
admet-7	269	8	the	the	DET
admet-7	269	9	preference	preference	NOUN
admet-7	269	10	of	of	ADP
admet-7	269	11	the	the	DET
admet-7	269	12	investigators	investigator	NOUN
admet-7	269	13	.	.	PUNCT
admet-7	270	1	the	the	DET
admet-7	270	2	evolution	evolution	NOUN
admet-7	270	3	from	from	ADP
admet-7	270	4	conventional	conventional	ADJ
admet-7	270	5	tace	tace	NOUN
admet-7	270	6	towards	towards	ADP
admet-7	270	7	debtace	debtace	NOUN
admet-7	270	8	will	will	AUX
admet-7	270	9	hopefully	hopefully	ADV
admet-7	270	10	help	help	VERB
admet-7	270	11	to	to	PART
admet-7	270	12	harmonize	harmonize	VERB
admet-7	270	13	the	the	DET
admet-7	270	14	implementation	implementation	NOUN
admet-7	270	15	procedure	procedure	NOUN
admet-7	270	16	.	.	PUNCT
admet-7	271	1	admet	admet	PROPN
admet-7	271	2	&	&	CCONJ
admet-7	271	3	dmpk	dmpk	PROPN
admet-7	271	4	1(3	1(3	NUM
admet-7	271	5	)	)	PUNCT
admet-7	271	6	(	(	PUNCT
admet-7	271	7	2013	2013	NUM
admet-7	271	8	)	)	PUNCT
admet-7	271	9	29	29	NUM
admet-7	271	10	-	-	SYM
admet-7	271	11	44	44	NUM
admet-7	271	12	doxorubicin	doxorubicin	NOUN
admet-7	271	13	and	and	CCONJ
admet-7	271	14	hcc	hcc	PROPN
admet-7	271	15	doi	doi	PROPN
admet-7	271	16	:	:	PUNCT
admet-7	271	17	10.5599	10.5599	NUM
admet-7	271	18	/	/	SYM
admet-7	271	19	admet.1.3.7	admet.1.3.7	NOUN
admet-7	271	20	39	39	NUM
admet-7	271	21	5.2	5.2	NUM
admet-7	271	22	.	.	PUNCT
admet-7	271	23	combination	combination	NOUN
admet-7	271	24	with	with	ADP
admet-7	271	25	targeted	target	VERB
admet-7	271	26	chemotherapy	chemotherapy	NOUN
admet-7	271	27	targeted	target	VERB
admet-7	271	28	chemotherapy	chemotherapy	NOUN
admet-7	271	29	such	such	ADJ
admet-7	271	30	as	as	ADP
admet-7	271	31	sorafenib	sorafenib	NOUN
admet-7	271	32	represents	represent	VERB
admet-7	271	33	a	a	DET
admet-7	271	34	different	different	ADJ
admet-7	271	35	mechanism	mechanism	NOUN
admet-7	271	36	of	of	ADP
admet-7	271	37	action	action	NOUN
admet-7	271	38	against	against	ADP
admet-7	271	39	hcc	hcc	PROPN
admet-7	271	40	by	by	ADP
admet-7	271	41	acting	act	VERB
admet-7	271	42	on	on	ADP
admet-7	271	43	raf-1	raf-1	DET
admet-7	271	44	/	/	SYM
admet-7	271	45	vegf	vegf	NOUN
admet-7	271	46	cell	cell	NOUN
admet-7	271	47	signalling	signal	VERB
admet-7	271	48	pathways	pathway	NOUN
admet-7	271	49	.	.	PUNCT
admet-7	272	1	used	use	VERB
admet-7	272	2	as	as	ADP
admet-7	272	3	a	a	DET
admet-7	272	4	single	single	ADJ
admet-7	272	5	agent	agent	NOUN
admet-7	272	6	,	,	PUNCT
admet-7	272	7	sorafenib	sorafenib	NOUN
admet-7	272	8	can	can	AUX
admet-7	272	9	produce	produce	VERB
admet-7	272	10	tumour	tumour	NOUN
admet-7	272	11	shrinkage	shrinkage	NOUN
admet-7	272	12	and	and	CCONJ
admet-7	272	13	offer	offer	VERB
admet-7	272	14	a	a	DET
admet-7	272	15	survival	survival	NOUN
admet-7	272	16	advantage	advantage	NOUN
admet-7	272	17	of	of	ADP
admet-7	272	18	about	about	ADV
admet-7	272	19	3	3	NUM
admet-7	272	20	months	month	NOUN
admet-7	272	21	in	in	ADP
admet-7	272	22	advanced	advanced	ADJ
admet-7	272	23	hcc	hcc	PROPN
admet-7	272	24	patients	patient	NOUN
admet-7	273	1	[	[	X
admet-7	273	2	25	25	NUM
admet-7	273	3	]	]	PUNCT
admet-7	273	4	.	.	PUNCT
admet-7	274	1	given	give	VERB
admet-7	274	2	the	the	DET
admet-7	274	3	different	different	ADJ
admet-7	274	4	modes	mode	NOUN
admet-7	274	5	of	of	ADP
admet-7	274	6	actions	action	NOUN
admet-7	274	7	between	between	ADP
admet-7	274	8	the	the	DET
admet-7	274	9	kinase	kinase	PROPN
admet-7	274	10	inhibitor	inhibitor	NOUN
admet-7	274	11	(	(	PUNCT
admet-7	274	12	sorafenib	sorafenib	PROPN
admet-7	274	13	)	)	PUNCT
admet-7	274	14	and	and	CCONJ
admet-7	274	15	the	the	DET
admet-7	274	16	cytotoxic	cytotoxic	ADJ
admet-7	274	17	agent	agent	NOUN
admet-7	274	18	(	(	PUNCT
admet-7	274	19	doxorubicin	doxorubicin	PROPN
admet-7	274	20	)	)	PUNCT
admet-7	274	21	,	,	PUNCT
admet-7	274	22	it	it	PRON
admet-7	274	23	is	be	AUX
admet-7	274	24	perfectly	perfectly	ADV
admet-7	274	25	reasonable	reasonable	ADJ
admet-7	274	26	to	to	PART
admet-7	274	27	evaluate	evaluate	VERB
admet-7	274	28	the	the	DET
admet-7	274	29	combination	combination	NOUN
admet-7	274	30	of	of	ADP
admet-7	274	31	these	these	DET
admet-7	274	32	two	two	NUM
admet-7	274	33	classes	class	NOUN
admet-7	274	34	of	of	ADP
admet-7	274	35	drug	drug	NOUN
admet-7	274	36	and	and	CCONJ
admet-7	274	37	assess	assess	VERB
admet-7	274	38	the	the	DET
admet-7	274	39	clinical	clinical	ADJ
admet-7	274	40	benefits	benefit	NOUN
admet-7	274	41	that	that	PRON
admet-7	274	42	may	may	AUX
admet-7	274	43	bring	bring	VERB
admet-7	274	44	to	to	ADP
admet-7	274	45	hcc	hcc	PROPN
admet-7	274	46	patients	patient	NOUN
admet-7	274	47	.	.	PUNCT
admet-7	275	1	excitingly	excitingly	ADV
admet-7	275	2	,	,	PUNCT
admet-7	275	3	a	a	DET
admet-7	275	4	recent	recent	ADJ
admet-7	275	5	phase	phase	NOUN
admet-7	275	6	ii	ii	PROPN
admet-7	275	7	study	study	NOUN
admet-7	275	8	revealed	reveal	VERB
admet-7	275	9	the	the	DET
admet-7	275	10	combined	combined	ADJ
admet-7	275	11	use	use	NOUN
admet-7	275	12	of	of	ADP
admet-7	275	13	sorafenib	sorafenib	NOUN
admet-7	275	14	and	and	CCONJ
admet-7	275	15	doxorubicin	doxorubicin	PROPN
admet-7	275	16	(	(	PUNCT
admet-7	275	17	administrated	administrate	VERB
admet-7	275	18	as	as	ADP
admet-7	275	19	conventional	conventional	ADJ
admet-7	275	20	tace	tace	NOUN
admet-7	275	21	)	)	PUNCT
admet-7	275	22	in	in	ADP
admet-7	275	23	patients	patient	NOUN
admet-7	275	24	from	from	ADP
admet-7	275	25	the	the	DET
admet-7	275	26	asia	asia	PROPN
admet-7	275	27	-	-	PUNCT
admet-7	275	28	pacific	pacific	PROPN
admet-7	275	29	region	region	NOUN
admet-7	275	30	with	with	ADP
admet-7	275	31	intermediate	intermediate	ADJ
admet-7	275	32	hcc	hcc	PROPN
admet-7	276	1	[	[	X
admet-7	276	2	93	93	NUM
admet-7	276	3	]	]	PUNCT
admet-7	276	4	.	.	PUNCT
admet-7	277	1	the	the	DET
admet-7	277	2	disease	disease	NOUN
admet-7	277	3	control	control	NOUN
admet-7	277	4	rate	rate	NOUN
admet-7	277	5	and	and	CCONJ
admet-7	277	6	overall	overall	ADJ
admet-7	277	7	response	response	NOUN
admet-7	277	8	rate	rate	NOUN
admet-7	277	9	were	be	AUX
admet-7	277	10	reported	report	VERB
admet-7	277	11	to	to	PART
admet-7	277	12	be	be	AUX
admet-7	277	13	91.2	91.2	NUM
admet-7	277	14	%	%	NOUN
admet-7	277	15	and	and	CCONJ
admet-7	277	16	52.4	52.4	NUM
admet-7	277	17	%	%	NOUN
admet-7	277	18	,	,	PUNCT
admet-7	277	19	respectively	respectively	ADV
admet-7	277	20	.	.	PUNCT
admet-7	278	1	thus	thus	ADV
admet-7	278	2	,	,	PUNCT
admet-7	278	3	concurrent	concurrent	ADJ
admet-7	278	4	sorafenib	sorafenib	NOUN
admet-7	278	5	and	and	CCONJ
admet-7	278	6	doxorubicin	doxorubicin	PROPN
admet-7	278	7	-	-	PUNCT
admet-7	278	8	tace	tace	NOUN
admet-7	278	9	therapy	therapy	NOUN
admet-7	278	10	appears	appear	VERB
admet-7	278	11	to	to	PART
admet-7	278	12	be	be	AUX
admet-7	278	13	effective	effective	ADJ
admet-7	278	14	.	.	PUNCT
admet-7	279	1	similar	similar	ADJ
admet-7	279	2	clinical	clinical	ADJ
admet-7	279	3	studies	study	NOUN
admet-7	279	4	are	be	AUX
admet-7	279	5	currently	currently	ADV
admet-7	279	6	being	be	AUX
admet-7	279	7	conducted	conduct	VERB
admet-7	279	8	globally	globally	ADV
admet-7	279	9	[	[	X
admet-7	279	10	94,95	94,95	NOUN
admet-7	279	11	]	]	X
admet-7	279	12	.	.	PUNCT
admet-7	280	1	it	it	PRON
admet-7	280	2	is	be	AUX
admet-7	280	3	hoped	hope	VERB
admet-7	280	4	that	that	SCONJ
admet-7	280	5	the	the	DET
admet-7	280	6	findings	finding	NOUN
admet-7	280	7	from	from	ADP
admet-7	280	8	these	these	DET
admet-7	280	9	studies	study	NOUN
admet-7	280	10	corroborate	corroborate	VERB
admet-7	280	11	the	the	DET
admet-7	280	12	positive	positive	ADJ
admet-7	280	13	results	result	NOUN
admet-7	280	14	obtained	obtain	VERB
admet-7	280	15	from	from	ADP
admet-7	280	16	the	the	DET
admet-7	280	17	asia	asia	PROPN
admet-7	280	18	-	-	PUNCT
admet-7	280	19	pacific	pacific	PROPN
admet-7	280	20	region	region	NOUN
admet-7	281	1	[	[	X
admet-7	281	2	93	93	NUM
admet-7	281	3	]	]	PUNCT
admet-7	281	4	.	.	PUNCT
admet-7	282	1	other	other	ADJ
admet-7	282	2	molecularly	molecularly	ADV
admet-7	282	3	targeted	target	VERB
admet-7	282	4	agents	agent	NOUN
admet-7	282	5	,	,	PUNCT
admet-7	282	6	such	such	ADJ
admet-7	282	7	as	as	ADP
admet-7	282	8	bevacizumab	bevacizumab	NOUN
admet-7	282	9	/	/	SYM
admet-7	282	10	erlotinib	erlotinib	PROPN
admet-7	282	11	,	,	PUNCT
admet-7	282	12	are	be	AUX
admet-7	282	13	currently	currently	ADV
admet-7	282	14	under	under	ADP
admet-7	282	15	clinical	clinical	ADJ
admet-7	282	16	investigation	investigation	NOUN
admet-7	282	17	for	for	ADP
admet-7	282	18	therapy	therapy	NOUN
admet-7	282	19	for	for	ADP
admet-7	282	20	hcc	hcc	PROPN
admet-7	283	1	[	[	X
admet-7	283	2	96	96	NUM
admet-7	283	3	]	]	PUNCT
admet-7	283	4	.	.	PUNCT
admet-7	284	1	bevacizumab	bevacizumab	PROPN
admet-7	284	2	is	be	AUX
admet-7	284	3	a	a	DET
admet-7	284	4	humanized	humanize	VERB
admet-7	284	5	monoclonal	monoclonal	NOUN
admet-7	284	6	antibody	antibody	NOUN
admet-7	284	7	that	that	PRON
admet-7	284	8	inhibits	inhibit	VERB
admet-7	284	9	vascular	vascular	ADJ
admet-7	284	10	endothelial	endothelial	ADJ
admet-7	284	11	growth	growth	NOUN
admet-7	284	12	factor	factor	NOUN
admet-7	284	13	a	a	NOUN
admet-7	284	14	,	,	PUNCT
admet-7	284	15	while	while	SCONJ
admet-7	284	16	erlotinib	erlotinib	NOUN
admet-7	284	17	is	be	AUX
admet-7	284	18	a	a	DET
admet-7	284	19	reversible	reversible	ADJ
admet-7	284	20	tyrosine	tyrosine	NOUN
admet-7	284	21	kinase	kinase	NOUN
admet-7	284	22	inhibitor	inhibitor	NOUN
admet-7	284	23	that	that	PRON
admet-7	284	24	acts	act	VERB
admet-7	284	25	on	on	ADP
admet-7	284	26	the	the	DET
admet-7	284	27	epidermal	epidermal	ADJ
admet-7	284	28	growth	growth	NOUN
admet-7	284	29	factor	factor	NOUN
admet-7	284	30	receptor	receptor	NOUN
admet-7	284	31	[	[	X
admet-7	284	32	97	97	NUM
admet-7	284	33	]	]	PUNCT
admet-7	284	34	.	.	PUNCT
admet-7	285	1	as	as	ADP
admet-7	285	2	in	in	ADP
admet-7	285	3	the	the	DET
admet-7	285	4	case	case	NOUN
admet-7	285	5	of	of	ADP
admet-7	285	6	sorafenib	sorafenib	NOUN
admet-7	285	7	,	,	PUNCT
admet-7	285	8	these	these	DET
admet-7	285	9	drug	drug	NOUN
admet-7	285	10	actions	action	NOUN
admet-7	285	11	are	be	AUX
admet-7	285	12	based	base	VERB
admet-7	285	13	on	on	ADP
admet-7	285	14	different	different	ADJ
admet-7	285	15	mechanisms	mechanism	NOUN
admet-7	285	16	as	as	SCONJ
admet-7	285	17	compared	compare	VERB
admet-7	285	18	with	with	ADP
admet-7	285	19	doxorubicin	doxorubicin	PROPN
admet-7	285	20	.	.	PUNCT
admet-7	286	1	it	it	PRON
admet-7	286	2	would	would	AUX
admet-7	286	3	be	be	AUX
admet-7	286	4	of	of	ADP
admet-7	286	5	great	great	ADJ
admet-7	286	6	interest	interest	NOUN
admet-7	286	7	to	to	PART
admet-7	286	8	evaluate	evaluate	VERB
admet-7	286	9	their	their	PRON
admet-7	286	10	synergistic	synergistic	ADJ
admet-7	286	11	effects	effect	NOUN
admet-7	286	12	with	with	ADP
admet-7	286	13	doxorubicin	doxorubicin	PROPN
admet-7	286	14	and	and	CCONJ
admet-7	286	15	see	see	VERB
admet-7	286	16	if	if	SCONJ
admet-7	286	17	these	these	PRON
admet-7	286	18	might	might	AUX
admet-7	286	19	result	result	VERB
admet-7	286	20	in	in	ADP
admet-7	286	21	tumour	tumour	NOUN
admet-7	286	22	shrinkage	shrinkage	NOUN
admet-7	286	23	and	and	CCONJ
admet-7	286	24	enhanced	enhanced	ADJ
admet-7	286	25	survival	survival	NOUN
admet-7	286	26	.	.	PUNCT
admet-7	287	1	5.3	5.3	NUM
admet-7	287	2	.	.	PUNCT
admet-7	287	3	combination	combination	NOUN
admet-7	287	4	with	with	ADP
admet-7	287	5	other	other	ADJ
admet-7	287	6	treatment	treatment	NOUN
admet-7	287	7	options	option	NOUN
admet-7	287	8	doxorubicin	doxorubicin	NOUN
admet-7	287	9	-	-	PUNCT
admet-7	287	10	tace	tace	NOUN
admet-7	287	11	could	could	AUX
admet-7	287	12	offer	offer	VERB
admet-7	287	13	the	the	DET
admet-7	287	14	possibility	possibility	NOUN
admet-7	287	15	of	of	ADP
admet-7	287	16	extending	extend	VERB
admet-7	287	17	hcc	hcc	PROPN
admet-7	287	18	patients	patient	NOUN
admet-7	287	19	’	'	PUNCT
admet-7	287	20	lives	life	NOUN
admet-7	287	21	while	while	SCONJ
admet-7	287	22	waiting	wait	VERB
admet-7	287	23	for	for	ADP
admet-7	287	24	curative	curative	ADJ
admet-7	287	25	treatment	treatment	NOUN
admet-7	287	26	such	such	ADJ
admet-7	287	27	as	as	ADP
admet-7	287	28	a	a	DET
admet-7	287	29	liver	liver	NOUN
admet-7	287	30	transplant	transplant	NOUN
admet-7	287	31	.	.	PUNCT
admet-7	288	1	it	it	PRON
admet-7	288	2	has	have	AUX
admet-7	288	3	been	be	AUX
admet-7	288	4	pointed	point	VERB
admet-7	288	5	out	out	ADP
admet-7	288	6	that	that	SCONJ
admet-7	288	7	the	the	DET
admet-7	288	8	patient	patient	ADJ
admet-7	288	9	drop	drop	NOUN
admet-7	288	10	-	-	PUNCT
admet-7	288	11	off	off	NOUN
admet-7	288	12	(	(	PUNCT
admet-7	288	13	e.g.	e.g.	ADV
admet-7	288	14	death	death	NOUN
admet-7	288	15	)	)	PUNCT
admet-7	288	16	risk	risk	NOUN
admet-7	288	17	while	while	SCONJ
admet-7	288	18	awaiting	await	VERB
admet-7	288	19	liver	liver	NOUN
admet-7	288	20	transplantation	transplantation	NOUN
admet-7	288	21	for	for	ADP
admet-7	288	22	hcc	hcc	PROPN
admet-7	288	23	is	be	AUX
admet-7	288	24	22	22	NUM
admet-7	288	25	%	%	NOUN
admet-7	289	1	[	[	X
admet-7	289	2	98	98	NUM
admet-7	289	3	]	]	PUNCT
admet-7	289	4	.	.	PUNCT
admet-7	290	1	doxorubicin	doxorubicin	PROPN
admet-7	290	2	-	-	PUNCT
admet-7	290	3	tace	tace	NOUN
admet-7	290	4	treatment	treatment	NOUN
admet-7	290	5	significantly	significantly	ADV
admet-7	290	6	reduced	reduce	VERB
admet-7	290	7	the	the	DET
admet-7	290	8	drop	drop	VERB
admet-7	290	9	-	-	PUNCT
admet-7	290	10	off	off	ADP
admet-7	290	11	risk	risk	NOUN
admet-7	290	12	,	,	PUNCT
admet-7	290	13	resulting	result	VERB
admet-7	290	14	in	in	ADP
admet-7	290	15	longer	long	ADJ
admet-7	290	16	survival	survival	NOUN
admet-7	290	17	[	[	X
admet-7	290	18	98	98	NUM
admet-7	290	19	]	]	PUNCT
admet-7	290	20	.	.	PUNCT
admet-7	291	1	the	the	DET
admet-7	291	2	combination	combination	NOUN
admet-7	291	3	of	of	ADP
admet-7	291	4	tace	tace	NOUN
admet-7	291	5	with	with	ADP
admet-7	291	6	radiofrequency	radiofrequency	NOUN
admet-7	291	7	ablation	ablation	NOUN
admet-7	291	8	(	(	PUNCT
admet-7	291	9	rfa	rfa	NOUN
admet-7	291	10	)	)	PUNCT
admet-7	291	11	is	be	AUX
admet-7	291	12	a	a	DET
admet-7	291	13	promising	promising	ADJ
admet-7	291	14	approach	approach	NOUN
admet-7	291	15	to	to	ADP
admet-7	291	16	treating	treat	VERB
admet-7	291	17	hcc	hcc	PROPN
admet-7	291	18	.	.	PUNCT
admet-7	291	19	rfa	rfa	PROPN
admet-7	291	20	represents	represent	VERB
admet-7	291	21	an	an	DET
admet-7	291	22	attractive	attractive	ADJ
admet-7	291	23	alternative	alternative	NOUN
admet-7	291	24	to	to	ADP
admet-7	291	25	liver	liver	NOUN
admet-7	291	26	resection	resection	NOUN
admet-7	291	27	for	for	ADP
admet-7	291	28	patients	patient	NOUN
admet-7	291	29	with	with	ADP
admet-7	291	30	early	early	ADJ
admet-7	291	31	-	-	PUNCT
admet-7	291	32	stage	stage	NOUN
admet-7	291	33	hcc	hcc	PROPN
admet-7	291	34	.	.	PROPN
admet-7	291	35	rfa	rfa	PROPN
admet-7	291	36	uses	use	VERB
admet-7	291	37	radiofrequency	radiofrequency	NOUN
admet-7	291	38	energy	energy	NOUN
admet-7	291	39	-	-	PUNCT
admet-7	291	40	generated	generate	VERB
admet-7	291	41	heat	heat	NOUN
admet-7	291	42	to	to	PART
admet-7	291	43	destroy	destroy	VERB
admet-7	291	44	the	the	DET
admet-7	291	45	tumour	tumour	NOUN
admet-7	291	46	.	.	PUNCT
admet-7	292	1	the	the	DET
admet-7	292	2	technique	technique	NOUN
admet-7	292	3	works	work	VERB
admet-7	292	4	well	well	ADV
admet-7	292	5	with	with	ADP
admet-7	292	6	small	small	ADJ
admet-7	292	7	hcc	hcc	PROPN
admet-7	292	8	(	(	PUNCT
admet-7	292	9	<	<	X
admet-7	292	10	3	3	NUM
admet-7	292	11	cm	cm	NOUN
admet-7	292	12	)	)	PUNCT
admet-7	292	13	,	,	PUNCT
admet-7	292	14	with	with	ADP
admet-7	292	15	an	an	DET
admet-7	292	16	impressive	impressive	ADJ
admet-7	292	17	4	4	NUM
admet-7	292	18	-	-	PUNCT
admet-7	292	19	year	year	NOUN
admet-7	292	20	survival	survival	NOUN
admet-7	292	21	rate	rate	NOUN
admet-7	292	22	of	of	ADP
admet-7	292	23	66	66	NUM
admet-7	292	24	–	–	PUNCT
admet-7	292	25	82	82	NUM
admet-7	292	26	%	%	NOUN
admet-7	292	27	as	as	SCONJ
admet-7	292	28	reported	report	VERB
admet-7	292	29	in	in	ADP
admet-7	292	30	japan	japan	PROPN
admet-7	292	31	[	[	X
admet-7	292	32	99	99	NUM
admet-7	292	33	]	]	PUNCT
admet-7	292	34	.	.	PUNCT
admet-7	293	1	as	as	SCONJ
admet-7	293	2	the	the	DET
admet-7	293	3	size	size	NOUN
admet-7	293	4	of	of	ADP
admet-7	293	5	tumour	tumour	NOUN
admet-7	293	6	grows	grow	VERB
admet-7	293	7	beyond	beyond	ADP
admet-7	293	8	5	5	NUM
admet-7	293	9	cm	cm	NOUN
admet-7	293	10	,	,	PUNCT
admet-7	293	11	the	the	DET
admet-7	293	12	efficacy	efficacy	NOUN
admet-7	293	13	of	of	ADP
admet-7	293	14	rfa	rfa	NOUN
admet-7	293	15	is	be	AUX
admet-7	293	16	generally	generally	ADV
admet-7	293	17	reduced	reduce	VERB
admet-7	293	18	[	[	X
admet-7	293	19	100	100	NUM
admet-7	293	20	]	]	PUNCT
admet-7	293	21	,	,	PUNCT
admet-7	293	22	probably	probably	ADV
admet-7	293	23	due	due	ADJ
admet-7	293	24	to	to	ADP
admet-7	293	25	increased	increase	VERB
admet-7	293	26	blood	blood	NOUN
admet-7	293	27	flow	flow	NOUN
admet-7	293	28	leading	lead	VERB
admet-7	293	29	to	to	ADP
admet-7	293	30	heat	heat	NOUN
admet-7	293	31	loss	loss	NOUN
admet-7	293	32	and/or	and/or	CCONJ
admet-7	293	33	incomplete	incomplete	ADJ
admet-7	293	34	ablation	ablation	NOUN
admet-7	293	35	.	.	PUNCT
admet-7	294	1	it	it	PRON
admet-7	294	2	has	have	AUX
admet-7	294	3	been	be	AUX
admet-7	294	4	reported	report	VERB
admet-7	294	5	that	that	SCONJ
admet-7	294	6	by	by	ADP
admet-7	294	7	performing	perform	VERB
admet-7	294	8	hepatic	hepatic	ADJ
admet-7	294	9	intraarterial	intraarterial	ADJ
admet-7	294	10	embolization	embolization	NOUN
admet-7	294	11	ahead	ahead	ADV
admet-7	294	12	of	of	ADP
admet-7	294	13	rfa	rfa	NOUN
admet-7	294	14	treatment	treatment	NOUN
admet-7	294	15	(	(	PUNCT
admet-7	294	16	tace	tace	NOUN
admet-7	294	17	-	-	PUNCT
admet-7	294	18	rfa	rfa	NOUN
admet-7	294	19	)	)	PUNCT
admet-7	294	20	,	,	PUNCT
admet-7	294	21	the	the	DET
admet-7	294	22	heat	heat	NOUN
admet-7	294	23	sink	sink	NOUN
admet-7	294	24	effect	effect	NOUN
admet-7	294	25	mediated	mediate	VERB
admet-7	294	26	by	by	ADP
admet-7	294	27	hepatic	hepatic	ADJ
admet-7	294	28	arterial	arterial	NOUN
admet-7	294	29	flow	flow	NOUN
admet-7	294	30	should	should	AUX
admet-7	294	31	be	be	AUX
admet-7	294	32	minimized	minimize	VERB
admet-7	294	33	[	[	X
admet-7	294	34	101	101	NUM
admet-7	294	35	]	]	PUNCT
admet-7	294	36	.	.	PUNCT
admet-7	295	1	giving	give	VERB
admet-7	295	2	tace	tace	NOUN
admet-7	295	3	before	before	SCONJ
admet-7	295	4	rfa	rfa	NOUN
admet-7	295	5	administration	administration	NOUN
admet-7	295	6	offers	offer	VERB
admet-7	295	7	additional	additional	ADJ
admet-7	295	8	locoregional	locoregional	ADJ
admet-7	295	9	chemotherapy	chemotherapy	NOUN
admet-7	295	10	,	,	PUNCT
admet-7	295	11	which	which	PRON
admet-7	295	12	should	should	AUX
admet-7	295	13	result	result	VERB
admet-7	295	14	in	in	ADP
admet-7	295	15	better	well	ADJ
admet-7	295	16	response	response	NOUN
admet-7	295	17	and	and	CCONJ
admet-7	295	18	improved	improved	ADJ
admet-7	295	19	survival	survival	NOUN
admet-7	295	20	.	.	PUNCT
admet-7	296	1	clinical	clinical	ADJ
admet-7	296	2	studies	study	NOUN
admet-7	296	3	have	have	AUX
admet-7	296	4	been	be	AUX
admet-7	296	5	conducted	conduct	VERB
admet-7	296	6	to	to	PART
admet-7	296	7	evaluate	evaluate	VERB
admet-7	296	8	the	the	DET
admet-7	296	9	tace	tace	NOUN
admet-7	296	10	-	-	PUNCT
admet-7	296	11	rfa	rfa	NOUN
admet-7	296	12	procedure	procedure	NOUN
admet-7	296	13	in	in	ADP
admet-7	296	14	hcc	hcc	PROPN
admet-7	296	15	patients	patient	NOUN
admet-7	296	16	.	.	PUNCT
admet-7	297	1	cheng	cheng	PROPN
admet-7	297	2	et	et	PROPN
admet-7	297	3	al	al	PROPN
admet-7	297	4	.	.	PROPN
admet-7	297	5	were	be	AUX
admet-7	297	6	among	among	ADP
admet-7	297	7	the	the	DET
admet-7	297	8	first	first	ADJ
admet-7	297	9	to	to	PART
admet-7	297	10	report	report	VERB
admet-7	297	11	a	a	DET
admet-7	297	12	clinical	clinical	ADJ
admet-7	297	13	trial	trial	NOUN
admet-7	297	14	involving	involve	VERB
admet-7	297	15	tace	tace	NOUN
admet-7	297	16	-	-	PUNCT
admet-7	297	17	rfa	rfa	NOUN
admet-7	297	18	in	in	ADP
admet-7	297	19	patients	patient	NOUN
admet-7	297	20	with	with	ADP
admet-7	297	21	hcc	hcc	PROPN
admet-7	297	22	tumour	tumour	NOUN
admet-7	297	23	sizes	size	NOUN
admet-7	297	24	from	from	ADP
admet-7	297	25	3	3	NUM
admet-7	297	26	to	to	ADP
admet-7	297	27	7.5	7.5	NUM
admet-7	297	28	cm	cm	NOUN
admet-7	297	29	[	[	X
admet-7	297	30	102	102	NUM
admet-7	297	31	]	]	PUNCT
admet-7	297	32	.	.	PUNCT
admet-7	298	1	it	it	PRON
admet-7	298	2	has	have	AUX
admet-7	298	3	been	be	AUX
admet-7	298	4	shown	show	VERB
admet-7	298	5	that	that	SCONJ
admet-7	298	6	patients	patient	NOUN
admet-7	298	7	treated	treat	VERB
admet-7	298	8	with	with	ADP
admet-7	298	9	tace	tace	NOUN
admet-7	298	10	-	-	PUNCT
admet-7	298	11	rfa	rfa	NOUN
admet-7	298	12	had	have	VERB
admet-7	298	13	better	well	ADJ
admet-7	298	14	overall	overall	ADJ
admet-7	298	15	survival	survival	NOUN
admet-7	298	16	than	than	ADP
admet-7	298	17	those	those	PRON
admet-7	298	18	treated	treat	VERB
admet-7	298	19	with	with	ADP
admet-7	298	20	tace	tace	NOUN
admet-7	298	21	alone	alone	ADV
admet-7	298	22	or	or	CCONJ
admet-7	298	23	rfa	rfa	NOUN
admet-7	298	24	alone	alone	ADV
admet-7	298	25	.	.	PUNCT
admet-7	299	1	a	a	DET
admet-7	299	2	more	more	ADV
admet-7	299	3	recent	recent	ADJ
admet-7	299	4	study	study	NOUN
admet-7	299	5	also	also	ADV
admet-7	299	6	revealed	reveal	VERB
admet-7	299	7	a	a	DET
admet-7	299	8	similar	similar	ADJ
admet-7	299	9	picture	picture	NOUN
admet-7	299	10	[	[	X
admet-7	299	11	103	103	NUM
admet-7	299	12	]	]	PUNCT
admet-7	299	13	.	.	PUNCT
admet-7	300	1	with	with	ADP
admet-7	300	2	a	a	DET
admet-7	300	3	median	median	ADJ
admet-7	300	4	follow	follow	NOUN
admet-7	300	5	-	-	PUNCT
admet-7	300	6	up	up	NOUN
admet-7	300	7	of	of	ADP
admet-7	300	8	36	36	NUM
admet-7	300	9	months	month	NOUN
admet-7	300	10	,	,	PUNCT
admet-7	300	11	the	the	DET
admet-7	300	12	1-	1-	PROPN
admet-7	300	13	,	,	PUNCT
admet-7	300	14	3-	3-	NOUN
admet-7	300	15	,	,	PUNCT
admet-7	300	16	and	and	CCONJ
admet-7	300	17	4	4	NUM
admet-7	300	18	-	-	PUNCT
admet-7	300	19	year	year	NOUN
admet-7	300	20	overall	overall	ADJ
admet-7	300	21	survival	survival	NOUN
admet-7	300	22	for	for	ADP
admet-7	300	23	the	the	DET
admet-7	300	24	tace	tace	NOUN
admet-7	300	25	-	-	PUNCT
admet-7	300	26	rfa	rfa	NOUN
admet-7	300	27	treated	treat	VERB
admet-7	300	28	patients	patient	NOUN
admet-7	300	29	and	and	CCONJ
admet-7	300	30	the	the	DET
admet-7	300	31	rfa	rfa	NOUN
admet-7	300	32	treated	treat	VERB
admet-7	300	33	patients	patient	NOUN
admet-7	300	34	was	be	AUX
admet-7	300	35	92.6	92.6	NUM
admet-7	300	36	%	%	NOUN
admet-7	300	37	and	and	CCONJ
admet-7	300	38	66.6	66.6	NUM
admet-7	300	39	%	%	NOUN
admet-7	300	40	,	,	PUNCT
admet-7	300	41	61.8	61.8	NUM
admet-7	300	42	%	%	NOUN
admet-7	300	43	and	and	CCONJ
admet-7	300	44	85.3	85.3	NUM
admet-7	300	45	%	%	NOUN
admet-7	300	46	,	,	PUNCT
admet-7	300	47	and	and	CCONJ
admet-7	300	48	59	59	NUM
admet-7	300	49	%	%	NOUN
admet-7	300	50	and	and	CCONJ
admet-7	300	51	45.0	45.0	NUM
admet-7	300	52	%	%	NOUN
admet-7	300	53	,	,	PUNCT
admet-7	300	54	respectively	respectively	ADV
admet-7	300	55	.	.	PUNCT
admet-7	301	1	no	no	DET
admet-7	301	2	significant	significant	ADJ
admet-7	301	3	difference	difference	NOUN
admet-7	301	4	in	in	ADP
admet-7	301	5	toxicity	toxicity	NOUN
admet-7	301	6	profiles	profile	NOUN
admet-7	301	7	was	be	AUX
admet-7	301	8	observed	observe	VERB
admet-7	301	9	between	between	ADP
admet-7	301	10	the	the	DET
admet-7	301	11	tace	tace	NOUN
admet-7	301	12	-	-	PUNCT
admet-7	301	13	rfa	rfa	NOUN
admet-7	301	14	treated	treat	VERB
admet-7	301	15	patients	patient	NOUN
admet-7	301	16	and	and	CCONJ
admet-7	301	17	the	the	DET
admet-7	301	18	rfa	rfa	NOUN
admet-7	301	19	treated	treat	VERB
admet-7	301	20	patients	patient	NOUN
admet-7	301	21	.	.	PUNCT
admet-7	302	1	tam	tam	PROPN
admet-7	302	2	admet	admet	PROPN
admet-7	302	3	&	&	CCONJ
admet-7	302	4	dmpk	dmpk	PROPN
admet-7	302	5	1(3	1(3	NUM
admet-7	302	6	)	)	PUNCT
admet-7	302	7	(	(	PUNCT
admet-7	302	8	2013	2013	NUM
admet-7	302	9	)	)	PUNCT
admet-7	302	10	29	29	NUM
admet-7	302	11	-	-	SYM
admet-7	302	12	44	44	NUM
admet-7	302	13	40	40	NUM
admet-7	302	14	6	6	NUM
admet-7	302	15	.	.	PUNCT
admet-7	303	1	conclusions	conclusion	NOUN
admet-7	303	2	hcc	hcc	PROPN
admet-7	303	3	mortality	mortality	NOUN
admet-7	303	4	is	be	AUX
admet-7	303	5	high	high	ADJ
admet-7	303	6	,	,	PUNCT
admet-7	303	7	and	and	CCONJ
admet-7	303	8	the	the	DET
admet-7	303	9	treatment	treatment	NOUN
admet-7	303	10	options	option	NOUN
admet-7	303	11	are	be	AUX
admet-7	303	12	limited	limited	ADJ
admet-7	303	13	.	.	PUNCT
admet-7	304	1	surgical	surgical	ADJ
admet-7	304	2	procedures	procedure	NOUN
admet-7	304	3	such	such	ADJ
admet-7	304	4	as	as	ADP
admet-7	304	5	liver	liver	NOUN
admet-7	304	6	resection	resection	NOUN
admet-7	304	7	or	or	CCONJ
admet-7	304	8	liver	liver	NOUN
admet-7	304	9	transplantation	transplantation	NOUN
admet-7	304	10	are	be	AUX
admet-7	304	11	still	still	ADV
admet-7	304	12	regarded	regard	VERB
admet-7	304	13	as	as	ADP
admet-7	304	14	the	the	DET
admet-7	304	15	only	only	ADJ
admet-7	304	16	curative	curative	ADJ
admet-7	304	17	treatments	treatment	NOUN
admet-7	304	18	currently	currently	ADV
admet-7	304	19	available	available	ADJ
admet-7	304	20	.	.	PUNCT
admet-7	305	1	in	in	ADP
admet-7	305	2	general	general	ADJ
admet-7	305	3	,	,	PUNCT
admet-7	305	4	less	less	ADJ
admet-7	305	5	than	than	ADP
admet-7	305	6	20	20	NUM
admet-7	305	7	%	%	NOUN
admet-7	305	8	of	of	ADP
admet-7	305	9	hcc	hcc	PROPN
admet-7	305	10	patient	patient	NOUN
admet-7	305	11	are	be	AUX
admet-7	305	12	deemed	deem	VERB
admet-7	305	13	suitable	suitable	ADJ
admet-7	305	14	candidates	candidate	NOUN
admet-7	305	15	to	to	PART
admet-7	305	16	perform	perform	VERB
admet-7	305	17	curative	curative	ADJ
admet-7	305	18	resection	resection	NOUN
admet-7	305	19	.	.	PUNCT
admet-7	306	1	tace	tace	NOUN
admet-7	306	2	is	be	AUX
admet-7	306	3	emerging	emerge	VERB
admet-7	306	4	as	as	ADP
admet-7	306	5	a	a	DET
admet-7	306	6	promising	promising	ADJ
admet-7	306	7	palliative	palliative	ADJ
admet-7	306	8	treatment	treatment	NOUN
admet-7	306	9	for	for	ADP
admet-7	306	10	hcc	hcc	PROPN
admet-7	306	11	patients	patient	NOUN
admet-7	306	12	that	that	PRON
admet-7	306	13	are	be	AUX
admet-7	306	14	not	not	PART
admet-7	306	15	suitable	suitable	ADJ
admet-7	306	16	for	for	ADP
admet-7	306	17	surgical	surgical	ADJ
admet-7	306	18	procedures	procedure	NOUN
admet-7	306	19	.	.	PUNCT
admet-7	307	1	the	the	DET
admet-7	307	2	recently	recently	ADV
admet-7	307	3	developed	develop	VERB
admet-7	307	4	deb	deb	PROPN
admet-7	307	5	offers	offer	VERB
admet-7	307	6	some	some	DET
admet-7	307	7	operational	operational	ADJ
admet-7	307	8	convenience	convenience	NOUN
admet-7	307	9	in	in	ADP
admet-7	307	10	performing	perform	VERB
admet-7	307	11	the	the	DET
admet-7	307	12	tace	tace	NOUN
admet-7	307	13	procedure	procedure	NOUN
admet-7	307	14	.	.	PUNCT
admet-7	308	1	doxorubicin	doxorubicin	PROPN
admet-7	308	2	is	be	AUX
admet-7	308	3	one	one	NUM
admet-7	308	4	of	of	ADP
admet-7	308	5	the	the	DET
admet-7	308	6	most	most	ADV
admet-7	308	7	commonly	commonly	ADV
admet-7	308	8	used	use	VERB
admet-7	308	9	cytotoxic	cytotoxic	ADJ
admet-7	308	10	drugs	drug	NOUN
admet-7	308	11	in	in	ADP
admet-7	308	12	tace	tace	NOUN
admet-7	308	13	.	.	PUNCT
admet-7	309	1	despite	despite	SCONJ
admet-7	309	2	doxorubicin	doxorubicin	PROPN
admet-7	309	3	exhibiting	exhibit	VERB
admet-7	309	4	a	a	DET
admet-7	309	5	broad	broad	ADJ
admet-7	309	6	spectrum	spectrum	NOUN
admet-7	309	7	of	of	ADP
admet-7	309	8	anti	anti	ADJ
admet-7	309	9	-	-	ADJ
admet-7	309	10	tumour	tumour	ADJ
admet-7	309	11	activity	activity	NOUN
admet-7	309	12	,	,	PUNCT
admet-7	309	13	systemic	systemic	ADJ
admet-7	309	14	administration	administration	NOUN
admet-7	309	15	can	can	AUX
admet-7	309	16	often	often	ADV
admet-7	309	17	lead	lead	VERB
admet-7	309	18	to	to	ADP
admet-7	309	19	fatal	fatal	ADJ
admet-7	309	20	cardiotoxicity	cardiotoxicity	NOUN
admet-7	309	21	and	and	CCONJ
admet-7	309	22	adverse	adverse	ADJ
admet-7	309	23	side	side	NOUN
admet-7	309	24	effects	effect	NOUN
admet-7	309	25	.	.	PUNCT
admet-7	310	1	as	as	SCONJ
admet-7	310	2	a	a	DET
admet-7	310	3	liver	liver	NOUN
admet-7	310	4	directed	direct	VERB
admet-7	310	5	,	,	PUNCT
admet-7	310	6	locoregional	locoregional	ADJ
admet-7	310	7	procedure	procedure	NOUN
admet-7	310	8	,	,	PUNCT
admet-7	310	9	tace	tace	NOUN
admet-7	310	10	considerably	considerably	ADV
admet-7	310	11	reduces	reduce	VERB
admet-7	310	12	the	the	DET
admet-7	310	13	systemic	systemic	ADJ
admet-7	310	14	exposure	exposure	NOUN
admet-7	310	15	to	to	ADP
admet-7	310	16	doxorubicin	doxorubicin	PROPN
admet-7	310	17	,	,	PUNCT
admet-7	310	18	resulting	result	VERB
admet-7	310	19	in	in	ADP
admet-7	310	20	improved	improved	ADJ
admet-7	310	21	toxicity	toxicity	NOUN
admet-7	310	22	profiles	profile	NOUN
admet-7	310	23	,	,	PUNCT
admet-7	310	24	and	and	CCONJ
admet-7	310	25	has	have	AUX
admet-7	310	26	been	be	AUX
admet-7	310	27	shown	show	VERB
admet-7	310	28	to	to	PART
admet-7	310	29	be	be	AUX
admet-7	310	30	useful	useful	ADJ
admet-7	310	31	in	in	ADP
admet-7	310	32	preventing	prevent	VERB
admet-7	310	33	tumour	tumour	ADJ
admet-7	310	34	progression	progression	NOUN
admet-7	310	35	and	and	CCONJ
admet-7	310	36	in	in	ADP
admet-7	310	37	prolonging	prolong	VERB
admet-7	310	38	patients	patient	NOUN
admet-7	310	39	’	'	PUNCT
admet-7	310	40	lives	live	VERB
admet-7	310	41	.	.	PUNCT
admet-7	311	1	tace	tace	NOUN
admet-7	311	2	in	in	ADP
admet-7	311	3	combination	combination	NOUN
admet-7	311	4	with	with	ADP
admet-7	311	5	targeted	target	VERB
admet-7	311	6	chemotherapy	chemotherapy	NOUN
admet-7	311	7	,	,	PUNCT
admet-7	311	8	such	such	ADJ
admet-7	311	9	as	as	ADP
admet-7	311	10	sorafenib	sorafenib	NOUN
admet-7	311	11	,	,	PUNCT
admet-7	311	12	has	have	AUX
admet-7	311	13	already	already	ADV
admet-7	311	14	demonstrated	demonstrate	VERB
admet-7	311	15	clinical	clinical	ADJ
admet-7	311	16	advantages	advantage	NOUN
admet-7	311	17	in	in	ADP
admet-7	311	18	the	the	DET
admet-7	311	19	asia	asia	PROPN
admet-7	311	20	-	-	PUNCT
admet-7	311	21	pacific	pacific	PROPN
admet-7	311	22	region	region	NOUN
admet-7	311	23	.	.	PUNCT
admet-7	312	1	moreover	moreover	ADV
admet-7	312	2	,	,	PUNCT
admet-7	312	3	concurrent	concurrent	ADJ
admet-7	312	4	use	use	NOUN
admet-7	312	5	of	of	ADP
admet-7	312	6	tace	tace	NOUN
admet-7	312	7	and	and	CCONJ
admet-7	312	8	rfa	rfa	NOUN
admet-7	312	9	has	have	AUX
admet-7	312	10	shown	show	VERB
admet-7	312	11	promising	promising	ADJ
admet-7	312	12	survival	survival	NOUN
admet-7	312	13	benefits	benefit	NOUN
admet-7	312	14	in	in	ADP
admet-7	312	15	several	several	ADJ
admet-7	312	16	clinical	clinical	ADJ
admet-7	312	17	studies	study	NOUN
admet-7	312	18	.	.	PUNCT
admet-7	313	1	it	it	PRON
admet-7	313	2	is	be	AUX
admet-7	313	3	envisaged	envisage	VERB
admet-7	313	4	that	that	SCONJ
admet-7	313	5	doxorubicin	doxorubicin	PROPN
admet-7	313	6	administration	administration	PROPN
admet-7	313	7	via	via	ADP
admet-7	313	8	tace	tace	NOUN
admet-7	313	9	could	could	AUX
admet-7	313	10	be	be	AUX
admet-7	313	11	one	one	NUM
admet-7	313	12	more	more	ADV
admet-7	313	13	useful	useful	ADJ
admet-7	313	14	tool	tool	NOUN
admet-7	313	15	in	in	ADP
admet-7	313	16	combatting	combat	VERB
admet-7	313	17	hcc	hcc	PROPN
admet-7	313	18	as	as	SCONJ
admet-7	313	19	it	it	PRON
admet-7	313	20	offers	offer	VERB
admet-7	313	21	the	the	DET
admet-7	313	22	exciting	exciting	ADJ
admet-7	313	23	possibility	possibility	NOUN
admet-7	313	24	of	of	ADP
admet-7	313	25	enhancing	enhance	VERB
admet-7	313	26	the	the	DET
admet-7	313	27	currently	currently	ADV
admet-7	313	28	available	available	ADJ
admet-7	313	29	therapies	therapy	NOUN
admet-7	313	30	for	for	ADP
admet-7	313	31	hcc	hcc	PROPN
admet-7	313	32	patients	patient	NOUN
admet-7	313	33	.	.	PUNCT
admet-7	314	1	obviously	obviously	ADV
admet-7	314	2	,	,	PUNCT
admet-7	314	3	more	more	ADV
admet-7	314	4	clinical	clinical	ADJ
admet-7	314	5	studies	study	NOUN
admet-7	314	6	are	be	AUX
admet-7	314	7	required	require	VERB
admet-7	314	8	to	to	PART
admet-7	314	9	fully	fully	ADV
admet-7	314	10	evaluate	evaluate	VERB
admet-7	314	11	the	the	DET
admet-7	314	12	clinical	clinical	ADJ
admet-7	314	13	benefits	benefit	NOUN
admet-7	314	14	of	of	ADP
admet-7	314	15	these	these	DET
admet-7	314	16	combined	combine	VERB
admet-7	314	17	approaches	approach	NOUN
admet-7	314	18	.	.	PUNCT
admet-7	315	1	references	reference	NOUN
admet-7	315	2	[	[	X
admet-7	315	3	1	1	NUM
admet-7	315	4	]	]	PUNCT
admet-7	315	5	globocan	globocan	PROPN
admet-7	315	6	2008	2008	NUM
admet-7	315	7	.	.	PUNCT
admet-7	316	1	international	international	ADJ
admet-7	316	2	agency	agency	NOUN
admet-7	316	3	for	for	ADP
admet-7	316	4	cancer	cancer	NOUN
admet-7	316	5	research	research	NOUN
admet-7	316	6	liver	liver	NOUN
admet-7	316	7	cancer	cancer	NOUN
admet-7	316	8	fact	fact	NOUN
admet-7	316	9	sheet	sheet	NOUN
admet-7	316	10	,	,	PUNCT
admet-7	316	11	http://globocan.iarc.fr/	http://globocan.iarc.fr/	PROPN
admet-7	316	12	(	(	PUNCT
admet-7	316	13	accessed	access	VERB
admet-7	316	14	16	16	NUM
admet-7	316	15	may	may	NOUN
admet-7	316	16	,	,	PUNCT
admet-7	316	17	2013	2013	NUM
admet-7	316	18	)	)	PUNCT
admet-7	317	1	[	[	X
admet-7	317	2	2	2	X
admet-7	317	3	]	]	PUNCT
admet-7	317	4	hepatocellular	hepatocellular	ADJ
admet-7	317	5	carcinoma	carcinoma	NOUN
admet-7	317	6	:	:	PUNCT
admet-7	317	7	esmo	esmo	VERB
admet-7	317	8	clinical	clinical	ADJ
admet-7	317	9	practice	practice	NOUN
admet-7	317	10	guidelines	guideline	NOUN
admet-7	317	11	for	for	ADP
admet-7	317	12	diagnosis	diagnosis	NOUN
admet-7	317	13	,	,	PUNCT
admet-7	317	14	treatment	treatment	NOUN
admet-7	317	15	and	and	CCONJ
admet-7	317	16	follow	follow	NOUN
admet-7	317	17	-	-	PUNCT
admet-7	317	18	up	up	NOUN
admet-7	317	19	,	,	PUNCT
admet-7	317	20	european	european	ADJ
admet-7	317	21	society	society	NOUN
admet-7	317	22	for	for	ADP
admet-7	317	23	medical	medical	ADJ
admet-7	317	24	oncology	oncology	NOUN
admet-7	317	25	(	(	PUNCT
admet-7	317	26	2012	2012	NUM
admet-7	317	27	)	)	PUNCT
admet-7	317	28	.	.	PUNCT
admet-7	318	1	[	[	X
admet-7	318	2	3	3	NUM
admet-7	318	3	]	]	PUNCT
admet-7	318	4	a.	a.	NOUN
admet-7	318	5	forner	forner	NOUN
admet-7	318	6	,	,	PUNCT
admet-7	318	7	j.m	j.m	PROPN
admet-7	318	8	.	.	PROPN
admet-7	318	9	llovet	llovet	PROPN
admet-7	318	10	,	,	PUNCT
admet-7	318	11	j.	j.	PROPN
admet-7	318	12	bruix	bruix	PROPN
admet-7	318	13	,	,	PUNCT
admet-7	318	14	lancet	lancet	NOUN
admet-7	318	15	31	31	NUM
admet-7	318	16	(	(	PUNCT
admet-7	318	17	2012	2012	NUM
admet-7	318	18	)	)	PUNCT
admet-7	318	19	1245	1245	NUM
admet-7	318	20	-	-	SYM
admet-7	318	21	1255	1255	NUM
admet-7	318	22	.	.	PUNCT
admet-7	319	1	[	[	X
admet-7	319	2	4	4	NUM
admet-7	319	3	]	]	X
admet-7	319	4	f.x	f.x	PROPN
admet-7	319	5	.	.	PROPN
admet-7	319	6	bosch	bosch	PROPN
admet-7	319	7	,	,	PUNCT
admet-7	319	8	j.	j.	PROPN
admet-7	319	9	ribes	ribes	PROPN
admet-7	319	10	,	,	PUNCT
admet-7	319	11	m.	m.	NOUN
admet-7	319	12	díaz	díaz	NOUN
admet-7	319	13	,	,	PUNCT
admet-7	319	14	r.	r.	PROPN
admet-7	319	15	cléries	cléries	PROPN
admet-7	319	16	,	,	PUNCT
admet-7	319	17	gastroenterology	gastroenterology	NOUN
admet-7	319	18	127	127	NUM
admet-7	319	19	(	(	PUNCT
admet-7	319	20	2004	2004	NUM
admet-7	319	21	)	)	PUNCT
admet-7	319	22	s5	s5	PROPN
admet-7	319	23	-	-	NOUN
admet-7	319	24	s16	s16	NOUN
admet-7	319	25	.	.	PUNCT
admet-7	320	1	[	[	X
admet-7	320	2	5	5	X
admet-7	320	3	]	]	X
admet-7	320	4	e.e	e.e	PROPN
admet-7	320	5	.	.	PROPN
admet-7	320	6	calle	calle	PROPN
admet-7	320	7	,	,	PUNCT
admet-7	320	8	c.	c.	PROPN
admet-7	320	9	rodriguez	rodriguez	PROPN
admet-7	320	10	,	,	PUNCT
admet-7	320	11	k.	k.	PROPN
admet-7	320	12	walker	walker	PROPN
admet-7	320	13	-	-	PUNCT
admet-7	320	14	thurmond	thurmond	PROPN
admet-7	320	15	k	k	PROPN
admet-7	320	16	,	,	PUNCT
admet-7	320	17	m.j	m.j	PROPN
admet-7	320	18	.	.	PROPN
admet-7	320	19	thun	thun	PROPN
admet-7	320	20	,	,	PUNCT
admet-7	320	21	the	the	DET
admet-7	320	22	new	new	PROPN
admet-7	320	23	england	england	PROPN
admet-7	320	24	journal	journal	PROPN
admet-7	320	25	of	of	ADP
admet-7	320	26	medicine	medicine	NOUN
admet-7	320	27	348	348	NUM
admet-7	320	28	(	(	PUNCT
admet-7	320	29	2003	2003	NUM
admet-7	320	30	)	)	PUNCT
admet-7	320	31	1625	1625	NUM
admet-7	320	32	-	-	SYM
admet-7	320	33	1638	1638	NUM
admet-7	320	34	.	.	PUNCT
admet-7	321	1	[	[	X
admet-7	321	2	6	6	NUM
admet-7	321	3	]	]	PUNCT
admet-7	321	4	j.	j.	PROPN
admet-7	321	5	bruix	bruix	PROPN
admet-7	321	6	,	,	PUNCT
admet-7	321	7	j.m	j.m	PROPN
admet-7	321	8	.	.	PROPN
admet-7	321	9	llovet	llovet	PROPN
admet-7	321	10	,	,	PUNCT
admet-7	321	11	lancet	lancet	NOUN
admet-7	321	12	373	373	NUM
admet-7	321	13	(	(	PUNCT
admet-7	321	14	2009	2009	NUM
admet-7	321	15	)	)	PUNCT
admet-7	321	16	614	614	NUM
admet-7	321	17	-	-	SYM
admet-7	321	18	616	616	NUM
admet-7	321	19	.	.	PUNCT
admet-7	322	1	[	[	X
admet-7	322	2	7	7	X
admet-7	322	3	]	]	X
admet-7	322	4	s.c	s.c	PROPN
admet-7	322	5	.	.	PROPN
admet-7	322	6	chuang	chuang	PROPN
admet-7	322	7	,	,	PUNCT
admet-7	322	8	c.	c.	PROPN
admet-7	322	9	la	la	PROPN
admet-7	322	10	vecchia	vecchia	PROPN
admet-7	322	11	,	,	PUNCT
admet-7	322	12	p.	p.	NOUN
admet-7	322	13	boffetta	boffetta	NOUN
admet-7	322	14	,	,	PUNCT
admet-7	322	15	cancer	cancer	NOUN
admet-7	322	16	letters	letter	NOUN
admet-7	322	17	286	286	NUM
admet-7	322	18	(	(	PUNCT
admet-7	322	19	2009	2009	NUM
admet-7	322	20	)	)	PUNCT
admet-7	322	21	9	9	NUM
admet-7	322	22	-	-	SYM
admet-7	322	23	14	14	NUM
admet-7	322	24	.	.	PUNCT
admet-7	323	1	[	[	X
admet-7	323	2	8	8	X
admet-7	323	3	]	]	PUNCT
admet-7	323	4	k.	k.	PROPN
admet-7	323	5	yoshikawa	yoshikawa	PROPN
admet-7	323	6	,	,	PUNCT
admet-7	323	7	h.	h.	PROPN
admet-7	323	8	kitaoka	kitaoka	PROPN
admet-7	323	9	,	,	PUNCT
admet-7	323	10	the	the	DET
admet-7	323	11	japanese	japanese	ADJ
admet-7	323	12	journal	journal	NOUN
admet-7	323	13	of	of	ADP
admet-7	323	14	surgery	surgery	NOUN
admet-7	323	15	1	1	NUM
admet-7	323	16	(	(	PUNCT
admet-7	323	17	1971	1971	NUM
admet-7	323	18	)	)	PUNCT
admet-7	323	19	256	256	NUM
admet-7	323	20	-	-	SYM
admet-7	323	21	262	262	NUM
admet-7	323	22	.	.	PUNCT
admet-7	324	1	[	[	X
admet-7	324	2	9	9	NUM
admet-7	324	3	]	]	X
admet-7	324	4	r.b	r.b	PROPN
admet-7	324	5	.	.	PROPN
admet-7	324	6	weiss	weiss	PROPN
admet-7	324	7	,	,	PUNCT
admet-7	324	8	seminars	seminar	NOUN
admet-7	324	9	in	in	ADP
admet-7	324	10	oncology	oncology	NOUN
admet-7	324	11	19	19	NUM
admet-7	324	12	(	(	PUNCT
admet-7	324	13	1992	1992	NUM
admet-7	324	14	)	)	PUNCT
admet-7	324	15	670–686	670–686	NUM
admet-7	324	16	.	.	PUNCT
admet-7	325	1	[	[	X
admet-7	325	2	10	10	NUM
admet-7	325	3	]	]	X
admet-7	325	4	d.d	d.d	PROPN
admet-7	325	5	.	.	PROPN
admet-7	325	6	von	von	PROPN
admet-7	325	7	hoff	hoff	PROPN
admet-7	325	8	dd	dd	PROPN
admet-7	325	9	,	,	PUNCT
admet-7	325	10	m.w	m.w	PROPN
admet-7	325	11	.	.	PROPN
admet-7	325	12	layard	layard	PROPN
admet-7	325	13	,	,	PUNCT
admet-7	325	14	p.	p.	PROPN
admet-7	325	15	basa	basa	PROPN
admet-7	325	16	,	,	PUNCT
admet-7	325	17	h.l	h.l	PROPN
admet-7	325	18	.	.	PROPN
admet-7	325	19	davis	davis	PROPN
admet-7	325	20	,	,	PUNCT
admet-7	325	21	a.l	a.l	PROPN
admet-7	325	22	.	.	PROPN
admet-7	325	23	von	von	PROPN
admet-7	325	24	hoff	hoff	PROPN
admet-7	325	25	,	,	PUNCT
admet-7	325	26	m.	m.	NOUN
admet-7	325	27	rozencweig	rozencweig	PROPN
admet-7	325	28	,	,	PUNCT
admet-7	325	29	f.m	f.m	PROPN
admet-7	325	30	.	.	PROPN
admet-7	325	31	muggia	muggia	NOUN
admet-7	325	32	,	,	PUNCT
admet-7	325	33	annals	annal	NOUN
admet-7	325	34	of	of	ADP
admet-7	325	35	internal	internal	ADJ
admet-7	325	36	medicine	medicine	NOUN
admet-7	325	37	91	91	NUM
admet-7	325	38	(	(	PUNCT
admet-7	325	39	1979	1979	NUM
admet-7	325	40	)	)	PUNCT
admet-7	325	41	710–717	710–717	NUM
admet-7	325	42	.	.	PUNCT
admet-7	326	1	[	[	X
admet-7	326	2	11	11	NUM
admet-7	326	3	]	]	X
admet-7	326	4	b.i	b.i	PROPN
admet-7	326	5	.	.	PROPN
admet-7	326	6	carr	carr	PROPN
admet-7	326	7	,	,	PUNCT
admet-7	326	8	s.	s.	PROPN
admet-7	326	9	nagalla	nagalla	PROPN
admet-7	326	10	,	,	PUNCT
admet-7	326	11	in	in	ADP
admet-7	326	12	hepatocellular	hepatocellular	ADJ
admet-7	326	13	carcinoma	carcinoma	NOUN
admet-7	326	14	:	:	PUNCT
admet-7	326	15	diagnosis	diagnosis	NOUN
admet-7	326	16	and	and	CCONJ
admet-7	326	17	treatment	treatment	NOUN
admet-7	326	18	,	,	PUNCT
admet-7	326	19	brain	brain	NOUN
admet-7	326	20	carr	carr	NOUN
admet-7	326	21	(	(	PUNCT
admet-7	326	22	ed	ed	NOUN
admet-7	326	23	)	)	PUNCT
admet-7	326	24	.	.	PUNCT
admet-7	326	25	,	,	PUNCT
admet-7	326	26	humana	humana	PROPN
admet-7	326	27	press	press	PROPN
admet-7	326	28	,	,	PUNCT
admet-7	326	29	new	new	PROPN
admet-7	326	30	york	york	PROPN
admet-7	326	31	,	,	PUNCT
admet-7	326	32	usa	usa	PROPN
admet-7	326	33	,	,	PUNCT
admet-7	326	34	2010	2010	NUM
admet-7	326	35	,	,	PUNCT
admet-7	326	36	p.	p.	NOUN
admet-7	326	37	527	527	NUM
admet-7	326	38	.	.	PUNCT
admet-7	327	1	[	[	X
admet-7	327	2	12	12	NUM
admet-7	327	3	]	]	X
admet-7	327	4	m.c	m.c	PROPN
admet-7	327	5	.	.	PROPN
admet-7	327	6	kew	kew	PROPN
admet-7	327	7	,	,	PUNCT
admet-7	327	8	h.a	h.a	PROPN
admet-7	327	9	.	.	PROPN
admet-7	327	10	dos	dos	PROPN
admet-7	327	11	santos	santos	PROPN
admet-7	327	12	,	,	PUNCT
admet-7	327	13	s.	s.	PROPN
admet-7	327	14	sherlock	sherlock	PROPN
admet-7	327	15	,	,	PUNCT
admet-7	327	16	british	british	PROPN
admet-7	327	17	medical	medical	ADJ
admet-7	327	18	journal	journal	PROPN
admet-7	327	19	4	4	NUM
admet-7	327	20	(	(	PUNCT
admet-7	327	21	1971	1971	NUM
admet-7	327	22	)	)	PUNCT
admet-7	328	1	408–411	408–411	NUM
admet-7	328	2	.	.	PUNCT
admet-7	329	1	[	[	X
admet-7	329	2	13	13	NUM
admet-7	329	3	]	]	PUNCT
admet-7	329	4	a.	a.	NOUN
admet-7	329	5	forner	forner	NOUN
admet-7	329	6	,	,	PUNCT
admet-7	329	7	a.j	a.j	PROPN
admet-7	329	8	.	.	PROPN
admet-7	329	9	hessheimer	hessheimer	PROPN
admet-7	329	10	,	,	PUNCT
admet-7	329	11	m.	m.	NOUN
admet-7	329	12	isabel	isabel	PROPN
admet-7	329	13	real	real	PROPN
admet-7	329	14	m	m	PROPN
admet-7	329	15	,	,	PUNCT
admet-7	329	16	j.	j.	PROPN
admet-7	329	17	bruix	bruix	PROPN
admet-7	329	18	,	,	PUNCT
admet-7	329	19	critical	critical	ADJ
admet-7	329	20	reviews	review	NOUN
admet-7	329	21	in	in	ADP
admet-7	329	22	oncology	oncology	NOUN
admet-7	329	23	/	/	SYM
admet-7	329	24	hematology	hematology	NOUN
admet-7	329	25	60	60	NUM
admet-7	329	26	(	(	PUNCT
admet-7	329	27	2006	2006	NUM
admet-7	329	28	)	)	PUNCT
admet-7	329	29	89–98	89–98	NUM
admet-7	329	30	.	.	PUNCT
admet-7	330	1	[	[	X
admet-7	330	2	14	14	NUM
admet-7	330	3	]	]	X
admet-7	330	4	b.h	b.h	PROPN
admet-7	330	5	.	.	PUNCT
admet-7	331	1	zhang	zhang	PROPN
admet-7	331	2	,	,	PUNCT
admet-7	331	3	b.h	b.h	PROPN
admet-7	331	4	.	.	PROPN
admet-7	331	5	,	,	PUNCT
admet-7	331	6	yang	yang	PROPN
admet-7	331	7	,	,	PUNCT
admet-7	331	8	z.y	z.y	PROPN
admet-7	331	9	.	.	PROPN
admet-7	331	10	tang	tang	PROPN
admet-7	331	11	,	,	PUNCT
admet-7	331	12	journal	journal	NOUN
admet-7	331	13	of	of	ADP
admet-7	331	14	cancer	cancer	NOUN
admet-7	331	15	research	research	NOUN
admet-7	331	16	and	and	CCONJ
admet-7	331	17	clinical	clinical	ADJ
admet-7	331	18	oncology	oncology	NOUN
admet-7	331	19	130	130	NUM
admet-7	331	20	(	(	PUNCT
admet-7	331	21	2004	2004	NUM
admet-7	331	22	)	)	PUNCT
admet-7	331	23	417	417	NUM
admet-7	331	24	–	–	PUNCT
admet-7	331	25	422	422	NUM
admet-7	331	26	.	.	PUNCT
admet-7	332	1	[	[	X
admet-7	332	2	15	15	NUM
admet-7	332	3	]	]	X
admet-7	332	4	t.	t.	PROPN
admet-7	332	5	shuto	shuto	PROPN
admet-7	332	6	,	,	PUNCT
admet-7	332	7	k.	k.	PROPN
admet-7	332	8	hirohashi	hirohashi	PROPN
admet-7	332	9	,	,	PUNCT
admet-7	332	10	s.	s.	PROPN
admet-7	332	11	kubo	kubo	PROPN
admet-7	332	12	,	,	PUNCT
admet-7	332	13	h.	h.	PROPN
admet-7	332	14	tanaka	tanaka	PROPN
admet-7	332	15	,	,	PUNCT
admet-7	332	16	t.	t.	PROPN
admet-7	332	17	tsukamoto	tsukamoto	NOUN
admet-7	332	18	,	,	PUNCT
admet-7	332	19	t.	t.	PROPN
admet-7	332	20	yamamoto	yamamoto	PROPN
admet-7	332	21	,	,	PUNCT
admet-7	332	22	t.	t.	NOUN
admet-7	332	23	ikebe	ikebe	PROPN
admet-7	332	24	,	,	PUNCT
admet-7	332	25	h.	h.	PROPN
admet-7	332	26	kinoshita	kinoshita	PROPN
admet-7	332	27	,	,	PUNCT
admet-7	332	28	surgery	surgery	NOUN
admet-7	332	29	today	today	NOUN
admet-7	332	30	28	28	NUM
admet-7	332	31	(	(	PUNCT
admet-7	332	32	1998	1998	NUM
admet-7	332	33	)	)	PUNCT
admet-7	332	34	1124–1129	1124–1129	NUM
admet-7	332	35	http://globocan.iarc.fr/	http://globocan.iarc.fr/	PROPN
admet-7	332	36	admet	admet	PROPN
admet-7	332	37	&	&	CCONJ
admet-7	332	38	dmpk	dmpk	PROPN
admet-7	332	39	1(3	1(3	NUM
admet-7	332	40	)	)	PUNCT
admet-7	332	41	(	(	PUNCT
admet-7	332	42	2013	2013	NUM
admet-7	332	43	)	)	PUNCT
admet-7	332	44	29	29	NUM
admet-7	332	45	-	-	SYM
admet-7	332	46	44	44	NUM
admet-7	332	47	doxorubicin	doxorubicin	NOUN
admet-7	332	48	and	and	CCONJ
admet-7	332	49	hcc	hcc	PROPN
admet-7	332	50	doi	doi	PROPN
admet-7	332	51	:	:	PUNCT
admet-7	332	52	10.5599	10.5599	NUM
admet-7	332	53	/	/	SYM
admet-7	332	54	admet.1.3.7	admet.1.3.7	NOUN
admet-7	332	55	41	41	NUM
admet-7	333	1	[	[	X
admet-7	333	2	16	16	NUM
admet-7	333	3	]	]	X
admet-7	333	4	x.d	x.d	PROPN
admet-7	333	5	.	.	PROPN
admet-7	333	6	zhou	zhou	PROPN
admet-7	333	7	,	,	PUNCT
admet-7	333	8	z.y	z.y	PROPN
admet-7	333	9	.	.	PROPN
admet-7	333	10	tang	tang	PROPN
admet-7	333	11	,	,	PUNCT
admet-7	333	12	b.h	b.h	PROPN
admet-7	333	13	.	.	PROPN
admet-7	333	14	yang	yang	PROPN
admet-7	333	15	bh	bh	PROPN
admet-7	333	16	,	,	PUNCT
admet-7	333	17	z.y	z.y	PROPN
admet-7	333	18	.	.	PROPN
admet-7	333	19	lin	lin	PROPN
admet-7	333	20	,	,	PUNCT
admet-7	333	21	z.c	z.c	PROPN
admet-7	333	22	.	.	PROPN
admet-7	333	23	ma	ma	PROPN
admet-7	333	24	,	,	PUNCT
admet-7	333	25	s.l	s.l	PROPN
admet-7	333	26	.	.	PROPN
admet-7	333	27	ye	ye	PROPN
admet-7	333	28	,	,	PUNCT
admet-7	333	29	z.q	z.q	PROPN
admet-7	333	30	.	.	PROPN
admet-7	333	31	wu	wu	PROPN
admet-7	333	32	,	,	PUNCT
admet-7	333	33	j.	j.	PROPN
admet-7	333	34	fan	fan	PROPN
admet-7	333	35	,	,	PUNCT
admet-7	333	36	l.x	l.x	PROPN
admet-7	333	37	.	.	PROPN
admet-7	333	38	qin	qin	PROPN
admet-7	333	39	,	,	PUNCT
admet-7	333	40	b.h	b.h	PROPN
admet-7	333	41	.	.	PUNCT
admet-7	333	42	zheng	zheng	PROPN
admet-7	333	43	,	,	PUNCT
admet-7	333	44	cancer	cancer	NOUN
admet-7	333	45	91:1479–1486	91:1479–1486	NUM
admet-7	333	46	[	[	X
admet-7	333	47	17	17	NUM
admet-7	333	48	]	]	X
admet-7	333	49	v.	v.	CCONJ
admet-7	333	50	mazzaferro	mazzaferro	PROPN
admet-7	333	51	,	,	PUNCT
admet-7	333	52	e.	e.	PROPN
admet-7	333	53	regalia	regalia	PROPN
admet-7	333	54	,	,	PUNCT
admet-7	333	55	r.	r.	PROPN
admet-7	333	56	doci	doci	PROPN
admet-7	333	57	,	,	PUNCT
admet-7	333	58	s.	s.	PROPN
admet-7	333	59	andreola	andreola	PROPN
admet-7	333	60	,	,	PUNCT
admet-7	333	61	a.	a.	PROPN
admet-7	333	62	pulvirenti	pulvirenti	PROPN
admet-7	333	63	,	,	PUNCT
admet-7	333	64	f.	f.	PROPN
admet-7	333	65	bozzetti	bozzetti	PROPN
admet-7	333	66	,	,	PUNCT
admet-7	333	67	f.	f.	PROPN
admet-7	333	68	montalto	montalto	PROPN
admet-7	333	69	,	,	PUNCT
admet-7	333	70	m.	m.	NOUN
admet-7	333	71	ammatuna	ammatuna	PROPN
admet-7	333	72	,	,	PUNCT
admet-7	333	73	a.	a.	PROPN
admet-7	333	74	morabito	morabito	PROPN
admet-7	333	75	,	,	PUNCT
admet-7	333	76	l.	l.	PROPN
admet-7	333	77	gennari	gennari	PROPN
admet-7	333	78	,	,	PUNCT
admet-7	333	79	the	the	DET
admet-7	333	80	new	new	PROPN
admet-7	333	81	england	england	PROPN
admet-7	333	82	journal	journal	PROPN
admet-7	333	83	of	of	ADP
admet-7	333	84	medicine	medicine	PROPN
admet-7	333	85	334	334	NUM
admet-7	333	86	(	(	PUNCT
admet-7	333	87	1996	1996	NUM
admet-7	333	88	)	)	PUNCT
admet-7	334	1	693–699	693–699	NUM
admet-7	334	2	[	[	X
admet-7	334	3	18	18	NUM
admet-7	334	4	]	]	X
admet-7	334	5	j.m	j.m	PROPN
admet-7	334	6	.	.	PROPN
admet-7	334	7	llovet	llovet	PROPN
admet-7	334	8	,	,	PUNCT
admet-7	334	9	j.	j.	PROPN
admet-7	334	10	bruix	bruix	PROPN
admet-7	334	11	,	,	PUNCT
admet-7	334	12	j.	j.	PROPN
admet-7	334	13	fuster	fuster	PROPN
admet-7	334	14	,	,	PUNCT
admet-7	334	15	j.c	j.c	PROPN
admet-7	334	16	.	.	PROPN
admet-7	334	17	garcia	garcia	PROPN
admet-7	334	18	-	-	PUNCT
admet-7	334	19	valdecasas	valdecasas	PROPN
admet-7	334	20	,	,	PUNCT
admet-7	334	21	l.	l.	PROPN
admet-7	334	22	grande	grande	PROPN
admet-7	334	23	,	,	PUNCT
admet-7	334	24	a.	a.	NOUN
admet-7	334	25	franca	franca	NOUN
admet-7	334	26	,	,	PUNCT
admet-7	334	27	c.	c.	PROPN
admet-7	334	28	brú	brú	PROPN
admet-7	334	29	,	,	PUNCT
admet-7	334	30	m.	m.	PROPN
admet-7	334	31	navasa	navasa	PROPN
admet-7	334	32	,	,	PUNCT
admet-7	334	33	m.c	m.c	PROPN
admet-7	334	34	.	.	PROPN
admet-7	334	35	ayuso	ayuso	PROPN
admet-7	334	36	,	,	PUNCT
admet-7	334	37	m.	m.	PROPN
admet-7	334	38	solé	solé	PROPN
admet-7	334	39	,	,	PUNCT
admet-7	334	40	m.i	m.i	PROPN
admet-7	334	41	.	.	PROPN
admet-7	334	42	real	real	PROPN
admet-7	334	43	,	,	PUNCT
admet-7	334	44	r.	r.	PROPN
admet-7	334	45	vilana	vilana	PROPN
admet-7	334	46	,	,	PUNCT
admet-7	334	47	a.	a.	PROPN
admet-7	334	48	rimola	rimola	PROPN
admet-7	334	49	,	,	PUNCT
admet-7	334	50	j.visa	j.visa	PROPN
admet-7	334	51	,	,	PUNCT
admet-7	334	52	j.	j.	PROPN
admet-7	334	53	rodés	rodés	PROPN
admet-7	334	54	,	,	PUNCT
admet-7	334	55	hepatology	hepatology	NOUN
admet-7	334	56	27	27	NUM
admet-7	334	57	(	(	PUNCT
admet-7	334	58	1998	1998	NUM
admet-7	334	59	)	)	PUNCT
admet-7	334	60	1572–1577	1572–1577	NUM
admet-7	335	1	[	[	X
admet-7	335	2	19	19	NUM
admet-7	335	3	]	]	PUNCT
admet-7	335	4	k.	k.	PROPN
admet-7	335	5	ohnishi	ohnishi	PROPN
admet-7	335	6	,	,	PUNCT
admet-7	335	7	h.	h.	PROPN
admet-7	335	8	yoshioka	yoshioka	PROPN
admet-7	335	9	,	,	PUNCT
admet-7	335	10	s.	s.	PROPN
admet-7	335	11	ito	ito	PROPN
admet-7	335	12	,	,	PUNCT
admet-7	335	13	k.	k.	PROPN
admet-7	335	14	fujiwara	fujiwara	PROPN
admet-7	335	15	,	,	PUNCT
admet-7	335	16	hepatology	hepatology	NOUN
admet-7	335	17	27	27	NUM
admet-7	335	18	(	(	PUNCT
admet-7	335	19	1998	1998	NUM
admet-7	335	20	)	)	PUNCT
admet-7	335	21	67	67	NUM
admet-7	335	22	-	-	SYM
admet-7	335	23	72	72	NUM
admet-7	335	24	.	.	PUNCT
admet-7	336	1	[	[	X
admet-7	336	2	20	20	NUM
admet-7	336	3	]	]	PUNCT
admet-7	336	4	t.	t.	PROPN
admet-7	336	5	shibata	shibata	PROPN
admet-7	336	6	,	,	PUNCT
admet-7	336	7	y.	y.	PROPN
admet-7	336	8	iimuro	iimuro	PROPN
admet-7	336	9	,	,	PUNCT
admet-7	336	10	y.	y.	PROPN
admet-7	336	11	yamamoto	yamamoto	PROPN
admet-7	336	12	,	,	PUNCT
admet-7	336	13	y.	y.	PROPN
admet-7	336	14	maetani	maetani	PROPN
admet-7	336	15	,	,	PUNCT
admet-7	336	16	f.	f.	PROPN
admet-7	336	17	ametani	ametani	PROPN
admet-7	336	18	,	,	PUNCT
admet-7	336	19	k.	k.	PROPN
admet-7	336	20	itoh	itoh	PROPN
admet-7	336	21	,	,	PUNCT
admet-7	336	22	j.	j.	PROPN
admet-7	336	23	konishi	konishi	PROPN
admet-7	336	24	,	,	PUNCT
admet-7	336	25	radiology	radiology	NOUN
admet-7	336	26	223	223	NUM
admet-7	336	27	(	(	PUNCT
admet-7	336	28	2002	2002	NUM
admet-7	336	29	)	)	PUNCT
admet-7	336	30	331	331	NUM
admet-7	336	31	-	-	SYM
admet-7	336	32	337	337	NUM
admet-7	336	33	.	.	PUNCT
admet-7	337	1	[	[	X
admet-7	337	2	21	21	NUM
admet-7	337	3	]	]	X
admet-7	337	4	r.	r.	PROPN
admet-7	337	5	adam	adam	PROPN
admet-7	337	6	,	,	PUNCT
admet-7	337	7	e.j	e.j	PROPN
admet-7	337	8	.	.	PROPN
admet-7	337	9	hagopian	hagopian	PROPN
admet-7	337	10	,	,	PUNCT
admet-7	337	11	m.	m.	NOUN
admet-7	337	12	linhares	linhare	NOUN
admet-7	337	13	,	,	PUNCT
admet-7	337	14	j.	j.	PROPN
admet-7	337	15	krissat	krissat	PROPN
admet-7	337	16	,	,	PUNCT
admet-7	337	17	e.	e.	PROPN
admet-7	337	18	savier	savier	PROPN
admet-7	337	19	,	,	PUNCT
admet-7	337	20	d.	d.	PROPN
admet-7	337	21	azoulay	azoulay	PROPN
admet-7	337	22	,	,	PUNCT
admet-7	337	23	f.	f.	PROPN
admet-7	337	24	kunstlinger	kunstlinger	PROPN
admet-7	337	25	,	,	PUNCT
admet-7	337	26	d.	d.	PROPN
admet-7	337	27	castaing	castaing	PROPN
admet-7	337	28	,	,	PUNCT
admet-7	337	29	h.	h.	PROPN
admet-7	337	30	bismuth	bismuth	NOUN
admet-7	337	31	,	,	PUNCT
admet-7	337	32	archives	archive	NOUN
admet-7	337	33	of	of	ADP
admet-7	337	34	surgery	surgery	NOUN
admet-7	337	35	137	137	NUM
admet-7	337	36	(	(	PUNCT
admet-7	337	37	2002	2002	NUM
admet-7	337	38	)	)	PUNCT
admet-7	337	39	1332	1332	NUM
admet-7	337	40	-	-	SYM
admet-7	337	41	1340	1340	NUM
admet-7	337	42	.	.	PUNCT
admet-7	338	1	[	[	X
admet-7	338	2	22	22	NUM
admet-7	338	3	]	]	X
admet-7	338	4	c.m	c.m	PROPN
admet-7	338	5	.	.	PROPN
admet-7	338	6	pacella	pacella	PROPN
admet-7	338	7	,	,	PUNCT
admet-7	338	8	g.	g.	PROPN
admet-7	338	9	bizzarri	bizzarri	PROPN
admet-7	338	10	,	,	PUNCT
admet-7	338	11	f.	f.	PROPN
admet-7	338	12	magnolfi	magnolfi	PROPN
admet-7	338	13	,	,	PUNCT
admet-7	338	14	p.	p.	PROPN
admet-7	338	15	cecconi	cecconi	PROPN
admet-7	338	16	,	,	PUNCT
admet-7	338	17	b.	b.	PROPN
admet-7	338	18	caspani	caspani	PROPN
admet-7	338	19	,	,	PUNCT
admet-7	338	20	v.	v.	PROPN
admet-7	338	21	anelli	anelli	PROPN
admet-7	338	22	,	,	PUNCT
admet-7	338	23	a.	a.	NOUN
admet-7	338	24	bianchini	bianchini	PROPN
admet-7	338	25	,	,	PUNCT
admet-7	338	26	d.	d.	PROPN
admet-7	338	27	valle	valle	PROPN
admet-7	338	28	,	,	PUNCT
admet-7	338	29	s.	s.	PROPN
admet-7	338	30	pacella	pacella	PROPN
admet-7	338	31	,	,	PUNCT
admet-7	338	32	g.	g.	PROPN
admet-7	338	33	manenti	manenti	PROPN
admet-7	338	34	,	,	PUNCT
admet-7	338	35	z.	z.	PROPN
admet-7	338	36	rossi	rossi	PROPN
admet-7	338	37	,	,	PUNCT
admet-7	338	38	radiology	radiology	NOUN
admet-7	338	39	221	221	NUM
admet-7	338	40	(	(	PUNCT
admet-7	338	41	2001	2001	NUM
admet-7	338	42	)	)	PUNCT
admet-7	338	43	712	712	NUM
admet-7	338	44	-	-	SYM
admet-7	338	45	720	720	NUM
admet-7	338	46	.	.	PUNCT
admet-7	339	1	[	[	X
admet-7	339	2	23	23	NUM
admet-7	339	3	]	]	X
admet-7	339	4	p.	p.	NOUN
admet-7	339	5	simmonds	simmond	NOUN
admet-7	339	6	,	,	PUNCT
admet-7	339	7	british	british	PROPN
admet-7	339	8	medical	medical	PROPN
admet-7	339	9	journal	journal	PROPN
admet-7	339	10	321	321	NUM
admet-7	339	11	(	(	PUNCT
admet-7	339	12	2000	2000	NUM
admet-7	339	13	)	)	PUNCT
admet-7	339	14	531	531	NUM
admet-7	339	15	-	-	SYM
admet-7	339	16	535	535	NUM
admet-7	339	17	.	.	PUNCT
admet-7	340	1	[	[	X
admet-7	340	2	24	24	NUM
admet-7	340	3	]	]	X
admet-7	340	4	r.k	r.k	PROPN
admet-7	340	5	.	.	PROPN
admet-7	340	6	kelley	kelley	PROPN
admet-7	340	7	,	,	PUNCT
admet-7	340	8	a.p	a.p	PROPN
admet-7	340	9	.	.	PROPN
admet-7	340	10	venook	venook	PROPN
admet-7	340	11	,	,	PUNCT
admet-7	340	12	journal	journal	NOUN
admet-7	340	13	of	of	ADP
admet-7	340	14	clinical	clinical	ADJ
admet-7	340	15	oncology	oncology	NOUN
admet-7	340	16	,	,	PUNCT
admet-7	340	17	26	26	NUM
admet-7	340	18	(	(	PUNCT
admet-7	340	19	2008	2008	NUM
admet-7	340	20	)	)	PUNCT
admet-7	340	21	5845	5845	NUM
admet-7	340	22	-	-	SYM
admet-7	340	23	5848	5848	NUM
admet-7	340	24	.	.	PUNCT
admet-7	341	1	[	[	X
admet-7	341	2	25	25	NUM
admet-7	341	3	]	]	X
admet-7	341	4	j.m	j.m	PROPN
admet-7	341	5	.	.	PROPN
admet-7	341	6	llovet	llovet	PROPN
admet-7	341	7	,	,	PUNCT
admet-7	341	8	s.	s.	PROPN
admet-7	341	9	ricci	ricci	PROPN
admet-7	341	10	,	,	PUNCT
admet-7	341	11	v.	v.	PROPN
admet-7	341	12	mazzaferro	mazzaferro	PROPN
admet-7	341	13	,	,	PUNCT
admet-7	341	14	p.	p.	PROPN
admet-7	341	15	hilgard	hilgard	PROPN
admet-7	341	16	,	,	PUNCT
admet-7	341	17	e.	e.	PROPN
admet-7	341	18	gane	gane	PROPN
admet-7	341	19	,	,	PUNCT
admet-7	341	20	j.f	j.f	PROPN
admet-7	341	21	.	.	PROPN
admet-7	341	22	blanc	blanc	NOUN
admet-7	341	23	,	,	PUNCT
admet-7	341	24	a.c	a.c	PROPN
admet-7	341	25	.	.	PROPN
admet-7	341	26	de	de	PROPN
admet-7	341	27	oliveira	oliveira	PROPN
admet-7	341	28	,	,	PUNCT
admet-7	341	29	a.	a.	PROPN
admet-7	341	30	santoro	santoro	PROPN
admet-7	341	31	,	,	PUNCT
admet-7	341	32	j.l	j.l	PROPN
admet-7	341	33	.	.	PROPN
admet-7	341	34	raoul	raoul	PROPN
admet-7	341	35	,	,	PUNCT
admet-7	341	36	a.	a.	NOUN
admet-7	341	37	forner	forner	NOUN
admet-7	341	38	,	,	PUNCT
admet-7	341	39	m.	m.	NOUN
admet-7	341	40	schwartz	schwartz	PROPN
admet-7	341	41	,	,	PUNCT
admet-7	341	42	c.	c.	PROPN
admet-7	341	43	porta	porta	PROPN
admet-7	341	44	,	,	PUNCT
admet-7	341	45	s.	s.	PROPN
admet-7	341	46	zeuzem	zeuzem	PROPN
admet-7	341	47	,	,	PUNCT
admet-7	341	48	l.	l.	PROPN
admet-7	341	49	bolondi	bolondi	PROPN
admet-7	341	50	,	,	PUNCT
admet-7	341	51	t.f	t.f	PROPN
admet-7	341	52	.	.	PROPN
admet-7	341	53	greten	greten	PROPN
admet-7	341	54	,	,	PUNCT
admet-7	341	55	p.r	p.r	PROPN
admet-7	341	56	.	.	PROPN
admet-7	341	57	galle	galle	PROPN
admet-7	341	58	,	,	PUNCT
admet-7	341	59	j.f	j.f	PROPN
admet-7	341	60	.	.	PROPN
admet-7	341	61	seitz	seitz	PROPN
admet-7	341	62	,	,	PUNCT
admet-7	341	63	i.	i.	PROPN
admet-7	341	64	borbath	borbath	PROPN
admet-7	341	65	,	,	PUNCT
admet-7	341	66	d.	d.	PROPN
admet-7	341	67	häussinger	häussinger	PROPN
admet-7	341	68	,	,	PUNCT
admet-7	341	69	t.	t.	PROPN
admet-7	341	70	giannaris	giannaris	PROPN
admet-7	341	71	,	,	PUNCT
admet-7	341	72	m.	m.	NOUN
admet-7	341	73	shan	shan	PROPN
admet-7	341	74	,	,	PUNCT
admet-7	341	75	m.	m.	NOUN
admet-7	341	76	moscovici	moscovici	PROPN
admet-7	341	77	,	,	PUNCT
admet-7	341	78	d.	d.	PROPN
admet-7	341	79	voliotis	voliotis	PROPN
admet-7	341	80	,	,	PUNCT
admet-7	341	81	j.	j.	PROPN
admet-7	341	82	bruix	bruix	PROPN
admet-7	341	83	,	,	PUNCT
admet-7	341	84	the	the	DET
admet-7	341	85	new	new	PROPN
admet-7	341	86	england	england	PROPN
admet-7	341	87	journal	journal	PROPN
admet-7	341	88	of	of	ADP
admet-7	341	89	medicine	medicine	NOUN
admet-7	341	90	359	359	NUM
admet-7	341	91	(	(	PUNCT
admet-7	341	92	2008	2008	NUM
admet-7	341	93	)	)	PUNCT
admet-7	341	94	378	378	NUM
admet-7	341	95	-	-	SYM
admet-7	341	96	390	390	NUM
admet-7	341	97	.	.	PUNCT
admet-7	342	1	[	[	X
admet-7	342	2	26	26	NUM
admet-7	342	3	]	]	PUNCT
admet-7	342	4	a.	a.	PROPN
admet-7	342	5	kennedy	kennedy	PROPN
admet-7	342	6	,	,	PUNCT
admet-7	342	7	s.	s.	PROPN
admet-7	342	8	nag	nag	VERB
admet-7	342	9	,	,	PUNCT
admet-7	342	10	r.	r.	PROPN
admet-7	342	11	salem	salem	PROPN
admet-7	342	12	,	,	PUNCT
admet-7	342	13	r.	r.	PROPN
admet-7	342	14	murthy	murthy	PROPN
admet-7	342	15	,	,	PUNCT
admet-7	342	16	a.j	a.j	PROPN
admet-7	342	17	.	.	PROPN
admet-7	342	18	mcewan	mcewan	PROPN
admet-7	342	19	,	,	PUNCT
admet-7	342	20	c.	c.	PROPN
admet-7	342	21	nutting	nutting	PROPN
admet-7	342	22	,	,	PUNCT
admet-7	342	23	a.	a.	PROPN
admet-7	342	24	benson	benson	PROPN
admet-7	342	25	,	,	PUNCT
admet-7	342	26	j.	j.	PROPN
admet-7	342	27	espat	espat	PROPN
admet-7	342	28	,	,	PUNCT
admet-7	342	29	j.i	j.i	PROPN
admet-7	342	30	.	.	PROPN
admet-7	342	31	bilbao	bilbao	PROPN
admet-7	342	32	,	,	PUNCT
admet-7	342	33	r.a	r.a	PROPN
admet-7	342	34	.	.	PROPN
admet-7	342	35	sharma	sharma	PROPN
admet-7	342	36	,	,	PUNCT
admet-7	342	37	j.p	j.p	PROPN
admet-7	342	38	.	.	PROPN
admet-7	342	39	thomas	thomas	PROPN
admet-7	342	40	,	,	PUNCT
admet-7	342	41	d.	d.	PROPN
admet-7	342	42	coldwell	coldwell	PROPN
admet-7	342	43	,	,	PUNCT
admet-7	342	44	international	international	ADJ
admet-7	342	45	journal	journal	NOUN
admet-7	342	46	of	of	ADP
admet-7	342	47	radiation	radiation	NOUN
admet-7	342	48	oncology	oncology	NOUN
admet-7	342	49	,	,	PUNCT
admet-7	342	50	biology	biology	NOUN
admet-7	342	51	and	and	CCONJ
admet-7	342	52	physics	physics	NOUN
admet-7	342	53	68	68	NUM
admet-7	342	54	(	(	PUNCT
admet-7	342	55	2007	2007	NUM
admet-7	342	56	)	)	PUNCT
admet-7	343	1	13–23	13–23	NUM
admet-7	343	2	.	.	PUNCT
admet-7	344	1	[	[	X
admet-7	344	2	27	27	NUM
admet-7	344	3	]	]	X
admet-7	344	4	d.l	d.l	PROPN
admet-7	344	5	.	.	PROPN
admet-7	344	6	bartlett	bartlett	PROPN
admet-7	344	7	,	,	PUNCT
admet-7	344	8	j.	j.	PROPN
admet-7	344	9	berlin	berlin	PROPN
admet-7	344	10	,	,	PUNCT
admet-7	344	11	g.y	g.y	PROPN
admet-7	344	12	.	.	PROPN
admet-7	344	13	lauwers	lauwers	PROPN
admet-7	344	14	,	,	PUNCT
admet-7	344	15	w.a	w.a	PROPN
admet-7	344	16	.	.	PROPN
admet-7	344	17	messersmith	messersmith	PROPN
admet-7	344	18	,	,	PUNCT
admet-7	344	19	n.j	n.j	PROPN
admet-7	344	20	.	.	PROPN
admet-7	344	21	petrelli	petrelli	PROPN
admet-7	344	22	,	,	PUNCT
admet-7	344	23	a.p	a.p	PROPN
admet-7	344	24	.	.	PROPN
admet-7	344	25	venook	venook	PROPN
admet-7	344	26	,	,	PUNCT
admet-7	344	27	annals	annal	NOUN
admet-7	344	28	of	of	ADP
admet-7	344	29	surgical	surgical	ADJ
admet-7	344	30	oncology	oncology	NOUN
admet-7	344	31	13	13	NUM
admet-7	344	32	(	(	PUNCT
admet-7	344	33	2006	2006	NUM
admet-7	344	34	)	)	PUNCT
admet-7	344	35	1284	1284	NUM
admet-7	344	36	-	-	SYM
admet-7	344	37	1292	1292	NUM
admet-7	344	38	.	.	PUNCT
admet-7	345	1	[	[	X
admet-7	345	2	28	28	NUM
admet-7	345	3	]	]	X
admet-7	345	4	j.w	j.w	PROPN
admet-7	345	5	.	.	PROPN
admet-7	345	6	chung	chung	PROPN
admet-7	345	7	,	,	PUNCT
admet-7	345	8	hepatogastroenterology	hepatogastroenterology	NOUN
admet-7	345	9	45	45	NUM
admet-7	345	10	suppl	suppl	ADJ
admet-7	345	11	3	3	NUM
admet-7	345	12	(	(	PUNCT
admet-7	345	13	1998	1998	NUM
admet-7	345	14	)	)	PUNCT
admet-7	345	15	,	,	PUNCT
admet-7	345	16	1236	1236	NUM
admet-7	345	17	-	-	SYM
admet-7	345	18	1241	1241	NUM
admet-7	345	19	.	.	PUNCT
admet-7	346	1	[	[	X
admet-7	346	2	29	29	NUM
admet-7	346	3	]	]	X
admet-7	346	4	e.	e.	PROPN
admet-7	346	5	liapi	liapi	PROPN
admet-7	346	6	,	,	PUNCT
admet-7	346	7	k.h	k.h	PROPN
admet-7	346	8	.	.	PROPN
admet-7	346	9	lee	lee	PROPN
admet-7	346	10	,	,	PUNCT
admet-7	346	11	c.c	c.c	PROPN
admet-7	346	12	.	.	PROPN
admet-7	346	13	georgiades	georgiades	PROPN
admet-7	346	14	,	,	PUNCT
admet-7	346	15	k.	k.	PROPN
admet-7	346	16	hong	hong	PROPN
admet-7	346	17	,	,	PUNCT
admet-7	346	18	j.f.h	j.f.h	PROPN
admet-7	346	19	.	.	PUNCT
admet-7	346	20	geschwind	geschwind	PROPN
admet-7	346	21	,	,	PUNCT
admet-7	346	22	techniques	technique	NOUN
admet-7	346	23	in	in	ADP
admet-7	346	24	vascular	vascular	ADJ
admet-7	346	25	&	&	CCONJ
admet-7	346	26	interventional	interventional	ADJ
admet-7	346	27	radiology	radiology	NOUN
admet-7	346	28	10	10	NUM
admet-7	346	29	(	(	PUNCT
admet-7	346	30	2007	2007	NUM
admet-7	346	31	)	)	PUNCT
admet-7	346	32	261	261	NUM
admet-7	346	33	-	-	SYM
admet-7	346	34	269	269	NUM
admet-7	346	35	.	.	PUNCT
admet-7	347	1	[	[	X
admet-7	347	2	30	30	NUM
admet-7	347	3	]	]	X
admet-7	347	4	c.	c.	PROPN
admet-7	347	5	breedis	breedis	PROPN
admet-7	347	6	,	,	PUNCT
admet-7	347	7	g.	g.	PROPN
admet-7	347	8	young	young	PROPN
admet-7	347	9	,	,	PUNCT
admet-7	347	10	the	the	DET
admet-7	347	11	american	american	PROPN
admet-7	347	12	journal	journal	PROPN
admet-7	347	13	of	of	ADP
admet-7	347	14	pathology	pathology	PROPN
admet-7	347	15	30	30	NUM
admet-7	347	16	(	(	PUNCT
admet-7	347	17	1954	1954	NUM
admet-7	347	18	)	)	PUNCT
admet-7	347	19	969	969	NUM
admet-7	347	20	-	-	SYM
admet-7	347	21	977	977	NUM
admet-7	347	22	.	.	PUNCT
admet-7	348	1	[	[	X
admet-7	348	2	31	31	NUM
admet-7	348	3	]	]	PUNCT
admet-7	348	4	t.	t.	PROPN
admet-7	348	5	nakashima	nakashima	PROPN
admet-7	348	6	,	,	PUNCT
admet-7	348	7	m.	m.	PROPN
admet-7	348	8	kojiro	kojiro	PROPN
admet-7	348	9	,	,	PUNCT
admet-7	348	10	seminars	seminar	NOUN
admet-7	348	11	in	in	ADP
admet-7	348	12	liver	liver	NOUN
admet-7	348	13	disease	disease	NOUN
admet-7	348	14	6	6	NUM
admet-7	348	15	(	(	PUNCT
admet-7	348	16	1986	1986	NUM
admet-7	348	17	)	)	PUNCT
admet-7	348	18	259	259	NUM
admet-7	348	19	-	-	SYM
admet-7	348	20	266	266	NUM
admet-7	348	21	.	.	PUNCT
admet-7	349	1	[	[	X
admet-7	349	2	32	32	NUM
admet-7	349	3	]	]	X
admet-7	349	4	s.w	s.w	PROPN
admet-7	349	5	.	.	PROPN
admet-7	349	6	shin	shin	PROPN
admet-7	349	7	,	,	PUNCT
admet-7	349	8	korean	korean	ADJ
admet-7	349	9	journal	journal	NOUN
admet-7	349	10	of	of	ADP
admet-7	349	11	radiology	radiology	NOUN
admet-7	349	12	10	10	NUM
admet-7	349	13	(	(	PUNCT
admet-7	349	14	2009	2009	NUM
admet-7	349	15	)	)	PUNCT
admet-7	349	16	425	425	NUM
admet-7	349	17	-	-	SYM
admet-7	349	18	434	434	NUM
admet-7	349	19	.	.	PUNCT
admet-7	350	1	[	[	X
admet-7	350	2	33	33	NUM
admet-7	350	3	]	]	X
admet-7	350	4	c.m	c.m	PROPN
admet-7	350	5	.	.	PROPN
admet-7	350	6	lo	lo	PROPN
admet-7	350	7	,	,	PUNCT
admet-7	350	8	h.	h.	PROPN
admet-7	350	9	ngan	ngan	PROPN
admet-7	350	10	,	,	PUNCT
admet-7	350	11	w.k	w.k	PROPN
admet-7	350	12	.	.	PROPN
admet-7	350	13	tso	tso	PROPN
admet-7	350	14	,	,	PUNCT
admet-7	350	15	c.l	c.l	PROPN
admet-7	350	16	.	.	PROPN
admet-7	350	17	liu	liu	PROPN
admet-7	350	18	,	,	PUNCT
admet-7	350	19	c.m	c.m	PROPN
admet-7	350	20	.	.	PROPN
admet-7	350	21	lam	lam	PROPN
admet-7	350	22	,	,	PUNCT
admet-7	350	23	r.t	r.t	PROPN
admet-7	350	24	.	.	PROPN
admet-7	350	25	poon	poon	NOUN
admet-7	350	26	,	,	PUNCT
admet-7	350	27	s.t	s.t	PROPN
admet-7	350	28	.	.	PROPN
admet-7	350	29	fan	fan	PROPN
admet-7	350	30	,	,	PUNCT
admet-7	350	31	j.	j.	PROPN
admet-7	350	32	wong	wong	PROPN
admet-7	350	33	,	,	PUNCT
admet-7	350	34	hepatology	hepatology	NOUN
admet-7	350	35	35	35	NUM
admet-7	350	36	(	(	PUNCT
admet-7	350	37	2002	2002	NUM
admet-7	350	38	)	)	PUNCT
admet-7	350	39	1164	1164	NUM
admet-7	350	40	-	-	SYM
admet-7	350	41	1171	1171	NUM
admet-7	350	42	.	.	PUNCT
admet-7	351	1	[	[	X
admet-7	351	2	34	34	NUM
admet-7	351	3	]	]	X
admet-7	351	4	j.m	j.m	PROPN
admet-7	351	5	.	.	PROPN
admet-7	351	6	llovet	llovet	PROPN
admet-7	351	7	,	,	PUNCT
admet-7	351	8	m.i	m.i	PROPN
admet-7	351	9	.	.	PROPN
admet-7	351	10	real	real	PROPN
admet-7	351	11	,	,	PUNCT
admet-7	351	12	x.	x.	PROPN
admet-7	351	13	montana	montana	PROPN
admet-7	351	14	,	,	PUNCT
admet-7	351	15	r.	r.	PROPN
admet-7	351	16	planas	planas	PROPN
admet-7	351	17	,	,	PUNCT
admet-7	351	18	s.	s.	PROPN
admet-7	351	19	coll	coll	PROPN
admet-7	351	20	,	,	PUNCT
admet-7	351	21	j.	j.	PROPN
admet-7	351	22	aponte	aponte	PROPN
admet-7	351	23	,	,	PUNCT
admet-7	351	24	c.	c.	PROPN
admet-7	351	25	ayuso	ayuso	PROPN
admet-7	351	26	,	,	PUNCT
admet-7	351	27	m.	m.	NOUN
admet-7	351	28	sala	sala	PROPN
admet-7	351	29	,	,	PUNCT
admet-7	351	30	j.	j.	PROPN
admet-7	351	31	muchart	muchart	PROPN
admet-7	351	32	,	,	PUNCT
admet-7	351	33	r.	r.	PROPN
admet-7	351	34	sola	sola	PROPN
admet-7	351	35	,	,	PUNCT
admet-7	351	36	j.	j.	PROPN
admet-7	351	37	rodes	rodes	PROPN
admet-7	351	38	,	,	PUNCT
admet-7	351	39	j.	j.	PROPN
admet-7	351	40	bruix	bruix	PROPN
admet-7	351	41	,	,	PUNCT
admet-7	351	42	lancet	lancet	NOUN
admet-7	351	43	359	359	NUM
admet-7	351	44	(	(	PUNCT
admet-7	351	45	2002	2002	NUM
admet-7	351	46	)	)	PUNCT
admet-7	351	47	1734	1734	NUM
admet-7	351	48	-	-	SYM
admet-7	351	49	1739	1739	NUM
admet-7	351	50	.	.	PUNCT
admet-7	352	1	[	[	X
admet-7	352	2	35	35	NUM
admet-7	352	3	]	]	X
admet-7	352	4	c.	c.	PROPN
admet-7	352	5	camma	camma	PROPN
admet-7	352	6	,	,	PUNCT
admet-7	352	7	f.	f.	PROPN
admet-7	352	8	schepis	schepis	PROPN
admet-7	352	9	,	,	PUNCT
admet-7	352	10	a.	a.	PROPN
admet-7	352	11	orlando	orlando	PROPN
admet-7	352	12	,	,	PUNCT
admet-7	352	13	m.	m.	NOUN
admet-7	352	14	albanese	albanese	PROPN
admet-7	352	15	,	,	PUNCT
admet-7	352	16	l.	l.	PROPN
admet-7	352	17	shahied	shahied	PROPN
admet-7	352	18	,	,	PUNCT
admet-7	352	19	f.	f.	PROPN
admet-7	352	20	trevisani	trevisani	PROPN
admet-7	352	21	,	,	PUNCT
admet-7	352	22	p.	p.	PROPN
admet-7	352	23	andreone	andreone	PROPN
admet-7	352	24	,	,	PUNCT
admet-7	352	25	a.	a.	NOUN
admet-7	352	26	craxi	craxi	PROPN
admet-7	352	27	,	,	PUNCT
admet-7	352	28	m.	m.	NOUN
admet-7	352	29	cottone	cottone	PROPN
admet-7	352	30	,	,	PUNCT
admet-7	352	31	radiology	radiology	NOUN
admet-7	352	32	224	224	NUM
admet-7	352	33	(	(	PUNCT
admet-7	352	34	2002	2002	NUM
admet-7	352	35	)	)	PUNCT
admet-7	352	36	47	47	NUM
admet-7	352	37	-	-	SYM
admet-7	352	38	54	54	NUM
admet-7	352	39	.	.	PUNCT
admet-7	353	1	[	[	X
admet-7	353	2	36	36	NUM
admet-7	353	3	]	]	X
admet-7	353	4	j.m	j.m	PROPN
admet-7	353	5	.	.	PROPN
admet-7	353	6	llovet	llovet	PROPN
admet-7	353	7	,	,	PUNCT
admet-7	353	8	j.	j.	PROPN
admet-7	353	9	bruix	bruix	PROPN
admet-7	353	10	,	,	PUNCT
admet-7	353	11	hepatology	hepatology	NOUN
admet-7	353	12	37	37	NUM
admet-7	353	13	(	(	PUNCT
admet-7	353	14	2003	2003	NUM
admet-7	353	15	)	)	PUNCT
admet-7	353	16	429	429	NUM
admet-7	353	17	-	-	SYM
admet-7	353	18	442	442	NUM
admet-7	353	19	.	.	PUNCT
admet-7	354	1	[	[	X
admet-7	354	2	37	37	NUM
admet-7	354	3	]	]	X
admet-7	354	4	h.	h.	PROPN
admet-7	354	5	nakamura	nakamura	PROPN
admet-7	354	6	,	,	PUNCT
admet-7	354	7	t.	t.	NOUN
admet-7	354	8	hashimoto	hashimoto	NOUN
admet-7	354	9	,	,	PUNCT
admet-7	354	10	h.	h.	PROPN
admet-7	354	11	oi	oi	PROPN
admet-7	354	12	,	,	PUNCT
admet-7	354	13	s.	s.	PROPN
admet-7	354	14	sawada	sawada	PROPN
admet-7	354	15	,	,	PUNCT
admet-7	354	16	radiology	radiology	NOUN
admet-7	354	17	170	170	NUM
admet-7	354	18	(	(	PUNCT
admet-7	354	19	1989	1989	NUM
admet-7	354	20	)	)	PUNCT
admet-7	354	21	783	783	NUM
admet-7	354	22	-	-	SYM
admet-7	354	23	786	786	NUM
admet-7	354	24	.	.	PUNCT
admet-7	355	1	[	[	X
admet-7	355	2	38	38	NUM
admet-7	355	3	]	]	X
admet-7	355	4	a.o	a.o	PROPN
admet-7	355	5	.	.	PROPN
admet-7	355	6	chan	chan	PROPN
admet-7	355	7	,	,	PUNCT
admet-7	355	8	m.f	m.f	PROPN
admet-7	355	9	.	.	PUNCT
admet-7	355	10	yuen	yuen	PROPN
admet-7	355	11	,	,	PUNCT
admet-7	355	12	c.k	c.k	PROPN
admet-7	355	13	.	.	PROPN
admet-7	355	14	hui	hui	PROPN
admet-7	355	15	,	,	PUNCT
admet-7	355	16	w.k	w.k	PROPN
admet-7	355	17	.	.	PROPN
admet-7	355	18	tso	tso	PROPN
admet-7	355	19	,	,	PUNCT
admet-7	355	20	c.l	c.l	PROPN
admet-7	355	21	.	.	PROPN
admet-7	355	22	lai	lai	PROPN
admet-7	355	23	,	,	PUNCT
admet-7	355	24	cancer	cancer	NOUN
admet-7	355	25	94	94	NUM
admet-7	355	26	(	(	PUNCT
admet-7	355	27	2002	2002	NUM
admet-7	355	28	)	)	PUNCT
admet-7	355	29	1747	1747	NUM
admet-7	355	30	-	-	SYM
admet-7	355	31	1752	1752	NUM
admet-7	355	32	.	.	PUNCT
admet-7	356	1	[	[	X
admet-7	356	2	39	39	NUM
admet-7	356	3	]	]	PUNCT
admet-7	356	4	j.	j.	PROPN
admet-7	356	5	gao	gao	PROPN
admet-7	356	6	,	,	PUNCT
admet-7	356	7	f.	f.	PROPN
admet-7	356	8	qian	qian	PROPN
admet-7	356	9	,	,	PUNCT
admet-7	356	10	a.	a.	PROPN
admet-7	356	11	szymanski	szymanski	PROPN
admet-7	356	12	-	-	PUNCT
admet-7	356	13	exner	exner	NOUN
admet-7	356	14	,	,	PUNCT
admet-7	356	15	n.	n.	PROPN
admet-7	356	16	stowe	stowe	PROPN
admet-7	356	17	,	,	PUNCT
admet-7	356	18	j.	j.	PROPN
admet-7	356	19	haaga	haaga	PROPN
admet-7	356	20	,	,	PUNCT
admet-7	356	21	journal	journal	NOUN
admet-7	356	22	of	of	ADP
admet-7	356	23	biomedical	biomedical	ADJ
admet-7	356	24	materials	material	NOUN
admet-7	356	25	research	research	NOUN
admet-7	356	26	62	62	NUM
admet-7	356	27	(	(	PUNCT
admet-7	356	28	2002	2002	NUM
admet-7	356	29	)	)	PUNCT
admet-7	356	30	308	308	NUM
admet-7	356	31	-	-	SYM
admet-7	356	32	314	314	NUM
admet-7	356	33	.	.	PUNCT
admet-7	357	1	[	[	X
admet-7	357	2	40	40	NUM
admet-7	357	3	]	]	PUNCT
admet-7	357	4	k.	k.	PROPN
admet-7	357	5	malagari	malagari	PROPN
admet-7	357	6	,	,	PUNCT
admet-7	357	7	expert	expert	NOUN
admet-7	357	8	review	review	NOUN
admet-7	357	9	of	of	ADP
admet-7	357	10	anticancer	anticancer	NOUN
admet-7	357	11	therapy	therapy	NOUN
admet-7	357	12	8	8	NUM
admet-7	357	13	(	(	PUNCT
admet-7	357	14	2008	2008	NUM
admet-7	357	15	)	)	PUNCT
admet-7	357	16	1643	1643	NUM
admet-7	357	17	-	-	SYM
admet-7	357	18	1650	1650	NUM
admet-7	357	19	.	.	PUNCT
admet-7	358	1	[	[	X
admet-7	358	2	41	41	NUM
admet-7	358	3	]	]	X
admet-7	358	4	m.	m.	NOUN
admet-7	358	5	sadick	sadick	PROPN
admet-7	358	6	,	,	PUNCT
admet-7	358	7	s.	s.	PROPN
admet-7	358	8	haas	haas	PROPN
admet-7	358	9	,	,	PUNCT
admet-7	358	10	m.	m.	NOUN
admet-7	358	11	loehr	loehr	PROPN
admet-7	358	12	,	,	PUNCT
admet-7	358	13	m.	m.	PROPN
admet-7	358	14	elshwi	elshwi	PROPN
admet-7	358	15	,	,	PUNCT
admet-7	358	16	m.v	m.v	PROPN
admet-7	358	17	.	.	PROPN
admet-7	358	18	singer	singer	PROPN
admet-7	358	19	,	,	PUNCT
admet-7	358	20	j.	j.	PROPN
admet-7	358	21	brade	brade	PROPN
admet-7	358	22	,	,	PUNCT
admet-7	358	23	s.o	s.o	PROPN
admet-7	358	24	.	.	PROPN
admet-7	358	25	schoenberg	schoenberg	PROPN
admet-7	358	26	,	,	PUNCT
admet-7	358	27	s.j	s.j	PROPN
admet-7	358	28	.	.	PROPN
admet-7	358	29	diehl	diehl	PROPN
admet-7	358	30	,	,	PUNCT
admet-7	358	31	onkologie	onkologie	PROPN
admet-7	358	32	33	33	NUM
admet-7	358	33	(	(	PUNCT
admet-7	358	34	2010	2010	NUM
admet-7	358	35	)	)	PUNCT
admet-7	358	36	31	31	NUM
admet-7	358	37	-	-	SYM
admet-7	358	38	37	37	NUM
admet-7	358	39	.	.	PUNCT
admet-7	359	1	[	[	X
admet-7	359	2	42	42	NUM
admet-7	359	3	]	]	X
admet-7	359	4	a.l	a.l	PROPN
admet-7	359	5	.	.	PROPN
admet-7	359	6	lewis	lewis	PROPN
admet-7	359	7	,	,	PUNCT
admet-7	359	8	m.w	m.w	PROPN
admet-7	359	9	.	.	PROPN
admet-7	359	10	gonzalez	gonzalez	PROPN
admet-7	359	11	,	,	PUNCT
admet-7	359	12	a.w	a.w	PROPN
admet-7	359	13	.	.	PROPN
admet-7	359	14	lloyd	lloyd	PROPN
admet-7	359	15	,	,	PUNCT
admet-7	359	16	b.	b.	PROPN
admet-7	359	17	hall	hall	PROPN
admet-7	359	18	,	,	PUNCT
admet-7	359	19	y.q	y.q	PROPN
admet-7	359	20	.	.	PROPN
admet-7	359	21	tang	tang	PROPN
admet-7	359	22	,	,	PUNCT
admet-7	359	23	s.l	s.l	PROPN
admet-7	359	24	.	.	PROPN
admet-7	359	25	willis	willis	PROPN
admet-7	359	26	,	,	PUNCT
admet-7	359	27	s.w	s.w	PROPN
admet-7	359	28	.	.	PROPN
admet-7	359	29	leppard	leppard	PROPN
admet-7	359	30	,	,	PUNCT
admet-7	359	31	l.c	l.c	PROPN
admet-7	359	32	.	.	PROPN
admet-7	359	33	wolfenden	wolfenden	PROPN
admet-7	359	34	,	,	PUNCT
admet-7	359	35	r.r	r.r	PROPN
admet-7	359	36	.	.	PROPN
admet-7	359	37	palmer	palmer	PROPN
admet-7	359	38	,	,	PUNCT
admet-7	359	39	p.w	p.w	PROPN
admet-7	359	40	.	.	PROPN
admet-7	359	41	stratford	stratford	PROPN
admet-7	359	42	,	,	PUNCT
admet-7	359	43	journal	journal	NOUN
admet-7	359	44	of	of	ADP
admet-7	359	45	vascular	vascular	ADJ
admet-7	359	46	and	and	CCONJ
admet-7	359	47	interventional	interventional	ADJ
admet-7	359	48	radiology	radiology	NOUN
admet-7	359	49	17	17	NUM
admet-7	359	50	(	(	PUNCT
admet-7	359	51	2006	2006	NUM
admet-7	359	52	)	)	PUNCT
admet-7	359	53	335	335	NUM
admet-7	359	54	-	-	SYM
admet-7	359	55	342	342	NUM
admet-7	359	56	.	.	PUNCT
admet-7	360	1	[	[	X
admet-7	360	2	43	43	NUM
admet-7	360	3	]	]	X
admet-7	360	4	j.	j.	PROPN
admet-7	360	5	kettenbach	kettenbach	PROPN
admet-7	360	6	,	,	PUNCT
admet-7	360	7	a.	a.	NOUN
admet-7	360	8	stadler	stadler	PROPN
admet-7	360	9	,	,	PUNCT
admet-7	360	10	i.v	i.v	PROPN
admet-7	360	11	.	.	PROPN
admet-7	360	12	katzler	katzler	PROPN
admet-7	360	13	,	,	PUNCT
admet-7	360	14	r.	r.	PROPN
admet-7	360	15	schernthaner	schernthaner	PROPN
admet-7	360	16	,	,	PUNCT
admet-7	360	17	m.	m.	NOUN
admet-7	360	18	blum	blum	PROPN
admet-7	360	19	,	,	PUNCT
admet-7	360	20	j.	j.	PROPN
admet-7	360	21	lammer	lammer	PROPN
admet-7	360	22	,	,	PUNCT
admet-7	360	23	t.	t.	NOUN
admet-7	360	24	rand	rand	NOUN
admet-7	360	25	,	,	PUNCT
admet-7	360	26	cardiovascular	cardiovascular	ADJ
admet-7	360	27	and	and	CCONJ
admet-7	360	28	interventional	interventional	ADJ
admet-7	360	29	radiology	radiology	NOUN
admet-7	360	30	31	31	NUM
admet-7	360	31	(	(	PUNCT
admet-7	360	32	2008	2008	NUM
admet-7	360	33	)	)	PUNCT
admet-7	360	34	468	468	NUM
admet-7	360	35	-	-	SYM
admet-7	360	36	476	476	NUM
admet-7	360	37	.	.	PUNCT
admet-7	361	1	tam	tam	PROPN
admet-7	361	2	admet	admet	PROPN
admet-7	361	3	&	&	CCONJ
admet-7	361	4	dmpk	dmpk	PROPN
admet-7	361	5	1(3	1(3	NUM
admet-7	361	6	)	)	PUNCT
admet-7	361	7	(	(	PUNCT
admet-7	361	8	2013	2013	NUM
admet-7	361	9	)	)	PUNCT
admet-7	361	10	29	29	NUM
admet-7	361	11	-	-	SYM
admet-7	361	12	44	44	NUM
admet-7	361	13	42	42	NUM
admet-7	361	14	[	[	X
admet-7	361	15	44	44	NUM
admet-7	361	16	]	]	PUNCT
admet-7	361	17	j.	j.	PROPN
admet-7	361	18	lammer	lammer	PROPN
admet-7	361	19	,	,	PUNCT
admet-7	361	20	k.	k.	PROPN
admet-7	361	21	malagari	malagari	PROPN
admet-7	361	22	,	,	PUNCT
admet-7	361	23	t.	t.	PROPN
admet-7	361	24	vogl	vogl	PROPN
admet-7	361	25	,	,	PUNCT
admet-7	361	26	f.	f.	PROPN
admet-7	361	27	pilleul	pilleul	PROPN
admet-7	361	28	,	,	PUNCT
admet-7	361	29	a.	a.	NOUN
admet-7	361	30	denys	denys	PROPN
admet-7	361	31	,	,	PUNCT
admet-7	361	32	a.	a.	PROPN
admet-7	361	33	watkinson	watkinson	PROPN
admet-7	361	34	,	,	PUNCT
admet-7	361	35	m.	m.	NOUN
admet-7	361	36	pitton	pitton	PROPN
admet-7	361	37	,	,	PUNCT
admet-7	361	38	g.	g.	PROPN
admet-7	361	39	sergent	sergent	PROPN
admet-7	361	40	,	,	PUNCT
admet-7	361	41	t.	t.	NOUN
admet-7	361	42	pfammatter	pfammatter	NOUN
admet-7	361	43	,	,	PUNCT
admet-7	361	44	s.	s.	PROPN
admet-7	361	45	terraz	terraz	PROPN
admet-7	361	46	,	,	PUNCT
admet-7	361	47	y.	y.	PROPN
admet-7	361	48	benhamou	benhamou	PROPN
admet-7	361	49	,	,	PUNCT
admet-7	361	50	y.	y.	PROPN
admet-7	361	51	avajon	avajon	NOUN
admet-7	361	52	,	,	PUNCT
admet-7	361	53	t.	t.	NOUN
admet-7	361	54	gruenberger	gruenberger	NOUN
admet-7	361	55	,	,	PUNCT
admet-7	361	56	m.	m.	NOUN
admet-7	361	57	pomoni	pomoni	NOUN
admet-7	361	58	,	,	PUNCT
admet-7	361	59	h.	h.	PROPN
admet-7	361	60	langenberger	langenberger	PROPN
admet-7	361	61	,	,	PUNCT
admet-7	361	62	m.	m.	NOUN
admet-7	361	63	schuchmann	schuchmann	PROPN
admet-7	361	64	,	,	PUNCT
admet-7	361	65	j.	j.	PROPN
admet-7	361	66	dumortier	dumortier	PROPN
admet-7	361	67	,	,	PUNCT
admet-7	361	68	c.	c.	PROPN
admet-7	361	69	mueller	mueller	PROPN
admet-7	361	70	,	,	PUNCT
admet-7	361	71	p.	p.	NOUN
admet-7	361	72	chevallier	chevallier	NOUN
admet-7	361	73	,	,	PUNCT
admet-7	361	74	r.	r.	PROPN
admet-7	361	75	lencioni	lencioni	PROPN
admet-7	361	76	,	,	PUNCT
admet-7	361	77	p.v	p.v	PROPN
admet-7	361	78	.	.	PROPN
admet-7	361	79	investigators	investigator	NOUN
admet-7	361	80	,	,	PUNCT
admet-7	361	81	cardiovascular	cardiovascular	ADJ
admet-7	361	82	and	and	CCONJ
admet-7	361	83	interventional	interventional	ADJ
admet-7	361	84	radiology	radiology	NOUN
admet-7	361	85	33	33	NUM
admet-7	361	86	(	(	PUNCT
admet-7	361	87	2010	2010	NUM
admet-7	361	88	)	)	PUNCT
admet-7	361	89	41	41	NUM
admet-7	361	90	-	-	SYM
admet-7	361	91	52	52	NUM
admet-7	361	92	.	.	PUNCT
admet-7	362	1	[	[	X
admet-7	362	2	45	45	NUM
admet-7	362	3	]	]	PUNCT
admet-7	362	4	k.	k.	PROPN
admet-7	362	5	malagari	malagari	PROPN
admet-7	362	6	,	,	PUNCT
admet-7	362	7	m.	m.	NOUN
admet-7	362	8	pomoni	pomoni	NOUN
admet-7	362	9	,	,	PUNCT
admet-7	362	10	h.	h.	PROPN
admet-7	362	11	moschouris	moschouris	PROPN
admet-7	362	12	,	,	PUNCT
admet-7	362	13	e.	e.	PROPN
admet-7	362	14	bouma	bouma	PROPN
admet-7	362	15	,	,	PUNCT
admet-7	362	16	j.	j.	PROPN
admet-7	362	17	koskinas	koskinas	PROPN
admet-7	362	18	,	,	PUNCT
admet-7	362	19	a.	a.	NOUN
admet-7	362	20	stefaniotou	stefaniotou	NOUN
admet-7	362	21	,	,	PUNCT
admet-7	362	22	a.	a.	NOUN
admet-7	362	23	marinis	marinis	PROPN
admet-7	362	24	,	,	PUNCT
admet-7	362	25	a.	a.	PROPN
admet-7	362	26	kelekis	kelekis	PROPN
admet-7	362	27	,	,	PUNCT
admet-7	362	28	e.	e.	PROPN
admet-7	362	29	alexopoulou	alexopoulou	PROPN
admet-7	362	30	,	,	PUNCT
admet-7	362	31	a.	a.	NOUN
admet-7	362	32	chatziioannou	chatziioannou	PROPN
admet-7	362	33	,	,	PUNCT
admet-7	362	34	k.	k.	PROPN
admet-7	362	35	chatzimichael	chatzimichael	PROPN
admet-7	362	36	,	,	PUNCT
admet-7	362	37	s.	s.	PROPN
admet-7	362	38	dourakis	dourakis	PROPN
admet-7	362	39	,	,	PUNCT
admet-7	362	40	n.	n.	PROPN
admet-7	362	41	kelekis	kelekis	PROPN
admet-7	362	42	,	,	PUNCT
admet-7	362	43	s.	s.	PROPN
admet-7	362	44	rizos	rizos	PROPN
admet-7	362	45	,	,	PUNCT
admet-7	362	46	d.	d.	PROPN
admet-7	362	47	kelekis	kelekis	PROPN
admet-7	362	48	,	,	PUNCT
admet-7	362	49	cardiovascular	cardiovascular	ADJ
admet-7	362	50	and	and	CCONJ
admet-7	362	51	interventional	interventional	ADJ
admet-7	362	52	radiology	radiology	NOUN
admet-7	362	53	35	35	NUM
admet-7	362	54	(	(	PUNCT
admet-7	362	55	2012	2012	NUM
admet-7	362	56	)	)	PUNCT
admet-7	362	57	1119–1128	1119–1128	NOUN
admet-7	362	58	.	.	PUNCT
admet-7	363	1	[	[	X
admet-7	363	2	46	46	NUM
admet-7	363	3	]	]	X
admet-7	363	4	r.	r.	PROPN
admet-7	363	5	yamada	yamada	PROPN
admet-7	363	6	,	,	PUNCT
admet-7	363	7	m.	m.	NOUN
admet-7	363	8	sato	sato	PROPN
admet-7	363	9	,	,	PUNCT
admet-7	363	10	m.	m.	NOUN
admet-7	363	11	kawabata	kawabata	PROPN
admet-7	363	12	,	,	PUNCT
admet-7	363	13	h.	h.	PROPN
admet-7	363	14	nakatsuka	nakatsuka	PROPN
admet-7	363	15	,	,	PUNCT
admet-7	363	16	k.	k.	PROPN
admet-7	363	17	nakamura	nakamura	PROPN
admet-7	363	18	,	,	PUNCT
admet-7	363	19	s.	s.	PROPN
admet-7	363	20	takashima	takashima	PROPN
admet-7	363	21	,	,	PUNCT
admet-7	363	22	radiology	radiology	NOUN
admet-7	363	23	148	148	NUM
admet-7	363	24	(	(	PUNCT
admet-7	363	25	1983	1983	NUM
admet-7	363	26	)	)	PUNCT
admet-7	363	27	397	397	NUM
admet-7	363	28	-	-	SYM
admet-7	363	29	401	401	NUM
admet-7	363	30	.	.	PUNCT
admet-7	364	1	[	[	X
admet-7	364	2	47	47	NUM
admet-7	364	3	]	]	X
admet-7	364	4	doxorubicin	doxorubicin	PROPN
admet-7	364	5	official	official	PROPN
admet-7	364	6	fda	fda	PROPN
admet-7	364	7	information	information	NOUN
admet-7	364	8	,	,	PUNCT
admet-7	364	9	http://www.drugs.com/pro/doxorubicin.html	http://www.drugs.com/pro/doxorubicin.html	PROPN
admet-7	364	10	(	(	PUNCT
admet-7	364	11	accessed	access	VERB
admet-7	364	12	28	28	NUM
admet-7	364	13	may	may	NOUN
admet-7	364	14	,	,	PUNCT
admet-7	364	15	2013	2013	NUM
admet-7	364	16	)	)	PUNCT
admet-7	364	17	.	.	PUNCT
admet-7	365	1	[	[	X
admet-7	365	2	48	48	NUM
admet-7	365	3	]	]	PUNCT
admet-7	365	4	lipodox	lipodox	VERB
admet-7	365	5	official	official	ADJ
admet-7	365	6	fda	fda	PROPN
admet-7	365	7	information	information	NOUN
admet-7	365	8	,	,	PUNCT
admet-7	365	9	http://www.drugs.com/pro/lipodox.html	http://www.drugs.com/pro/lipodox.html	PUNCT
admet-7	365	10	(	(	PUNCT
admet-7	365	11	accessed	access	VERB
admet-7	365	12	28	28	NUM
admet-7	365	13	may	may	NOUN
admet-7	365	14	,	,	PUNCT
admet-7	365	15	2013	2013	NUM
admet-7	365	16	)	)	PUNCT
admet-7	365	17	.	.	PUNCT
admet-7	366	1	[	[	X
admet-7	366	2	49	49	NUM
admet-7	366	3	]	]	PUNCT
admet-7	366	4	pso	pso	NOUN
admet-7	366	5	096	096	NUM
admet-7	366	6	-	-	SYM
admet-7	366	7	10	10	NUM
admet-7	366	8	doxorubicin	doxorubicin	ADJ
admet-7	366	9	hydrochloride	hydrochloride	NOUN
admet-7	366	10	(	(	PUNCT
admet-7	366	11	in	in	ADP
admet-7	366	12	heat	heat	NOUN
admet-7	366	13	sensitive	sensitive	ADJ
admet-7	366	14	liposomes	liposome	NOUN
admet-7	366	15	)	)	PUNCT
admet-7	366	16	,	,	PUNCT
admet-7	366	17	http://www.ema.europa.eu/docs/en_gb/document_library/orphan_designation/2011/03/wc500	http://www.ema.europa.eu/docs/en_gb/document_library/orphan_designation/2011/03/wc500	PROPN
admet-7	366	18	102686.pdf	102686.pdf	PROPN
admet-7	366	19	(	(	PUNCT
admet-7	366	20	accessed	access	VERB
admet-7	366	21	28	28	NUM
admet-7	366	22	may	may	NOUN
admet-7	366	23	,	,	PUNCT
admet-7	366	24	2013	2013	NUM
admet-7	366	25	)	)	PUNCT
admet-7	366	26	.	.	PUNCT
admet-7	367	1	[	[	X
admet-7	367	2	50	50	NUM
admet-7	367	3	]	]	X
admet-7	367	4	g.	g.	PROPN
admet-7	367	5	powis	powis	PROPN
admet-7	367	6	,	,	PUNCT
admet-7	367	7	pharmacology	pharmacology	NOUN
admet-7	367	8	&	&	CCONJ
admet-7	367	9	therapeutics	therapeutic	NOUN
admet-7	367	10	35	35	NUM
admet-7	367	11	(	(	PUNCT
admet-7	367	12	1987	1987	NUM
admet-7	367	13	)	)	PUNCT
admet-7	368	1	57–162	57–162	NUM
admet-7	368	2	.	.	PUNCT
admet-7	369	1	[	[	X
admet-7	369	2	51	51	NUM
admet-7	369	3	]	]	X
admet-7	369	4	c.a	c.a	PROPN
admet-7	369	5	.	.	PROPN
admet-7	369	6	frederick	frederick	PROPN
admet-7	369	7	,	,	PUNCT
admet-7	369	8	l.d	l.d	PROPN
admet-7	369	9	.	.	PROPN
admet-7	369	10	williams	williams	PROPN
admet-7	369	11	,	,	PUNCT
admet-7	369	12	g.	g.	PROPN
admet-7	369	13	ughetto	ughetto	PROPN
admet-7	369	14	,	,	PUNCT
admet-7	369	15	g.a	g.a	PROPN
admet-7	369	16	.	.	PROPN
admet-7	369	17	van	van	PROPN
admet-7	369	18	der	der	PROPN
admet-7	369	19	marel	marel	PROPN
admet-7	369	20	,	,	PUNCT
admet-7	369	21	j.h	j.h	PROPN
admet-7	369	22	.	.	PROPN
admet-7	369	23	van	van	PROPN
admet-7	369	24	boom	boom	NOUN
admet-7	369	25	,	,	PUNCT
admet-7	369	26	a	a	DET
admet-7	369	27	rich	rich	ADJ
admet-7	369	28	,	,	PUNCT
admet-7	369	29	a.h	a.h	PROPN
admet-7	369	30	.	.	PROPN
admet-7	369	31	wang	wang	PROPN
admet-7	369	32	,	,	PUNCT
admet-7	369	33	biochemistry	biochemistry	NOUN
admet-7	369	34	29	29	NUM
admet-7	369	35	(	(	PUNCT
admet-7	369	36	1990	1990	NUM
admet-7	369	37	)	)	PUNCT
admet-7	369	38	2538–2549	2538–2549	NUM
admet-7	369	39	.	.	PUNCT
admet-7	370	1	[	[	X
admet-7	370	2	52	52	NUM
admet-7	370	3	]	]	PUNCT
admet-7	370	4	f.	f.	PROPN
admet-7	370	5	penault	penault	PROPN
admet-7	370	6	-	-	PUNCT
admet-7	370	7	llorca	llorca	NOUN
admet-7	370	8	,	,	PUNCT
admet-7	370	9	a.	a.	NOUN
admet-7	370	10	cayre	cayre	PROPN
admet-7	370	11	,	,	PUNCT
admet-7	370	12	f.	f.	PROPN
admet-7	370	13	bouchet	bouchet	PROPN
admet-7	370	14	mishellany	mishellany	PROPN
admet-7	370	15	,	,	PUNCT
admet-7	370	16	s.	s.	PROPN
admet-7	370	17	amat	amat	PROPN
admet-7	370	18	,	,	PUNCT
admet-7	370	19	v.	v.	ADP
admet-7	370	20	feillel	feillel	PROPN
admet-7	370	21	,	,	PUNCT
admet-7	370	22	g.	g.	PROPN
admet-7	370	23	le	le	PROPN
admet-7	370	24	bouedec	bouedec	PROPN
admet-7	370	25	,	,	PUNCT
admet-7	370	26	j.p	j.p	PROPN
admet-7	370	27	.	.	PROPN
admet-7	370	28	ferriere	ferriere	PROPN
admet-7	370	29	,	,	PUNCT
admet-7	370	30	m.	m.	NOUN
admet-7	370	31	de	de	PROPN
admet-7	370	32	latour	latour	PROPN
admet-7	370	33	,	,	PUNCT
admet-7	370	34	p.	p.	NOUN
admet-7	370	35	chollet	chollet	PROPN
admet-7	370	36	,	,	PUNCT
admet-7	370	37	international	international	ADJ
admet-7	370	38	journal	journal	NOUN
admet-7	370	39	of	of	ADP
admet-7	370	40	oncology	oncology	NOUN
admet-7	370	41	22	22	NUM
admet-7	370	42	(	(	PUNCT
admet-7	370	43	2003	2003	NUM
admet-7	370	44	)	)	PUNCT
admet-7	370	45	1319–1325	1319–1325	NUM
admet-7	370	46	;	;	PUNCT
admet-7	370	47	[	[	X
admet-7	370	48	53	53	NUM
admet-7	370	49	]	]	PUNCT
admet-7	370	50	v.	v.	CCONJ
admet-7	370	51	stearns	stearns	PROPN
admet-7	370	52	,	,	PUNCT
admet-7	370	53	b.	b.	PROPN
admet-7	370	54	singh	singh	PROPN
admet-7	370	55	,	,	PUNCT
admet-7	370	56	t.	t.	PROPN
admet-7	370	57	tsangaris	tsangaris	PROPN
admet-7	370	58	,	,	PUNCT
admet-7	370	59	j.g	j.g	PROPN
admet-7	370	60	.	.	PROPN
admet-7	370	61	crawford	crawford	PROPN
admet-7	370	62	,	,	PUNCT
admet-7	370	63	a.	a.	PROPN
admet-7	370	64	novielli	novielli	PROPN
admet-7	370	65	,	,	PUNCT
admet-7	370	66	m.j	m.j	PROPN
admet-7	370	67	.	.	PROPN
admet-7	370	68	ellis	ellis	PROPN
admet-7	370	69	,	,	PUNCT
admet-7	370	70	c.	c.	PROPN
admet-7	370	71	isaacs	isaacs	PROPN
admet-7	370	72	,	,	PUNCT
admet-7	370	73	m.	m.	NOUN
admet-7	370	74	pennanen	pennanen	PROPN
admet-7	370	75	,	,	PUNCT
admet-7	370	76	c.	c.	PROPN
admet-7	370	77	tibery	tibery	PROPN
admet-7	370	78	,	,	PUNCT
admet-7	370	79	a.	a.	PROPN
admet-7	370	80	farhad	farhad	PROPN
admet-7	370	81	,	,	PUNCT
admet-7	370	82	r.	r.	PROPN
admet-7	370	83	slack	slack	PROPN
admet-7	370	84	,	,	PUNCT
admet-7	370	85	d.f	d.f	PROPN
admet-7	370	86	.	.	PROPN
admet-7	370	87	hayes	hayes	PROPN
admet-7	370	88	,	,	PUNCT
admet-7	370	89	clinical	clinical	ADJ
admet-7	370	90	cancer	cancer	NOUN
admet-7	370	91	research	research	NOUN
admet-7	370	92	9	9	NUM
admet-7	370	93	(	(	PUNCT
admet-7	370	94	2003	2003	NUM
admet-7	370	95	)	)	PUNCT
admet-7	370	96	124–133	124–133	NUM
admet-7	370	97	.	.	PUNCT
admet-7	371	1	[	[	X
admet-7	371	2	54	54	NUM
admet-7	371	3	]	]	X
admet-7	371	4	n.r	n.r	PROPN
admet-7	371	5	.	.	PROPN
admet-7	371	6	bachur	bachur	PROPN
admet-7	371	7	,	,	PUNCT
admet-7	371	8	s.l	s.l	PROPN
admet-7	371	9	.	.	PROPN
admet-7	371	10	gordon	gordon	PROPN
admet-7	371	11	,	,	PUNCT
admet-7	371	12	m.v	m.v	PROPN
admet-7	371	13	.	.	PROPN
admet-7	371	14	gee	gee	PROPN
admet-7	371	15	,	,	PUNCT
admet-7	371	16	molecular	molecular	ADJ
admet-7	371	17	pharmacology	pharmacology	NOUN
admet-7	371	18	13	13	NUM
admet-7	371	19	(	(	PUNCT
admet-7	371	20	1977	1977	NUM
admet-7	371	21	)	)	PUNCT
admet-7	371	22	901–910	901–910	NUM
admet-7	371	23	.	.	PUNCT
admet-7	372	1	[	[	X
admet-7	372	2	55	55	NUM
admet-7	372	3	]	]	X
admet-7	372	4	n.r	n.r	PROPN
admet-7	372	5	.	.	PROPN
admet-7	372	6	bachur	bachur	PROPN
admet-7	372	7	,	,	PUNCT
admet-7	372	8	m.	m.	NOUN
admet-7	372	9	gee	gee	PROPN
admet-7	372	10	,	,	PUNCT
admet-7	372	11	journal	journal	NOUN
admet-7	372	12	of	of	ADP
admet-7	372	13	pharmacology	pharmacology	NOUN
admet-7	372	14	and	and	CCONJ
admet-7	372	15	experimental	experimental	ADJ
admet-7	372	16	therapeutics	therapeutic	NOUN
admet-7	372	17	197	197	NUM
admet-7	372	18	(	(	PUNCT
admet-7	372	19	1976	1976	NUM
admet-7	372	20	)	)	PUNCT
admet-7	373	1	681–686	681–686	NUM
admet-7	373	2	.	.	PUNCT
admet-7	374	1	[	[	X
admet-7	374	2	56	56	NUM
admet-7	374	3	]	]	X
admet-7	374	4	j.	j.	PROPN
admet-7	374	5	cummings	cummings	PROPN
admet-7	374	6	,	,	PUNCT
admet-7	374	7	l.	l.	PROPN
admet-7	374	8	anderson	anderson	PROPN
admet-7	374	9	,	,	PUNCT
admet-7	374	10	n	n	PRON
admet-7	374	11	willmott	willmott	PROPN
admet-7	374	12	,	,	PUNCT
admet-7	374	13	j.f	j.f	PROPN
admet-7	374	14	.	.	PROPN
admet-7	374	15	smyth	smyth	PROPN
admet-7	374	16	,	,	PUNCT
admet-7	374	17	european	european	PROPN
admet-7	374	18	journal	journal	PROPN
admet-7	374	19	of	of	ADP
admet-7	374	20	cancer	cancer	NOUN
admet-7	374	21	27	27	NUM
admet-7	374	22	(	(	PUNCT
admet-7	374	23	1991	1991	NUM
admet-7	374	24	)	)	PUNCT
admet-7	374	25	532–535	532–535	NUM
admet-7	374	26	.	.	PUNCT
admet-7	375	1	[	[	X
admet-7	375	2	57	57	NUM
admet-7	375	3	]	]	X
admet-7	375	4	j.h	j.h	PROPN
admet-7	375	5	.	.	PROPN
admet-7	375	6	doroshow	doroshow	PROPN
admet-7	375	7	,	,	PUNCT
admet-7	375	8	cancer	cancer	NOUN
admet-7	375	9	research	research	NOUN
admet-7	375	10	43	43	NUM
admet-7	375	11	(	(	PUNCT
admet-7	375	12	1983	1983	NUM
admet-7	375	13	)	)	PUNCT
admet-7	375	14	4543–4551	4543–4551	NUM
admet-7	375	15	.	.	PUNCT
admet-7	376	1	[	[	X
admet-7	376	2	58	58	NUM
admet-7	376	3	]	]	X
admet-7	376	4	d.w	d.w	PROPN
admet-7	376	5	.	.	PROPN
admet-7	376	6	reif	reif	PROPN
admet-7	376	7	,	,	PUNCT
admet-7	376	8	free	free	ADJ
admet-7	376	9	radical	radical	ADJ
admet-7	376	10	biology	biology	NOUN
admet-7	376	11	and	and	CCONJ
admet-7	376	12	medicine	medicine	NOUN
admet-7	376	13	12	12	NUM
admet-7	376	14	(	(	PUNCT
admet-7	376	15	1992	1992	NUM
admet-7	376	16	)	)	PUNCT
admet-7	376	17	417–427	417–427	NUM
admet-7	376	18	.	.	PUNCT
admet-7	377	1	[	[	X
admet-7	377	2	59	59	NUM
admet-7	377	3	]	]	SYM
admet-7	377	4	d.a	d.a	PROPN
admet-7	377	5	.	.	PROPN
admet-7	377	6	gewirtz	gewirtz	PROPN
admet-7	377	7	,	,	PUNCT
admet-7	377	8	biochemical	biochemical	ADJ
admet-7	377	9	pharmacology	pharmacology	NOUN
admet-7	377	10	57	57	NUM
admet-7	377	11	(	(	PUNCT
admet-7	377	12	1999	1999	NUM
admet-7	377	13	)	)	PUNCT
admet-7	378	1	727–741	727–741	NUM
admet-7	378	2	[	[	SYM
admet-7	378	3	60	60	NUM
admet-7	378	4	]	]	SYM
admet-7	378	5	p.m.	p.m.	NOUN
admet-7	378	6	kanter	kanter	PROPN
admet-7	378	7	,	,	PUNCT
admet-7	378	8	h.s	h.s	PROPN
admet-7	378	9	.	.	PROPN
admet-7	378	10	schwartz	schwartz	PROPN
admet-7	378	11	,	,	PUNCT
admet-7	378	12	leukemia	leukemia	NOUN
admet-7	378	13	research	research	NOUN
admet-7	378	14	3	3	NUM
admet-7	378	15	(	(	PUNCT
admet-7	378	16	1979	1979	NUM
admet-7	378	17	)	)	PUNCT
admet-7	378	18	277–283	277–283	NUM
admet-7	378	19	.	.	PUNCT
admet-7	379	1	[	[	X
admet-7	379	2	61	61	NUM
admet-7	379	3	]	]	X
admet-7	379	4	c.e	c.e	PROPN
admet-7	379	5	.	.	PROPN
admet-7	379	6	myers	myers	PROPN
admet-7	379	7	,	,	PUNCT
admet-7	379	8	w.p	w.p	PROPN
admet-7	379	9	.	.	PROPN
admet-7	379	10	mcguire	mcguire	PROPN
admet-7	379	11	,	,	PUNCT
admet-7	379	12	r.h	r.h	PROPN
admet-7	379	13	.	.	PROPN
admet-7	379	14	liss	liss	PROPN
admet-7	379	15	,	,	PUNCT
admet-7	379	16	i.	i.	PROPN
admet-7	379	17	ifrim	ifrim	PROPN
admet-7	379	18	,	,	PUNCT
admet-7	379	19	k.	k.	PROPN
admet-7	379	20	grotzinger	grotzinger	PROPN
admet-7	379	21	,	,	PUNCT
admet-7	379	22	r.c	r.c	PROPN
admet-7	379	23	.	.	PROPN
admet-7	379	24	young	young	PROPN
admet-7	379	25	,	,	PUNCT
admet-7	379	26	science	science	NOUN
admet-7	379	27	197	197	NUM
admet-7	379	28	(	(	PUNCT
admet-7	379	29	1977	1977	NUM
admet-7	379	30	)	)	PUNCT
admet-7	379	31	165–167	165–167	NUM
admet-7	379	32	.	.	PUNCT
admet-7	380	1	[	[	X
admet-7	380	2	62	62	NUM
admet-7	380	3	]	]	X
admet-7	380	4	d.h	d.h	PROPN
admet-7	380	5	.	.	PROPN
admet-7	380	6	huffman	huffman	PROPN
admet-7	380	7	,	,	PUNCT
admet-7	380	8	n.r	n.r	PROPN
admet-7	380	9	.	.	PROPN
admet-7	380	10	bachur	bachur	PROPN
admet-7	380	11	,	,	PUNCT
admet-7	380	12	cancer	cancer	NOUN
admet-7	380	13	research	research	NOUN
admet-7	380	14	32	32	NUM
admet-7	380	15	(	(	PUNCT
admet-7	380	16	1972	1972	NUM
admet-7	380	17	)	)	PUNCT
admet-7	380	18	600–605	600–605	NUM
admet-7	380	19	.	.	PUNCT
admet-7	381	1	[	[	X
admet-7	381	2	63	63	NUM
admet-7	381	3	]	]	X
admet-7	381	4	n.k	n.k	PROPN
admet-7	381	5	.	.	PROPN
admet-7	381	6	ahmed	ahmed	PROPN
admet-7	381	7	,	,	PUNCT
admet-7	381	8	r.l	r.l	PROPN
admet-7	381	9	.	.	PROPN
admet-7	381	10	felsted	felste	VERB
admet-7	381	11	,	,	PUNCT
admet-7	381	12	n.r	n.r	PROPN
admet-7	381	13	bachur	bachur	PROPN
admet-7	381	14	,	,	PUNCT
admet-7	381	15	journal	journal	NOUN
admet-7	381	16	of	of	ADP
admet-7	381	17	pharmacology	pharmacology	NOUN
admet-7	381	18	and	and	CCONJ
admet-7	381	19	experimental	experimental	ADJ
admet-7	381	20	therapeutics	therapeutic	NOUN
admet-7	381	21	209	209	NUM
admet-7	381	22	(	(	PUNCT
admet-7	381	23	1979	1979	NUM
admet-7	381	24	)	)	PUNCT
admet-7	381	25	12–19	12–19	NOUN
admet-7	381	26	.	.	PUNCT
admet-7	382	1	[	[	X
admet-7	382	2	64	64	NUM
admet-7	382	3	]	]	PUNCT
admet-7	382	4	k.	k.	NOUN
admet-7	382	5	mross	mross	PROPN
admet-7	382	6	,	,	PUNCT
admet-7	382	7	p.	p.	PROPN
admet-7	382	8	maessen	maessen	PROPN
admet-7	382	9	,	,	PUNCT
admet-7	382	10	w.j	w.j	PROPN
admet-7	382	11	.	.	PROPN
admet-7	382	12	van	van	PROPN
admet-7	382	13	der	der	PROPN
admet-7	382	14	vijgh	vijgh	ADV
admet-7	382	15	,	,	PUNCT
admet-7	382	16	h.	h.	PROPN
admet-7	382	17	gall	gall	PROPN
admet-7	382	18	,	,	PUNCT
admet-7	382	19	e.	e.	PROPN
admet-7	382	20	boven	boven	PROPN
admet-7	382	21	,	,	PUNCT
admet-7	382	22	h.m	h.m	PROPN
admet-7	382	23	.	.	PROPN
admet-7	382	24	pinedo	pinedo	PROPN
admet-7	382	25	,	,	PUNCT
admet-7	382	26	journal	journal	NOUN
admet-7	382	27	of	of	ADP
admet-7	382	28	clinical	clinical	ADJ
admet-7	382	29	oncology	oncology	NOUN
admet-7	382	30	6	6	NUM
admet-7	382	31	(	(	PUNCT
admet-7	382	32	1988	1988	NUM
admet-7	382	33	)	)	PUNCT
admet-7	382	34	517	517	NUM
admet-7	382	35	-	-	SYM
admet-7	382	36	526	526	NUM
admet-7	382	37	.	.	PUNCT
admet-7	383	1	[	[	X
admet-7	383	2	65	65	NUM
admet-7	383	3	]	]	X
admet-7	383	4	w.j	w.j	PROPN
admet-7	383	5	.	.	PROPN
admet-7	383	6	pigram	pigram	PROPN
admet-7	383	7	,	,	PUNCT
admet-7	383	8	w.	w.	PROPN
admet-7	383	9	fuller	fuller	PROPN
admet-7	383	10	,	,	PUNCT
admet-7	383	11	l.d	l.d	PROPN
admet-7	383	12	.	.	PROPN
admet-7	383	13	hamilton	hamilton	PROPN
admet-7	383	14	,	,	PUNCT
admet-7	383	15	nature	nature	NOUN
admet-7	383	16	235	235	NUM
admet-7	383	17	(	(	PUNCT
admet-7	383	18	1972	1972	NUM
admet-7	383	19	)	)	PUNCT
admet-7	383	20	17–19	17–19	NUM
admet-7	383	21	.	.	PUNCT
admet-7	384	1	[	[	X
admet-7	384	2	66	66	NUM
admet-7	384	3	]	]	X
admet-7	384	4	e.n	e.n	PROPN
admet-7	384	5	.	.	PROPN
admet-7	384	6	dessypris	dessypris	PROPN
admet-7	384	7	,	,	PUNCT
admet-7	384	8	d.e	d.e	PROPN
admet-7	384	9	.	.	PROPN
admet-7	384	10	brenner	brenner	PROPN
admet-7	384	11	,	,	PUNCT
admet-7	384	12	m.r	m.r	PROPN
admet-7	384	13	.	.	PROPN
admet-7	384	14	baer	baer	PROPN
admet-7	384	15	,	,	PUNCT
admet-7	384	16	k.r	k.r	PROPN
admet-7	384	17	.	.	PROPN
admet-7	384	18	hande	hande	PROPN
admet-7	384	19	,	,	PUNCT
admet-7	384	20	cancer	cancer	NOUN
admet-7	384	21	research	research	NOUN
admet-7	384	22	48	48	NUM
admet-7	384	23	(	(	PUNCT
admet-7	384	24	1988	1988	NUM
admet-7	384	25	)	)	PUNCT
admet-7	384	26	503	503	NUM
admet-7	384	27	-	-	SYM
admet-7	384	28	506	506	NUM
admet-7	384	29	.	.	PUNCT
admet-7	385	1	[	[	X
admet-7	385	2	67	67	NUM
admet-7	385	3	]	]	X
admet-7	385	4	d.w	d.w	PROPN
admet-7	385	5	.	.	PROPN
admet-7	385	6	yesair	yesair	PROPN
admet-7	385	7	,	,	PUNCT
admet-7	385	8	p.s	p.s	PROPN
admet-7	385	9	.	.	PROPN
admet-7	385	10	thayer	thayer	PROPN
admet-7	385	11	,	,	PUNCT
admet-7	385	12	s.	s.	PROPN
admet-7	385	13	mcnitt	mcnitt	PROPN
admet-7	385	14	,	,	PUNCT
admet-7	385	15	k.	k.	PROPN
admet-7	385	16	teague	teague	PROPN
admet-7	385	17	,	,	PUNCT
admet-7	385	18	european	european	PROPN
admet-7	385	19	journal	journal	PROPN
admet-7	385	20	of	of	ADP
admet-7	385	21	cancer	cancer	NOUN
admet-7	385	22	16	16	NUM
admet-7	385	23	(	(	PUNCT
admet-7	385	24	1980	1980	NUM
admet-7	385	25	)	)	PUNCT
admet-7	385	26	901	901	NUM
admet-7	385	27	-	-	SYM
admet-7	385	28	907	907	NUM
admet-7	385	29	.	.	PUNCT
admet-7	386	1	[	[	X
admet-7	386	2	68	68	NUM
admet-7	386	3	]	]	X
admet-7	386	4	r.d	r.d	PROPN
admet-7	386	5	.	.	PROPN
admet-7	386	6	olson	olson	PROPN
admet-7	386	7	,	,	PUNCT
admet-7	386	8	p.s	p.s	PROPN
admet-7	386	9	.	.	PROPN
admet-7	386	10	mushlin	mushlin	PROPN
admet-7	386	11	,	,	PUNCT
admet-7	386	12	d.e	d.e	PROPN
admet-7	386	13	.	.	PROPN
admet-7	386	14	brenner	brenner	PROPN
admet-7	386	15	,	,	PUNCT
admet-7	386	16	s.	s.	PROPN
admet-7	386	17	fleischer	fleischer	PROPN
admet-7	386	18	,	,	PUNCT
admet-7	386	19	b.j	b.j	PROPN
admet-7	386	20	.	.	PROPN
admet-7	386	21	cusack	cusack	PROPN
admet-7	386	22	,	,	PUNCT
admet-7	386	23	b.k	b.k	PROPN
admet-7	386	24	.	.	PROPN
admet-7	386	25	chang	chang	PROPN
admet-7	386	26	,	,	PUNCT
admet-7	386	27	r.j	r.j	PROPN
admet-7	386	28	.	.	PROPN
admet-7	386	29	boucek	boucek	PROPN
admet-7	386	30	,	,	PUNCT
admet-7	386	31	proceedings	proceeding	NOUN
admet-7	386	32	of	of	ADP
admet-7	386	33	the	the	DET
admet-7	386	34	national	national	PROPN
admet-7	386	35	academy	academy	PROPN
admet-7	386	36	of	of	ADP
admet-7	386	37	sciences	sciences	PROPN
admet-7	386	38	85	85	NUM
admet-7	386	39	(	(	PUNCT
admet-7	386	40	1988	1988	NUM
admet-7	386	41	)	)	PUNCT
admet-7	386	42	3585	3585	NUM
admet-7	386	43	-	-	SYM
admet-7	386	44	3589	3589	NUM
admet-7	386	45	.	.	PUNCT
admet-7	387	1	[	[	X
admet-7	387	2	69	69	NUM
admet-7	387	3	]	]	X
admet-7	387	4	p.k	p.k	PROPN
admet-7	387	5	.	.	PROPN
admet-7	387	6	singal	singal	PROPN
admet-7	387	7	,	,	PUNCT
admet-7	387	8	t.	t.	PROPN
admet-7	387	9	li	li	PROPN
admet-7	387	10	,	,	PUNCT
admet-7	387	11	d.	d.	PROPN
admet-7	387	12	kumar	kumar	PROPN
admet-7	387	13	,	,	PUNCT
admet-7	387	14	i	i	PRON
admet-7	387	15	danelisen	danelisen	VERB
admet-7	387	16	,	,	PUNCT
admet-7	387	17	n.	n.	NOUN
admet-7	387	18	iliskovic	iliskovic	PROPN
admet-7	387	19	,	,	PUNCT
admet-7	387	20	molecular	molecular	ADJ
admet-7	387	21	and	and	CCONJ
admet-7	387	22	cellular	cellular	ADJ
admet-7	387	23	biochemistry	biochemistry	NOUN
admet-7	387	24	207	207	NUM
admet-7	387	25	(	(	PUNCT
admet-7	387	26	2000	2000	NUM
admet-7	387	27	)	)	PUNCT
admet-7	388	1	77–85	77–85	NUM
admet-7	388	2	.	.	PUNCT
admet-7	389	1	[	[	X
admet-7	389	2	70	70	NUM
admet-7	389	3	]	]	X
admet-7	389	4	m.r	m.r	PROPN
admet-7	389	5	.	.	PROPN
admet-7	389	6	bristow	bristow	PROPN
admet-7	389	7	,	,	PUNCT
admet-7	389	8	p.d	p.d	PROPN
admet-7	389	9	.	.	PROPN
admet-7	389	10	thompson	thompson	PROPN
admet-7	389	11	,	,	PUNCT
admet-7	389	12	r.p	r.p	PROPN
admet-7	389	13	.	.	PROPN
admet-7	389	14	martin	martin	PROPN
admet-7	389	15	,	,	PUNCT
admet-7	389	16	j.m	j.m	PROPN
admet-7	389	17	.	.	PROPN
admet-7	389	18	mason	mason	PROPN
admet-7	389	19	,	,	PUNCT
admet-7	389	20	m.e	m.e	PROPN
admet-7	389	21	.	.	PROPN
admet-7	389	22	billingham	billingham	PROPN
admet-7	389	23	,	,	PUNCT
admet-7	389	24	d.c	d.c	PROPN
admet-7	389	25	.	.	PROPN
admet-7	389	26	harrison	harrison	PROPN
admet-7	389	27	,	,	PUNCT
admet-7	389	28	american	american	PROPN
admet-7	389	29	journal	journal	PROPN
admet-7	389	30	of	of	ADP
admet-7	389	31	medicine	medicine	NOUN
admet-7	389	32	65	65	NUM
admet-7	389	33	(	(	PUNCT
admet-7	389	34	1978	1978	NUM
admet-7	389	35	)	)	PUNCT
admet-7	389	36	823–832	823–832	NUM
admet-7	389	37	.	.	PUNCT
admet-7	390	1	[	[	X
admet-7	390	2	71	71	NUM
admet-7	390	3	]	]	X
admet-7	390	4	k.j	k.j	PROPN
admet-7	390	5	.	.	PROPN
admet-7	390	6	schimmel	schimmel	PROPN
admet-7	390	7	,	,	PUNCT
admet-7	390	8	d.j	d.j	PROPN
admet-7	390	9	.	.	PROPN
admet-7	390	10	richel	richel	PROPN
admet-7	390	11	,	,	PUNCT
admet-7	390	12	r.b	r.b	PROPN
admet-7	390	13	.	.	PROPN
admet-7	390	14	van	van	PROPN
admet-7	390	15	den	den	PROPN
admet-7	390	16	brink	brink	PROPN
admet-7	390	17	,	,	PUNCT
admet-7	390	18	h.j	h.j	PROPN
admet-7	390	19	.	.	PROPN
admet-7	390	20	guchelaar	guchelaar	NOUN
admet-7	390	21	,	,	PUNCT
admet-7	390	22	cancer	cancer	NOUN
admet-7	390	23	treatment	treatment	NOUN
admet-7	390	24	review	review	NOUN
admet-7	390	25	30	30	NUM
admet-7	390	26	(	(	PUNCT
admet-7	390	27	2004	2004	NUM
admet-7	390	28	)	)	PUNCT
admet-7	391	1	181–191	181–191	NUM
admet-7	391	2	.	.	PUNCT
admet-7	392	1	http://www.drugs.com/pro/doxorubicin.html	http://www.drugs.com/pro/doxorubicin.html	VERB
admet-7	392	2	http://www.drugs.com/pro/lipodox.html	http://www.drugs.com/pro/lipodox.html	PROPN
admet-7	392	3	http://www.ema.europa.eu/docs/en_gb/document_library/orphan_designation/2011/03/wc500102686.pdf	http://www.ema.europa.eu/docs/en_gb/document_library/orphan_designation/2011/03/wc500102686.pdf	PROPN
admet-7	392	4	http://www.ema.europa.eu/docs/en_gb/document_library/orphan_designation/2011/03/wc500102686.pdf	http://www.ema.europa.eu/docs/en_gb/document_library/orphan_designation/2011/03/wc500102686.pdf	PROPN
admet-7	392	5	admet	admet	PROPN
admet-7	392	6	&	&	CCONJ
admet-7	392	7	dmpk	dmpk	PROPN
admet-7	392	8	1(3	1(3	NUM
admet-7	392	9	)	)	PUNCT
admet-7	392	10	(	(	PUNCT
admet-7	392	11	2013	2013	NUM
admet-7	392	12	)	)	PUNCT
admet-7	392	13	29	29	NUM
admet-7	392	14	-	-	SYM
admet-7	392	15	44	44	NUM
admet-7	392	16	doxorubicin	doxorubicin	NOUN
admet-7	392	17	and	and	CCONJ
admet-7	392	18	hcc	hcc	PROPN
admet-7	392	19	doi	doi	PROPN
admet-7	392	20	:	:	PUNCT
admet-7	392	21	10.5599	10.5599	NUM
admet-7	392	22	/	/	SYM
admet-7	392	23	admet.1.3.7	admet.1.3.7	NOUN
admet-7	393	1	43	43	NUM
admet-7	394	1	[	[	X
admet-7	394	2	72	72	NUM
admet-7	394	3	]	]	X
admet-7	394	4	s.	s.	PROPN
admet-7	394	5	wang	wang	PROPN
admet-7	394	6	,	,	PUNCT
admet-7	394	7	s.	s.	PROPN
admet-7	394	8	kotamraju	kotamraju	PROPN
admet-7	394	9	,	,	PUNCT
admet-7	394	10	e.	e.	PROPN
admet-7	394	11	konorev	konorev	PROPN
admet-7	394	12	,	,	PUNCT
admet-7	394	13	s.	s.	PROPN
admet-7	394	14	kalivendi	kalivendi	PROPN
admet-7	394	15	,	,	PUNCT
admet-7	394	16	j.	j.	PROPN
admet-7	394	17	joseph	joseph	PROPN
admet-7	394	18	,	,	PUNCT
admet-7	394	19	b.	b.	PROPN
admet-7	394	20	kalyanaraman	kalyanaraman	PROPN
admet-7	394	21	,	,	PUNCT
admet-7	394	22	biochemical	biochemical	ADJ
admet-7	394	23	journal	journal	NOUN
admet-7	394	24	367	367	NUM
admet-7	394	25	(	(	PUNCT
admet-7	394	26	2002	2002	NUM
admet-7	394	27	)	)	PUNCT
admet-7	395	1	729–740	729–740	NUM
admet-7	395	2	.	.	PUNCT
admet-7	396	1	[	[	X
admet-7	396	2	73	73	NUM
admet-7	396	3	]	]	PUNCT
admet-7	396	4	g.	g.	PROPN
admet-7	396	5	minotti	minotti	PROPN
admet-7	396	6	,	,	PUNCT
admet-7	396	7	chemical	chemical	ADJ
admet-7	396	8	research	research	NOUN
admet-7	396	9	in	in	ADP
admet-7	396	10	toxicology	toxicology	NOUN
admet-7	396	11	6	6	NUM
admet-7	396	12	(	(	PUNCT
admet-7	396	13	1993	1993	NUM
admet-7	396	14	)	)	PUNCT
admet-7	396	15	134–146	134–146	NUM
admet-7	396	16	.	.	PUNCT
admet-7	397	1	[	[	X
admet-7	397	2	74	74	NUM
admet-7	397	3	]	]	PUNCT
admet-7	397	4	g.	g.	PROPN
admet-7	397	5	cairo	cairo	PROPN
admet-7	397	6	,	,	PUNCT
admet-7	397	7	s.	s.	PROPN
admet-7	397	8	recalcati	recalcati	PROPN
admet-7	397	9	,	,	PUNCT
admet-7	397	10	a.	a.	NOUN
admet-7	397	11	pietrangelo	pietrangelo	NOUN
admet-7	397	12	,	,	PUNCT
admet-7	397	13	g.	g.	PROPN
admet-7	397	14	minotti	minotti	PROPN
admet-7	397	15	,	,	PUNCT
admet-7	397	16	free	free	ADJ
admet-7	397	17	radical	radical	ADJ
admet-7	397	18	biology	biology	NOUN
admet-7	397	19	and	and	CCONJ
admet-7	397	20	medicine	medicine	NOUN
admet-7	397	21	32	32	NUM
admet-7	397	22	(	(	PUNCT
admet-7	397	23	2002	2002	NUM
admet-7	397	24	)	)	PUNCT
admet-7	397	25	1237	1237	NUM
admet-7	397	26	–	–	PUNCT
admet-7	397	27	1243	1243	NUM
admet-7	397	28	.	.	PUNCT
admet-7	398	1	[	[	X
admet-7	398	2	75	75	NUM
admet-7	398	3	]	]	X
admet-7	398	4	g.	g.	PROPN
admet-7	398	5	minotti	minotti	PROPN
admet-7	398	6	,	,	PUNCT
admet-7	398	7	a.f	a.f	PROPN
admet-7	398	8	.	.	PROPN
admet-7	398	9	cavaliere	cavaliere	PROPN
admet-7	398	10	,	,	PUNCT
admet-7	398	11	a.	a.	NOUN
admet-7	398	12	mordente	mordente	PROPN
admet-7	398	13	,	,	PUNCT
admet-7	398	14	m.	m.	NOUN
admet-7	398	15	rossi	rossi	PROPN
admet-7	398	16	,	,	PUNCT
admet-7	398	17	r.	r.	PROPN
admet-7	398	18	schiavello	schiavello	PROPN
admet-7	398	19	,	,	PUNCT
admet-7	398	20	r.	r.	PROPN
admet-7	398	21	zamparelli	zamparelli	PROPN
admet-7	398	22	,	,	PUNCT
admet-7	398	23	g.f	g.f	PROPN
admet-7	398	24	.	.	PROPN
admet-7	398	25	possati	possati	PROPN
admet-7	398	26	,	,	PUNCT
admet-7	398	27	journal	journal	NOUN
admet-7	398	28	of	of	ADP
admet-7	398	29	clinical	clinical	ADJ
admet-7	398	30	investigation	investigation	NOUN
admet-7	398	31	95	95	NUM
admet-7	398	32	(	(	PUNCT
admet-7	398	33	1995	1995	NUM
admet-7	398	34	)	)	PUNCT
admet-7	398	35	1595–1605	1595–1605	NUM
admet-7	398	36	.	.	PUNCT
admet-7	399	1	[	[	X
admet-7	399	2	76	76	NUM
admet-7	399	3	]	]	SYM
admet-7	399	4	p.m.	p.m.	NOUN
admet-7	399	5	sokolove	sokolove	PROPN
admet-7	399	6	,	,	PUNCT
admet-7	399	7	m.b	m.b	PROPN
admet-7	399	8	.	.	PROPN
admet-7	399	9	kester	kester	PROPN
admet-7	399	10	,	,	PUNCT
admet-7	399	11	j.	j.	PROPN
admet-7	399	12	haynes	haynes	PROPN
admet-7	399	13	,	,	PUNCT
admet-7	399	14	biochemical	biochemical	ADJ
admet-7	399	15	pharmacology	pharmacology	NOUN
admet-7	399	16	,	,	PUNCT
admet-7	399	17	46	46	NUM
admet-7	399	18	(	(	PUNCT
admet-7	399	19	1993	1993	NUM
admet-7	399	20	)	)	PUNCT
admet-7	399	21	691	691	NUM
admet-7	399	22	-	-	SYM
admet-7	399	23	697	697	NUM
admet-7	399	24	.	.	PUNCT
admet-7	400	1	[	[	X
admet-7	400	2	77	77	NUM
admet-7	400	3	]	]	SYM
admet-7	400	4	p.m.	p.m.	NOUN
admet-7	400	5	sokolove	sokolove	PROPN
admet-7	400	6	,	,	PUNCT
admet-7	400	7	r.g	r.g	PROPN
admet-7	400	8	.	.	PROPN
admet-7	400	9	shinaberry	shinaberry	NOUN
admet-7	400	10	,	,	PUNCT
admet-7	400	11	biochemical	biochemical	ADJ
admet-7	400	12	pharmacology	pharmacology	NOUN
admet-7	400	13	,	,	PUNCT
admet-7	400	14	37	37	NUM
admet-7	400	15	(	(	PUNCT
admet-7	400	16	1988	1988	NUM
admet-7	400	17	)	)	PUNCT
admet-7	400	18	803	803	NUM
admet-7	400	19	-	-	SYM
admet-7	400	20	812	812	NUM
admet-7	400	21	.	.	PUNCT
admet-7	401	1	[	[	X
admet-7	401	2	78	78	NUM
admet-7	401	3	]	]	X
admet-7	401	4	t.v	t.v	PROPN
admet-7	401	5	.	.	NOUN
admet-7	401	6	goolsby	goolsby	PROPN
admet-7	401	7	,	,	PUNCT
admet-7	401	8	f.a	f.a	PROPN
admet-7	401	9	.	.	PROPN
admet-7	401	10	lombardo	lombardo	PROPN
admet-7	401	11	,	,	PUNCT
admet-7	401	12	seminars	seminar	NOUN
admet-7	401	13	in	in	ADP
admet-7	401	14	oncology	oncology	NOUN
admet-7	401	15	33	33	NUM
admet-7	401	16	(	(	PUNCT
admet-7	401	17	2006	2006	NUM
admet-7	401	18	)	)	PUNCT
admet-7	401	19	139	139	NUM
admet-7	401	20	-	-	SYM
admet-7	401	21	143	143	NUM
admet-7	401	22	.	.	PUNCT
admet-7	402	1	[	[	X
admet-7	402	2	79	79	NUM
admet-7	402	3	]	]	X
admet-7	402	4	h.a	h.a	PROPN
admet-7	402	5	.	.	PROPN
admet-7	402	6	burris	burris	PROPN
admet-7	402	7	,	,	PUNCT
admet-7	402	8	j.	j.	PROPN
admet-7	402	9	hurtig	hurtig	PROPN
admet-7	402	10	,	,	PUNCT
admet-7	402	11	the	the	DET
admet-7	402	12	oncologist	oncologist	NOUN
admet-7	402	13	15	15	NUM
admet-7	402	14	(	(	PUNCT
admet-7	402	15	2010	2010	NUM
admet-7	402	16	)	)	PUNCT
admet-7	402	17	1227	1227	NUM
admet-7	402	18	-	-	SYM
admet-7	402	19	1237	1237	NUM
admet-7	402	20	.	.	PUNCT
admet-7	403	1	[	[	X
admet-7	403	2	80	80	NUM
admet-7	403	3	]	]	X
admet-7	403	4	c.m	c.m	PROPN
admet-7	403	5	.	.	PROPN
admet-7	403	6	camaggi	camaggi	PROPN
admet-7	403	7	,	,	PUNCT
admet-7	403	8	r.	r.	PROPN
admet-7	403	9	comparsi	comparsi	PROPN
admet-7	403	10	,	,	PUNCT
admet-7	403	11	e.	e.	PROPN
admet-7	403	12	strocchi	strocchi	PROPN
admet-7	403	13	,	,	PUNCT
admet-7	403	14	f.	f.	PROPN
admet-7	403	15	testoni	testoni	PROPN
admet-7	403	16	,	,	PUNCT
admet-7	403	17	b.	b.	PROPN
admet-7	403	18	angelelli	angelelli	PROPN
admet-7	403	19	,	,	PUNCT
admet-7	403	20	f.	f.	PROPN
admet-7	403	21	pannuti	pannuti	PROPN
admet-7	403	22	,	,	PUNCT
admet-7	403	23	cancer	cancer	NOUN
admet-7	403	24	chemotherapy	chemotherapy	NOUN
admet-7	403	25	and	and	CCONJ
admet-7	403	26	pharmacology	pharmacology	NOUN
admet-7	403	27	21	21	NUM
admet-7	403	28	(	(	PUNCT
admet-7	403	29	1988	1988	NUM
admet-7	403	30	)	)	PUNCT
admet-7	403	31	221	221	NUM
admet-7	403	32	-	-	SYM
admet-7	403	33	228	228	NUM
admet-7	403	34	.	.	PUNCT
admet-7	404	1	[	[	X
admet-7	404	2	81	81	NUM
admet-7	404	3	]	]	PUNCT
admet-7	404	4	s.c	s.c	PROPN
admet-7	404	5	.	.	PROPN
admet-7	404	6	piscitelli	piscitelli	PROPN
admet-7	404	7	,	,	PUNCT
admet-7	404	8	k.a	k.a	PROPN
admet-7	404	9	.	.	PROPN
admet-7	404	10	rodvold	rodvold	ADJ
admet-7	404	11	,	,	PUNCT
admet-7	404	12	d.a	d.a	PROPN
admet-7	404	13	.	.	PROPN
admet-7	404	14	rushing	rushing	PROPN
admet-7	404	15	,	,	PUNCT
admet-7	404	16	d.a	d.a	PROPN
admet-7	404	17	.	.	PROPN
admet-7	404	18	tewksbury	tewksbury	PROPN
admet-7	404	19	,	,	PUNCT
admet-7	404	20	clinical	clinical	ADJ
admet-7	404	21	pharmacology	pharmacology	NOUN
admet-7	404	22	&	&	CCONJ
admet-7	404	23	therapeutics	therapeutic	NOUN
admet-7	404	24	53	53	NUM
admet-7	404	25	(	(	PUNCT
admet-7	404	26	1993	1993	NUM
admet-7	404	27	)	)	PUNCT
admet-7	404	28	555	555	NUM
admet-7	404	29	-	-	SYM
admet-7	404	30	561	561	NUM
admet-7	404	31	.	.	PUNCT
admet-7	405	1	[	[	X
admet-7	405	2	82	82	NUM
admet-7	405	3	]	]	PUNCT
admet-7	405	4	a.	a.	NOUN
admet-7	405	5	gabizon	gabizon	PROPN
admet-7	405	6	,	,	PUNCT
admet-7	405	7	h.	h.	PROPN
admet-7	405	8	shmeeda	shmeeda	PROPN
admet-7	405	9	,	,	PUNCT
admet-7	405	10	y.	y.	PROPN
admet-7	405	11	barenholz	barenholz	PROPN
admet-7	405	12	,	,	PUNCT
admet-7	405	13	clinical	clinical	ADJ
admet-7	405	14	pharmacokinetics	pharmacokinetic	NOUN
admet-7	405	15	42	42	NUM
admet-7	405	16	(	(	PUNCT
admet-7	405	17	2003	2003	NUM
admet-7	405	18	)	)	PUNCT
admet-7	405	19	419	419	NUM
admet-7	405	20	-	-	SYM
admet-7	405	21	436	436	NUM
admet-7	405	22	.	.	PUNCT
admet-7	406	1	[	[	X
admet-7	406	2	83	83	NUM
admet-7	406	3	]	]	SYM
admet-7	406	4	s.n	s.n	PROPN
admet-7	406	5	.	.	PROPN
admet-7	406	6	hilmer	hilmer	PROPN
admet-7	406	7	,	,	PUNCT
admet-7	406	8	v.c	v.c	PROPN
admet-7	406	9	.	.	PROPN
admet-7	406	10	cogger	cogger	PROPN
admet-7	406	11	,	,	PUNCT
admet-7	406	12	m.	m.	NOUN
admet-7	406	13	muller	muller	PROPN
admet-7	406	14	,	,	PUNCT
admet-7	406	15	d.g	d.g	PROPN
admet-7	406	16	.	.	PROPN
admet-7	406	17	le	le	PROPN
admet-7	406	18	couteur	couteur	PROPN
admet-7	406	19	,	,	PUNCT
admet-7	406	20	drug	drug	NOUN
admet-7	406	21	metabolism	metabolism	NOUN
admet-7	406	22	and	and	CCONJ
admet-7	406	23	disposition	disposition	NOUN
admet-7	406	24	32	32	NUM
admet-7	406	25	(	(	PUNCT
admet-7	406	26	2004	2004	NUM
admet-7	406	27	)	)	PUNCT
admet-7	407	1	794–799	794–799	NUM
admet-7	407	2	.	.	PUNCT
admet-7	408	1	[	[	X
admet-7	408	2	84	84	NUM
admet-7	408	3	]	]	X
admet-7	408	4	p.j	p.j	PROPN
admet-7	408	5	.	.	PROPN
admet-7	408	6	johnson	johnson	PROPN
admet-7	408	7	,	,	PUNCT
admet-7	408	8	c.	c.	PROPN
admet-7	408	9	kalayci	kalayci	PROPN
admet-7	408	10	,	,	PUNCT
admet-7	408	11	n.	n.	PROPN
admet-7	408	12	dobbs	dobbs	PROPN
admet-7	408	13	,	,	PUNCT
admet-7	408	14	n.	n.	PROPN
admet-7	408	15	raby	raby	PROPN
admet-7	408	16	,	,	PUNCT
admet-7	408	17	e.m	e.m	PROPN
admet-7	408	18	.	.	PROPN
admet-7	408	19	metivier	metivier	PROPN
admet-7	408	20	,	,	PUNCT
admet-7	408	21	l.	l.	PROPN
admet-7	408	22	summers	summers	PROPN
admet-7	408	23	,	,	PUNCT
admet-7	408	24	p.	p.	PROPN
admet-7	408	25	harper	harper	PROPN
admet-7	408	26	,	,	PUNCT
admet-7	408	27	r.	r.	PROPN
admet-7	408	28	williams	williams	PROPN
admet-7	408	29	,	,	PUNCT
admet-7	408	30	journal	journal	NOUN
admet-7	408	31	of	of	ADP
admet-7	408	32	hepatology	hepatology	NOUN
admet-7	408	33	13	13	NUM
admet-7	408	34	(	(	PUNCT
admet-7	408	35	1991	1991	NUM
admet-7	408	36	)	)	PUNCT
admet-7	408	37	120	120	NUM
admet-7	408	38	-	-	SYM
admet-7	408	39	127	127	NUM
admet-7	408	40	.	.	PUNCT
admet-7	409	1	[	[	X
admet-7	409	2	85	85	NUM
admet-7	409	3	]	]	X
admet-7	409	4	m.v	m.v	PROPN
admet-7	409	5	.	.	PROPN
admet-7	409	6	gonzalez	gonzalez	PROPN
admet-7	409	7	,	,	PUNCT
admet-7	409	8	y.	y.	PROPN
admet-7	409	9	tang	tang	PROPN
admet-7	409	10	,	,	PUNCT
admet-7	409	11	g.j	g.j	PROPN
admet-7	409	12	.	.	PROPN
admet-7	409	13	phillips	phillips	PROPN
admet-7	409	14	,	,	PUNCT
admet-7	409	15	a.w	a.w	PROPN
admet-7	409	16	.	.	PROPN
admet-7	409	17	lloyd	lloyd	PROPN
admet-7	409	18	,	,	PUNCT
admet-7	409	19	b.	b.	PROPN
admet-7	409	20	hall	hall	PROPN
admet-7	409	21	,	,	PUNCT
admet-7	409	22	p.w	p.w	PROPN
admet-7	409	23	.	.	PROPN
admet-7	409	24	stratford	stratford	PROPN
admet-7	409	25	,	,	PUNCT
admet-7	409	26	a.l	a.l	PROPN
admet-7	409	27	.	.	PROPN
admet-7	409	28	lewis	lewis	PROPN
admet-7	409	29	,	,	PUNCT
admet-7	409	30	journal	journal	NOUN
admet-7	409	31	of	of	ADP
admet-7	409	32	materials	material	NOUN
admet-7	409	33	science	science	NOUN
admet-7	409	34	materials	material	NOUN
admet-7	409	35	in	in	ADP
admet-7	409	36	medicine	medicine	NOUN
admet-7	409	37	19	19	NUM
admet-7	409	38	(	(	PUNCT
admet-7	409	39	2008	2008	NUM
admet-7	409	40	)	)	PUNCT
admet-7	409	41	767	767	NUM
admet-7	409	42	-	-	SYM
admet-7	409	43	775	775	NUM
admet-7	409	44	.	.	PUNCT
admet-7	410	1	[	[	X
admet-7	410	2	86	86	NUM
admet-7	410	3	]	]	PUNCT
admet-7	410	4	k.	k.	PROPN
admet-7	410	5	hong	hong	PROPN
admet-7	410	6	,	,	PUNCT
admet-7	410	7	a.	a.	PROPN
admet-7	410	8	khwaja	khwaja	PROPN
admet-7	410	9	,	,	PUNCT
admet-7	410	10	e.	e.	PROPN
admet-7	410	11	liapi	liapi	PROPN
admet-7	410	12	,	,	PUNCT
admet-7	410	13	m.s	m.s	PROPN
admet-7	410	14	.	.	PROPN
admet-7	410	15	torbenson	torbenson	PROPN
admet-7	410	16	,	,	PUNCT
admet-7	410	17	c.s	c.s	PROPN
admet-7	410	18	.	.	PROPN
admet-7	410	19	georgiades	georgiades	PROPN
admet-7	410	20	,	,	PUNCT
admet-7	410	21	j.f	j.f	PROPN
admet-7	410	22	.	.	PROPN
admet-7	410	23	geschwind	geschwind	PROPN
admet-7	410	24	,	,	PUNCT
admet-7	410	25	clinical	clinical	ADJ
admet-7	410	26	cancer	cancer	NOUN
admet-7	410	27	research	research	NOUN
admet-7	410	28	12	12	NUM
admet-7	410	29	(	(	PUNCT
admet-7	410	30	2006	2006	NUM
admet-7	410	31	)	)	PUNCT
admet-7	410	32	2563	2563	NUM
admet-7	410	33	-	-	SYM
admet-7	410	34	2567	2567	NUM
admet-7	410	35	.	.	PUNCT
admet-7	411	1	[	[	X
admet-7	411	2	87	87	NUM
admet-7	411	3	]	]	SYM
admet-7	411	4	r.t.p	r.t.p	NOUN
admet-7	411	5	.	.	PUNCT
admet-7	411	6	poon	poon	NOUN
admet-7	411	7	,	,	PUNCT
admet-7	411	8	w.k	w.k	PROPN
admet-7	411	9	.	.	PROPN
admet-7	411	10	tso	tso	PROPN
admet-7	411	11	,	,	PUNCT
admet-7	411	12	r.w.c	r.w.c	PROPN
admet-7	411	13	.	.	PROPN
admet-7	411	14	pang	pang	NOUN
admet-7	411	15	,	,	PUNCT
admet-7	411	16	k.k.c	k.k.c	NOUN
admet-7	411	17	.	.	PUNCT
admet-7	412	1	ng	ng	PROPN
admet-7	412	2	,	,	PUNCT
admet-7	412	3	r.	r.	PROPN
admet-7	412	4	woo	woo	PROPN
admet-7	412	5	,	,	PUNCT
admet-7	412	6	k.s	k.s	PROPN
admet-7	412	7	.	.	PROPN
admet-7	412	8	tai	tai	PROPN
admet-7	412	9	,	,	PUNCT
admet-7	412	10	s.t	s.t	PROPN
admet-7	412	11	.	.	PROPN
admet-7	412	12	fan	fan	PROPN
admet-7	412	13	,	,	PUNCT
admet-7	412	14	clinical	clinical	ADJ
admet-7	412	15	gastroenterology	gastroenterology	NOUN
admet-7	412	16	and	and	CCONJ
admet-7	412	17	hepatology	hepatology	NOUN
admet-7	412	18	5	5	NUM
admet-7	412	19	(	(	PUNCT
admet-7	412	20	2007	2007	NUM
admet-7	412	21	)	)	PUNCT
admet-7	412	22	1100–1108	1100–1108	NUM
admet-7	412	23	.	.	PUNCT
admet-7	413	1	[	[	X
admet-7	413	2	88	88	NUM
admet-7	413	3	]	]	PUNCT
admet-7	413	4	m.	m.	NOUN
admet-7	413	5	varela	varela	PROPN
admet-7	413	6	,	,	PUNCT
admet-7	413	7	m.i	m.i	PROPN
admet-7	413	8	.	.	PROPN
admet-7	413	9	real	real	ADJ
admet-7	413	10	,	,	PUNCT
admet-7	413	11	m.	m.	NOUN
admet-7	413	12	burrel	burrel	PROPN
admet-7	413	13	,	,	PUNCT
admet-7	413	14	a.	a.	NOUN
admet-7	413	15	forner	forner	NOUN
admet-7	413	16	,	,	PUNCT
admet-7	413	17	m.	m.	NOUN
admet-7	413	18	sala	sala	PROPN
admet-7	413	19	,	,	PUNCT
admet-7	413	20	m.	m.	NOUN
admet-7	413	21	brunet	brunet	PROPN
admet-7	413	22	,	,	PUNCT
admet-7	413	23	c.	c.	PROPN
admet-7	413	24	ayuso	ayuso	PROPN
admet-7	413	25	,	,	PUNCT
admet-7	413	26	l.	l.	PROPN
admet-7	413	27	castells	castells	PROPN
admet-7	413	28	,	,	PUNCT
admet-7	413	29	x.	x.	PROPN
admet-7	413	30	montana	montana	PROPN
admet-7	413	31	,	,	PUNCT
admet-7	413	32	j.m	j.m	PROPN
admet-7	413	33	.	.	PROPN
admet-7	413	34	llovet	llovet	PROPN
admet-7	413	35	,	,	PUNCT
admet-7	413	36	j.	j.	PROPN
admet-7	413	37	bruix	bruix	PROPN
admet-7	413	38	,	,	PUNCT
admet-7	413	39	journal	journal	NOUN
admet-7	413	40	of	of	ADP
admet-7	413	41	hepatology	hepatology	NOUN
admet-7	413	42	46	46	NUM
admet-7	413	43	(	(	PUNCT
admet-7	413	44	2007	2007	NUM
admet-7	413	45	)	)	PUNCT
admet-7	413	46	474–481	474–481	NUM
admet-7	413	47	.	.	PUNCT
admet-7	414	1	[	[	X
admet-7	414	2	89	89	NUM
admet-7	414	3	]	]	X
admet-7	414	4	j.	j.	PROPN
admet-7	414	5	namur	namur	PROPN
admet-7	414	6	,	,	PUNCT
admet-7	414	7	s.j	s.j	PROPN
admet-7	414	8	.	.	PROPN
admet-7	414	9	citron	citron	PROPN
admet-7	414	10	,	,	PUNCT
admet-7	414	11	m.t	m.t	PROPN
admet-7	414	12	.	.	PROPN
admet-7	414	13	sellers	seller	NOUN
admet-7	414	14	,	,	PUNCT
admet-7	414	15	m.h	m.h	PROPN
admet-7	414	16	.	.	PROPN
admet-7	414	17	dupuis	dupuis	PROPN
admet-7	414	18	,	,	PUNCT
admet-7	414	19	m.	m.	NOUN
admet-7	414	20	wassef	wassef	PROPN
admet-7	414	21	,	,	PUNCT
admet-7	414	22	m.	m.	NOUN
admet-7	414	23	manfait	manfait	PROPN
admet-7	414	24	,	,	PUNCT
admet-7	414	25	a.	a.	NOUN
admet-7	414	26	laurent	laurent	PROPN
admet-7	414	27	,	,	PUNCT
admet-7	414	28	journal	journal	NOUN
admet-7	414	29	of	of	ADP
admet-7	414	30	hepatology	hepatology	NOUN
admet-7	414	31	55	55	NUM
admet-7	414	32	(	(	PUNCT
admet-7	414	33	2011	2011	NUM
admet-7	414	34	)	)	PUNCT
admet-7	414	35	1332–1338	1332–1338	NUM
admet-7	414	36	.	.	PUNCT
admet-7	415	1	[	[	X
admet-7	415	2	90	90	NUM
admet-7	415	3	]	]	PUNCT
admet-7	415	4	r.	r.	PROPN
admet-7	415	5	lencioni	lencioni	PROPN
admet-7	415	6	,	,	PUNCT
admet-7	415	7	t.	t.	PROPN
admet-7	415	8	de	de	X
admet-7	415	9	baere	baere	PROPN
admet-7	415	10	,	,	PUNCT
admet-7	415	11	m.	m.	NOUN
admet-7	415	12	burrel	burrel	PROPN
admet-7	415	13	,	,	PUNCT
admet-7	415	14	j.g	j.g	PROPN
admet-7	415	15	.	.	PROPN
admet-7	415	16	caridi	caridi	PROPN
admet-7	415	17	,	,	PUNCT
admet-7	415	18	j.	j.	PROPN
admet-7	415	19	lammer	lammer	PROPN
admet-7	415	20	,	,	PUNCT
admet-7	415	21	k.	k.	PROPN
admet-7	415	22	malagari	malagari	PROPN
admet-7	415	23	,	,	PUNCT
admet-7	415	24	r.c.g	r.c.g	PROPN
admet-7	415	25	.	.	PUNCT
admet-7	416	1	martin	martin	PROPN
admet-7	416	2	,	,	PUNCT
admet-7	416	3	e.	e.	PROPN
admet-7	416	4	o’grady	o’grady	PROPN
admet-7	416	5	,	,	PUNCT
admet-7	416	6	m.i	m.i	PROPN
admet-7	416	7	.	.	PROPN
admet-7	416	8	real	real	PROPN
admet-7	416	9	,	,	PUNCT
admet-7	416	10	t.j	t.j	PROPN
admet-7	416	11	.	.	PROPN
admet-7	416	12	vogl	vogl	PROPN
admet-7	416	13	,	,	PUNCT
admet-7	416	14	a.	a.	PROPN
admet-7	416	15	watkinson	watkinson	PROPN
admet-7	416	16	,	,	PUNCT
admet-7	416	17	j.f.h	j.f.h	PROPN
admet-7	416	18	.	.	PUNCT
admet-7	416	19	geschwind	geschwind	NOUN
admet-7	416	20	,	,	PUNCT
admet-7	416	21	cardiovascular	cardiovascular	ADJ
admet-7	416	22	and	and	CCONJ
admet-7	416	23	interventional	interventional	ADJ
admet-7	416	24	radiology	radiology	NOUN
admet-7	416	25	35	35	NUM
admet-7	416	26	(	(	PUNCT
admet-7	416	27	2012	2012	NUM
admet-7	416	28	)	)	PUNCT
admet-7	416	29	980–985	980–985	NUM
admet-7	416	30	.	.	PUNCT
admet-7	417	1	[	[	X
admet-7	417	2	91	91	NUM
admet-7	417	3	]	]	PUNCT
admet-7	417	4	a.	a.	NOUN
admet-7	417	5	fohlen	fohlen	PROPN
admet-7	417	6	,	,	PUNCT
admet-7	417	7	j.p	j.p	PROPN
admet-7	417	8	.	.	PROPN
admet-7	417	9	pelage	pelage	PROPN
admet-7	417	10	,	,	PUNCT
admet-7	417	11	in	in	ADP
admet-7	417	12	transcatheter	transcatheter	ADJ
admet-7	417	13	embolization	embolization	NOUN
admet-7	417	14	and	and	CCONJ
admet-7	417	15	therapy	therapy	NOUN
admet-7	417	16	,	,	PUNCT
admet-7	417	17	d.	d.	PROPN
admet-7	417	18	o.	o.	PROPN
admet-7	417	19	kessel	kessel	PROPN
admet-7	417	20	,	,	PUNCT
admet-7	417	21	c.e	c.e	PROPN
admet-7	417	22	.	.	PROPN
admet-7	417	23	ray	ray	PROPN
admet-7	417	24	,	,	PUNCT
admet-7	417	25	ed(s	ed(s	PROPN
admet-7	417	26	)	)	PUNCT
admet-7	417	27	.	.	PUNCT
admet-7	417	28	,	,	PUNCT
admet-7	417	29	springer	springer	NOUN
admet-7	417	30	,	,	PUNCT
admet-7	417	31	london	london	PROPN
admet-7	417	32	,	,	PUNCT
admet-7	417	33	uk	uk	PROPN
admet-7	417	34	,	,	PUNCT
admet-7	417	35	2010	2010	NUM
admet-7	417	36	,	,	PUNCT
admet-7	417	37	p.	p.	NOUN
admet-7	417	38	29	29	NUM
admet-7	417	39	.	.	PUNCT
admet-7	418	1	[	[	X
admet-7	418	2	92	92	NUM
admet-7	418	3	]	]	PUNCT
admet-7	418	4	m.	m.	NOUN
admet-7	418	5	brinckman	brinckman	NOUN
admet-7	418	6	,	,	PUNCT
admet-7	418	7	in	in	ADP
admet-7	418	8	transcatheter	transcatheter	ADJ
admet-7	418	9	embolization	embolization	NOUN
admet-7	418	10	and	and	CCONJ
admet-7	418	11	therapy	therapy	NOUN
admet-7	418	12	,	,	PUNCT
admet-7	418	13	d.	d.	PROPN
admet-7	418	14	o.	o.	PROPN
admet-7	418	15	kessel	kessel	PROPN
admet-7	418	16	,	,	PUNCT
admet-7	418	17	c.e	c.e	PROPN
admet-7	418	18	.	.	PROPN
admet-7	418	19	ray	ray	PROPN
admet-7	418	20	,	,	PUNCT
admet-7	418	21	ed(s	ed(s	PROPN
admet-7	418	22	)	)	PUNCT
admet-7	418	23	.	.	PUNCT
admet-7	418	24	,	,	PUNCT
admet-7	418	25	springer	springer	NOUN
admet-7	418	26	,	,	PUNCT
admet-7	418	27	london	london	PROPN
admet-7	418	28	,	,	PUNCT
admet-7	418	29	uk	uk	PROPN
admet-7	418	30	,	,	PUNCT
admet-7	418	31	2010	2010	NUM
admet-7	418	32	,	,	PUNCT
admet-7	418	33	p.	p.	NOUN
admet-7	418	34	41	41	NUM
admet-7	418	35	.	.	PUNCT
admet-7	419	1	[	[	X
admet-7	419	2	93	93	NUM
admet-7	419	3	]	]	X
admet-7	419	4	y.h	y.h	PROPN
admet-7	419	5	.	.	PROPN
admet-7	419	6	chung	chung	PROPN
admet-7	419	7	,	,	PUNCT
admet-7	419	8	g.	g.	PROPN
admet-7	419	9	han	han	PROPN
admet-7	419	10	,	,	PUNCT
admet-7	419	11	j.h	j.h	PROPN
admet-7	419	12	.	.	PROPN
admet-7	419	13	yoon	yoon	PROPN
admet-7	419	14	,	,	PUNCT
admet-7	419	15	j.	j.	PROPN
admet-7	419	16	yang	yang	PROPN
admet-7	419	17	,	,	PUNCT
admet-7	419	18	j.	j.	PROPN
admet-7	419	19	wang	wang	PROPN
admet-7	419	20	,	,	PUNCT
admet-7	419	21	g.l	g.l	PROPN
admet-7	419	22	.	.	PROPN
admet-7	419	23	shao	shao	PROPN
admet-7	419	24	,	,	PUNCT
admet-7	419	25	b.i	b.i	PROPN
admet-7	419	26	.	.	PROPN
admet-7	419	27	kim	kim	PROPN
admet-7	419	28	,	,	PUNCT
admet-7	419	29	t.y	t.y	PROPN
admet-7	419	30	.	.	PROPN
admet-7	419	31	lee	lee	PROPN
admet-7	419	32	,	,	PUNCT
admet-7	419	33	y.	y.	PROPN
admet-7	419	34	chao	chao	PROPN
admet-7	419	35	,	,	PUNCT
admet-7	419	36	international	international	ADJ
admet-7	419	37	journal	journal	NOUN
admet-7	419	38	of	of	ADP
admet-7	419	39	cancer	cancer	NOUN
admet-7	419	40	132	132	NUM
admet-7	419	41	(	(	PUNCT
admet-7	419	42	2013	2013	NUM
admet-7	419	43	)	)	PUNCT
admet-7	419	44	2448–2458	2448–2458	NUM
admet-7	419	45	.	.	PUNCT
admet-7	420	1	[	[	X
admet-7	420	2	94	94	NUM
admet-7	420	3	]	]	X
admet-7	420	4	chemoembolization	chemoembolization	NOUN
admet-7	420	5	with	with	ADP
admet-7	420	6	or	or	CCONJ
admet-7	420	7	without	without	ADP
admet-7	420	8	sorafenib	sorafenib	NOUN
admet-7	420	9	tosylate	tosylate	VERB
admet-7	420	10	in	in	ADP
admet-7	420	11	treating	treat	VERB
admet-7	420	12	patients	patient	NOUN
admet-7	420	13	with	with	ADP
admet-7	420	14	liver	liver	NOUN
admet-7	420	15	cancer	cancer	NOUN
admet-7	420	16	that	that	PRON
admet-7	420	17	can	can	AUX
admet-7	420	18	not	not	PART
admet-7	420	19	be	be	AUX
admet-7	420	20	removed	remove	VERB
admet-7	420	21	by	by	ADP
admet-7	420	22	surgery	surgery	NOUN
admet-7	420	23	,	,	PUNCT
admet-7	420	24	http://clinicaltrials.gov/ct2/show/nct01004978	http://clinicaltrials.gov/ct2/show/nct01004978	PUNCT
admet-7	420	25	(	(	PUNCT
admet-7	420	26	accessed	access	VERB
admet-7	420	27	30	30	NUM
admet-7	420	28	may	may	NOUN
admet-7	420	29	,	,	PUNCT
admet-7	420	30	2013	2013	NUM
admet-7	420	31	)	)	PUNCT
admet-7	420	32	.	.	PUNCT
admet-7	421	1	[	[	X
admet-7	421	2	95	95	NUM
admet-7	421	3	]	]	PUNCT
admet-7	421	4	transarterial	transarterial	ADJ
admet-7	421	5	chemoembolization	chemoembolization	NOUN
admet-7	421	6	using	use	VERB
admet-7	421	7	doxorubicin	doxorubicin	PROPN
admet-7	421	8	beads	bead	NOUN
admet-7	421	9	with	with	ADP
admet-7	421	10	or	or	CCONJ
admet-7	421	11	without	without	ADP
admet-7	421	12	sorafenib	sorafenib	NOUN
admet-7	421	13	tosylate	tosylate	VERB
admet-7	421	14	in	in	ADP
admet-7	421	15	treating	treat	VERB
admet-7	421	16	patients	patient	NOUN
admet-7	421	17	with	with	ADP
admet-7	421	18	liver	liver	NOUN
admet-7	421	19	cancer	cancer	NOUN
admet-7	421	20	that	that	PRON
admet-7	421	21	can	can	AUX
admet-7	421	22	not	not	PART
admet-7	421	23	be	be	AUX
admet-7	421	24	removed	remove	VERB
admet-7	421	25	by	by	ADP
admet-7	421	26	surgery	surgery	NOUN
admet-7	421	27	,	,	PUNCT
admet-7	421	28	http://clinicaltrials.gov/ct2/show/nct01324076	http://clinicaltrials.gov/ct2/show/nct01324076	PRON
admet-7	421	29	(	(	PUNCT
admet-7	421	30	accessed	access	VERB
admet-7	421	31	30	30	NUM
admet-7	421	32	may	may	NOUN
admet-7	421	33	,	,	PUNCT
admet-7	421	34	2013	2013	NUM
admet-7	421	35	)	)	PUNCT
admet-7	421	36	.	.	PUNCT
admet-7	422	1	[	[	X
admet-7	422	2	96	96	NUM
admet-7	422	3	]	]	SYM
admet-7	422	4	erlotinib	erlotinib	NOUN
admet-7	422	5	plus	plus	CCONJ
admet-7	422	6	bevacizumab	bevacizumab	NOUN
admet-7	422	7	in	in	ADP
admet-7	422	8	hepatocellular	hepatocellular	ADJ
admet-7	422	9	carcinoma	carcinoma	NOUN
admet-7	422	10	(	(	PUNCT
admet-7	422	11	hcc	hcc	PROPN
admet-7	422	12	)	)	PUNCT
admet-7	422	13	as	as	ADP
admet-7	422	14	second	second	ADJ
admet-7	422	15	-	-	PUNCT
admet-7	422	16	line	line	NOUN
admet-7	422	17	therapy	therapy	NOUN
admet-7	422	18	,	,	PUNCT
admet-7	422	19	http://clinicaltrials.gov/ct2/show/nct01180959	http://clinicaltrials.gov/ct2/show/nct01180959	PUNCT
admet-7	422	20	(	(	PUNCT
admet-7	422	21	accessed	access	VERB
admet-7	422	22	30	30	NUM
admet-7	422	23	may	may	NOUN
admet-7	422	24	,	,	PUNCT
admet-7	422	25	2013	2013	NUM
admet-7	422	26	)	)	PUNCT
admet-7	422	27	.	.	PUNCT
admet-7	423	1	http://clinicaltrials.gov/ct2/show/nct01004978	http://clinicaltrials.gov/ct2/show/nct01004978	X
admet-7	424	1	http://clinicaltrials.gov/ct2/show/nct01324076	http://clinicaltrials.gov/ct2/show/nct01324076	NUM
admet-7	424	2	http://clinicaltrials.gov/ct2/show/nct01180959	http://clinicaltrials.gov/ct2/show/nct01180959	PROPN
admet-7	424	3	tam	tam	PROPN
admet-7	424	4	admet	admet	PROPN
admet-7	424	5	&	&	CCONJ
admet-7	424	6	dmpk	dmpk	PROPN
admet-7	424	7	1(3	1(3	NUM
admet-7	424	8	)	)	PUNCT
admet-7	424	9	(	(	PUNCT
admet-7	424	10	2013	2013	NUM
admet-7	424	11	)	)	PUNCT
admet-7	424	12	29	29	NUM
admet-7	424	13	-	-	SYM
admet-7	424	14	44	44	NUM
admet-7	424	15	44	44	NUM
admet-7	424	16	[	[	X
admet-7	424	17	97	97	NUM
admet-7	424	18	]	]	X
admet-7	424	19	s.c	s.c	PROPN
admet-7	424	20	.	.	PROPN
admet-7	424	21	sweetman	sweetman	NOUN
admet-7	424	22	,	,	PUNCT
admet-7	424	23	(	(	PUNCT
admet-7	424	24	ed	ed	NOUN
admet-7	424	25	)	)	PUNCT
admet-7	424	26	.	.	PUNCT
admet-7	425	1	,	,	PUNCT
admet-7	425	2	martindale	martindale	PROPN
admet-7	425	3	:	:	PUNCT
admet-7	425	4	the	the	DET
admet-7	425	5	complete	complete	ADJ
admet-7	425	6	drug	drug	NOUN
admet-7	425	7	reference	reference	NOUN
admet-7	425	8	(	(	PUNCT
admet-7	425	9	35th	35th	ADJ
admet-7	425	10	edition	edition	NOUN
admet-7	425	11	ed	ed	NOUN
admet-7	425	12	.	.	PUNCT
admet-7	425	13	)	)	PUNCT
admet-7	425	14	,	,	PUNCT
admet-7	425	15	pharmaceutical	pharmaceutical	NOUN
admet-7	425	16	press	press	NOUN
admet-7	425	17	,	,	PUNCT
admet-7	425	18	london	london	PROPN
admet-7	425	19	,	,	PUNCT
admet-7	425	20	uk	uk	PROPN
admet-7	425	21	,	,	PUNCT
admet-7	425	22	electronic	electronic	ADJ
admet-7	425	23	version	version	NOUN
admet-7	425	24	,	,	PUNCT
admet-7	425	25	2006	2006	NUM
admet-7	425	26	.	.	PUNCT
admet-7	426	1	[	[	X
admet-7	426	2	98	98	NUM
admet-7	426	3	]	]	X
admet-7	426	4	c.	c.	PROPN
admet-7	426	5	frangakis	frangakis	PROPN
admet-7	426	6	,	,	PUNCT
admet-7	426	7	j.f	j.f	PROPN
admet-7	426	8	.	.	PROPN
admet-7	426	9	geschwind	geschwind	PROPN
admet-7	426	10	,	,	PUNCT
admet-7	426	11	d.	d.	PROPN
admet-7	426	12	kim	kim	PROPN
admet-7	426	13	,	,	PUNCT
admet-7	426	14	y.	y.	PROPN
admet-7	426	15	chen	chen	PROPN
admet-7	426	16	,	,	PUNCT
admet-7	426	17	a.	a.	PROPN
admet-7	426	18	koteish	koteish	PROPN
admet-7	426	19	,	,	PUNCT
admet-7	426	20	k.	k.	PROPN
admet-7	426	21	hong	hong	PROPN
admet-7	426	22	,	,	PUNCT
admet-7	426	23	e.	e.	PROPN
admet-7	426	24	liapi	liapi	PROPN
admet-7	426	25	,	,	PUNCT
admet-7	426	26	c.s	c.s	PROPN
admet-7	426	27	.	.	PROPN
admet-7	426	28	georgiades	georgiade	NOUN
admet-7	426	29	,	,	PUNCT
admet-7	426	30	cardiovascular	cardiovascular	ADJ
admet-7	426	31	and	and	CCONJ
admet-7	426	32	interventional	interventional	ADJ
admet-7	426	33	radiology	radiology	NOUN
admet-7	426	34	34	34	NUM
admet-7	426	35	(	(	PUNCT
admet-7	426	36	2011	2011	NUM
admet-7	426	37	)	)	PUNCT
admet-7	426	38	1254–1261	1254–1261	NUM
admet-7	426	39	.	.	PUNCT
admet-7	427	1	[	[	X
admet-7	427	2	99	99	NUM
admet-7	427	3	]	]	X
admet-7	427	4	y.	y.	PROPN
admet-7	427	5	minami	minami	PROPN
admet-7	427	6	,	,	PUNCT
admet-7	427	7	m.	m.	NOUN
admet-7	427	8	kudo	kudo	PROPN
admet-7	427	9	,	,	PUNCT
admet-7	427	10	international	international	ADJ
admet-7	427	11	journal	journal	NOUN
admet-7	427	12	of	of	ADP
admet-7	427	13	hepatology	hepatology	NOUN
admet-7	427	14	article	article	NOUN
admet-7	427	15	i	i	PROPN
admet-7	427	16	d	d	PROPN
admet-7	427	17	104685	104685	NUM
admet-7	427	18	(	(	PUNCT
admet-7	427	19	2011	2011	NUM
admet-7	427	20	)	)	PUNCT
admet-7	427	21	9	9	NUM
admet-7	427	22	pages	page	NOUN
admet-7	427	23	.	.	PUNCT
admet-7	428	1	[	[	X
admet-7	428	2	100	100	NUM
admet-7	428	3	]	]	PUNCT
admet-7	428	4	j.	j.	PROPN
admet-7	428	5	huang	huang	PROPN
admet-7	428	6	,	,	PUNCT
admet-7	428	7	l.	l.	PROPN
admet-7	428	8	yan	yan	PROPN
admet-7	428	9	,	,	PUNCT
admet-7	428	10	z.	z.	PROPN
admet-7	428	11	cheng	cheng	PROPN
admet-7	428	12	,	,	PUNCT
admet-7	428	13	h.	h.	PROPN
admet-7	428	14	wu	wu	PROPN
admet-7	428	15	,	,	PUNCT
admet-7	428	16	l.	l.	PROPN
admet-7	428	17	du	du	PROPN
admet-7	428	18	,	,	PUNCT
admet-7	428	19	j.	j.	PROPN
admet-7	428	20	wang	wang	PROPN
admet-7	428	21	,	,	PUNCT
admet-7	428	22	y.	y.	PROPN
admet-7	428	23	xu	xu	PROPN
admet-7	428	24	,	,	PUNCT
admet-7	428	25	y.	y.	PROPN
admet-7	428	26	zeng	zeng	PROPN
admet-7	428	27	,	,	PUNCT
admet-7	428	28	annals	annal	NOUN
admet-7	428	29	of	of	ADP
admet-7	428	30	surgery	surgery	NOUN
admet-7	428	31	252	252	NUM
admet-7	428	32	(	(	PUNCT
admet-7	428	33	2010	2010	NUM
admet-7	428	34	)	)	PUNCT
admet-7	428	35	903	903	NUM
admet-7	428	36	–	–	PUNCT
admet-7	428	37	912	912	NUM
admet-7	428	38	.	.	PUNCT
admet-7	429	1	[	[	X
admet-7	429	2	101	101	NUM
admet-7	429	3	]	]	PUNCT
admet-7	429	4	t.	t.	PROPN
admet-7	429	5	yamasaki	yamasaki	PROPN
admet-7	429	6	,	,	PUNCT
admet-7	429	7	f.	f.	PROPN
admet-7	429	8	kurokawa	kurokawa	PROPN
admet-7	429	9	,	,	PUNCT
admet-7	429	10	h.	h.	PROPN
admet-7	429	11	shirahashi	shirahashi	PROPN
admet-7	429	12	,	,	PUNCT
admet-7	429	13	n.	n.	PROPN
admet-7	429	14	kusano	kusano	PROPN
admet-7	429	15	,	,	PUNCT
admet-7	429	16	k.	k.	PROPN
admet-7	429	17	hironaka	hironaka	PROPN
admet-7	429	18	,	,	PUNCT
admet-7	429	19	k.	k.	PROPN
admet-7	429	20	okita	okita	PROPN
admet-7	429	21	,	,	PUNCT
admet-7	429	22	cancer	cancer	NOUN
admet-7	429	23	95	95	NUM
admet-7	429	24	(	(	PUNCT
admet-7	429	25	2002	2002	NUM
admet-7	429	26	)	)	PUNCT
admet-7	429	27	23532360	23532360	NUM
admet-7	429	28	.	.	PUNCT
admet-7	430	1	[	[	X
admet-7	430	2	102	102	NUM
admet-7	430	3	]	]	X
admet-7	430	4	b.q	b.q	PROPN
admet-7	430	5	.	.	PROPN
admet-7	430	6	cheng	cheng	PROPN
admet-7	430	7	,	,	PUNCT
admet-7	430	8	c.q	c.q	PROPN
admet-7	430	9	.	.	PROPN
admet-7	430	10	jia	jia	PROPN
admet-7	430	11	,	,	PUNCT
admet-7	430	12	c.t	c.t	PROPN
admet-7	430	13	.	.	PROPN
admet-7	430	14	liu	liu	PROPN
admet-7	430	15	,	,	PUNCT
admet-7	430	16	w.	w.	PROPN
admet-7	430	17	fan	fan	PROPN
admet-7	430	18	,	,	PUNCT
admet-7	430	19	q.l	q.l	PROPN
admet-7	430	20	.	.	PROPN
admet-7	430	21	wang	wang	PROPN
admet-7	430	22	,	,	PUNCT
admet-7	430	23	z.l	z.l	PROPN
admet-7	430	24	.	.	PROPN
admet-7	430	25	zhang	zhang	PROPN
admet-7	430	26	,	,	PUNCT
admet-7	430	27	c.h	c.h	PROPN
admet-7	430	28	.	.	PROPN
admet-7	430	29	yi	yi	PROPN
admet-7	430	30	,	,	PUNCT
admet-7	430	31	journal	journal	NOUN
admet-7	430	32	of	of	ADP
admet-7	430	33	the	the	DET
admet-7	430	34	american	american	PROPN
admet-7	430	35	medical	medical	PROPN
admet-7	430	36	association	association	PROPN
admet-7	430	37	299	299	NUM
admet-7	430	38	(	(	PUNCT
admet-7	430	39	2008	2008	NUM
admet-7	430	40	)	)	PUNCT
admet-7	430	41	1669–1677	1669–1677	NUM
admet-7	430	42	.	.	PUNCT
admet-7	431	1	[	[	X
admet-7	431	2	103	103	NUM
admet-7	431	3	]	]	X
admet-7	431	4	z.w	z.w	PROPN
admet-7	431	5	.	.	PUNCT
admet-7	431	6	peng	peng	PROPN
admet-7	431	7	,	,	PUNCT
admet-7	431	8	y.j	y.j	PROPN
admet-7	431	9	.	.	PROPN
admet-7	431	10	zhang	zhang	PROPN
admet-7	431	11	,	,	PUNCT
admet-7	431	12	m.s	m.s	PROPN
admet-7	431	13	.	.	PROPN
admet-7	431	14	chen	chen	PROPN
admet-7	431	15	,	,	PUNCT
admet-7	431	16	l.	l.	PROPN
admet-7	431	17	xu	xu	PROPN
admet-7	431	18	,	,	PUNCT
admet-7	431	19	h.h	h.h	PROPN
admet-7	431	20	.	.	PROPN
admet-7	431	21	liang	liang	PROPN
admet-7	431	22	,	,	PUNCT
admet-7	431	23	x.j	x.j	PROPN
admet-7	431	24	.	.	PROPN
admet-7	431	25	lin	lin	PROPN
admet-7	431	26	,	,	PUNCT
admet-7	432	1	r.p	r.p	PROPN
admet-7	432	2	.	.	PROPN
admet-7	432	3	guo	guo	PROPN
admet-7	432	4	,	,	PUNCT
admet-7	432	5	y.q	y.q	PROPN
admet-7	432	6	.	.	PROPN
admet-7	432	7	zhang	zhang	PROPN
admet-7	432	8	,	,	PUNCT
admet-7	432	9	w.y	w.y	PROPN
admet-7	432	10	.	.	PROPN
admet-7	432	11	lau	lau	PROPN
admet-7	432	12	,	,	PUNCT
admet-7	432	13	journal	journal	NOUN
admet-7	432	14	of	of	ADP
admet-7	432	15	clinical	clinical	ADJ
admet-7	432	16	oncology	oncology	NOUN
admet-7	432	17	31	31	NUM
admet-7	432	18	(	(	PUNCT
admet-7	432	19	2013	2013	NUM
admet-7	432	20	)	)	PUNCT
admet-7	432	21	426	426	NUM
admet-7	432	22	-	-	SYM
admet-7	432	23	432	432	NUM
admet-7	432	24	.	.	PUNCT
admet-7	433	1	©	©	PROPN
admet-7	433	2	2013	2013	NUM
admet-7	433	3	by	by	ADP
admet-7	433	4	the	the	DET
admet-7	433	5	authors	author	NOUN
admet-7	433	6	;	;	PUNCT
admet-7	433	7	licensee	licensee	PROPN
admet-7	433	8	iapc	iapc	PROPN
admet-7	433	9	,	,	PUNCT
admet-7	433	10	zagreb	zagreb	PROPN
admet-7	433	11	,	,	PUNCT
admet-7	433	12	croatia	croatia	PROPN
admet-7	433	13	.	.	PUNCT
admet-7	434	1	this	this	DET
admet-7	434	2	article	article	NOUN
admet-7	434	3	is	be	AUX
admet-7	434	4	an	an	DET
admet-7	434	5	open	open	ADJ
admet-7	434	6	-	-	PUNCT
admet-7	434	7	access	access	NOUN
admet-7	434	8	article	article	NOUN
admet-7	434	9	distributed	distribute	VERB
admet-7	434	10	under	under	ADP
admet-7	434	11	the	the	DET
admet-7	434	12	terms	term	NOUN
admet-7	434	13	and	and	CCONJ
admet-7	434	14	conditions	condition	NOUN
admet-7	434	15	of	of	ADP
admet-7	434	16	the	the	DET
admet-7	434	17	creative	creative	ADJ
admet-7	434	18	commons	common	NOUN
admet-7	434	19	attribution	attribution	NOUN
admet-7	434	20	license	license	NOUN
admet-7	434	21	(	(	PUNCT
admet-7	434	22	http://creativecommons.org/licenses/by/3.0/	http://creativecommons.org/licenses/by/3.0/	PROPN
admet-7	434	23	)	)	PUNCT
admet-7	434	24	http://creativecommons.org/licenses/by/3.0/	http://creativecommons.org/licenses/by/3.0/	PROPN